(4S)-6-chloro-4-(2-cyclopropylethynyl)-4-(trifluoromethyl)-2,4-dihydro-1H-3,1-benzoxazin-2-one
| Title | Journal |
|---|---|
| Triple Drug Combination of Zidovudine, Efavirenz and Lamivudine Loaded Lactoferrin Nanoparticles: an Effective Nano First-Line Regimen for HIV Therapy. | Pharmaceutical research 20170201 |
| Cytochrome P450 inhibition potential of new psychoactive substances of the tryptamine class. | Toxicology letters 20160122 |
| Transactivation Assays to Assess Canine and Rodent Pregnane X Receptor (PXR) and Constitutive Androstane Receptor (CAR) Activation. | PloS one 20160101 |
| Systems pharmacological analysis of drugs inducing stevens-johnson syndrome and toxic epidermal necrolysis. | Chemical research in toxicology 20150518 |
| Uralsaponins M-Y, antiviral triterpenoid saponins from the roots of Glycyrrhiza uralensis. | Journal of natural products 20140725 |
| Synthesis and biological evaluation of CHX-DAPYs as HIV-1 non-nucleoside reverse transcriptase inhibitors. | Bioorganic & medicinal chemistry 20140615 |
| Discovery of novel diarylpyrimidines as potent HIV NNRTIs via a structure-guided core-refining approach. | European journal of medicinal chemistry 20140610 |
| Preclinical characterization of BMS-791325, an allosteric inhibitor of hepatitis C Virus NS5B polymerase. | Antimicrobial agents and chemotherapy 20140601 |
| Structural modifications of CH(OH)-DAPYs as new HIV-1 non-nucleoside reverse transcriptase inhibitors. | Bioorganic & medicinal chemistry 20140415 |
| Discovery of nitropyridine derivatives as potent HIV-1 non-nucleoside reverse transcriptase inhibitors via a structure-based core refining approach. | European journal of medicinal chemistry 20140409 |
| Ruxolitinib and tofacitinib are potent and selective inhibitors of HIV-1 replication and virus reactivation in vitro. | Antimicrobial agents and chemotherapy 20140401 |
| Combination antiretroviral therapy (cART) component ritonavir significantly alters docetaxel exposure. | Cancer chemotherapy and pharmacology 20140401 |
| In vitro characterization of MK-1439, a novel HIV-1 nonnucleoside reverse transcriptase inhibitor. | Antimicrobial agents and chemotherapy 20140301 |
| Design and synthesis of N₁-aryl-benzimidazoles 2-substituted as novel HIV-1 non-nucleoside reverse transcriptase inhibitors. | Bioorganic & medicinal chemistry 20140215 |
| Discovery of MK-1439, an orally bioavailable non-nucleoside reverse transcriptase inhibitor potent against a wide range of resistant mutant HIV viruses. | Bioorganic & medicinal chemistry letters 20140201 |
| Highly active antiretroviral therapies are effective against HIV-1 cell-to-cell transmission. | PLoS pathogens 20140201 |
| Design, synthesis and preliminary SAR studies of novel N-arylmethyl substituted piperidine-linked aniline derivatives as potent HIV-1 NNRTIs. | Bioorganic & medicinal chemistry 20140101 |
| Phenylspirodrimanes with anti-HIV activity from the sponge-derived fungus Stachybotrys chartarum MXH-X73. | Journal of natural products 20131227 |
| Novel piperidinylamino-diarylpyrimidine derivatives with dual structural conformations as potent HIV-1 non-nucleoside reverse transcriptase inhibitors. | Bioorganic & medicinal chemistry letters 20131215 |
| Early identification of clinically relevant drug interactions with the human bile salt export pump (BSEP/ABCB11). | Toxicological sciences : an official journal of the Society of Toxicology 20131201 |
| Increasing extracellular protein concentration reduces intracellular antiretroviral drug concentration and antiviral effect. | AIDS research and human retroviruses 20131101 |
| In vitro and in vivo activities of AIC292, a novel HIV-1 nonnucleoside reverse transcriptase inhibitor. | Antimicrobial agents and chemotherapy 20131101 |
| Towards new C6-rigid S-DABO HIV-1 reverse transcriptase inhibitors: synthesis, biological investigation and molecular modeling studies. | Bioorganic & medicinal chemistry 20131101 |
| Optimization of diarylazines as anti-HIV agents with dramatically enhanced solubility. | Bioorganic & medicinal chemistry letters 20130915 |
| Identification of potent Yes1 kinase inhibitors using a library screening approach. | Bioorganic & medicinal chemistry letters 20130801 |
| Hypericum hircinum L. components as new single-molecule inhibitors of both HIV-1 reverse transcriptase-associated DNA polymerase and ribonuclease H activities. | Pathogens and disease 20130801 |
| Discovery of piperidine-linked pyridine analogues as potent non-nucleoside HIV-1 reverse transcriptase inhibitors. | ChemMedChem 20130701 |
| Polymeric nanoparticles containing combination antiretroviral drugs for HIV type 1 treatment. | AIDS research and human retroviruses 20130501 |
| Synthesis and biological evaluation of pyridazine derivatives as novel HIV-1 NNRTIs. | Bioorganic & medicinal chemistry 20130401 |
| Synthesis and biological evaluation of phosphonate analogues of nevirapine. | Bioorganic & medicinal chemistry letters 20130301 |
| Some hydrazones of 2-aroylamino-3-methylbutanohydrazide: synthesis, molecular modeling studies, and identification as stereoselective inhibitors of HIV-1. | Archiv der Pharmazie 20130201 |
| Dual inhibition of HIV-1 replication by integrase-LEDGF allosteric inhibitors is predominant at the post-integration stage. | Retrovirology 20130101 |
| DB-02, a C-6-cyclohexylmethyl substituted pyrimidinone HIV-1 reverse transcriptase inhibitor with nanomolar activity, displays an improved sensitivity against K103N or Y181C than S-DABOs. | PloS one 20130101 |
| Rational design of potent non-nucleoside inhibitors of HIV-1 reverse transcriptase. | Journal of medicinal chemistry 20121213 |
| Structure-based bioisosterism design, synthesis and biological evaluation of novel 1,2,4-triazin-6-ylthioacetamides as potent HIV-1 NNRTIs. | Bioorganic & medicinal chemistry letters 20121201 |
| Discovery of novel 2-(3-(2-chlorophenyl)pyrazin-2-ylthio)-N-arylacetamides as potent HIV-1 inhibitors using a structure-based bioisosterism approach. | Bioorganic & medicinal chemistry 20121201 |
| Structural modifications of 5,6-dihydroxypyrimidines with anti-HIV activity. | Bioorganic & medicinal chemistry letters 20121201 |
| Pharmacodynamic and antiretroviral activities of combination nanoformulated antiretrovirals in HIV-1-infected human peripheral blood lymphocyte-reconstituted mice. | The Journal of infectious diseases 20121115 |
| Role of FAP48 in HIV-associated lipodystrophy. | Journal of cellular biochemistry 20121101 |
| Concomitant efavirenz reduces pharmacokinetic exposure to the antimalarial drug artemether-lumefantrine in healthy volunteers. | Journal of acquired immune deficiency syndromes (1999) 20121101 |
| Novel method to assess antiretroviral target trough concentrations using in vitro susceptibility data. | Antimicrobial agents and chemotherapy 20121101 |
| Treatment of HIV infection with once-daily regimens. | Expert opinion on pharmacotherapy 20121101 |
| Population-based sequencing of the V3-loop can predict the virological response to maraviroc in treatment-naive patients of the MERIT trial. | Journal of acquired immune deficiency syndromes (1999) 20121101 |
| Effect of efavirenz versus nevirapine in antiretroviral-naive individuals in the HIV-CAUSAL Collaboration Cohort. | AIDS (London, England) 20121023 |
| Penicillium marneffei chylous ascites in acquired immune deficiency syndrome: a case report. | World journal of gastroenterology 20121007 |
| Pharmacokinetic and pharmacodynamic analysis of efavirenz dose reduction using an in vitro-in vivo extrapolation model. | Clinical pharmacology and therapeutics 20121001 |
| Emtricitabine/rilpivirine/tenofovir disoproxil fumarate single-tablet regimen: a guide to its use in HIV-1 infection. | Clinical drug investigation 20121001 |
| Adherence and persistence with non-nucleoside reverse transcriptase inhibitor-based antiretroviral regimens. | Expert opinion on pharmacotherapy 20121001 |
| Monitoring of HAART regime antiretrovirals in serum of acquired immunodeficiency syndrome patients by micellar liquid chromatography. | The Analyst 20120921 |
| Improved neuropsychological and neurological functioning across three antiretroviral regimens in diverse resource-limited settings: AIDS Clinical Trials Group study a5199, the International Neurological Study. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20120915 |
| Arylazolyl(azinyl)thioacetanilides. Part 10: design, synthesis and biological evaluation of novel substituted imidazopyridinylthioacetanilides as potent HIV-1 inhibitors. | Bioorganic & medicinal chemistry 20120915 |
| Bilateral oblique facial clefts and extremity anomaly in an infant after intrauterine efavirenz exposure and review of its teratogenic risk. | AIDS (London, England) 20120910 |
| Hyperparathyroidism and complications associated with vitamin D deficiency in HIV-infected adults in New York City, New York. | AIDS research and human retroviruses 20120901 |
| Prevalence of vitamin D deficiency and its related risk factor in a Spanish cohort of adult HIV-infected patients: effects of antiretroviral therapy. | AIDS research and human retroviruses 20120901 |
| Effect modification by sex and baseline CD4+ cell count among adults receiving combination antiretroviral therapy in Botswana: results from a clinical trial. | AIDS research and human retroviruses 20120901 |
| Amorphous-state characterization of efavirenz--polymer hot-melt extrusion systems for dissolution enhancement. | Journal of pharmaceutical sciences 20120901 |
| HIV-HCV co-infection facing HCV protease inhibitor licensing: implications for clinicians. | Liver international : official journal of the International Association for the Study of the Liver 20120901 |
| High frequency of vitamin D deficiency in HIV-infected patients: effects of HIV-related factors and antiretroviral drugs. | The Journal of antimicrobial chemotherapy 20120901 |
| Efavirenz is not a known teratogen. | The Pediatric infectious disease journal 20120901 |
| Significant pharmacokinetic interactions between artemether/lumefantrine and efavirenz or nevirapine in HIV-infected Ugandan adults. | The Journal of antimicrobial chemotherapy 20120901 |
| Sustained efficacy and safety of raltegravir after 5 years of combination antiretroviral therapy as initial treatment of HIV-1 infection: final results of a randomized, controlled, phase II study (Protocol 004). | Journal of acquired immune deficiency syndromes (1999) 20120901 |
| The use of HIV-1 integrase inhibitors in antiretroviral naive patients. | Current opinion in HIV and AIDS 20120901 |
| Drug-induced gynecomastia: an evidence-based review. | Expert opinion on drug safety 20120901 |
| Disubstituted thiourea derivatives and their activity on CNS: synthesis and biological evaluation. | European journal of medicinal chemistry 20120901 |
| Tolerability of HIV integrase inhibitors. | Current opinion in HIV and AIDS 20120901 |
| The effect of efavirenz versus nevirapine-containing regimens on immunologic, virologic and clinical outcomes in a prospective observational study. | AIDS (London, England) 20120824 |
| HIV-1 reverse transcriptase (RT) polymorphism 172K suppresses the effect of clinically relevant drug resistance mutations to both nucleoside and non-nucleoside RT inhibitors. | The Journal of biological chemistry 20120824 |
| Generic HIV drugs will widen US treatment net. | Nature 20120816 |
| Pharmacokinetics and safety of the lopinavir/ritonavir tablet 500/125 mg twice daily coadministered with efavirenz in healthy adult participants. | Journal of clinical pharmacology 20120801 |
| The associations among coping, nadir CD4+ T-cell count, and non-HIV-related variables with health-related quality of life among an ambulatory HIV-positive patient population. | Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation 20120801 |
| No increased risk of hepatotoxicity in long-term use of nonnucleoside reverse transcriptase inhibitors in HIV-infected patients. | HIV medicine 20120801 |
| Effect of gender and race on the week 48 findings in treatment-naïve, HIV-1-infected patients enrolled in the randomized, phase III trials ECHO and THRIVE. | HIV medicine 20120801 |
| Mid-dosing interval efavirenz plasma concentrations in HIV-1-infected children in Rwanda: treatment efficacy, tolerability, adherence, and the influence of CYP2B6 polymorphisms. | Journal of acquired immune deficiency syndromes (1999) 20120801 |
| Where rilpivirine meets with tenofovir, the start of a new anti-HIV drug combination era. | Biochemical pharmacology 20120801 |
| Efficacy and safety of rilpivirine in treatment-naive, HIV-1-infected patients with hepatitis B virus/hepatitis C virus coinfection enrolled in the Phase III randomized, double-blind ECHO and THRIVE trials. | The Journal of antimicrobial chemotherapy 20120801 |
| Case report of cytomegalovirus retinitis in an HIV-positive patient with a CD4-count nadir of 254 cells per μl. | Eye (London, England) 20120801 |
| Diverse combinatorial design, synthesis and in vitro evaluation of new HEPT analogues as potential non-nucleoside HIV-1 reverse transcription inhibitors. | European journal of medicinal chemistry 20120801 |
| Understanding the molecular mechanism of sequence dependent tenofovir removal by HIV-1 reverse transcriptase: differences in primer binding site versus polypurine tract. | Antiviral research 20120801 |
| Warfarin therapy in the HIV medical home model: low rates of therapeutic anticoagulation despite adherence and differences in dosing based on specific antiretrovirals. | AIDS patient care and STDs 20120801 |
| Comprehensive model of wild-type and mutant HIV-1 reverse transciptases. | Journal of computer-aided molecular design 20120801 |
| [A single tablet against HIV: new combination preparation improves therapy]. | Deutsche medizinische Wochenschrift (1946) 20120801 |
| Efficacy and safety of three antiretroviral regimens for initial treatment of HIV-1: a randomized clinical trial in diverse multinational settings. | PLoS medicine 20120801 |
| Assessing the effectiveness of antiretroviral regimens in cohort studies involving HIV-positive injection drug users. | AIDS (London, England) 20120731 |
| New nitrogen containing substituents at the indole-2-carboxamide yield high potent and broad spectrum indolylarylsulfone HIV-1 non-nucleoside reverse transcriptase inhibitors. | Journal of medicinal chemistry 20120726 |
| Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. | JAMA 20120725 |
| Discontinuation of Atripla as first-line therapy in HIV-1 infected individuals. | AIDS (London, England) 20120717 |
| Inflammation markers after randomization to abacavir/lamivudine or tenofovir/emtricitabine with efavirenz or atazanavir/ritonavir. | AIDS (London, England) 20120717 |
| Testing superiority at interim analyses in a non-inferiority trial. | Statistics in medicine 20120710 |
| Treatment outcomes of recommended first-line antiretroviral regimens in resource-limited clinics. | Journal of acquired immune deficiency syndromes (1999) 20120701 |
| Untreated HIV infection is associated with higher blood alcohol levels. | Journal of acquired immune deficiency syndromes (1999) 20120701 |
| Chiral resolution, absolute configuration assignment and biological activity of racemic diarylpyrimidine CH(OH)-DAPY as potent nonnucleoside HIV-1 reverse transcriptase inhibitors. | European journal of medicinal chemistry 20120701 |
| Tenofovir: quo vadis anno 2012 (where is it going in the year 2012)? | Medicinal research reviews 20120701 |
| Compartment-specific gene regulation of the CAR inducer efavirenz in vivo. | Clinical pharmacology and therapeutics 20120701 |
| Pharmacokinetic profiling of efavirenz-emtricitabine-tenofovir fixed dose combination in pregnant and non-pregnant rats. | Biopharmaceutics & drug disposition 20120701 |
| NNRTIs: future prospects. | Medecine et maladies infectieuses 20120701 |
| NNRTIs: pharmacological data. | Medecine et maladies infectieuses 20120701 |
| Efavirenz and psychosis: is there a link? | The Australian and New Zealand journal of psychiatry 20120701 |
| Optimising the manufacture, formulation, and dose of antiretroviral drugs for more cost-efficient delivery in resource-limited settings: a consensus statement. | The Lancet. Infectious diseases 20120701 |
| The dual role of pharmacogenetics in HIV treatment: mutations and polymorphisms regulating antiretroviral drug resistance and disposition. | Pharmacological reviews 20120701 |
| Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks. | Lancet (London, England) 20120630 |
| Biomimetic oxidation of aromatic xenobiotics: synthesis of the phenolic metabolites from the anti-HIV drug efavirenz. | Organic & biomolecular chemistry 20120621 |
| Design, synthesis, anti-HIV evaluation and molecular modeling of piperidine-linked amino-triazine derivatives as potent non-nucleoside reverse transcriptase inhibitors. | Bioorganic & medicinal chemistry 20120615 |
| Functionalized quantum dots with dopamine dithiocarbamate as the matrix for the quantification of efavirenz in human plasma and as affinity probes for rapid identification of microwave tryptic digested proteins in MALDI-TOF-MS. | Journal of proteomics 20120606 |
| Overall benefit of antiretroviral treatment on the risk of fracture in HIV: nested case-control analysis in a health-insured population. | AIDS (London, England) 20120601 |
| Resistance profiles of emtricitabine and lamivudine in tenofovir-containing regimens. | The Journal of antimicrobial chemotherapy 20120601 |
| Drug interaction of efavirenz and midazolam: efavirenz activates the CYP3A-mediated midazolam 1'-hydroxylation in vitro. | Drug metabolism and disposition: the biological fate of chemicals 20120601 |
| Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20120601 |
| Profile of stress and toxicity gene expression in human hepatic cells treated with Efavirenz. | Antiviral research 20120601 |
| Patient-reported symptoms on the antiretroviral regimen efavirenz/emtricitabine/tenofovir. | AIDS patient care and STDs 20120601 |
| Standing genetic variation and the evolution of drug resistance in HIV. | PLoS computational biology 20120601 |
| Disseminated penicilliosis in a Korean human immunodeficiency virus infected patient from Laos. | Journal of Korean medical science 20120601 |
| Nevirapine- and efavirenz-associated hepatotoxicity under programmatic conditions in Kenya and Mozambique. | International journal of STD & AIDS 20120601 |
| Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions. | Journal of medicinal chemistry 20120524 |
| WITHDRAWN: Effectiveness and safety of first-line tenofovir + emtricitabine + efavirenz for patients with HIV. | The Cochrane database of systematic reviews 20120516 |
| Disulfiram metabolite S-methyl-N,N-diethylthiocarbamate quantitation in human plasma with reverse phase ultra performance liquid chromatography and mass spectrometry. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20120515 |
| H2O2 signals via iron induction of VL30 retrotransposition correlated with cytotoxicity. | Free radical biology & medicine 20120515 |
| Rilpivirine: a second-generation nonnucleoside reverse transcriptase inhibitor. | American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20120515 |
| Oropharyngeal yeast colonization in HIV-infected outpatients in southern Taiwan: CD4 count, efavirenz therapy and intravenous drug use matter. | Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 20120501 |
| The influence of tuberculosis treatment on efavirenz clearance in patients co-infected with HIV and tuberculosis. | European journal of clinical pharmacology 20120501 |
| Effect of physical states of binders on high-shear wet granulation and granule properties: a mechanistic approach toward understanding high-shear wet granulation process, part 3: effect of binder rheological properties. | Journal of pharmaceutical sciences 20120501 |
| Use of dried blood spots for the determination of plasma concentrations of nevirapine and efavirenz. | The Journal of antimicrobial chemotherapy 20120501 |
| Efficacy and safety of rilpivirine (TMC278) versus efavirenz at 48 weeks in treatment-naive HIV-1-infected patients: pooled results from the phase 3 double-blind randomized ECHO and THRIVE Trials. | Journal of acquired immune deficiency syndromes (1999) 20120501 |
| Synthesis and biological evaluation of piperidine-substituted triazine derivatives as HIV-1 non-nucleoside reverse transcriptase inhibitors. | European journal of medicinal chemistry 20120501 |
| Rilpivirine: a next-generation non-nucleoside analogue for the treatment of HIV infection. | Expert opinion on pharmacotherapy 20120501 |
| Efavirenz severe hypersensitivity reaction: case report and rapid desensitization protocol development. | The Annals of pharmacotherapy 20120501 |
| Pregnancy and infant outcomes among HIV-infected women taking long-term ART with and without tenofovir in the DART trial. | PLoS medicine 20120501 |
| Impact of antiretroviral dosing frequency and pill burden on adherence among newly diagnosed, antiretroviral-naive HIV patients. | International journal of STD & AIDS 20120501 |
| Response to valacyclovir in an HIV-infected girl with Epstein Barr infection. | Indian pediatrics 20120501 |
| Etravirine: a review of its use in the management of treatment-experienced patients with HIV-1 infection. | Drugs 20120416 |
| Safety, tolerability, and pharmacokinetic interactions of the antituberculous agent TMC207 (bedaquiline) with efavirenz in healthy volunteers: AIDS Clinical Trials Group Study A5267. | Journal of acquired immune deficiency syndromes (1999) 20120415 |
| Contraceptive failure of etonogestrel implant in patients treated with antiretrovirals including efavirenz. | Contraception 20120401 |
| Influence of CYP2B6 516G>T polymorphism and interoccasion variability (IOV) on the population pharmacokinetics of efavirenz in HIV-infected South African children. | European journal of clinical pharmacology 20120401 |
| Pharmacokinetics of the nonnucleoside reverse transcriptase inhibitor efavirenz among HIV-infected Ugandans. | HIV medicine 20120401 |
| Dynamics of cognitive change in HIV-infected individuals commencing three different initial antiretroviral regimens: a randomized, controlled study. | HIV medicine 20120401 |
| Effects of the CYP2B6*6 allele on catalytic properties and inhibition of CYP2B6 in vitro: implication for the mechanism of reduced efavirenz metabolism and other CYP2B6 substrates in vivo. | Drug metabolism and disposition: the biological fate of chemicals 20120401 |
| Prevalence of etravirine resistance associated mutations in HIV-1 strains isolated from infected individuals failing efavirenz: comparison between subtype B and non-B genetic variants. | Journal of medical virology 20120401 |
| Associations between ABCB1, CYP2A6, CYP2B6, CYP2D6, and CYP3A5 alleles in relation to efavirenz and nevirapine pharmacokinetics in HIV-infected individuals. | Therapeutic drug monitoring 20120401 |
| Efavirenz dose reduction in HIV-infected patients. | HIV medicine 20120401 |
| Mechanism of efavirenz influence on methadone pharmacokinetics and pharmacodynamics. | Clinical pharmacology and therapeutics 20120401 |
| Worldwide variation in human drug-metabolism enzyme genes CYP2B6 and UGT2B7: implications for HIV/AIDS treatment. | Pharmacogenomics 20120401 |
| Effectiveness of generic and proprietary first-line anti-retroviral regimens in a primary health care setting in Lusaka, Zambia: a cohort study. | International journal of epidemiology 20120401 |
| HIV drug resistance interpreted by cumulative versus last genotypes in HIV-infected patients with multiple treatment failures. | Current HIV research 20120401 |
| HIV exposure through contact with body fluids. | Prescrire international 20120401 |
| [Reverse transcriptase inhibitors, protease inhibitors]. | Nihon rinsho. Japanese journal of clinical medicine 20120401 |
| Nanotechnology and the treatment of HIV infection. | Viruses 20120401 |
| Skin manifestation of Thai HIV infected patients in HAART era. | Journal of the Medical Association of Thailand = Chotmaihet thangphaet 20120401 |
| Library-based discovery and characterization of daphnane diterpenes as potent and selective HIV inhibitors in Daphne gnidium. | Journal of natural products 20120323 |
| A review of the virological efficacy of the 4 World Health Organization-recommended tenofovir-containing regimens for initial HIV therapy. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20120315 |
| Renal function in patients with HIV starting therapy with tenofovir and either efavirenz, lopinavir or atazanavir. | AIDS (London, England) 20120313 |
| Projecting the clinical benefits and risks of using efavirenz-containing antiretroviral therapy regimens in women of childbearing age. | AIDS (London, England) 20120313 |
| Safety and effectiveness of efavirenz versus nevirapine-based regimens in resource-limited settings: evidence, clinical practice and modelling projections. | AIDS (London, England) 20120313 |
| Rilpivirine. | Drugs 20120305 |
| Immunological characterisation of an unmasking TB-IRIS case. | South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde 20120302 |
| CYP2B6 genotype is a strong predictor of systemic exposure to efavirenz in HIV-infected Zimbabweans. | European journal of clinical pharmacology 20120301 |
| Efavirenz interference in urine screening immunoassays for tetrahydrocannabinol. | Annals of clinical biochemistry 20120301 |
| Efavirenz pharmacokinetics during the third trimester of pregnancy and postpartum. | Journal of acquired immune deficiency syndromes (1999) 20120301 |
| Safety and tolerability of antiretroviral therapy among HIV-infected children and adolescents in Uganda. | Journal of acquired immune deficiency syndromes (1999) 20120301 |
| Lopinavir/ritonavir single agent therapy as a universal combination antiretroviral therapy stopping strategy: results from the STOP 1 and STOP 2 studies. | The Journal of antimicrobial chemotherapy 20120301 |
| Costs and benefits of multidrug, multidose antiretroviral therapy for prevention of mother-to-child transmission of HIV in the Dominican Republic. | International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics 20120301 |
| Study on the structure and vibrational spectra of efavirenz conformers using DFT: comparison to experimental data. | Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy 20120301 |
| Lipid profiles for etravirine versus efavirenz in treatment-naive patients in the randomized, double-blind SENSE trial. | The Journal of antimicrobial chemotherapy 20120301 |
| Impact of efavirenz on intestinal metabolism and transport: insights from an interaction study with ezetimibe in healthy volunteers. | Clinical pharmacology and therapeutics 20120301 |
| Induction of CYP2C19 and CYP3A activity following repeated administration of efavirenz in healthy volunteers. | Clinical pharmacology and therapeutics 20120301 |
| Maintaining cost-effective access to antiretroviral drug therapy through a collaborative approach to drug procurement, consensus treatment guidelines and regular audit: the experience of London HIV commissioners and providers. | Sexually transmitted infections 20120301 |
| Exploring the complexity of the HIV-1 fitness landscape. | PLoS genetics 20120301 |
| No treatment versus 24 or 60 weeks of antiretroviral treatment during primary HIV infection: the randomized Primo-SHM trial. | PLoS medicine 20120301 |
| Identification of potential drug-drug interactions between antiretroviral drugs from prescriptions in the private health-care sector in South Africa. | International journal of STD & AIDS 20120301 |
| Atypical progressive multifocal leukoencephalopathy in HIV with a high CD4 count: the use of magnetic resonance imaging plus spectrometry studies. | International journal of STD & AIDS 20120301 |
| Effects of highly active antiretroviral therapy on cognitive functions in severely immune-compromised HIV-seropositive patients. | Journal of the neurological sciences 20120215 |
| WITHDRAWN. Effectiveness and safety of first-line tenofovir + emtricitabine + efavirenz for patients with HIV. | The Cochrane database of systematic reviews 20120215 |
| Cohort profile: The PharmAccess African (PASER-M) and the TREAT Asia (TASER-M) monitoring studies to evaluate resistance--HIV drug resistance in sub-Saharan Africa and the Asia-Pacific. | International journal of epidemiology 20120201 |
| Safety and efficacy of raltegravir in patients with HIV-1 and hepatitis B and/or C virus coinfection. | HIV medicine 20120201 |
| Prevalence of congenital anomalies in infants with in utero exposure to antiretrovirals. | The Pediatric infectious disease journal 20120201 |
| Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial. | The Lancet. Infectious diseases 20120201 |
| Hepatic safety of efavirenz in HIV/hepatitis C virus-coinfected patients with advanced liver fibrosis. | The Journal of infection 20120201 |
| HIV-1 tropism and CD4 T lymphocyte recovery in a prospective cohort of patients initiating HAART in Ribeirão Preto, Brazil. | Memorias do Instituto Oswaldo Cruz 20120201 |
| The efficiency of the human CD8+ T cell response: how should we quantify it, what determines it, and does it matter? | PLoS computational biology 20120201 |
| The perils of relying on anti-hepatitis B total core antibody in screening individuals infected with HIV. | International journal of STD & AIDS 20120201 |
| Lipid profile changes in Thai HIV and tuberculosis co-infected patients receiving non-nucleoside reverse transcriptase inhibitors-based antiretroviral therapy. | Journal of the Medical Association of Thailand = Chotmaihet thangphaet 20120201 |
| Incidence of low and high-energy fractures in persons with and without HIV infection: a Danish population-based cohort study. | AIDS (London, England) 20120128 |
| Effects of vitamin D deficiency and combination antiretroviral therapy on bone in HIV-positive patients. | AIDS (London, England) 20120128 |
| Mutations in the HIV-1 reverse transcriptase tryptophan repeat motif affect virion maturation and Gag-Pol packaging. | Virology 20120120 |
| Effect of efavirenz on UDP-glucuronosyltransferase 1A1, 1A4, 1A6, and 1A9 activities in human liver microsomes. | Molecules (Basel, Switzerland) 20120117 |
| Evidence-based guideline: Antiepileptic drug selection for people with HIV/AIDS: report of the Quality Standards Subcommittee of the American Academy of Neurology and the Ad Hoc Task Force of the Commission on Therapeutic Strategies of the International League Against Epilepsy. | Neurology 20120110 |
| Antiretroviral prophylaxis and the risk of cleft lip and palate: preliminary signal detection in the food and drug administration's adverse events reporting system database. | The Cleft palate-craniofacial journal : official publication of the American Cleft Palate-Craniofacial Association 20120101 |
| High pregnancy intentions and missed opportunities for patient-provider communication about fertility in a South African cohort of HIV-positive women on antiretroviral therapy. | AIDS and behavior 20120101 |
| Patient-reported outcomes and low-level residual HIV-RNA in adolescents perinatally infected with HIV-1 after switching to one-pill fixed-dose regimen. | AIDS care 20120101 |
| The rate of accumulation of nonnucleoside reverse transcriptase inhibitor (NNRTI) resistance in patients kept on a virologically failing regimen containing an NNRTI*. | HIV medicine 20120101 |
| Hypertriglyceridemia, Metabolic Syndrome, and Cardiovascular Disease in HIV-Infected Patients: Effects of Antiretroviral Therapy and Adipose Tissue Distribution. | International journal of vascular medicine 20120101 |
| Antiretroviral therapy initiation in France: adherence to national guidelines and outcome. | Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002) 20120101 |
| Anti-HIV-1 and cytotoxicity of the alkaloids of Erythrina abyssinica Lam. growing in Sudan. | Natural product research 20120101 |
| Reverse transcriptase genotypes in pediatric patients failing initial antiretroviral therapy in Gaborone, Botswana. | Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002) 20120101 |
| A randomized, pilot trial to evaluate glomerular filtration rate by creatinine or cystatin C in naive HIV-infected patients after tenofovir/emtricitabine in combination with atazanavir/ritonavir or efavirenz. | Journal of acquired immune deficiency syndromes (1999) 20120101 |
| The antiretroviral protease inhibitors indinavir and nelfinavir stimulate Mrp1-mediated GSH export from cultured brain astrocytes. | Journal of neurochemistry 20120101 |
| 5α-reductase inhibitors, antiviral and anti-tumor activities of some steroidal cyanopyridinone derivatives. | International journal of biological macromolecules 20120101 |
| Incidence of HIV-1 drug resistance among antiretroviral treatment-naive individuals starting modern therapy combinations. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20120101 |
| Genotypic and phenotypic characterization of HIV-1 isolates obtained from patients on rilpivirine therapy experiencing virologic failure in the phase 3 ECHO and THRIVE studies: 48-week analysis. | Journal of acquired immune deficiency syndromes (1999) 20120101 |
| Reasons for and correlates of antiretroviral treatment interruptions in a cohort of patients from public and private clinics in southern India. | AIDS care 20120101 |
| Tuberculosis in pregnancy: a review. | Journal of pregnancy 20120101 |
| The pathophysiology of HIV-/HAART-related metabolic syndrome leading to cardiovascular disorders: the emerging role of adipokines. | Experimental diabetes research 20120101 |
| Antiepileptic drug selection for people with HIV/AIDS: evidence-based guidelines from the ILAE and AAN. | Epilepsia 20120101 |
| Clinical practice guidelines within the Southern African Development Community: a descriptive study of the quality of guideline development and concordance with best evidence for five priority diseases. | Health research policy and systems 20120101 |
| Determinants of sustained viral suppression in HIV-infected patients with self-reported poor adherence to antiretroviral therapy. | PloS one 20120101 |
| Renal function declines more in tenofovir- than abacavir-based antiretroviral therapy in low-body weight treatment-naïve patients with HIV infection. | PloS one 20120101 |
| Vitamin D insufficiency and deficiency among HIV-1-infected patients in a tropical setting. | Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002) 20120101 |
| HIV infection and HERV expression: a review. | Retrovirology 20120101 |
| A predictive model for efavirenz dosing. | Pharmacogenomics 20120101 |
| Impact of the introduction of government use licenses on the drug expenditure on seven medicines in Thailand. | Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 20120101 |
| Emerging mutations and associated factors in patients displaying treatment failure on an etravirine-containing regimen. | Antiviral therapy 20120101 |
| Renal function in HIV-infected children and adolescents treated with tenofovir disoproxil fumarate and protease inhibitors. | BMC infectious diseases 20120101 |
| Treatment outcomes in HIV-infected adolescents attending a community-based antiretroviral therapy clinic in South Africa. | BMC infectious diseases 20120101 |
| The epidemiology and clinical correlates of HIV-1 co-receptor tropism in non-subtype B infections from India, Uganda and South Africa. | Journal of the International AIDS Society 20120101 |
| A transcriptional-switch model for Slr1738-controlled gene expression in the cyanobacterium Synechocystis. | BMC structural biology 20120101 |
| Immune reconstitution inflammatory syndrome from Penicillium marneffei in an HIV-infected child: a case report and review of literature. | BMC infectious diseases 20120101 |
| A flexible model of HIV-1 latency permitting evaluation of many primary CD4 T-cell reservoirs. | PloS one 20120101 |
| Pharmacokinetic parameters of once-daily rilpivirine following administration of efavirenz in healthy subjects. | Antiviral therapy 20120101 |
| Low rates of nucleoside reverse transcriptase inhibitor resistance in a well-monitored cohort in South Africa on antiretroviral therapy. | Antiviral therapy 20120101 |
| Risk factors for mortality among HIV-positive patients with and without active tuberculosis in Dar es Salaam, Tanzania. | Antiviral therapy 20120101 |
| Combination antiretroviral therapy and chronic HIV infection affect serum retinoid concentrations: longitudinal and cross-sectional assessments. | AIDS research and therapy 20120101 |
| An assessment of the accuracy and availability of data in electronic patient tracking systems for patients receiving HIV treatment in central Mozambique. | BMC health services research 20120101 |
| Prevalence of MDR1 C3435T and CYP2B6 G516T polymorphisms among HIV-1 infected South African patients. | Disease markers 20120101 |
| Evidence for a shift to anaerobic metabolism in adipose tissue in efavirenz-containing regimens for HIV with different nucleoside backbones. | Antiviral therapy 20120101 |
| Incidence of treatment-limiting toxicity with stavudine-based antiretroviral therapy in Cambodia: a retrospective cohort study. | PloS one 20120101 |
| A potential drug-herbal interaction between Ginkgo biloba and efavirenz. | Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002) 20120101 |
| Prospective evaluation of bone markers, parathormone and 1,25-(OH)₂ vitamin D in HIV-positive patients after the initiation of tenofovir/emtricitabine with atazanavir/ritonavir or efavirenz. | BMC infectious diseases 20120101 |
| Neuropsychological outcomes in adults commencing highly active anti-retroviral treatment in South Africa: a prospective study. | BMC infectious diseases 20120101 |
| A review of drug interactions with boceprevir and telaprevir: implications for HIV and transplant patients. | Annals of hepatology 20120101 |
| Expanding ART for treatment and prevention of HIV in South Africa: estimated cost and cost-effectiveness 2011-2050. | PloS one 20120101 |
| Factors predicting discordant virological and immunological responses to antiretroviral therapy in HIV-1 clade C infected Zulu/Xhosa in South Africa. | PloS one 20120101 |
| Suppression of pre adipocyte differentiation and promotion of adipocyte death by anti-HIV drugs. | In vivo (Athens, Greece) 20120101 |
| Reduced quantitative ultrasound bone mineral density in HIV-infected patients on antiretroviral therapy in Senegal. | PloS one 20120101 |
| Hyperhidrosis related to nevirapine therapy. | International journal of STD & AIDS 20120101 |
| Adverse drug reactions to antiretroviral therapy (ARVs): incidence, type and risk factors in Nigeria. | BMC clinical pharmacology 20120101 |
| Adherence to antiretroviral treatment and correlation with risk of hospitalization among commercially insured HIV patients in the United States. | PloS one 20120101 |
| Prevalence and risk factors for cervical squamous intraepithelial lesions among women infected with HIV-1 in Makurdi, Nigeria. | International journal of women's health 20120101 |
| The Reason for Regimen Change Among HIV/AIDS Patients Initiated on First Line Highly Active Antiretroviral Therapy in Southern Ethiopia. | North American journal of medical sciences 20120101 |
| Switching virally suppressed, treatment-experienced patients to a raltegravir-containing regimen does not alter levels of HIV-1 DNA. | PloS one 20120101 |
| Placement of leucine zipper motifs at the carboxyl terminus of HIV-1 protease significantly reduces virion production. | PloS one 20120101 |
| Successes and Challenges in an Integrated Tuberculosis/HIV Clinic in a Rural, Resource-Limited Setting: Experiences from Kericho, Kenya. | AIDS research and treatment 20120101 |
| Biophysical property and broad anti-HIV activity of albuvirtide, a 3-maleimimidopropionic acid-modified peptide fusion inhibitor. | PloS one 20120101 |
| Assessment of HBV flare in a randomized clinical trial in HIV/HBV coinfected subjects initiating HBV-active antiretroviral therapy in Thailand. | AIDS research and therapy 20120101 |
| Computational studies of difference in binding modes of peptide and non-peptide inhibitors to MDM2/MDMX based on molecular dynamics simulations. | International journal of molecular sciences 20120101 |
| Conference highlights of the 5th international workshop on HIV persistence during therapy, 6-9 December 2011, St. Maartin, West Indies. | AIDS research and therapy 20120101 |
| Reducing mother-to-child transmission of HIV: findings from an early infant diagnosis program in south-south region of Nigeria. | BMC public health 20120101 |
| Effectiveness and safety of 30 mg versus 40 mg stavudine regimens: a cohort study among HIV-infected adults initiating HAART in South Africa. | Journal of the International AIDS Society 20120101 |
| Survival from XDR-TB is associated with modifiable clinical characteristics in rural South Africa. | PloS one 20120101 |
| HIV-1 promotes intake of Leishmania parasites by enhancing phosphatidylserine-mediated, CD91/LRP-1-dependent phagocytosis in human macrophages. | PloS one 20120101 |
| Virologic failure of protease inhibitor-based second-line antiretroviral therapy without resistance in a large HIV treatment program in South Africa. | PloS one 20120101 |
| Not all are lost: interrupted laboratory monitoring, early death, and loss to follow-up (LTFU) in a large South African treatment program. | PloS one 20120101 |
| The level of DING proteins is increased in HIV-infected patients: in vitro and in vivo studies. | PloS one 20120101 |
| An autopsy study describing causes of death and comparing clinico-pathological findings among hospitalized patients in Kampala, Uganda. | PloS one 20120101 |
| Low prevalence of transmitted drug resistance in patients newly diagnosed with HIV-1 infection in Sweden 2003-2010. | PloS one 20120101 |
| Effect of Food on the Steady-State Pharmacokinetics of Tenofovir and Emtricitabine plus Efavirenz in Ugandan Adults. | AIDS research and treatment 20120101 |
| Regulation of reverse cholesterol transport - a comprehensive appraisal of available animal studies. | Nutrition & metabolism 20120101 |
| Antiretroviral outcomes in South African prisoners: a retrospective cohort analysis. | PloS one 20120101 |
| Incidence of adverse drug reactions in human immune deficiency virus-positive patients using highly active antiretroviral therapy. | Journal of advanced pharmaceutical technology & research 20120101 |
| A systematic review of the epidemiology, immunopathogenesis, diagnosis, and treatment of pleural TB in HIV-infected patients. | Clinical & developmental immunology 20120101 |
| Comparison of bone and renal effects in HIV-infected adults switching to abacavir or tenofovir based therapy in a randomized trial. | PloS one 20120101 |
| Impact of multi-targeted antiretroviral treatment on gut T cell depletion and HIV reservoir seeding during acute HIV infection. | PloS one 20120101 |
| Mitochondrial bioenergetic alterations in mouse neuroblastoma cells infected with Sindbis virus: implications to viral replication and neuronal death. | PloS one 20120101 |
| HIV RNA suppression and immune restoration: can we do better? | Clinical & developmental immunology 20120101 |
| HIV-1 phenotypic reverse transcriptase inhibitor drug resistance test interpretation is not dependent on the subtype of the virus backbone. | PloS one 20120101 |
| Prevalence of HIV Drug Resistance Mutations in HIV Type 1 Isolates in Antiretroviral Therapy Naïve Population from Northern India. | AIDS research and treatment 20120101 |
| Novel therapeutic strategies targeting HIV integrase. | BMC medicine 20120101 |
| The impact of herbal drug use on adverse drug reaction profiles of patients on antiretroviral therapy in zimbabwe. | AIDS research and treatment 20120101 |
| HIV-Antiretroviral Therapy Induced Liver, Gastrointestinal, and Pancreatic Injury. | International journal of hepatology 20120101 |
| Effects of highly active antiretroviral therapy on platelet activating factor metabolism in naive HIV-infected patients: ii) study of the abacavir/lamivudine/efavirenz HAART regimen. | International journal of immunopathology and pharmacology 20120101 |
| Liver toxicity of initial antiretroviral drug regimens including two nucleoside analogs plus one non-nucleoside analog or one ritonavir-boosted protease inhibitor in HIV/HCV-coinfected patients. | HIV clinical trials 20120101 |
| Second-site suppressors of HIV-1 capsid mutations: restoration of intracellular activities without correction of intrinsic capsid stability defects. | Retrovirology 20120101 |
| Recurrent deep venous thrombosis in an HIV-positive and injecting drug user woman. | Indian journal of sexually transmitted diseases and AIDS 20120101 |
| Pharmacokinetic interactions between the hormonal emergency contraception, levonorgestrel (Plan B), and Efavirenz. | Infectious diseases in obstetrics and gynecology 20120101 |
| Assessment of the impact of adherence and other predictors during HAART on various CD4 cell responses in resource-limited settings. | Patient preference and adherence 20120101 |
| Impact of Novel Resistance Profiles in HIV-1 Reverse Transcriptase on Phenotypic Resistance to NVP. | AIDS research and treatment 20120101 |
| Imported Plasmodium falciparum malaria in HIV-infected patients: a report of two cases. | Malaria journal 20120101 |
| High incidence of unplanned pregnancy after antiretroviral therapy initiation: findings from a prospective cohort study in South Africa. | PloS one 20120101 |
| Effectiveness of a prevention of mother-to-child HIV transmission programme in an urban hospital in Angola. | PloS one 20120101 |
| Young HIV-infected children and their adult caregivers prefer tablets to syrup antiretroviral medications in Africa. | PloS one 20120101 |
| Factors determining changes in initial antiretroviral therapy. | Revista da Associacao Medica Brasileira (1992) 20120101 |
| Cross-cultural adaptation and validation of the self-reporting questionnaire among HIV+ individuals in a rural ART program in southern Uganda. | HIV/AIDS (Auckland, N.Z.) 20120101 |
| New option for management of HIV-1 infection in treatment-naive patients: once-daily, fixed-dose combination of rilpivirine-emtricitabine-tenofovir. | HIV/AIDS (Auckland, N.Z.) 20120101 |
| Low-cost ultra-wide genotyping using Roche/454 pyrosequencing for surveillance of HIV drug resistance. | PloS one 20120101 |
| An insight into thermodynamic relationship between polymorphic forms of efavirenz. | Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques 20120101 |
| Sudden death of cardiac origin and psychotropic drugs. | Frontiers in pharmacology 20120101 |
| Impact of low-level-viremia on HIV-1 drug-resistance evolution among antiretroviral treated-patients. | PloS one 20120101 |
| A pharmacovigilance study of adults on highly active antiretroviral therapy, South Africa: 2007 - 2011. | The Pan African medical journal 20120101 |
| Prevalence of Drug Resistance and Associated Mutations in a Population of HIV-1(+) Puerto Ricans: 2006-2010. | AIDS research and treatment 20120101 |
| Stress studies of tenofovir disoproxil fumarate by HPTLC in bulk drug and pharmaceutical formulation. | TheScientificWorldJournal 20120101 |
| K65R in subtype C HIV-1 isolates from patients failing on a first-line regimen including d4T or AZT: comparison of Sanger and UDP sequencing data. | PloS one 20120101 |
| Outcomes of comprehensive care for children empirically treated for multidrug-resistant tuberculosis in a setting of high HIV prevalence. | PloS one 20120101 |
| Mononuclear phagocyte intercellular crosstalk facilitates transmission of cell-targeted nanoformulated antiretroviral drugs to human brain endothelial cells. | International journal of nanomedicine 20120101 |
| Meningeal Hemangiopericytoma with Intracranial Metastases in an HIV-Positive Male: Case Report and Review of the Literature. | Case reports in oncology 20120101 |
| Differences in lipid measurements by antiretroviral regimen exposure in cohorts from Asia and australia. | AIDS research and treatment 20120101 |
| Antiretroviral drugs: critical issues and recent advances. | Indian journal of pharmacology 20120101 |
| Effect of Formula Feeding and Breastfeeding on Child Growth, Infant Mortality, and HIV Transmission in Children Born to HIV-Infected Pregnant Women Who Received Triple Antiretroviral Therapy in a Resource-Limited Setting: Data from an HIV Cohort Study in India. | ISRN pediatrics 20120101 |
| Malaria and hiv in adults: when the parasite runs into the virus. | Mediterranean journal of hematology and infectious diseases 20120101 |
| Self-reported adherence supports patient preference for the single tablet regimen (STR) in the current cART era. | Patient preference and adherence 20120101 |
| Treatment outcomes among HIV-1 and HIV-2 infected children initiating antiretroviral therapy in a concentrated low prevalence setting in West Africa. | BMC pediatrics 20120101 |
| Efavirenz conceptions and regimen management in a prospective cohort of women on antiretroviral therapy. | Infectious diseases in obstetrics and gynecology 20120101 |
| Liver enzyme abnormalities and associated risk factors in HIV patients on efavirenz-based HAART with or without tuberculosis co-infection in Tanzania. | PloS one 20120101 |
| Once-daily single-tablet regimens: a long and winding road to excellence in antiretroviral treatment. | AIDS reviews 20120101 |
| Early versus delayed initiation of antiretroviral therapy for Indian HIV-Infected individuals with tuberculosis on antituberculosis treatment. | BMC infectious diseases 20120101 |
| Tenofovir use and renal insufficiency among pregnant and general adult population of HIV-infected, ART-naïve individuals in Lilongwe, Malawi. | PloS one 20120101 |
| Efficacy of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naïve HIV-1-infected patients: week-192 overall and subgroup analyses from STARTMRK. | HIV clinical trials 20120101 |
| Effects of antiretroviral therapy on autonomic function in early HIV infection: a preliminary report. | International journal of medical sciences 20120101 |
| Virological Response in Cerebrospinal Fluid to Antiretroviral Therapy in a Large Italian Cohort of HIV-Infected Patients with Neurological Disorders. | AIDS research and treatment 20120101 |
| T cell activation markers and African mitochondrial DNA haplogroups among non-Hispanic black participants in AIDS clinical trials group study 384. | PloS one 20120101 |
| Worsening endothelial function with efavirenz compared to protease inhibitors: a 12-month prospective study. | PloS one 20120101 |
| Efavirenz poisoning in a 12 year old HIV negative African boy. | The Pan African medical journal 20120101 |
| Influence of ABCB-1 C3435T polymorphisms on plasma nevirapine and efavirenz levels and their effects on virologic and immunological outcomes in HIV/TB co-infected Thai adults under anti-retroviral therapy. | The Southeast Asian journal of tropical medicine and public health 20120101 |
| Computationally-guided optimization of a docking hit to yield catechol diethers as potent anti-HIV agents. | Journal of medicinal chemistry 20111222 |
| Comparative outcomes of tenofovir-based and zidovudine-based antiretroviral therapy regimens in Lusaka, Zambia. | Journal of acquired immune deficiency syndromes (1999) 20111215 |
| Neither proteinuria nor albuminuria is associated with endothelial dysfunction in HIV-infected patients without diabetes or hypertension. | The Journal of infectious diseases 20111215 |
| Docking analysis and resistance evaluation of clinically relevant mutations associated with the HIV-1 non-nucleoside reverse transcriptase inhibitors nevirapine, efavirenz and etravirine. | ChemMedChem 20111209 |
| Simultaneous determination of efavirenz, rifampicin and its metabolite desacetyl rifampicin levels in human plasma. | Journal of pharmaceutical and biomedical analysis 20111205 |
| Pharmacotoxicology of monocyte-macrophage nanoformulated antiretroviral drug uptake and carriage. | Nanotoxicology 20111201 |
| Serum Nevirapine and Efavirenz concentrations and effect of concomitant rifampicin in HIV infected children on antiretroviral therapy. | Indian pediatrics 20111201 |
| Human immunodeficiency virus type 1 endocytic trafficking through macrophage bridging conduits facilitates spread of infection. | Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology 20111201 |
| Mitochondrial genomics and CD4 T-cell count recovery after antiretroviral therapy initiation in AIDS clinical trials group study 384. | Journal of acquired immune deficiency syndromes (1999) 20111201 |
| Pediatric underdosing of efavirenz: a pharmacokinetic study in Uganda. | Journal of acquired immune deficiency syndromes (1999) 20111201 |
| Efavirenz and 8-hydroxyefavirenz induce cell death via a JNK- and BimEL-dependent mechanism in primary human hepatocytes. | Toxicology and applied pharmacology 20111201 |
| Non-linear mixed effects modeling of antiretroviral drug response after administration of lopinavir, atazanavir and efavirenz containing regimens to treatment-naïve HIV-1 infected patients. | Journal of pharmacokinetics and pharmacodynamics 20111201 |
| Design, synthesis and biological evaluation of cycloalkyl arylpyrimidines (CAPYs) as HIV-1 NNRTIs. | Bioorganic & medicinal chemistry 20111201 |
| Quinoline tricyclic derivatives. Design, synthesis and evaluation of the antiviral activity of three new classes of RNA-dependent RNA polymerase inhibitors. | Bioorganic & medicinal chemistry 20111201 |
| Point-of-care capillary blood lactate measurements in human immunodeficiency virus-uninfected children with in utero exposure to human immunodeficiency virus and antiretroviral medications. | The Pediatric infectious disease journal 20111201 |
| Protease inhibitor-associated QT interval prolongation. | The Annals of pharmacotherapy 20111201 |
| Emerging trends of drug-resistant HIV-1 among drug-treated patients in former blood donors in Hubei, China: a three-year surveillance from 2004 to 2006. | Virologica Sinica 20111201 |
| Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). | PLoS computational biology 20111201 |
| Treatment challenges in co-infected HIV and TB children. | Indian pediatrics 20111201 |
| 'Getting to zero': a steep path ahead. | The Indian journal of medical research 20111201 |
| Antiretroviral therapy in Indian setting: when & what to start with, when & what to switch to? | The Indian journal of medical research 20111201 |
| Optimizing adherence to antiretroviral therapy. | The Indian journal of medical research 20111201 |
| Diagnosis & treatment of tuberculosis in HIV co-infected patients. | The Indian journal of medical research 20111201 |
| HIV serodiscordant relationships in India: translating science to practice. | The Indian journal of medical research 20111201 |
| Paediatric HIV--trends & challenges. | The Indian journal of medical research 20111201 |
| Phase 2 double-blind, randomized trial of etravirine versus efavirenz in treatment-naive patients: 48-week results. | AIDS (London, England) 20111128 |
| Safety of efavirenz in the first trimester of pregnancy: an updated systematic review and meta-analysis. | AIDS (London, England) 20111128 |
| Initial viral decay to assess the relative antiretroviral potency of protease inhibitor-sparing, nonnucleoside reverse transcriptase inhibitor-sparing, and nucleoside reverse transcriptase inhibitor-sparing regimens for first-line therapy of HIV infection. | AIDS (London, England) 20111128 |
| How much do antiretroviral drugs penetrate into the central nervous system? | Journal of medicine and life 20111114 |
| Role of non-nucleoside reverse transcriptase inhibitors in treating HIV-infected children. | Drugs 20111112 |
| Analysis of clinically relevant substrates of CYP2B6 enzyme by computational methods. | Journal of molecular modeling 20111101 |
| A systematic review of the psychiatric side-effects of efavirenz. | AIDS and behavior 20111101 |
| Absence seizures associated with efavirenz initiation. | The Pediatric infectious disease journal 20111101 |
| Genotypic resistance at viral rebound among patients who received lopinavir/ritonavir-based or efavirenz-based first antiretroviral therapy in South Africa. | Journal of acquired immune deficiency syndromes (1999) 20111101 |
| Antiretroviral therapy responses among children attending a large public clinic in Soweto, South Africa. | The Pediatric infectious disease journal 20111101 |
| Cost and cost-effectiveness of switching from d4T or AZT to a TDF-based first-line regimen in a resource-limited setting in rural Lesotho. | Journal of acquired immune deficiency syndromes (1999) 20111101 |
| Efavirenz is a substrate and in turn modulates the expression of the efflux transporter ABCG2/BCRP in the gastrointestinal tract of the rat. | Biochemical pharmacology 20111101 |
| Q172H replacement overcomes effects on the metabolism of cyclophosphamide and efavirenz caused by CYP2B6 variant with Arg262. | Drug metabolism and disposition: the biological fate of chemicals 20111101 |
| Comparative effectiveness of initial antiretroviral therapy regimens: ACTG 5095 and 5142 clinical trials relative to ART-CC cohort study. | Journal of acquired immune deficiency syndromes (1999) 20111101 |
| In vitro activity of antiretroviral drugs against Plasmodium falciparum. | Antimicrobial agents and chemotherapy 20111101 |
| Plasma concentrations of efavirenz are associated with body weight in HIV-positive individuals. | The Journal of antimicrobial chemotherapy 20111101 |
| HIV-1 reverse transcriptase connection subdomain mutations involved in resistance to approved non-nucleoside inhibitors. | Antiviral research 20111101 |
| Liver toxicity associated with antiretroviral therapy including efavirenz or ritonavir-boosted protease inhibitors in a cohort of HIV/hepatitis C virus co-infected patients. | The Journal of antimicrobial chemotherapy 20111101 |
| Autophagy as a rescue mechanism in efavirenz-induced mitochondrial dysfunction: a lesson from hepatic cells. | Autophagy 20111101 |
| Potential pharmacokinetic interactions between antiretrovirals and medicinal plants used as complementary and African traditional medicines. | Biopharmaceutics & drug disposition 20111101 |
| Management of common adverse effects in the era of highly active antiretroviral therapy in south east Ethiopia. | North American journal of medical sciences 20111101 |
| Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis. | The New England journal of medicine 20111020 |
| Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: final results. | The Journal of infectious diseases 20111015 |
| Novel diarylpyridinones, diarylpyridazinones and diarylphthalazinones as potential HIV-1 nonnucleoside reverse transcriptase inhibitors (NNRTIs). | Bioorganic & medicinal chemistry 20111015 |
| Synergistic encapsulation of the anti-HIV agent efavirenz within mixed poloxamine/poloxamer polymeric micelles. | Nanomedicine : nanotechnology, biology, and medicine 20111001 |
| Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the Western Cape, South Africa. | Journal of medical virology 20111001 |
| Long-term effect of efavirenz autoinduction on plasma/peripheral blood mononuclear cell drug exposure and CD4 count is influenced by UGT2B7 and CYP2B6 genotypes among HIV patients. | The Journal of antimicrobial chemotherapy 20111001 |
| HIV-1-resistance-associated mutations after failure of first-line antiretroviral treatment among children in resource-poor regions: a systematic review. | The Lancet. Infectious diseases 20111001 |
| Arylazolylthioacetanilide. Part 8: Design, synthesis and biological evaluation of novel 2-(2-(2,4-dichlorophenyl)-2H-1,2,4-triazol-3-ylthio)-N-arylacetamides as potent HIV-1 inhibitors. | European journal of medicinal chemistry 20111001 |
| Efficacy and safety of once-daily nevirapine- or efavirenz-based antiretroviral therapy in HIV-associated tuberculosis: a randomized clinical trial. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20111001 |
| Deep V3 sequencing for HIV type 1 tropism in treatment-naive patients: a reanalysis of the MERIT trial of maraviroc. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20111001 |
| 1-[2-(2-Benzoyl- and 2-benzylphenoxy)ethyl]uracils as potent anti-HIV-1 agents. | Bioorganic & medicinal chemistry 20111001 |
| Population pharmacokinetics of lopinavir/ritonavir (Kaletra) in HIV-infected patients. | Therapeutic drug monitoring 20111001 |
| Long-term treatment with raltegravir or efavirenz combined with tenofovir/emtricitabine for treatment-naive human immunodeficiency virus-1-infected patients: 156-week results from STARTMRK. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20111001 |
| Multiple sclerosis typical clinical and MRI findings in a patient with HIV infection. | Journal of neurovirology 20111001 |
| Deep molecular characterization of HIV-1 dynamics under suppressive HAART. | PLoS pathogens 20111001 |
| [Effect of highly active anti-retroviral therapy on prevention of mother to child transmission of HIV and on infant growth and development]. | Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine] 20111001 |
| Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1. | Annals of internal medicine 20110920 |
| Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1. | Annals of internal medicine 20110920 |
| Compromising mitochondrial function with the antiretroviral drug efavirenz induces cell survival-promoting autophagy. | Hepatology (Baltimore, Md.) 20110902 |
| A retrospective study of HIV antiretroviral treatment persistence in a commercially insured population in the United States. | AIDS care 20110901 |
| Polymorphic variants of cytochrome P450 2B6 (CYP2B6.4-CYP2B6.9) exhibit altered rates of metabolism for bupropion and efavirenz: a charge-reversal mutation in the K139E variant (CYP2B6.8) impairs formation of a functional cytochrome p450-reductase complex. | The Journal of pharmacology and experimental therapeutics 20110901 |
| Comparison of abacavir/lamivudine and tenofovir/emtricitabine among treatment-naive HIV-infected patients initiating therapy. | Journal of acquired immune deficiency syndromes (1999) 20110901 |
| Cytochrome P450 2B6 (CYP2B6) and constitutive androstane receptor (CAR) polymorphisms are associated with early discontinuation of efavirenz-containing regimens. | The Journal of antimicrobial chemotherapy 20110901 |
| Drug resistance profiles among HIV-1-infected children experiencing delayed switch and 12-month efficacy after using second-line antiretroviral therapy: an observational cohort study in rural China. | Journal of acquired immune deficiency syndromes (1999) 20110901 |
| Synthesis of new 2'-deoxy-2'-fluoro-4'-azido nucleoside analogues as potent anti-HIV agents. | European journal of medicinal chemistry 20110901 |
| Effect of rifampicin and CYP2B6 genotype on long-term efavirenz autoinduction and plasma exposure in HIV patients with or without tuberculosis. | Clinical pharmacology and therapeutics 20110901 |
| Synthesis and structure-activity relationship of novel diarylpyrimidines with hydromethyl linker (CH(OH)-DAPYs) as HIV-1 NNRTIs. | Bioorganic & medicinal chemistry 20110901 |
| A376S in the connection subdomain of HIV-1 reverse transcriptase confers increased risk of virological failure to nevirapine therapy. | The Journal of infectious diseases 20110901 |
| Significant effects of antiretroviral therapy on global gene expression in brain tissues of patients with HIV-1-associated neurocognitive disorders. | PLoS pathogens 20110901 |
| Cost-effectiveness of early versus standard antiretroviral therapy in HIV-infected adults in Haiti. | PLoS medicine 20110901 |
| Modulation of cell differentiation, proliferation, and tumor growth by dihydrobenzyloxopyrimidine non-nucleoside reverse transcriptase inhibitors. | Journal of medicinal chemistry 20110825 |
| Treatment switches during pregnancy among HIV-positive women on antiretroviral therapy at conception. | AIDS (London, England) 20110824 |
| Ritonavir-boosted atazanavir exposure is associated with an increased rate of renal stones compared with efavirenz, ritonavir-boosted lopinavir and ritonavir-boosted darunavir. | AIDS (London, England) 20110824 |
| Cell-to-cell spread of HIV permits ongoing replication despite antiretroviral therapy. | Nature 20110817 |
| Effect of specific ART drugs on lipid changes and the need for lipid management in children with HIV. | Journal of acquired immune deficiency syndromes (1999) 20110815 |
| DRESS syndrome associated with raltegravir. | Dermatology online journal 20110815 |
| Neurocognitive consequences of HIV infection in older adults: an evaluation of the 'cortical' hypothesis. | AIDS and behavior 20110801 |
| A computational study of CYP3A4 mediated drug interaction profiles for anti-HIV drugs. | Journal of molecular modeling 20110801 |
| Easier said than done: World Health Organization recommendations for prevention of mother-to-child transmission of HIV-areas of concern. | AIDS research and human retroviruses 20110801 |
| Effect of nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy on dysglycemia and insulin sensitivity in South African HIV-infected patients. | Journal of acquired immune deficiency syndromes (1999) 20110801 |
| Effects of nevirapine and efavirenz on human adipocyte differentiation, gene expression, and release of adipokines and cytokines. | Antiviral research 20110801 |
| Comparative effectiveness of continuing a virologically effective first-line boosted protease inhibitor combination or of switching to a three-drug regimen containing either efavirenz, nevirapine or abacavir. | The Journal of antimicrobial chemotherapy 20110801 |
| Effect of antiretroviral drugs on the quality of semen. | Journal of medical virology 20110801 |
| HIV/AIDS patients display lower relative bioavailability of efavirenz than healthy subjects. | Clinical pharmacokinetics 20110801 |
| UPLC-MS/MS quantification of nanoformulated ritonavir, indinavir, atazanavir, and efavirenz in mouse serum and tissues. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20110801 |
| Prevalence of etravirine-associated mutations in clinical samples with genotypic resistance to nevirapine and efavirenz in Brazilian clinics. | Journal of acquired immune deficiency syndromes (1999) 20110801 |
| Prevalence of antiretroviral drug resistance mutations and HIV-I subtypes among newly-diagnosed drug-naïve persons visiting a voluntary testing and counselling centre in northeastern South Africa. | Journal of health, population, and nutrition 20110801 |
| A randomized cross-over study to compare raltegravir and efavirenz (SWITCH-ER study). | AIDS (London, England) 20110731 |
| Clinical efficacy of raltegravir against B and non-B subtype HIV-1 in phase III clinical studies. | AIDS (London, England) 20110717 |
| HIV/AIDS and the road to Rome. | Lancet (London, England) 20110716 |
| Rilpivirine: a step forward in tailored HIV treatment. | Lancet (London, England) 20110716 |
| Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial. | Lancet (London, England) 20110716 |
| Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial. | Lancet (London, England) 20110716 |
| Battles with donors cloud Malawi's HIV prevention plan. | Lancet (London, England) 20110716 |
| Synthesis and biological evaluation of novel 5-alkyl-2-arylthio-6-((3,4-dihydroquinolin-1(2H)-yl)methyl)pyrimidin-4(3H)-ones as potent non-nucleoside HIV-1 reverse transcriptase inhibitors. | Bioorganic & medicinal chemistry 20110715 |
| Peripheral and central fat changes in subjects randomized to abacavir-lamivudine or tenofovir-emtricitabine with atazanavir-ritonavir or efavirenz: ACTG Study A5224s. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20110715 |
| Association between HIV infection, antiretroviral therapy, and risk of acute myocardial infarction: a cohort and nested case-control study using Québec's public health insurance database. | Journal of acquired immune deficiency syndromes (1999) 20110701 |
| The male genital tract is not a pharmacological sanctuary from efavirenz. | Clinical pharmacology and therapeutics 20110701 |
| Impact of HAART exposure and associated lipodystrophy on advanced liver fibrosis in HIV/HCV-coinfected patients. | Journal of viral hepatitis 20110701 |
| Usefulness of methadone plasma concentration measurement in patients receiving nevirapine or efavirenz. | The American journal of drug and alcohol abuse 20110701 |
| Injury secondary to antiretroviral agents: retrospective analysis of a regional poison center database. | The western journal of emergency medicine 20110701 |
| Treatment outcomes and cost-effectiveness of shifting management of stable ART patients to nurses in South Africa: an observational cohort. | PLoS medicine 20110701 |
| Short-term virological efficacy, immune reconstitution, tolerance, and adherence of once-daily dosing of didanosine, lamivudine, and efavirenz in HIV-1-infected African children: ANRS 12103 Burkiname. | Journal of acquired immune deficiency syndromes (1999) 20110701 |
| Bioactive neolignans and lignans from the bark of Machilus robusta. | Journal of natural products 20110624 |
| Lindenane disesquiterpenoids with anti-HIV-1 activity from Chloranthus japonicus. | Journal of natural products 20110624 |
| Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224s, a substudy of ACTG A5202. | The Journal of infectious diseases 20110615 |
| Surface-active derivative of inulin (Inutec® SP1) is a superior carrier for solid dispersions with a high drug load. | Journal of pharmaceutical sciences 20110601 |
| Identification of human UGT isoforms responsible for glucuronidation of efavirenz and its three hydroxy metabolites. | Xenobiotica; the fate of foreign compounds in biological systems 20110601 |
| Non-nucleoside reverse transcriptase inhibitors efavirenz and nevirapine inhibit cytochrome C oxidase in mouse brain regions. | Neurochemical research 20110601 |
| The HIV protease inhibitor nelfinavir inhibits Kaposi's sarcoma-associated herpesvirus replication in vitro. | Antimicrobial agents and chemotherapy 20110601 |
| Integration of population pharmacokinetics and pharmacogenetics: an aid to optimal nevirapine dose selection in HIV-infected individuals. | The Journal of antimicrobial chemotherapy 20110601 |
| Beliefs about antiretroviral therapy, treatment adherence and quality of life in a 48-week randomised study of continuation of zidovudine/lamivudine or switch to tenofovir DF/emtricitabine, each with efavirenz. | AIDS care 20110601 |
| Therapeutic drug monitoring of protease inhibitors and efavirenz in HIV-infected individuals with active substance-related disorders. | Therapeutic drug monitoring 20110601 |
| Management of HIV infection in treatment-naive patients: a review of the most current recommendations. | American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20110601 |
| Timing of initiation of antiretroviral therapy in human immunodeficiency virus (HIV)--associated tuberculous meningitis. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20110601 |
| AIDS diarrhea and antiretroviral drug concentrations: a matched-pair cohort study in Port au Prince, Haiti. | The American journal of tropical medicine and hygiene 20110601 |
| Pharmacology and immuno-virologic efficacy of once-a-day HAART in African HIV-infected children: ANRS 12103 phase II trial. | Bulletin of the World Health Organization 20110601 |
| The effect of highly active antiretroviral therapy on the survival of HIV-infected children in a resource-deprived setting: a cohort study. | PLoS medicine 20110601 |
| Clathrin facilitates the morphogenesis of retrovirus particles. | PLoS pathogens 20110601 |
| Major HIV resistance mutations in untreated Romanian patients. | Journal of medicine and life 20110515 |
| Risk of triple-class virological failure in children with HIV: a retrospective cohort study. | Lancet (London, England) 20110507 |
| [Efavirenz in fixed combination with tenofovir and emtricitabine. Long-term effectiveness verified in new studies]. | MMW Fortschritte der Medizin 20110505 |
| [Long-term therapy strategy with raltegravir. Appropriate in all illness phases]. | MMW Fortschritte der Medizin 20110505 |
| [Persistence in focus. Atazanavir proves itself anew in long-term therapy]. | MMW Fortschritte der Medizin 20110505 |
| A comparison of the long-term durability of nevirapine, efavirenz and lopinavir in routine clinical practice in Europe: a EuroSIDA study. | HIV medicine 20110501 |
| Change in high-sensitivity c-reactive protein levels following initiation of efavirenz-based antiretroviral regimens in HIV-infected individuals. | AIDS research and human retroviruses 20110501 |
| Molecular recognition of the antiretroviral drug abacavir: towards the development of a novel carbazole-based fluorosensor. | Journal of fluorescence 20110501 |
| Alizarine derivatives as new dual inhibitors of the HIV-1 reverse transcriptase-associated DNA polymerase and RNase H activities effective also on the RNase H activity of non-nucleoside resistant reverse transcriptases. | The FEBS journal 20110501 |
| HIV-1 integrase inhibitor resistance and its clinical implications. | The Journal of infectious diseases 20110501 |
| Effectiveness of early antiretroviral therapy initiation to improve survival among HIV-infected adults with tuberculosis: a retrospective cohort study. | PLoS medicine 20110501 |
| CTL escape mediated by proteasomal destruction of an HIV-1 cryptic epitope. | PLoS pathogens 20110501 |
| Inhibition of both HIV-1 reverse transcription and gene expression by a cyclic peptide that binds the Tat-transactivating response element (TAR) RNA. | PLoS pathogens 20110501 |
| Hepatotoxicity in patients co-infected with tuberculosis and HIV-1 while receiving non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy and rifampicin-containing anti-tuberculosis regimen. | The Southeast Asian journal of tropical medicine and public health 20110501 |
| Human immunodeficiency virus therapeutics and pharmacogenomics. | Indian journal of human genetics 20110501 |
| Diarylpyrimidine-dihydrobenzyloxopyrimidine hybrids: new, wide-spectrum anti-HIV-1 agents active at (sub)-nanomolar level. | Journal of medicinal chemistry 20110428 |
| Efficacy of NNRTI-based antiretroviral therapy initiated during acute HIV infection. | AIDS (London, England) 20110424 |
| Hospitalization for severe malnutrition among HIV-infected children starting antiretroviral therapy. | AIDS (London, England) 20110424 |
| Efavirenz associated with cognitive disorders in otherwise asymptomatic HIV-infected patients. | Neurology 20110419 |
| A randomized crossover study to determine relative bioequivalence of tenofovir, emtricitabine, and efavirenz (Atripla) fixed-dose combination tablet compared with a compounded oral liquid formulation derived from the tablet. | Journal of acquired immune deficiency syndromes (1999) 20110415 |
| Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1. | Annals of internal medicine 20110405 |
| Cohort profile: Hlabisa HIV treatment and care programme. | International journal of epidemiology 20110401 |
| Proper laboratory notebook practices: protecting your intellectual property. | Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology 20110401 |
| Cost-effectiveness of atazanavir/ritonavir compared with lopinavir/ritonavir in treatment-naïve human immunodeficiency virus-1 patients in Sweden. | Scandinavian journal of infectious diseases 20110401 |
| Impact of the N348I mutation in HIV-1 reverse transcriptase on nonnucleoside reverse transcriptase inhibitor resistance in non-subtype B HIV-1. | Antimicrobial agents and chemotherapy 20110401 |
| [HIV infected women with intense bone and muscular pain and general weakness]. | Enfermedades infecciosas y microbiologia clinica 20110401 |
| Failure of initial therapy with two nucleosides and efavirenz is not associated with early emergence of mutations in the C-terminus of HIV-1 reverse transcriptase. | Journal of acquired immune deficiency syndromes (1999) 20110401 |
| Cardiovascular risk factors in patients on long-term treatment with nevirapine- or efavirenz-based regimens. | The Journal of antimicrobial chemotherapy 20110401 |
| In silico prediction of efavirenz and rifampicin drug-drug interaction considering weight and CYP2B6 phenotype. | British journal of clinical pharmacology 20110401 |
| Management of adult active tuberculosis disease in era of HIV pandemic, current practices and future perspectives. | Infectious disorders drug targets 20110401 |
| First-line antiretroviral treatment of HIV-infected children. A choice largely based on adult data. | Prescrire international 20110401 |
| [Comparative study of two anti-antiretroviral protocols used for treatment of a cohort of HIV 1-positive patients followed at the Institute of Public Health and Hygiene in Dakar, Senegal]. | Medecine tropicale : revue du Corps de sante colonial 20110401 |
| Clinical management of HIV drug resistance. | Viruses 20110401 |
| Clinical applications of drug desensitization in the Asia-Pacific region. | Asia Pacific allergy 20110401 |
| Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infection. | AIDS (London, England) 20110327 |
| Vitamin D deficiency in HIV-infected patients: associated with non-nucleoside reverse transcriptase inhibitor or efavirenz use? | AIDS (London, England) 20110327 |
| Do nevirapine and efavirenz affect vitamin D homeostasis similarly? | AIDS (London, England) 20110327 |
| Is lower serum 25-hydroxy vitamin D associated with efavirenz or the non-nucleoside reverse transcriptase inhibitor class? | AIDS (London, England) 20110327 |
| A HPLC-MS method for the simultaneous quantification of fourteen antiretroviral agents in peripheral blood mononuclear cell of HIV infected patients optimized using medium corpuscular volume evaluation. | Journal of pharmaceutical and biomedical analysis 20110325 |
| Indolylarylsulfones as HIV-1 non-nucleoside reverse transcriptase inhibitors: new cyclic substituents at indole-2-carboxamide. | Journal of medicinal chemistry 20110324 |
| Asymmetric autocatalysis enables an improved synthesis of efavirenz. | Angewandte Chemie (International ed. in English) 20110321 |
| Analyses of nanoformulated antiretroviral drug charge, size, shape and content for uptake, drug release and antiviral activities in human monocyte-derived macrophages. | Journal of controlled release : official journal of the Controlled Release Society 20110310 |
| Bone mineral density changes in protease inhibitor-sparing vs. nucleoside reverse transcriptase inhibitor-sparing highly active antiretroviral therapy: data from a randomized trial. | HIV medicine 20110301 |
| Virologic failure and second-line antiretroviral therapy in children in South Africa--the IeDEA Southern Africa collaboration. | Journal of acquired immune deficiency syndromes (1999) 20110301 |
| Oral pharmacokinetics of the anti-HIV efavirenz encapsulated within polymeric micelles. | Biomaterials 20110301 |
| HIV/HCV co-infection: pathogenesis, clinical complications, treatment, and new therapeutic technologies. | Current HIV/AIDS reports 20110301 |
| Lactic acidosis after concomitant treatment with metformin and tenofovir in a patient with HIV infection. | Journal of renal care 20110301 |
| Age-related skeletal muscle decline is similar in HIV-infected and uninfected individuals. | The journals of gerontology. Series A, Biological sciences and medical sciences 20110301 |
| A randomized controlled trial comparing the effects of counseling and alarm device on HAART adherence and virologic outcomes. | PLoS medicine 20110301 |
| Blockade of neuronal α7-nAChR by α-conotoxin ImI explained by computational scanning and energy calculations. | PLoS computational biology 20110301 |
| Mycobacterium lentiflavum in drinking water supplies, Australia. | Emerging infectious diseases 20110301 |
| HIV-1 drug resistance emergence among breastfeeding infants born to HIV-infected mothers during a single-arm trial of triple-antiretroviral prophylaxis for prevention of mother-to-child transmission: a secondary analysis. | PLoS medicine 20110301 |
| Depressogenic effects of medications: a review. | Dialogues in clinical neuroscience 20110301 |
| Hepatotoxicity from first line antiretroviral therapy: an experience from a resource limited setting. | African health sciences 20110301 |
| Viral decay rates are similar in HIV-infected patients with and without TB coinfection during treatment with an Efavirenz-based regimen. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20110215 |
| Dyslipidemia among HIV-infected Patients with tuberculosis taking once-daily nonnucleoside reverse-transcriptase inhibitor-based antiretroviral therapy in India. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20110215 |
| Dream changes following initiation of efavirenz treatment. | Medicina clinica 20110212 |
| Quantifying the risks and benefits of efavirenz use in HIV-infected women of childbearing age in the USA. | HIV medicine 20110201 |
| Theoretical studies on the molecular basis of HIV-1RT/NNRTIs interactions. | Journal of enzyme inhibition and medicinal chemistry 20110201 |
| Estimating the risk of HIV transmission from homosexual men receiving treatment to their HIV-uninfected partners. | Sexually transmitted infections 20110201 |
| [Two cases of Fanconi's syndrome induced by tenofovir in the Ivory Coast]. | Medecine et maladies infectieuses 20110201 |
| Standard measures are inadequate to monitor pediatric adherence in a resource-limited setting. | AIDS and behavior 20110201 |
| Pregnancy outcomes in women exposed to efavirenz and nevirapine: an appraisal of the IeDEA West Africa and ANRS Databases, Abidjan, Côte d'Ivoire. | Journal of acquired immune deficiency syndromes (1999) 20110201 |
| Long-term effectiveness and safety of didanosine combined with lamivudine and efavirenz or nevirapine in antiretroviral-naive patients: a 9-year cohort study in Senegal. | Tropical medicine & international health : TM & IH 20110201 |
| Efavirenz concentrations in CSF exceed IC50 for wild-type HIV. | The Journal of antimicrobial chemotherapy 20110201 |
| In Vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor. | Antimicrobial agents and chemotherapy 20110201 |
| Approach to dyslipidemia, lipodystrophy, and cardiovascular risk in patients with HIV infection. | Current atherosclerosis reports 20110201 |
| Adherence to HIV therapeutic drug monitoring guidelines in The Netherlands. | Therapeutic drug monitoring 20110201 |
| Low vitamin D among HIV-infected adults: prevalence of and risk factors for low vitamin D Levels in a cohort of HIV-infected adults and comparison to prevalence among adults in the US general population. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20110201 |
| Pharmacokinetic interaction between efavirenz and rifampicin in healthy volunteers. | International journal of clinical pharmacology and therapeutics 20110201 |
| Lack of effect from a previous single dose of nevirapine on virologic and immunologic responses after 6 months of antiretroviral regimens containing either efavirenz or lopinavir-ritonavir. | Pharmacotherapy 20110201 |
| Hepatitis E virus and neurologic disorders. | Emerging infectious diseases 20110201 |
| Clinical Trial Report: TMC278 (Rilpivirine) Versus Efavirenz as Initial Therapy in Treatment-Naïve, HIV-1-Infected Patients. | Current infectious disease reports 20110201 |
| Genital tract sequestration of SIV following acute infection. | PLoS pathogens 20110201 |
| Nevirapine induced Stevens-Johnson syndrome in an HIV infected patient. | Indian journal of pharmacology 20110201 |
| Paradoxically elevated efavirenz concentrations in HIV/tuberculosis-coinfected patients with CYP2B6 516TT genotype on rifampin-containing antituberculous therapy. | AIDS (London, England) 20110128 |
| A comparison of neuropsychiatric adverse events during 12 weeks of treatment with etravirine and efavirenz in a treatment-naive, HIV-1-infected population. | AIDS (London, England) 20110128 |
| Higher efficacy of nevirapine than efavirenz to achieve HIV-1 plasma viral load below 1 copy/ml. | AIDS (London, England) 20110128 |
| Low level of the K103N HIV-1 above a threshold is associated with virological failure in treatment-naive individuals undergoing efavirenz-containing therapy. | AIDS (London, England) 20110128 |
| Association of pharmacogenetic markers with premature discontinuation of first-line anti-HIV therapy: an observational cohort study. | The Journal of infectious diseases 20110115 |
| Allosteric suppression of HIV-1 reverse transcriptase structural dynamics upon inhibitor binding. | Biophysical journal 20110105 |
| European mitochondrial DNA haplogroups and metabolic changes during antiretroviral therapy in AIDS Clinical Trials Group Study A5142. | AIDS (London, England) 20110102 |
| A randomized crossover study to compare efavirenz and etravirine treatment. | AIDS (London, England) 20110102 |
| A phase IV, double-blind, multicentre, randomized, placebo-controlled, pilot study to assess the feasibility of switching individuals receiving efavirenz with continuing central nervous system adverse events to etravirine. | AIDS (London, England) 20110102 |
| Anti-HIV drugs nevirapine and efavirenz affect anxiety-related behavior and cognitive performance in mice. | Neurotoxicity research 20110101 |
| Improvement in vitamin D deficiency following antiretroviral regime change: Results from the MONET trial. | AIDS research and human retroviruses 20110101 |
| Stavudine toxicity in women is the main reason for treatment change in a 3-year prospective cohort of adult patients started on first-line antiretroviral treatment in Uganda. | Journal of acquired immune deficiency syndromes (1999) 20110101 |
| Determination of the antiretroviral drug nevirapine in diluted alkaline electrolyte by adsorptive stripping voltammetry at the mercury film electrode. | Combinatorial chemistry & high throughput screening 20110101 |
| Drug susceptibility of human immunodeficiency virus type 1-derived pseudoviruses from treatment-experienced patients to protease inhibitors and reverse transcriptase inhibitors, using a modified single-round assay. | Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology 20110101 |
| Four year follow-up of simplification therapy with once-daily emtricitabine, didanosine and efavirenz in HIV-infected patients (ALIZE ANRS 099 trial). | The Journal of antimicrobial chemotherapy 20110101 |
| [Immune reconstitution inflammatory syndrome associated with eosinophilic pustular folliculitis in an HIV-infected patient]. | Medecine et maladies infectieuses 20110101 |
| [Rate of genotypic mutations and resistance to antiretroviral drugs in a general hospital]. | Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria 20110101 |
| The assessment of metabolic syndrome in UK patients with HIV using two different definitions: CREATE 2 study. | Current medical research and opinion 20110101 |
| The toxicogenetics of antiretroviral therapy: the evil inside. | Current medicinal chemistry 20110101 |
| Use of biological knowledge to inform the analysis of gene-gene interactions involved in modulating virologic failure with efavirenz-containing treatment regimens in ART-naïve ACTG clinical trials participants. | Pacific Symposium on Biocomputing. Pacific Symposium on Biocomputing 20110101 |
| Immunophenotypical Switch versus Tumor Heterogeneity in a Patient with HIV-Associated Diffuse Large B-Cell Lymphoma. | Pathology research international 20110101 |
| Long-term safety from the raltegravir clinical development program. | Current HIV research 20110101 |
| Aminotransferase serum levels decrease after initiating antiretroviral treatment in HIV infected patients. | Current HIV research 20110101 |
| Understanding diabetes in patients with HIV/AIDS. | Diabetology & metabolic syndrome 20110101 |
| Timing of antiretroviral therapy for HIV in the setting of TB treatment. | Clinical & developmental immunology 20110101 |
| Expenditures for the care of HIV-infected patients in rural areas in China's antiretroviral therapy programs. | BMC medicine 20110101 |
| An antiretroviral/zinc combination gel provides 24 hours of complete protection against vaginal SHIV infection in macaques. | PloS one 20110101 |
| K70Q adds high-level tenofovir resistance to 'Q151M complex' HIV reverse transcriptase through the enhanced discrimination mechanism. | PloS one 20110101 |
| Genital warts and infection with human immunodeficiency virus in high-risk women in Burkina Faso: a longitudinal study. | BMC infectious diseases 20110101 |
| Quality of data collection in a large HIV observational clinic database in sub-Saharan Africa: implications for clinical research and audit of care. | Journal of the International AIDS Society 20110101 |
| Culture conversion among HIV co-infected multidrug-resistant tuberculosis patients in Tugela Ferry, South Africa. | PloS one 20110101 |
| Replicative phenotyping adds value to genotypic resistance testing in heavily pre-treated HIV-infected individuals--the Swiss HIV Cohort Study. | Journal of translational medicine 20110101 |
| Long-term CD4+ T-cell count evolution after switching from regimens including HIV nucleoside reverse transcriptase inhibitors (NRTI) plus protease inhibitors to regimens containing NRTI plus non-NRTI or only NRTI. | BMC infectious diseases 20110101 |
| Clinical use of CCR5 inhibitors in HIV and beyond. | Journal of translational medicine 20110101 |
| Intensified treatment with high dose rifampicin and levofloxacin compared to standard treatment for adult patients with tuberculous meningitis (TBM-IT): protocol for a randomized controlled trial. | Trials 20110101 |
| Human immunodeficiency virus type 2 in two Saudi families. | Annals of Saudi medicine 20110101 |
| [Study of meta-trajectories of CD4 cells count from taxonomy in the antiretroviral response of efavirenz-based regimen with naive symptomatic patients in Abidjan]. | Annales pharmaceutiques francaises 20110101 |
| Adherence and virologic suppression during the first 24 weeks on antiretroviral therapy among women in Johannesburg, South Africa - a prospective cohort study. | BMC public health 20110101 |
| A biregional survey and review of first-line treatment failure and second-line paediatric antiretroviral access and use in Asia and southern Africa. | Journal of the International AIDS Society 20110101 |
| Development of Buffalo Hump in the course of antiretroviral therapy including raltegravir and unboosted atazanavir: a case report and review of the literature. | Journal of medical case reports 20110101 |
| HIV-1 infected patients with suppressed plasma viremia on treatment have pro-inflammatory HDL. | Lipids in health and disease 20110101 |
| Alanine zipper-like coiled-coil domains are necessary for homotypic dimerization of plant GAGA-factors in the nucleus and nucleolus. | PloS one 20110101 |
| Management of HIV-1 associated hepatitis in patients with acquired immunodeficiency syndrome: role of a successful control of viral replication. | AIDS research and therapy 20110101 |
| Weight and height z-scores improve after initiating ART among HIV-infected children in rural Zambia: a cohort study. | BMC infectious diseases 20110101 |
| Timely HAART initiation may pave the way for a better viral control. | BMC infectious diseases 20110101 |
| Efavirenz-based combination antiretroviral therapy after peripartum single-dose nevirapine. | International journal of STD & AIDS 20110101 |
| Neurobehavioral effects in HIV-positive individuals receiving highly active antiretroviral therapy (HAART) in Gaborone, Botswana. | PloS one 20110101 |
| Prevalence of potential drug-drug interactions involving antiretroviral drugs in a large Kenyan cohort. | PloS one 20110101 |
| Rilpivirine: a new addition to the anti-HIV-1 armamentarium. | Drugs of today (Barcelona, Spain : 1998) 20110101 |
| Correcting for mortality among patients lost to follow up on antiretroviral therapy in South Africa: a cohort analysis. | PloS one 20110101 |
| Antiretroviral therapy outcomes in HIV-infected children after adjusting protease inhibitor dosing during tuberculosis treatment. | PloS one 20110101 |
| Time for gender mainstreaming in editorial policies. | Journal of the International AIDS Society 20110101 |
| Incidence and predictors of immune reconstitution inflammatory syndrome in a rural area of Mozambique. | PloS one 20110101 |
| Drug efficacy by direct and adjusted indirect comparison to placebo: An illustration by Mycobacterium avium complex prophylaxis in HIV. | AIDS research and therapy 20110101 |
| Maraviroc can improve lipid profiles in dyslipidemic patients with HIV: results from the MERIT trial. | HIV clinical trials 20110101 |
| 'Dynamic range' of inferred phenotypic HIV drug resistance values in clinical practice. | PloS one 20110101 |
| Renal safety of a tenofovir-containing first line regimen: experience from an antiretroviral cohort in rural Lesotho. | PloS one 20110101 |
| Highly active antiretroviral therapy: Does it Sound toxic? | Journal of pharmacy & bioallied sciences 20110101 |
| Driving a decade of change: HIV/AIDS, patents and access to medicines for all. | Journal of the International AIDS Society 20110101 |
| The effect of efavirenz on the pharmacokinetics of an oral contraceptive containing ethinyl estradiol and norgestimate in healthy HIV-negative women. | Antiviral therapy 20110101 |
| Successful efavirenz dose reduction guided by therapeutic drug monitoring. | Antiviral therapy 20110101 |
| Interaction between antiretroviral drugs and acenocoumarol. | Antiviral therapy 20110101 |
| Machine learning on normalized protein sequences. | BMC research notes 20110101 |
| Patient-reported adverse drug reactions and drug-drug interactions: a cross-sectional study on Malaysian HIV/AIDS patients. | Medical principles and practice : international journal of the Kuwait University, Health Science Centre 20110101 |
| HIV quasispecies dynamics during pro-active treatment switching: impact on multi-drug resistance and resistance archiving in latent reservoirs. | PloS one 20110101 |
| Comparison of intima-media thickness and ophthalmic artery resistance index for assessing subclinical atherosclerosis in HIV-1-infected patients. | Cardiovascular ultrasound 20110101 |
| Cost effectiveness of a pharmacy-only refill program in a large urban HIV/AIDS clinic in Uganda. | PloS one 20110101 |
| Open-label randomized multicenter selection study of once daily antiretroviral treatment regimen comparing ritonavir-boosted atazanavir to efavirenz with fixed-dose abacavir and lamivudine. | Internal medicine (Tokyo, Japan) 20110101 |
| Nutrition and inflammation serum biomarkers are associated with 12-week mortality among malnourished adults initiating antiretroviral therapy in Zambia. | Journal of the International AIDS Society 20110101 |
| Results of antiretroviral treatment interruption and intensification in advanced multi-drug resistant HIV infection from the OPTIMA trial. | PloS one 20110101 |
| Activation of latent HIV using drug-loaded nanoparticles. | PloS one 20110101 |
| Four-year treatment outcomes of adult patients enrolled in Mozambique's rapidly expanding antiretroviral therapy program. | PloS one 20110101 |
| Pharmacology and metabolism of anidulafungin, caspofungin and micafungin in the treatment of invasive candidosis: review of the literature. | European journal of medical research 20110101 |
| HIV-1 accessory protein Vpr: relevance in the pathogenesis of HIV and potential for therapeutic intervention. | Retrovirology 20110101 |
| HIV Suppression among Patients on Treatment in Vietnam: A Review of HIV Viral Load Testing in a Public Urban Clinic in Ho Chi Minh City. | AIDS research and treatment 20110101 |
| Long-Term Outcome of an HIV-Treatment Programme in Rural Africa: Viral Suppression despite Early Mortality. | AIDS research and treatment 20110101 |
| Antiretroviral Therapy for HIV-2 Infection: Recommendations for Management in Low-Resource Settings. | AIDS research and treatment 20110101 |
| Outcomes of Universal Access to Antiretroviral Therapy (ART) in Georgia. | AIDS research and treatment 20110101 |
| Utilization patterns and projected demand of antiretroviral drugs in low- and middle-income countries. | AIDS research and treatment 20110101 |
| A risk-factor guided approach to reducing lactic acidosis and hyperlactatemia in patients on antiretroviral therapy. | PloS one 20110101 |
| Reduced emergence of the M184V/I resistance mutation when antiretroviral-naïve subjects use emtricitabine versus lamivudine in regimens composed of two NRTIs plus the NNRTI efavirenz. | HIV clinical trials 20110101 |
| Improved antiretroviral treatment outcome in a rural African setting is associated with cART initiation at higher CD4 cell counts and better general health condition. | BMC infectious diseases 20110101 |
| Long-term renal safety of tenofovir disoproxil fumarate in vertically HIV-infected children, adolescents and young adults: a 60-month follow-up study. | Clinical drug investigation 20110101 |
| Excellent adherence to antiretrovirals in HIV+ Zambian children is compromised by disrupted routine, HIV nondisclosure, and paradoxical income effects. | PloS one 20110101 |
| HIV-Associated Tuberculosis in the Newborn and Young Infant. | International journal of pediatrics 20110101 |
| Evaluation of WHO Criteria for Viral Failure in Patients on Antiretroviral Treatment in Resource-Limited Settings. | AIDS research and treatment 20110101 |
| Effect of reverse transcriptase inhibitors on LINE-1 and Ty1 reverse transcriptase activities and on LINE-1 retrotransposition. | BMC biochemistry 20110101 |
| Economic modeling of the combined effects of HIV-disease, cholesterol and lipoatrophy based on ACTG 5142 trial data. | Cost effectiveness and resource allocation : C/E 20110101 |
| Performance of Cpred/Cobs concentration ratios as a metric reflecting adherence to antidepressant drug therapy. | Neuropsychiatric disease and treatment 20110101 |
| HIV-infected children in rural Zambia achieve good immunologic and virologic outcomes two years after initiating antiretroviral therapy. | PloS one 20110101 |
| Targeted maximum likelihood estimation of effect modification parameters in survival analysis. | The international journal of biostatistics 20110101 |
| Factors influencing retention in care after starting antiretroviral therapy in a rural South African programme. | PloS one 20110101 |
| Inhibitory activity of 9-phenylcyclohepta[d]pyrimidinedione derivatives against different strains of HIV-1 as non-nucleoside reverse transcriptase inhibitors. | Virology journal 20110101 |
| Cross-sectional detection of acute HIV infection: timing of transmission, inflammation and antiretroviral therapy. | PloS one 20110101 |
| The net cost of incorporating resistance testing into HIV/AIDS treatment in South Africa: a Markov model with primary data. | Journal of the International AIDS Society 20110101 |
| Virologic outcomes of HAART with concurrent use of cytochrome P450 enzyme-inducing antiepileptics: a retrospective case control study. | AIDS research and therapy 20110101 |
| The role of HIV and antiretroviral therapy in bone disease. | AIDS reviews 20110101 |
| Contribution of cytochrome P450 and ABCB1 genetic variability on methadone pharmacokinetics, dose requirements, and response. | PloS one 20110101 |
| Barriers to initiation of antiretrovirals during antituberculosis therapy in Africa. | PloS one 20110101 |
| Predicted susceptibility of etravirine in HIV patients experiencing virological failure secondary to non-nucleoside reverse transcriptase inhibitor resistance in Argentina. | Enfermedades infecciosas y microbiologia clinica 20110101 |
| Clinical utility of maraviroc. | Clinical drug investigation 20110101 |
| Marked increase in etravirine and saquinavir plasma concentrations during atovaquone/proguanil prophylaxis. | Malaria journal 20110101 |
| Added value of deep sequencing relative to population sequencing in heavily pre-treated HIV-1-infected subjects. | PloS one 20110101 |
| Management of the kidney transplant patient with chronic hepatitis C infection. | International journal of nephrology 20110101 |
| Safety and tolerability of antiretrovirals during pregnancy. | Infectious diseases in obstetrics and gynecology 20110101 |
| Incidence and risk factors of serious adverse events during antituberculous treatment in Rwanda: a prospective cohort study. | PloS one 20110101 |
| Asking the right questions: developing evidence-based strategies for treating HIV in women and children. | BMC public health 20110101 |
| Presentation and outcome of tuberculous meningitis in a high HIV prevalence setting. | PloS one 20110101 |
| Outcome assessment of a dedicated HIV positive health care worker clinic at a central hospital in Malawi: a retrospective observational study. | PloS one 20110101 |
| Contraception in HIV-positive female adolescents. | AIDS research and therapy 20110101 |
| HIV and HAART-Associated Dyslipidemia. | The open cardiovascular medicine journal 20110101 |
| A template-dependent dislocation mechanism potentiates K65R reverse transcriptase mutation development in subtype C variants of HIV-1. | PloS one 20110101 |
| Impact of UGT2B7 His268Tyr polymorphism on the outcome of adjuvant epirubicin treatment in breast cancer. | Breast cancer research : BCR 20110101 |
| Clinical predictors of immune reconstitution following combination antiretroviral therapy in patients from the Australian HIV Observational Database. | PloS one 20110101 |
| On-line reaction monitoring of lithiation of halogen substituted acetanilides via in situ calorimetry, ATR spectroscopy, and endoscopy. | Chimia 20110101 |
| Use of non-nucleoside analogues together with rifampin in HIV patients with tuberculosis. | HIV clinical trials 20110101 |
| Efavirenz and rifampicin in the South African context: is there a need to dose-increase efavirenz with concurrent rifampicin therapy? | Antiviral therapy 20110101 |
| Lactic acidosis and symptomatic hyperlactataemia in a randomized trial of first-line therapy in HIV-infected adults in South Africa. | Antiviral therapy 20110101 |
| Update on the optimal use of voriconazole for invasive fungal infections. | Infection and drug resistance 20110101 |
| Patterns of resistance development with integrase inhibitors in HIV. | Infection and drug resistance 20110101 |
| Surveillance of transmitted antiretroviral drug resistance among HIV-1 infected women attending antenatal clinics in Chitungwiza, Zimbabwe. | PloS one 20110101 |
| Early mortality and AIDS progression despite high initial antiretroviral therapy adherence and virologic suppression in Botswana. | PloS one 20110101 |
| Rebound of residual plasma viremia after initial decrease following addition of intravenous immunoglobulin to effective antiretroviral treatment of HIV. | AIDS research and therapy 20110101 |
| Immune reconstitution and inflammatory syndrome due to disseminated tuberculosis in a case of human immunodeficiency virus 2 infection. | Indian journal of pharmacology 20110101 |
| Tenofovir nephrotoxicity: 2011 update. | AIDS research and treatment 20110101 |
| Virological breakthrough: a risk factor for loss to followup in a large community-based cohort on antiretroviral therapy. | AIDS research and treatment 20110101 |
| The role of unintegrated DNA in HIV infection. | Retrovirology 20110101 |
| Oral lesions associated with nevirapine-related Stevens Johnson syndrome: A report of four cases. | Journal of oral and maxillofacial pathology : JOMFP 20110101 |
| Tuberculosis: current situation, challenges and overview of its control programs in India. | Journal of global infectious diseases 20110101 |
| Improved survival of HIV-1-infected patients with progressive multifocal leukoencephalopathy receiving early 5-drug combination antiretroviral therapy. | PloS one 20110101 |
| Minor HIV-1 variants with the K103N resistance mutation during intermittent efavirenz-containing antiretroviral therapy and virological failure. | PloS one 20110101 |
| Time to and Predictors of CD4+ T-Lymphocytes Recovery in HIV-Infected Children Initiating Highly Active Antiretroviral Therapy in Ghana. | AIDS research and treatment 20110101 |
| Antiretroviral treatment reverses HIV-associated anemia in rural Tanzania. | BMC infectious diseases 20110101 |
| Association of age with mortality and virological and immunological response to antiretroviral therapy in rural South African adults. | PloS one 20110101 |
| Reappearance of minority K103N HIV-1 variants after interruption of ART initiated during primary HIV-1 infection. | PloS one 20110101 |
| Non-cirrhotic portal hypertension in human immunodeficiency virus-infected patients: a new challenge in antiretroviral therapy era. | The open AIDS journal 20110101 |
| Does HAART efficacy translate to effectiveness? Evidence for a trial effect. | PloS one 20110101 |
| Predictors of Weight Change in Male HIV-Positive Injection Drug Users Initiating Antiretroviral Therapy in Hanoi, Vietnam. | AIDS research and treatment 20110101 |
| Immunovirological response to combined antiretroviral therapy and drug resistance patterns in children: 1- and 2-year outcomes in rural Uganda. | BMC pediatrics 20110101 |
| HIV-1 mutational pathways under multidrug therapy. | AIDS research and therapy 20110101 |
| Measuring enzymatic HIV-1 susceptibility to two reverse transcriptase inhibitors as a rapid and simple approach to HIV-1 drug-resistance testing. | PloS one 20110101 |
| Impact of small body weight on tenofovir-associated renal dysfunction in HIV-infected patients: a retrospective cohort study of Japanese patients. | PloS one 20110101 |
| Alternative antiretroviral monitoring strategies for HIV-infected patients in east Africa: opportunities to save more lives? | Journal of the International AIDS Society 20110101 |
| Graves' Disease as a Manifestation of Immune Reconstitution in HIV-Infected Individuals after Initiation of Highly Active Antiretroviral Therapy. | AIDS research and treatment 20110101 |
| Induction maintenance concept for HAART as initial treatment in HIV infected infants. | European journal of medical research 20110101 |
| Effectiveness of protease inhibitor monotherapy versus combination antiretroviral maintenance therapy: a meta-analysis. | PloS one 20110101 |
| Long-term outcomes of liver transplant patients with human immunodeficiency virus infection and end-stage-liver-disease: single center experience. | European journal of medical research 20110101 |
| Dyslipidaemia in HIV-infected women on antiretroviral therapy. Analysis of 922 patients from the Spanish VACH cohort. | BMC women's health 20110101 |
| [Evidence-based therapeutic drug monitoring for efavirenz]. | Therapie 20110101 |
| [Modeling of antiretroviral response from taxonomy of CD4 cells count trajectories in profound immunodeficiency setting]. | Therapie 20110101 |
| Anemia and iron homeostasis in a cohort of HIV-infected patients in Indonesia. | BMC infectious diseases 20110101 |
| Pregnancy and virologic response to antiretroviral therapy in South Africa. | PloS one 20110101 |
| Antihyperlipidemic effects of Pleurotus ostreatus (oyster mushrooms) in HIV-infected individuals taking antiretroviral therapy. | BMC complementary and alternative medicine 20110101 |
| Government use licenses in Thailand: an assessment of the health and economic impacts. | Globalization and health 20110101 |
| Cost-effectiveness of nucleoside reverse transcriptase inhibitor pairs in efavirenz-based regimens for treatment-naïve adults with HIV infection in the United States. | Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 20110101 |
| Birth outcomes in South African women receiving highly active antiretroviral therapy: a retrospective observational study. | Journal of the International AIDS Society 20110101 |
| Treatment simplification in HIV-infected adults as a strategy to prevent toxicity, improve adherence, quality of life and decrease healthcare costs. | Patient preference and adherence 20110101 |
| Prevention of perinatal HIV transmission: the Perinatal HIV Hotline perspective. | Topics in antiviral medicine 20110101 |
| Modeling HIV/AIDS drug price determinants in Brazil: is generic competition a myth? | PloS one 20110101 |
| Nephrotoxicity of HAART. | AIDS research and treatment 20110101 |
| HIV-Associated Venous Thromboembolism. | Mediterranean journal of hematology and infectious diseases 20110101 |
| HIV drug resistance (HIVDR) in antiretroviral therapy-naïve patients in Tanzania not eligible for WHO threshold HIVDR survey is dramatically high. | PloS one 20110101 |
| Pilot, randomized study assessing safety, tolerability and efficacy of simplified LPV/r maintenance therapy in HIV patients on the 1 PI-based regimen. | PloS one 20110101 |
| Diffuse interstitial lung infiltrates in a smoker with human immunodeficiency virus infection. | Lung India : official organ of Indian Chest Society 20110101 |
| X4 tropic multi-drug resistant quasi-species detected at the time of primary HIV-1 infection remain exclusive or at least dominant far from PHI. | PloS one 20110101 |
| Bone mineral density in HIV-negative men participating in a tenofovir pre-exposure prophylaxis randomized clinical trial in San Francisco. | PloS one 20110101 |
| Government use licenses in Thailand: The power of evidence, civil movement and political leadership. | Globalization and health 20110101 |
| Statistical methods in recent HIV noninferiority trials: reanalysis of 11 trials. | PloS one 20110101 |
| Long-term virological, immunological and mortality outcomes in a cohort of HIV-infected female sex workers treated with highly active antiretroviral therapy in Africa. | BMC public health 20110101 |
| A longitudinal study of stavudine-associated toxicities in a large cohort of South African HIV infected subjects. | BMC infectious diseases 20110101 |
| Lyme neuroborreliosis in HIV-1 positive men successfully treated with oral doxycycline: a case series and literature review. | Journal of medical case reports 20110101 |
| ReishiMax, mushroom based dietary supplement, inhibits adipocyte differentiation, stimulates glucose uptake and activates AMPK. | BMC complementary and alternative medicine 20110101 |
| Calculation of direct antiretroviral treatment costs and potential cost savings by using generics in the German HIV ClinSurv cohort. | PloS one 20110101 |
| Will adoption of the 2010 WHO ART guidelines for HIV-infected TB patients increase the demand for ART services in India? | PloS one 20110101 |
| First-line antiretroviral therapy and dyslipidemia in people living with HIV-1 in Cameroon: a cross-sectional study. | AIDS research and therapy 20110101 |
| Polymorphism in Gag gene cleavage sites of HIV-1 non-B subtype and virological outcome of a first-line lopinavir/ritonavir single drug regimen. | PloS one 20110101 |
| Trends in the clinical characteristics of HIV-infected patients initiating antiretroviral therapy in Kenya, Uganda and Tanzania between 2002 and 2009. | Journal of the International AIDS Society 20110101 |
| The first decade of antiretroviral therapy in Africa. | Globalization and health 20110101 |
| Enrollment characteristics and risk behaviors of injection drug users participating in the Bangkok Tenofovir Study, Thailand. | PloS one 20110101 |
| Flexible catalytic site conformations implicated in modulation of HIV-1 protease autoprocessing reactions. | Retrovirology 20110101 |
| Promoting male involvement to improve PMTCT uptake and reduce antenatal HIV infection: a cluster randomized controlled trial protocol. | BMC public health 20110101 |
| A win-win solution?: A critical analysis of tiered pricing to improve access to medicines in developing countries. | Globalization and health 20110101 |
| High rates of adherence and treatment success in a public and public-private HIV clinic in India: potential benefits of standardized national care delivery systems. | BMC health services research 20110101 |
| Challenges associated with tyrosine kinase inhibitor therapy for metastatic thyroid cancer. | Journal of thyroid research 20110101 |
| HAART induced adverse drug reactions: a retrospective analysis at a tertiary referral health care center in India. | The International journal of risk & safety in medicine 20110101 |
| Meeting the demand for more sophisticated study designs. A proposal for a new type of clinical trial: the hybrid design. | BMJ open 20110101 |
| Immunological failure despite virological suppression in HIV seropositive individuals on antiretroviral therapy. | Indian journal of sexually transmitted diseases and AIDS 20110101 |
| Preventive fluid and dietary therapy for urolithiasis: An appraisal of strength, controversies and lacunae of current literature. | Indian journal of urology : IJU : journal of the Urological Society of India 20110101 |
| Resource utilization and cost-effectiveness of counselor- vs. provider-based rapid point-of-care HIV screening in the emergency department. | PloS one 20110101 |
| Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens. | Antiviral therapy 20110101 |
| South Asian Consensus Guidelines for the rational management of diabetes in human immunodeficiency virus/acquired immunodeficiency syndrome. | Indian journal of endocrinology and metabolism 20110101 |
| Human immunodeficiency virus endocrinopathy. | Indian journal of endocrinology and metabolism 20110101 |
| Comparative effectiveness of efavirenz, protease inhibitors, and raltegravir-based regimens as first-line treatment for HIV-infected adults: a mixed treatment comparison. | HIV clinical trials 20110101 |
| Increase of transmitted drug resistance among HIV-infected sub-Saharan Africans residing in Spain in contrast to the native population. | PloS one 20110101 |
| The antiretroviral efficacy of highly active antiretroviral therapy and plasma nevirapine concentrations in HIV-TB co-infected Indian patients receiving rifampicin based antituberculosis treatment. | AIDS research and therapy 20110101 |
| Mycobacterium genavense as a cause of subacute pneumonia in patients with severe cellular immunodeficiency. | BMC infectious diseases 20110101 |
| Incidence and risk factors of antiretroviral treatment failure in treatment-naïve HIV-infected patients at Chiang Mai University Hospital, Thailand. | AIDS research and therapy 20110101 |
| Nevirapine plasma concentrations are associated with virologic response and hepatotoxicity in Chinese patients with HIV infection. | PloS one 20110101 |
| An inducible cell-cell fusion system with integrated ability to measure the efficiency and specificity of HIV-1 entry inhibitors. | PloS one 20110101 |
| Utility of routine viral load, CD4 cell count, and clinical monitoring among adults with HIV receiving antiretroviral therapy in Uganda: randomised trial. | BMJ (Clinical research ed.) 20110101 |
| Effect of anemia on hepatotoxicity of HAART in HIV patients in Benin city. | Nigerian medical journal : journal of the Nigeria Medical Association 20110101 |
| It is time to consider third-line options in antiretroviral-experienced paediatric patients? | Journal of the International AIDS Society 20110101 |
| 8-Modified-2'-deoxyadenosine analogues induce delayed polymerization arrest during HIV-1 reverse transcription. | PloS one 20110101 |
| Undernutrition among HIV-positive children in Dar es Salaam, Tanzania: antiretroviral therapy alone is not enough. | BMC public health 20110101 |
| Prevalence and predictors of kaposi sarcoma herpes virus seropositivity: a cross-sectional analysis of HIV-infected adults initiating ART in Johannesburg, South Africa. | Infectious agents and cancer 20110101 |
| Impact of comorbidities and drug therapy on development of renal impairment in a predominantly African American and Hispanic HIV clinic population. | HIV/AIDS (Auckland, N.Z.) 20110101 |
| Antiretroviral therapy initiated soon after HIV diagnosis as standard care: potential to save lives? | HIV/AIDS (Auckland, N.Z.) 20110101 |
| Safety, efficacy, and pharmacokinetics of rilpivirine: systematic review with an emphasis on resource-limited settings. | HIV/AIDS (Auckland, N.Z.) 20110101 |
| Characteristics of foot fractures in HIV-infected patients previously treated with tenofovir versus non-tenofovir-containing highly active antiretroviral therapy. | HIV/AIDS (Auckland, N.Z.) 20110101 |
| Growth hormone and tesamorelin in the management of HIV-associated lipodystrophy. | HIV/AIDS (Auckland, N.Z.) 20110101 |
| Role of raltegravir in the management of HIV-1 infection. | HIV/AIDS (Auckland, N.Z.) 20110101 |
| Can linear regression modeling help clinicians in the interpretation of genotypic resistance data? An application to derive a lopinavir-score. | PloS one 20110101 |
| National prevalence and trends of HIV transmitted drug resistance in Mexico. | PloS one 20110101 |
| Adherence to highly active antiretroviral treatment in HIV-infected Rwandan women. | PloS one 20110101 |
| AtriplaR/anti-TB combination in TB/HIV patients. Drug in focus. | BMC research notes 20110101 |
| Opportunistic infections in relation to antiretroviral status among AIDS patients from south India. | Indian journal of medical microbiology 20110101 |
| Mother-to-child transmission of human immunodeficiency virus in aten years period. | Reproductive health 20110101 |
| Resistance patterns selected by nevirapine vs. efavirenz in HIV-infected patients failing first-line antiretroviral treatment: a bayesian analysis. | PloS one 20110101 |
| Which compound to select in lead optimization? Prospectively validated proteochemometric models guide preclinical development. | PloS one 20110101 |
| TRAF6 and IRF7 control HIV replication in macrophages. | PloS one 20110101 |
| Prolonged control of replication-competent dual- tropic human immunodeficiency virus-1 following cessation of highly active antiretroviral therapy. | Retrovirology 20110101 |
| Nevirapine induced exfoliative dermatitis in an HIV-infected patient. | Indian journal of pharmacology 20110101 |
| Pharmacokinetics of antiretroviral drugs in anatomical sanctuary sites: the male and female genital tract. | Antiviral therapy 20110101 |
| Correlation between lamivudine plasma concentrations and patient self-reported adherence to antiretroviral treatment in experienced HIV patients. | Therapeutics and clinical risk management 20110101 |
| Pharmacogenetic & pharmacokinetic biomarker for efavirenz based ARV and rifampicin based anti-TB drug induced liver injury in TB-HIV infected patients. | PloS one 20110101 |
| Cost-effectiveness analysis of initial HIV treatment under Italian guidelines. | ClinicoEconomics and outcomes research : CEOR 20110101 |
| Label-free electrochemical detection of the specific oligonucleotide sequence of dengue virus type 1 on pencil graphite electrodes. | Sensors (Basel, Switzerland) 20110101 |
| Rate and determinants of treatment response to different antiretroviral combination strategies in subjects presenting at HIV-1 diagnosis with advanced disease. | BMC infectious diseases 20110101 |
| A multifaceted analysis of HIV-1 protease multidrug resistance phenotypes. | BMC bioinformatics 20110101 |
| In silico identification of structure requirement for novel thiazole and oxazole derivatives as potent fructose 1,6-bisphosphatase inhibitors. | International journal of molecular sciences 20110101 |
| Intensification of antiretroviral therapy with a CCR5 antagonist in patients with chronic HIV-1 infection: effect on T cells latently infected. | PloS one 20110101 |
| Risk factors for default from tuberculosis treatment in HIV-infected individuals in the state of Pernambuco, Brazil: a prospective cohort study. | BMC infectious diseases 20110101 |
| Prevalence of discordant immunologic and virologic responses in patients with AIDS under antiretroviral therapy in a specialized care center in Brazil. | Revista do Instituto de Medicina Tropical de Sao Paulo 20110101 |
| Prevalence and impact of minority variant drug resistance mutations in primary HIV-1 infection. | PloS one 20110101 |
| Emergence of HBV resistance to lamivudine (3TC) in HIV/HBV co-infected patients in The Gambia, West Africa. | BMC research notes 20110101 |
| Estimating loss to follow-up in HIV-infected patients on antiretroviral therapy: the effect of the competing risk of death in Zambia and Switzerland. | PloS one 20110101 |
| Evaluation of cellular phenotypes implicated in immunopathogenesis and monitoring immune reconstitution inflammatory syndrome in HIV/leprosy cases. | PloS one 20110101 |
| Early mortality in adults initiating antiretroviral therapy (ART) in low- and middle-income countries (LMIC): a systematic review and meta-analysis. | PloS one 20110101 |
| Nanomedicine as an emerging approach against intracellular pathogens. | International journal of nanomedicine 20110101 |
| Twice-daily versus once-daily antiretroviral therapy and coformulation strategies in HIV-infected adults: benefits, risks, or burden? | Patient preference and adherence 20110101 |
| Comparative manufacture and cell-based delivery of antiretroviral nanoformulations. | International journal of nanomedicine 20110101 |
| Lipodystrophy in HIV patients: its challenges and management approaches. | HIV/AIDS (Auckland, N.Z.) 20110101 |
| Drug-resistant tuberculosis: emerging treatment options. | Clinical pharmacology : advances and applications 20110101 |
| Artemether-Lumefantrine Combination Therapy for Treatment of Uncomplicated Malaria: The Potential for Complex Interactions with Antiretroviral Drugs in HIV-Infected Individuals. | Malaria research and treatment 20110101 |
| Disseminated infections due to Immune Reconstitution Inflammatory Syndrome after highly active antiretroviral therapy--report of 3 cases from Nigeria. | The Pan African medical journal 20110101 |
| Pharmacogenetics and gender association with psychotic episodes on nortriptyline lower doses: patient cases. | ISRN pharmaceutics 20110101 |
| Undiagnosed HIV Presenting with Lymphoid Interstitial Pneumonitis. | Case reports in infectious diseases 20110101 |
| Syphilitic Aortic Aneurysm in a Young HIV-Infected Man: Case Presentation. | Case reports in infectious diseases 20110101 |
| Rilpivirine and complera: new first-line treatment options. | BETA : bulletin of experimental treatments for AIDS : a publication of the San Francisco AIDS Foundation 20110101 |
| Clinical Use of Inhibitors of HIV-1 Integration: Problems and Prospects. | Acta naturae 20110101 |
| Simple, precise and accurate HPLC method of analysis for nevirapine suspension from human plasma. | Indian journal of pharmaceutical sciences 20110101 |
| Dissolution enhancement of efavirenz by solid dispersion and PEGylation techniques. | International journal of pharmaceutical investigation 20110101 |
| Nuclear receptor-mediated induction of CYP450 by antiretrovirals: functional consequences of NR1I2 (PXR) polymorphisms and differential prevalence in whites and sub-Saharan Africans. | Journal of acquired immune deficiency syndromes (1999) 20101215 |
| Evaluating patients for second-line antiretroviral therapy in India: the role of targeted viral load testing. | Journal of acquired immune deficiency syndromes (1999) 20101215 |
| HIV-1 viral escape in cerebrospinal fluid of subjects on suppressive antiretroviral treatment. | The Journal of infectious diseases 20101215 |
| Efavirenz binding site in HIV-1 reverse transcriptase monomers. | Biochemistry 20101214 |
| Efavirenz or nevirapine in three-drug combination therapy with two nucleoside-reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral-naïve individuals. | The Cochrane database of systematic reviews 20101208 |
| Efavirenz/emtricitabine/tenofovir disoproxil fumarate single-tablet regimen (Atripla®): a review of its use in the management of HIV infection. | Drugs 20101203 |
| Nanoformulated antiretroviral drug combinations extend drug release and antiretroviral responses in HIV-1-infected macrophages: implications for neuroAIDS therapeutics. | Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology 20101201 |
| Real-time adherence monitoring for HIV antiretroviral therapy. | AIDS and behavior 20101201 |
| Tribal ethnicity and CYP2B6 genetics in Ugandan and Zimbabwean populations in the UK: implications for efavirenz dosing in HIV infection. | The Journal of antimicrobial chemotherapy 20101201 |
| Implications of efavirenz for neuropsychiatry: a review. | The International journal of neuroscience 20101201 |
| A highly sensitive ultra performance liquid chromatography-tandem mass spectrometric (UPLC-MS/MS) technique for quantitation of protein free and bound efavirenz (EFV) in human seminal and blood plasma. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20101201 |
| Changing baseline characteristics among patients in the China National Free Antiretroviral Treatment Program, 2002-09. | International journal of epidemiology 20101201 |
| Interview with Dr. Mark Cockett: current trends in screening for antiviral therapeutics. Interviewed by Nina N. Brahme and Devin J. Noblin. | The Yale journal of biology and medicine 20101201 |
| HIV capsid is a tractable target for small molecule therapeutic intervention. | PLoS pathogens 20101201 |
| The evolutionary analysis of emerging low frequency HIV-1 CXCR4 using variants through time--an ultra-deep approach. | PLoS computational biology 20101201 |
| Scaling up the 2010 World Health Organization HIV Treatment Guidelines in resource-limited settings: a model-based analysis. | PLoS medicine 20101201 |
| Maraviroc is a substrate for OATP1B1 in vitro and maraviroc plasma concentrations are influenced by SLCO1B1 521 T>C polymorphism. | Pharmacogenetics and genomics 20101201 |
| Comparison of the Mechanisms of Drug Resistance among HIV, Hepatitis B, and Hepatitis C. | Viruses 20101201 |
| HIV-2 goes global: an unaddressed issue in Indian anti-retroviral programmes. | The Indian journal of medical research 20101201 |
| Characteristics, immunological response & treatment outcomes of HIV-2 compared with HIV-1 & dual infections (HIV 1/2) in Mumbai. | The Indian journal of medical research 20101201 |
| Clinical features and serum biomarkers in HIV immune reconstitution inflammatory syndrome after cryptococcal meningitis: a prospective cohort study. | PLoS medicine 20101201 |
| Minimum effective plasma concentration of efavirenz in treatment-naïve Chinese HIV-infected patients. | International journal of STD & AIDS 20101201 |
| Cidofovir Activity against Poxvirus Infections. | Viruses 20101201 |
| Liver injury in HIV-1-infected patients receiving non-nucleosides reverse transcriptase inhibitors-based antiretroviral therapy. | Chinese medical journal 20101201 |
| Central nervous system disorders after starting antiretroviral therapy in South Africa. | AIDS (London, England) 20101127 |
| A single tablet regimen is associated with higher adherence and viral suppression than multiple tablet regimens in HIV+ homeless and marginally housed people. | AIDS (London, England) 20101127 |
| Adverse effects after HAART Initiation in resource-limited settings: a prospective study from Mysore, India. | Journal of infection in developing countries 20101124 |
| Discovery and SAR of a series of 4,6-diamino-1,3,5-triazin-2-ol as novel non-nucleoside reverse transcriptase inhibitors of HIV-1. | Bioorganic & medicinal chemistry letters 20101115 |
| A randomized factorial trial comparing 4 treatment regimens in treatment-naive HIV-infected persons with AIDS and/or a CD4 cell count <200 cells/μL in South Africa. | The Journal of infectious diseases 20101115 |
| A 96-well plate assay for CYP4503A induction using cryopreserved human hepatocytes. | Drug metabolism and disposition: the biological fate of chemicals 20101101 |
| Impact of hepatitis C and liver fibrosis on antiretroviral plasma drug concentrations in HIV-HCV co-infected patients: the HEPADOSE study. | The Journal of antimicrobial chemotherapy 20101101 |
| Differential impact of the HIV-1 non-nucleoside reverse transcriptase inhibitor mutations K103N and M230L on viral replication and enzyme function. | The Journal of antimicrobial chemotherapy 20101101 |
| Strategies for nevirapine initiation in HIV-infected children taking pediatric fixed-dose combination 'baby pills' in Zambia: a randomized controlled trial. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20101101 |
| Long-term efavirenz autoinduction and its effect on plasma exposure in HIV patients. | Clinical pharmacology and therapeutics 20101101 |
| 'Bullfrog neck,' a unique morphologic trait in HIV lipodystrophy: case series and review of the literature. | Archives of dermatology 20101101 |
| HIV-1 induces DCIR expression in CD4+ T cells. | PLoS pathogens 20101101 |
| Emergence of drug resistant mutations after single dose nevirapine exposure in HIV-1 infected pregnant women in south India. | The Indian journal of medical research 20101101 |
| First-line raltegravir. No evidence of comparative effectiveness. | Prescrire international 20101101 |
| Maraviroc first-line therapy for HIV infection. Too risky. | Prescrire international 20101101 |
| Role of HIV Subtype Diversity in the Development of Resistance to Antiviral Drugs. | Viruses 20101101 |
| Effect of raltegravir-containing intensification on HIV burden and T-cell activation in multiple gut sites of HIV-positive adults on suppressive antiretroviral therapy. | AIDS (London, England) 20101023 |
| Inhibition of HIV-1 by non-nucleoside reverse transcriptase inhibitors via an induced fit mechanism-Importance of slow dissociation and relaxation rates for antiviral efficacy. | Biochemical pharmacology 20101015 |
| Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20101015 |
| Exploration of piperidine-4-yl-aminopyrimidines as HIV-1 reverse transcriptase inhibitors. N-Phenyl derivatives with broad potency against resistant mutant viruses. | Bioorganic & medicinal chemistry letters 20101015 |
| Determination of salivary efavirenz by liquid chromatography coupled with tandem mass spectrometry. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20101015 |
| Tenofovir or zidovudine in three-drug combination therapy with one nucleoside reverse transcriptase inhibitor and one non-nucleoside reverse transcriptase inhibitor for initial treatment of HIV infection in antiretroviral-naïve individuals. | The Cochrane database of systematic reviews 20101006 |
| Efavirenz directly modulates the oestrogen receptor and induces breast cancer cell growth. | HIV medicine 20101001 |
| CYP2B6 polymorphism and nonnucleoside reverse transcriptase inhibitor plasma concentrations in Chinese HIV-infected patients. | Therapeutic drug monitoring 20101001 |
| Lersivirine, a nonnucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus type 1. | Antimicrobial agents and chemotherapy 20101001 |
| The convergence of therapeutic drug monitoring and pharmacogenetic testing to optimize efavirenz therapy. | Therapeutic drug monitoring 20101001 |
| Antiretroviral release from poly(DL-lactide-co-glycolide) nanoparticles in mice. | The Journal of antimicrobial chemotherapy 20101001 |
| Efavirenz versus boosted atazanavir or zidovudine and abacavir in antiretroviral treatment-naive, HIV-infected subjects: week 48 data from the Altair study. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20101001 |
| Efavirenz plasma concentrations and cytochrome 2B6 polymorphisms. | The Annals of pharmacotherapy 20101001 |
| Decreased plasma efavirenz concentrations in a patient receiving rifabutin. | American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20101001 |
| Incidence of atazanavir-associated hyperbilirubinemia in Korean HIV patients: 30 months follow-up results in a population with low UDP-glucuronosyltransferase1A1*28 allele frequency. | Journal of Korean medical science 20101001 |
| Plasma efavirenz in HIV infected children treated with generic antiretroviral drugs in India. | Indian pediatrics 20101001 |
| Differential effects of efavirenz and lopinavir/ritonavir on human adipocyte differentiation, gene expression and release of adipokines and pro-inflammatory cytokines. | Current HIV research 20101001 |
| Safety and tolerability of lersivirine, a nonnucleoside reverse transcriptase inhibitor, during a 28-day, randomized, placebo-controlled, Phase I clinical study in healthy male volunteers. | Clinical therapeutics 20101001 |
| Deleterious pharmacokinetic interaction between bexarotene and efavirenz. | AIDS (London, England) 20100910 |
| HPLC-MS method for the quantification of nine anti-HIV drugs from dry plasma spot on glass filter and their long term stability in different conditions. | Journal of pharmaceutical and biomedical analysis 20100905 |
| Prevalence of mutations and determinants of genotypic resistance to etravirine (TMC125) in a large Italian resistance database (ARCA). | HIV medicine 20100901 |
| Abdominal tuberculosis: sonographic diagnosis and treatment response in HIV-positive adults in rural South Africa. | International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases 20100901 |
| Raltegravir versus Efavirenz regimens in treatment-naive HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses. | Journal of acquired immune deficiency syndromes (1999) 20100901 |
| Randomized comparison of renal effects, efficacy, and safety with once-daily abacavir/lamivudine versus tenofovir/emtricitabine, administered with efavirenz, in antiretroviral-naive, HIV-1-infected adults: 48-week results from the ASSERT study. | Journal of acquired immune deficiency syndromes (1999) 20100901 |
| N-alkylation of poloxamines modulates micellar assembly and encapsulation and release of the antiretroviral efavirenz. | European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V 20100901 |
| Drug resistance is widespread among children who receive long-term antiretroviral treatment at a rural Tanzanian hospital. | The Journal of antimicrobial chemotherapy 20100901 |
| Haplotype structure of CYP2B6 and association with plasma efavirenz concentrations in a Chilean HIV cohort. | The Journal of antimicrobial chemotherapy 20100901 |
| Effect of CYP2B6, ABCB1, and CYP3A5 polymorphisms on efavirenz pharmacokinetics and treatment response: an AIDS Clinical Trials Group study. | The Journal of infectious diseases 20100901 |
| KI and WU polyomaviruses and CD4+ cell counts in HIV-1-infected patients, Italy. | Emerging infectious diseases 20100901 |
| [Genetic barrier to antiretroviral drug-resistance. Focus on raltegravir, the first integrase inhibitor]. | Medecine et maladies infectieuses 20100901 |
| Influence of host genetic factors on efavirenz plasma and intracellular pharmacokinetics in HIV-1-infected patients. | Pharmacogenomics 20100901 |
| N348I in HIV-1 reverse transcriptase can counteract the nevirapine-mediated bias toward RNase H cleavage during plus-strand initiation. | The Journal of biological chemistry 20100827 |
| Predicting virologic failure among HIV-1-infected children receiving antiretroviral therapy in Tanzania: a cross-sectional study. | Journal of acquired immune deficiency syndromes (1999) 20100801 |
| Human immunodeficiency virus-infection induces major changes in high-density lipoprotein particle size distribution and composition: the effect of antiretroviral treatment and disease severity. | Clinical chemistry and laboratory medicine 20100801 |
| A less sensitive detector does not necessarily result in a less sensitive method: fast quantification of 13 antiretroviral analytes in plasma with liquid chromatography coupled with tandem mass spectrometry. | Clinical chemistry and laboratory medicine 20100801 |
| Methadone, buprenorphine, and street drug interactions with antiretroviral medications. | Current HIV/AIDS reports 20100801 |
| Birth defects among children born to human immunodeficiency virus-infected women: pediatric AIDS clinical trials protocols 219 and 219C. | The Pediatric infectious disease journal 20100801 |
| Switching from efavirenz to nevirapine. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20100801 |
| Biaryl ethers as potent allosteric inhibitors of reverse transcriptase and its key mutant viruses: aryl substituted pyrazole as a surrogate for the pyrazolopyridine motif. | Bioorganic & medicinal chemistry letters 20100801 |
| No changes in efavirenz plasma concentrations in HIV-infected patients who switch from Stocrin to Atripla. | Journal of acquired immune deficiency syndromes (1999) 20100801 |
| Enhanced oxidative stress and increased mitochondrial mass during efavirenz-induced apoptosis in human hepatic cells. | British journal of pharmacology 20100801 |
| Using touchscreen electronic medical record systems to support and monitor national scale-up of antiretroviral therapy in Malawi. | PLoS medicine 20100801 |
| The effect of raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: a randomized controlled trial. | PLoS medicine 20100801 |
| HIV-1 Populations in Semen Arise through Multiple Mechanisms. | PLoS pathogens 20100801 |
| Low frequency of liver enzyme elevation in HIV-infected patients attending a large urban treatment centre in Uganda. | International journal of STD & AIDS 20100801 |
| Is there Emergence of Clinical HBV Resistance Under Long-Term HBV Combination Therapy? A Challenging Case Report. | Viruses 20100801 |
| Efavirenz is associated with severe vitamin D deficiency and increased alkaline phosphatase. | AIDS (London, England) 20100731 |
| Isoniazid-associated hepatitis and antiretroviral drugs during tuberculosis prophylaxis in hiv-infected adults in Botswana. | American journal of respiratory and critical care medicine 20100715 |
| Discovery of piperidin-4-yl-aminopyrimidines as HIV-1 reverse transcriptase inhibitors. N-benzyl derivatives with broad potency against resistant mutant viruses. | Bioorganic & medicinal chemistry letters 20100715 |
| Hybrid diarylbenzopyrimidine non-nucleoside reverse transcriptase inhibitors as promising new leads for improved anti-HIV-1 chemotherapy. | Bioorganic & medicinal chemistry 20100715 |
| Early versus standard antiretroviral therapy for HIV-infected adults in Haiti. | The New England journal of medicine 20100715 |
| The non-nucleoside reverse transcriptase inhibitor efavirenz stimulates replication of human immunodeficiency virus type 1 harboring certain non-nucleoside resistance mutations. | Virology 20100705 |
| Improved HIV and substance abuse treatment outcomes for released HIV-infected prisoners: the impact of buprenorphine treatment. | Journal of urban health : bulletin of the New York Academy of Medicine 20100701 |
| Disseminated bartonellosis presenting as neuroretinitis in a young adult with human immunodeficiency virus infection. | The Pediatric infectious disease journal 20100701 |
| Efavirenz primary and secondary metabolism in vitro and in vivo: identification of novel metabolic pathways and cytochrome P450 2A6 as the principal catalyst of efavirenz 7-hydroxylation. | Drug metabolism and disposition: the biological fate of chemicals 20100701 |
| Pharmacokinetics of lopinavir-ritonavir with and without nonnucleoside reverse transcriptase inhibitors in Ugandan HIV-infected adults. | Antimicrobial agents and chemotherapy 20100701 |
| Constrained patterns of covariation and clustering of HIV-1 non-nucleoside reverse transcriptase inhibitor resistance mutations. | The Journal of antimicrobial chemotherapy 20100701 |
| Inhibition of mitochondrial function by efavirenz increases lipid content in hepatic cells. | Hepatology (Baltimore, Md.) 20100701 |
| Synthesis and anti-HIV activity of 2-naphthyl substituted DAPY analogues as non-nucleoside reverse transcriptase inhibitors. | Bioorganic & medicinal chemistry 20100701 |
| Immune reconstitution in severely immunosuppressed antiretroviral-naive HIV type 1-infected patients using a nonnucleoside reverse transcriptase inhibitor-based or a boosted protease inhibitor-based antiretroviral regimen: three-year results (The Advanz Trial): a randomized, controlled trial. | AIDS research and human retroviruses 20100701 |
| Nevirapine-induced stevens johnson-syndrome and fulminant hepatic failure requiring liver transplantation. | American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 20100701 |
| FDA notifications. FDA approves efavirenz insert revisions. | AIDS alert 20100701 |
| Response to first line HAART using CD4 cell counts experience in a university hospital in Kingston. | The West Indian medical journal 20100701 |
| Safety of efavirenz in first-trimester of pregnancy: a systematic review and meta-analysis of outcomes from observational cohorts. | AIDS (London, England) 20100619 |
| Using electronic drug monitor feedback to improve adherence to antiretroviral therapy among HIV-positive patients in China. | AIDS and behavior 20100601 |
| Successful paediatric HIV treatment in rural primary care in Africa. | Archives of disease in childhood 20100601 |
| Antiretroviral therapy and bone mineral measurements in HIV-infected youths. | Bone 20100601 |
| Slow binding-tight binding interaction between benzimidazol-2-one inhibitors and HIV-1 reverse transcriptase containing the lysine 103 to asparagine mutation. | Antiviral research 20100601 |
| Pharmacokinetics of the treatment switch from efavirenz to nevirapine. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20100601 |
| Using mechanistic models to simulate comparative effectiveness trials of therapy and to estimate long-term outcomes in HIV care. | Medical care 20100601 |
| Efavirenz plasma concentrations at 1, 3, and 6 months post-antiretroviral therapy initiation in HIV type 1-infected South African children. | AIDS research and human retroviruses 20100601 |
| Patients infected with HIV type 1 subtype CRF01_AE and failing first-line nevirapine- and efavirenz-based regimens demonstrate considerable cross-resistance to etravirine. | AIDS research and human retroviruses 20100601 |
| [HIV-therapy-associated immune reconstitution syndrome presenting as immunogenic hyperthyroidism]. | Deutsche medizinische Wochenschrift (1946) 20100601 |
| Recent FDA approvals and changes. | AIDS patient care and STDs 20100601 |
| Zidovudine-induced reversible pure red cell aplasia. | Indian journal of pharmacology 20100601 |
| Impact of superdisintegrants on efavirenz release from tablet formulations. | Acta pharmaceutica (Zagreb, Croatia) 20100601 |
| Lower atovaquone/proguanil concentrations in patients taking efavirenz, lopinavir/ritonavir or atazanavir/ritonavir. | AIDS (London, England) 20100515 |
| Mass spectrometry and renal calculi. | Journal of medicine and life 20100515 |
| Assessment of the susceptibility of mutant HIV-1 to antiviral agents. | Journal of virological methods 20100501 |
| In vitro resistance development for RO-0335, a novel diphenylether nonnucleoside reverse transcriptase inhibitor. | Antiviral research 20100501 |
| Nonnucleoside reverse transcriptase inhibitor concentrations during treatment interruptions and the emergence of resistance: a substudy of the ISS-PART Trial. | AIDS research and human retroviruses 20100501 |
| Differential effects of efavirenz, lopinavir/r, and atazanavir/r on the initial viral decay rate in treatment naïve HIV-1-infected patients. | AIDS research and human retroviruses 20100501 |
| Breast enlargement in an HIV-infected man on combined antiretroviral therapy: what if it was carcinoma? | International journal of STD & AIDS 20100501 |
| [Protease inhibitor or non-nucleoside reverse transcriptase inhibitor. ACTG study 5202 in focus]. | MMW Fortschritte der Medizin 20100429 |
| The relation between treatment outcome and efavirenz, atazanavir or lopinavir exposure in the NORTHIV trial of treatment-naïve HIV-1 infected patients. | European journal of clinical pharmacology 20100401 |
| Antiretroviral therapy hepatotoxicity: Prevalence, risk factors, and clinical characteristics in a cohort of Han Chinese. | Hepatology research : the official journal of the Japan Society of Hepatology 20100401 |
| Prospective, randomized, open label trial of Efavirenz vs Lopinavir/Ritonavir in HIV+ treatment-naive subjects with CD4+<200 cell/mm3 in Mexico. | Journal of acquired immune deficiency syndromes (1999) 20100401 |
| A highly concentrated and taste-improved aqueous formulation of efavirenz for a more appropriate pediatric management of the anti-HIV therapy. | Current HIV research 20100401 |
| Using of nevirapine is associated with intermediate and reduced response to etravirine among HIV-infected patients who experienced virologic failure in a resource-limited setting. | Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology 20100401 |
| Synthesis and biological evaluation of 4-(hydroxyimino)arylmethyl diarylpyrimidine analogues as potential non-nucleoside reverse transcriptase inhibitors against HIV. | Bioorganic & medicinal chemistry 20100401 |
| FDA notifications. FDA tentatively approves efavirenz cross-scored tablets. | AIDS alert 20100401 |
| HIV-1 RT Inhibitors with a Novel Mechanism of Action: NNRTIs that Compete with the Nucleotide Substrate. | Viruses 20100401 |
| Raltegravir: in treatment-naive patients with HIV-1 infection. | Drugs 20100326 |
| Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide. | British journal of cancer 20100316 |
| Does choice of combination antiretroviral therapy (cART) alter changes in cerebral function testing after 48 weeks in treatment-naive, HIV-1-infected individuals commencing cART? A randomized, controlled study. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20100315 |
| Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1 infection. | The Journal of infectious diseases 20100315 |
| Impact of human leukocyte antigen-B*51-restricted cytotoxic T-lymphocyte pressure on mutation patterns of nonnucleoside reverse transcriptase inhibitor resistance. | AIDS (London, England) 20100313 |
| [Evolution of HIV-1 drug resistance in patients failing combination antiretroviral therapy]. | Zhonghua yi xue za zhi 20100309 |
| Association between cervical dysplasia and human papillomavirus in HIV seropositive women from Johannesburg South Africa. | Cancer causes & control : CCC 20100301 |
| Viral sanctuaries during highly active antiretroviral therapy in a nonhuman primate model for AIDS. | Journal of virology 20100301 |
| Adverse drug reactions to antiretroviral therapy (ART): an experience of spontaneous reporting and intensive monitoring from ART centre in India. | Pharmacoepidemiology and drug safety 20100301 |
| The impact of once-nightly versus twice-daily dosing and baseline beliefs about HAART on adherence to efavirenz-based HAART over 48 weeks: the NOCTE study. | Journal of acquired immune deficiency syndromes (1999) 20100301 |
| Pre-existing minority drug-resistant HIV-1 variants, adherence, and risk of antiretroviral treatment failure. | The Journal of infectious diseases 20100301 |
| Low frequency nonnucleoside reverse-transcriptase inhibitor-resistant variants contribute to failure of efavirenz-containing regimens in treatment- experienced patients. | The Journal of infectious diseases 20100301 |
| Substitution of nevirapine because of efavirenz toxicity in AIDS clinical trials group A5095. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20100301 |
| N1-Heterocyclic pyrimidinediones as non-nucleoside inhibitors of HIV-1 reverse transcriptase. | Bioorganic & medicinal chemistry letters 20100301 |
| N1-Alkyl pyrimidinediones as non-nucleoside inhibitors of HIV-1 reverse transcriptase. | Bioorganic & medicinal chemistry letters 20100301 |
| Abstracts of the 16th Annual Society on NeuroImmune Pharmacology (SNIP) Conference. April 13-17, 2010. Manhattan Beach, California, USA. | Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology 20100301 |
| HIV type 1 antiretroviral resistance mutations in subtypes B, C, and F in the City of São Paulo, Brazil. | AIDS research and human retroviruses 20100301 |
| Single-tablet Quad regimen achieves high rate of virologic suppression. | AIDS patient care and STDs 20100301 |
| Switch from protease inhibitor- to efavirenz-based antiretroviral therapy improves quality of life, treatment satisfaction and adherence with low rates of virological failure in virologically suppressed patients. | International journal of STD & AIDS 20100301 |
| Elvucitabine data released at CROI. | AIDS patient care and STDs 20100301 |
| Analysis of RT sequences of subtype C HIV-type 1 isolates from indian patients at failure of a first-line treatment according to clinical and/or immunological WHO guidelines. | AIDS research and human retroviruses 20100301 |
| FDA notifications. Updated Atripla label approved. | AIDS alert 20100301 |
| Histological effects of long term consumption of nutmeg on the medial geniculate body of adult Wistar rats. | North American journal of medical sciences 20100301 |
| Timing of initiation of antiretroviral drugs during tuberculosis therapy. | The New England journal of medicine 20100225 |
| Alteration of pharmacokinetics of proguanil in healthy volunteers following concurrent administration of efavirenz. | European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 20100219 |
| Novel 1,3-dihydro-benzimidazol-2-ones and their analogues as potent non-nucleoside HIV-1 reverse transcriptase inhibitors. | Bioorganic & medicinal chemistry 20100215 |
| HIV infection of the male genital tract--consequences for sexual transmission and reproduction. | International journal of andrology 20100201 |
| TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1. | Antimicrobial agents and chemotherapy 20100201 |
| Similar antiviral efficacy and tolerability between efavirenz and lopinavir/ritonavir, administered with abacavir/lamivudine (Kivexa), in antiretroviral-naïve patients: a 48-week, multicentre, randomized study (Lake Study). | Antiviral research 20100201 |
| Antiviral efficacy of the novel compound BIT225 against HIV-1 release from human macrophages. | Antimicrobial agents and chemotherapy 20100201 |
| Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study. | The Journal of infectious diseases 20100201 |
| Antiretroviral prescribing patterns in treatment-naïve patients in the United States. | AIDS patient care and STDs 20100201 |
| Bioavailability in healthy adults of efavirenz capsule contents mixed with a small amount of food. | American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20100201 |
| Patient-reported outcomes in virologically suppressed, HIV-1-Infected subjects after switching to a simplified, single-tablet regimen of efavirenz, emtricitabine, and tenofovir DF. | AIDS patient care and STDs 20100201 |
| Recent FDA approvals and changes. | AIDS patient care and STDs 20100201 |
| Effectiveness of non-nucleoside reverse-transcriptase inhibitor-based antiretroviral therapy in women previously exposed to a single intrapartum dose of nevirapine: a multi-country, prospective cohort study. | PLoS medicine 20100201 |
| Acute psychosis under efavirenz in a HIV patient. | La Tunisie medicale 20100201 |
| HIV treatment information. | Project Inform perspective 20100201 |
| [Establishment and application of a high-throughput screening assay for premature activation of HIV-1 precursors]. | Yao xue xue bao = Acta pharmaceutica Sinica 20100201 |
| HIV Genetic Diversity and Drug Resistance. | Viruses 20100201 |
| Etravirine resistance associated mutations in HIV-infected patients failing efavirenz or nevirapine in the Spanish antiretroviral resistance database. | AIDS (London, England) 20100128 |
| Efavirenz binding to HIV-1 reverse transcriptase monomers and dimers. | Biochemistry 20100126 |
| Birth defects following exposure to efavirenz-based antiretroviral therapy during pregnancy: a study at a regional South African hospital. | AIDS (London, England) 20100116 |
| An improved kinetics approach to describe the physical stability of amorphous solid dispersions. | International journal of pharmaceutics 20100115 |
| Treatment modification in human immunodeficiency virus-infected individuals starting combination antiretroviral therapy between 2005 and 2008. | Archives of internal medicine 20100111 |
| Efficacy and safety of TMC278 in antiretroviral-naive HIV-1 patients: week 96 results of a phase IIb randomized trial. | AIDS (London, England) 20100102 |
| Antiretroviral treatment changes in adults from Côte d'Ivoire: the roles of tuberculosis and pregnancy. | AIDS (London, England) 20100102 |
| Non-nucleoside reverse transcriptase inhibitor efavirenz increases monolayer permeability of human coronary artery endothelial cells. | Atherosclerosis 20100101 |
| Pharmacogenetics of antiretrovirals. | Antiviral research 20100101 |
| Non-nucleoside reverse transcriptase inhibitors (NNRTIs), their discovery, development, and use in the treatment of HIV-1 infection: a review of the last 20 years (1989-2009). | Antiviral research 20100101 |
| HIV-1 viral load and phenotypic antiretroviral drug resistance assays based on reverse transcriptase activity in comparison to amplification based HIV-1 RNA and genotypic assays. | Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology 20100101 |
| Factors influencing lopinavir and atazanavir plasma concentration. | The Journal of antimicrobial chemotherapy 20100101 |
| [Interactions with antiretroviral drugs]. | Der Internist 20100101 |
| Dose adjustment of the non-nucleoside reverse transcriptase inhibitors during concurrent rifampicin-containing tuberculosis therapy: one size does not fit all. | Expert opinion on drug metabolism & toxicology 20100101 |
| Intracellular Pharmacokinetics of Antiretroviral Drugs in HIV-Infected Patients, and their Correlation with Drug Action. | Clinical pharmacokinetics 20100101 |
| Efavirenz in the therapy of HIV infection. | Expert opinion on drug metabolism & toxicology 20100101 |
| Acute urinary retention due to viral coinfections (HIV, HBV, VZV). | Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002) 20100101 |
| Non-nucleoside reverse transcriptase inhibitor outcomes among combination antiretroviral therapy-treated adults in Botswana. | AIDS (London, England) 20100101 |
| Efavirenz-loaded polymeric micelles for pediatric anti-HIV pharmacotherapy with significantly higher oral bioavailability [corrected]. | Nanomedicine (London, England) 20100101 |
| Integrase inhibitors: a novel class of antiretroviral agents. | The Annals of pharmacotherapy 20100101 |
| Sequencing of antiretroviral therapy in children in low- and middle-income countries. | Current opinion in HIV and AIDS 20100101 |
| Pharmacokinetics of low-dose protease inhibitors and efavirenz in low- and middle-income countries. | Current opinion in HIV and AIDS 20100101 |
| Modelling imperfect adherence to HIV induction therapy. | BMC infectious diseases 20100101 |
| Successful viral suppression with subsequent efavirenz-based regimen in HIV-1-infected patients who stop nevirapine prior to discontinuation of the NRTI backbone. | Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002) 20100101 |
| Anticoagulant therapy for nodular regenerative hyperplasia in a HIV-infected patient. | BMC gastroenterology 20100101 |
| Systemic administration of antiretrovirals prior to exposure prevents rectal and intravenous HIV-1 transmission in humanized BLT mice. | PloS one 20100101 |
| Mother-to-child transmission of HIV: experience at a referral hospital in Saudi Arabia. | Annals of Saudi medicine 20100101 |
| The mitochondria-independent cytotoxic effect of nelfinavir on leukemia cells can be enhanced by sorafenib-mediated mcl-1 downregulation and mitochondrial membrane destabilization. | Molecular cancer 20100101 |
| The mutation T477A in HIV-1 reverse transcriptase (RT) restores normal proteolytic processing of RT in virus with Gag-Pol mutated in the p51-RNH cleavage site. | Retrovirology 20100101 |
| Perturbation of the P-body component Mov10 inhibits HIV-1 infectivity. | PloS one 20100101 |
| Only slight impact of predicted replicative capacity for therapy response prediction. | PloS one 20100101 |
| The tuberculosis challenge in a rural South African HIV programme. | BMC infectious diseases 20100101 |
| Antiretroviral (ARV) Therapy in Resource Poor Countries: What do we Need in Real Life? | The open AIDS journal 20100101 |
| Patent Pooling for Promoting Access to Antiretroviral Drugs (ARVs) - A Strategic Option for India. | The open AIDS journal 20100101 |
| Mitochondrial changes during D-drug-containing once-daily therapy in HIV-positive treatment-naive patients. | Antiviral therapy 20100101 |
| Update on the efficacy, effectiveness and safety of artemether-lumefantrine combination therapy for treatment of uncomplicated malaria. | Therapeutics and clinical risk management 20100101 |
| Profile of etravirine for the treatment of HIV infection. | Therapeutics and clinical risk management 20100101 |
| Nevirapine-associated early hepatotoxicity: incidence, risk factors, and associated mortality in a primary care ART programme in South Africa. | PloS one 20100101 |
| Hepatotoxicity and effectiveness of a Nevirapine-based antiretroviral therapy in HIV-infected patients with or without viral hepatitis B or C infection in Cameroon. | BMC public health 20100101 |
| Designing ARVs Patent Pool Up to Trade & Policy Evolutionary Dynamics. | The open AIDS journal 20100101 |
| Impact of ritonavir, atazanavir and their combination on the CYP3A4 induction potential of efavirenz in primary human hepatocytes. | Drug metabolism letters 20100101 |
| Antiretroviral treatment adherence among HIV patients in KwaZulu-Natal, South Africa. | BMC public health 20100101 |
| Simplification of antiretroviral therapy with etravirine. | AIDS reviews 20100101 |
| Technology Development Through Pooling ARV Drug Patents: A Vision from China. | The open AIDS journal 20100101 |
| Decreased NK Cell FcRgamma in HIV-1 infected individuals receiving combination antiretroviral therapy: a cross sectional study. | PloS one 20100101 |
| Response of a simian immunodeficiency virus (SIVmac251) to raltegravir: a basis for a new treatment for simian AIDS and an animal model for studying lentiviral persistence during antiretroviral therapy. | Retrovirology 20100101 |
| Abacavir/lamivudine combination in the treatment of HIV: a review. | Therapeutics and clinical risk management 20100101 |
| Efficacy, safety and pharmacokinetic of once-daily boosted saquinavir (1500/100 mg) together with 2 nucleos(t)ide reverse transcriptase inhibitors in real life: a multicentre prospective study. | AIDS research and therapy 20100101 |
| A cluster randomized trial of routine HIV-1 viral load monitoring in Zambia: study design, implementation, and baseline cohort characteristics. | PloS one 20100101 |
| High survival and treatment success sustained after two and three years of first-line ART for children in Cambodia. | Journal of the International AIDS Society 20100101 |
| The UNITAID Patent Pool Initiative: Bringing Patents Together for the Common Good. | The open AIDS journal 20100101 |
| Effects of CYP2B6 G516T polymorphisms on plasma efavirenz and nevirapine levels when co-administered with rifampicin in HIV/TB co-infected Thai adults. | AIDS research and therapy 20100101 |
| Clinical deterioration during antituberculosis treatment in Africa: incidence, causes and risk factors. | BMC infectious diseases 20100101 |
| When to start antiretroviral therapy in resource-limited settings: a human rights analysis. | BMC international health and human rights 20100101 |
| Positive and negative drug selection pressures on the N348I connection domain mutation: new insights from in vivo data. | Antiviral therapy 20100101 |
| Darunavir/ritonavir and efavirenz exert differential effects on MRP1 transporter expression and function in healthy volunteers. | Antiviral therapy 20100101 |
| Better health-related quality of life after switching from a virologically effective regimen to a regimen containing efavirenz or nevirapine. | AIDS care 20100101 |
| Pharmacokinetic characterization of three doses of tipranavir boosted with ritonavir on highly active antiretroviral therapy in treatment-experienced HIV-1 patients. | HIV clinical trials 20100101 |
| HIV-1 subtype C-infected individuals maintaining high viral load as potential targets for the 'test-and-treat' approach to reduce HIV transmission. | PloS one 20100101 |
| [Use of a fixed-dose combination of Efavirenz-Emtricitabine-Tenofovir in a tertiary hospital]. | Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria 20100101 |
| Increasing rates of obesity among HIV-infected persons during the HIV epidemic. | PloS one 20100101 |
| Long-term efficacy and safety of efavirenz dose reduction to 200 mg once daily in a Caucasian patient with HIV. | Clinical drug investigation 20100101 |
| A randomized, controlled, trial of short cycle intermittent compared to continuous antiretroviral therapy for the treatment of HIV infection in Uganda. | PloS one 20100101 |
| A modified method for determination of lumefantrine in human plasma by HPLC-UV and combination of protein precipitation and solid-phase extraction: application to a pharmacokinetic study. | Analytical chemistry insights 20100101 |
| Raltegravir, tenofovir, and emtricitabine in an HIV-infected patient with HCV chronic hepatitis, NNRTI intolerance and protease inhibitors-induced severe liver toxicity. | European journal of medical research 20100101 |
| The influence of HAART on the efficacy and safety of pegylated interferon and ribavirin therapy for the treatment of chronic HCV infection in HIV-positive Individuals. | European journal of medical research 20100101 |
| A penalized mixture model approach in genotype/phenotype association analysis for quantitative phenotypes. | Cancer informatics 20100101 |
| Excluding pregnancy among women initiating antiretroviral therapy: efficacy of a family planning job aid. | BMC public health 20100101 |
| Incident tuberculosis during antiretroviral therapy contributes to suboptimal immune reconstitution in a large urban HIV clinic in sub-Saharan Africa. | PloS one 20100101 |
| Early adherence to antiretroviral medication as a predictor of long-term HIV virological suppression: five-year follow up of an observational cohort. | PloS one 20100101 |
| Antiretroviral treatment start-time during primary SIV(mac) infection in macaques exerts a different impact on early viral replication and dissemination. | PloS one 20100101 |
| Semen may harbor HIV despite effective HAART: another piece in the puzzle. | PloS one 20100101 |
| Intervening in global markets to improve access to HIV/AIDS treatment: an analysis of international policies and the dynamics of global antiretroviral medicines markets. | Globalization and health 20100101 |
| Recent key advances in human immunodeficiency virus medicine and implications for China. | AIDS research and therapy 20100101 |
| Reduced referral and case fatality rates for severe symptomatic hyperlactataemia in a South African public sector antiretroviral programme: a retrospective observational study. | AIDS research and therapy 20100101 |
| Serum phosphate predicts early mortality in adults starting antiretroviral therapy in Lusaka, Zambia: a prospective cohort study. | PloS one 20100101 |
| Outcomes of highly active antiretroviral therapy in the context of universal access to healthcare: the U.S. Military HIV Natural History Study. | AIDS research and therapy 20100101 |
| Neurologic complications of HIV disease and their treatment. | Topics in HIV medicine : a publication of the International AIDS Society, USA 20100101 |
| Association between initiation of antiretroviral therapy with efavirenz and decreases in 25-hydroxyvitamin D. | Antiviral therapy 20100101 |
| Gender differences in clinical, immunological, and virological outcomes in highly active antiretroviral-treated HIV-HCV coinfected patients. | Patient preference and adherence 20100101 |
| One-pill once-a-day HAART: a simplification strategy that improves adherence and quality of life of HIV-infected subjects. | Patient preference and adherence 20100101 |
| 5th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention: summary of key research and implications for policy and practice - clinical sciences. | Journal of the International AIDS Society 20100101 |
| Cerebrospinal fluid neopterin: an informative biomarker of central nervous system immune activation in HIV-1 infection. | AIDS research and therapy 20100101 |
| Rates and reasons for early change of first HAART in HIV-1-infected patients in 7 sites throughout the Caribbean and Latin America. | PloS one 20100101 |
| Twelve-year experience of nevirapine use: benefits and convenience for long-term management in a French cohort of HIV-1-infected patients. | HIV clinical trials 20100101 |
| A decline in new HIV infections in South Africa: estimating HIV incidence from three national HIV surveys in 2002, 2005 and 2008. | PloS one 20100101 |
| Transmission of human immunodeficiency virus I drug resistance - a case report. What are the clinical implications? | European journal of medical research 20100101 |
| Generic and low dose antiretroviral therapy in adults and children: implication for scaling up treatment in resource limited settings. | AIDS research and therapy 20100101 |
| Analysis of neuropsychiatric adverse events during clinical trials of efavirenz in antiretroviral-naive patients: a systematic review. | AIDS reviews 20100101 |
| Effect of trimethoprim-sulphamethoxazole on the risk of malaria in HIV-infected Ugandan children living in an area of widespread antifolate resistance. | Malaria journal 20100101 |
| The impact of Highly Active Antiretroviral Therapy (HAART) on the clinical features of HIV - related oral lesions in Nigeria. | AIDS research and therapy 20100101 |
| Tamoxifen enhances the cytotoxic effects of nelfinavir in breast cancer cells. | Breast cancer research : BCR 20100101 |
| Financing equitable access to antiretroviral treatment in South Africa. | BMC health services research 20100101 |
| Improving the evidence base of Markov models used to estimate the costs of scaling up antiretroviral programmes in resource-limited settings. | BMC health services research 20100101 |
| Making it happen, level 2. | Global health action 20100101 |
| Common mental disorders in TB/HIV co-infected patients in Ethiopia. | BMC infectious diseases 20100101 |
| Development of a liposomal nanodelivery system for nevirapine. | Journal of biomedical science 20100101 |
| Ultra-fast analysis of plasma and intracellular levels of HIV protease inhibitors in children: a clinical application of MALDI mass spectrometry. | PloS one 20100101 |
| Dynamics of HIV-1 quasispecies during antiviral treatment dissected using ultra-deep pyrosequencing. | PloS one 20100101 |
| Lack of association between stavudine exposure and lipoatrophy, dysglycaemia, hyperlactataemia and hypertriglyceridaemia: a prospective cross sectional study. | AIDS research and therapy 20100101 |
| Contrasting predictors of poor antiretroviral therapy outcomes in two South African HIV programmes: a cohort study. | BMC public health 20100101 |
| Low haemoglobin predicts early mortality among adults starting antiretroviral therapy in an HIV care programme in South Africa: a cohort study. | BMC public health 20100101 |
| Viral decay kinetics in the highly active antiretroviral therapy-treated rhesus macaque model of AIDS. | PloS one 20100101 |
| Secular trends in pediatric antiretroviral treatment programs in rural and urban Zambia: a retrospective cohort study. | BMC pediatrics 20100101 |
| Immunological response to highly active antiretroviral therapy following treatment for prevention of mother to child transmission of HIV-1: a study in Côte d'Ivoire. | Journal of the International AIDS Society 20100101 |
| Growth, immune and viral responses in HIV infected African children receiving highly active antiretroviral therapy: a prospective cohort study. | BMC pediatrics 20100101 |
| Discontinuation of standard first-line antiretroviral therapy in a cohort of 1434 Malawian children. | Journal of the International AIDS Society 20100101 |
| Mycotic aneurysm of the inferior gluteal artery caused by non-typhi Salmonella in a man infected with HIV: a case report. | Journal of medical case reports 20100101 |
| Presence of the CYP2B6 516G> T polymorphism, increased plasma Efavirenz concentrations and early neuropsychiatric side effects in South African HIV-infected patients. | AIDS research and therapy 20100101 |
| Efficacy and safety of maraviroc versus efavirenz, both with zidovudine/lamivudine: 96-week results from the MERIT study. | HIV clinical trials 20100101 |
| Lipoprotein levels and cardiovascular risk in HIV-infected and uninfected Rwandan women. | AIDS research and therapy 20100101 |
| Stigmatizing attitudes and low levels of knowledge but high willingness to participate in HIV management: a community-based survey of pharmacies in Pune, India. | BMC public health 20100101 |
| Susceptibility of the human retrovirus XMRV to antiretroviral inhibitors. | Retrovirology 20100101 |
| Structure activity relationship of dendrimer microbicides with dual action antiviral activity. | PloS one 20100101 |
| Adverse events in a cohort of HIV infected pregnant and non-pregnant women treated with nevirapine versus non-nevirapine antiretroviral medication. | PloS one 20100101 |
| Assessing the performance of a computer-based policy model of HIV and AIDS. | PloS one 20100101 |
| Knowledge and adherence to antiretroviral therapy among adult people living with HIV/AIDS treated in the health care centers of the association 'Espoir Vie Togo' in Togo, West Africa. | BMC clinical pharmacology 20100101 |
| Economic outcomes of patients receiving antiretroviral therapy for HIV/AIDS in South Africa are sustained through three years on treatment. | PloS one 20100101 |
| Clinical, virological and immunological responses in Danish HIV patients receiving raltegravir as part of a salvage regimen. | Clinical epidemiology 20100101 |
| Population uptake of antiretroviral treatment through primary care in rural South Africa. | BMC public health 20100101 |
| Aging, human immunodeficiency virus, and bone health. | Clinical interventions in aging 20100101 |
| Lymphoma in HIV patients: Varied presentations. | Indian journal of medical and paediatric oncology : official journal of Indian Society of Medical & Paediatric Oncology 20100101 |
| Renal impairment after switching from stavudine/lamivudine to tenofovir/lamivudine in NNRTI-based antiretroviral regimens. | AIDS research and therapy 20100101 |
| Subtype-associated differences in HIV-1 reverse transcription affect the viral replication. | Retrovirology 20100101 |
| Task shifting in Mozambique: cross-sectional evaluation of non-physician clinicians' performance in HIV/AIDS care. | Human resources for health 20100101 |
| Patients present earlier and survival has improved, but pre-ART attrition is high in a six-year HIV cohort data from Ethiopia. | PloS one 20100101 |
| Prevalence of transmitted drug resistance and impact of transmitted resistance on treatment success in the German HIV-1 Seroconverter Cohort. | PloS one 20100101 |
| Effects of maraviroc and efavirenz on markers of immune activation and inflammation and associations with CD4+ cell rises in HIV-infected patients. | PloS one 20100101 |
| A comparative analysis of HIV drug resistance interpretation based on short reverse transcriptase sequences versus full sequences. | AIDS research and therapy 20100101 |
| Selective killing of human immunodeficiency virus infected cells by non-nucleoside reverse transcriptase inhibitor-induced activation of HIV protease. | Retrovirology 20100101 |
| The global pediatric antiretroviral market: analyses of product availability and utilization reveal challenges for development of pediatric formulations and HIV/AIDS treatment in children. | BMC pediatrics 20100101 |
| Safety and efficacy after switch to a saquinavir-containing antiretroviral regimen in protease inhibitor pretreated HIV-positive patients. | European journal of medical research 20100101 |
| Genotypic evaluation of etravirine sensitivity of clinical human immunodeficiency virus type 1 (HIV-1) isolates carrying resistance mutations to nevirapine and efavirenz. | Acta clinica Belgica 20100101 |
| Progress in antiretroviral drug delivery using nanotechnology. | International journal of nanomedicine 20100101 |
| Routine HIV screening in France: clinical impact and cost-effectiveness. | PloS one 20100101 |
| Impact of drug stock-outs on death and retention to care among HIV-infected patients on combination antiretroviral therapy in Abidjan, Côte d'Ivoire. | PloS one 20100101 |
| Neuropsychiatric complications of efavirenz therapy: suggestions for a new research paradigm. | The Journal of neuropsychiatry and clinical neurosciences 20100101 |
| Reduced dose of stavudine and lipoatrophy in HIV-infected patients in Cameroon. | Antiviral therapy 20100101 |
| Tenofovir disoproxil fumarate and bone mineral density: a 60-month longitudinal study in a cohort of HIV-infected youths. | Antiviral therapy 20100101 |
| Baseline severe anaemia should not preclude use of zidovudine in antiretroviral-eligible patients in resource-limited settings. | Journal of the International AIDS Society 20100101 |
| Long-term adherence to antiretroviral treatment and program drop-out in a high-risk urban setting in sub-Saharan Africa: a prospective cohort study. | PloS one 20100101 |
| Immune reconstitution inflammatory syndrome presenting as chylothorax in a patient with HIV and Mycobacterium tuberculosis coinfection: a case report. | BMC infectious diseases 20100101 |
| Antiretroviral therapy optimisation without genotype resistance testing: a perspective on treatment history based models. | PloS one 20100101 |
| Gender-related mortality for HIV-infected patients on highly active antiretroviral therapy (HAART) in rural Uganda. | International journal of women's health 20100101 |
| Contraceptive use and method preference among women in Soweto, South Africa: the influence of expanding access to HIV care and treatment services. | PloS one 20100101 |
| Uridine metabolism in HIV-1-infected patients: effect of infection, of antiretroviral therapy and of HIV-1/ART-associated lipodystrophy syndrome. | PloS one 20100101 |
| Decrease of vitamin D concentration in patients with HIV infection on a non nucleoside reverse transcriptase inhibitor-containing regimen. | AIDS research and therapy 20100101 |
| Can herpes simplex virus type 2 suppression slow HIV disease progression: a study protocol for the VALacyclovir In Delaying Antiretroviral Treatment Entry (VALIDATE) trial. | Trials 20100101 |
| Development, clinical utility, and place in therapy of posaconazole for prevention and treatment of invasive fungal infections. | Drug design, development and therapy 20100101 |
| The importance of clinic attendance in the first six months on antiretroviral treatment: a retrospective analysis at a large public sector HIV clinic in South Africa. | Journal of the International AIDS Society 20100101 |
| Pharmacokinetics and acceptability of once- versus twice-daily lamivudine and abacavir in HIV type-1-infected Ugandan children in the ARROW Trial. | Antiviral therapy 20100101 |
| Advances and challenges in protein-ligand docking. | International journal of molecular sciences 20100101 |
| Immune restoration disease and changes in CD4+ T-cell count in HIV- infected patients during highly active antiretroviral therapy at Zewditu memorial hospital, Addis Ababa, Ethiopia. | AIDS research and therapy 20100101 |
| Methods development for blood borne macrophage carriage of nanoformulated antiretroviral drugs. | Journal of visualized experiments : JoVE 20100101 |
| Trends in CD4 counts in HIV-infected patients with HIV viral load monitoring while on combination antiretroviral treatment: results from The TREAT Asia HIV Observational Database. | BMC infectious diseases 20100101 |
| Tetherin restricts direct cell-to-cell infection of HIV-1. | Retrovirology 20100101 |
| Criticality of timing for anti-HIV therapy initiation. | PloS one 20100101 |
| Oral pre-exposure prophylaxis by anti-retrovirals raltegravir and maraviroc protects against HIV-1 vaginal transmission in a humanized mouse model. | PloS one 20100101 |
| Simultaneous spectrophotometric estimation of tenofovir disoproxil fumarate and Lamivudine in three component tablet formulation containing efavirenz. | Indian journal of pharmaceutical sciences 20100101 |
| Efficacy and Safety of Abacavir/Lamivudine/Zidovudine Plus Tenofovir in HBV/HIV-1 Coinfected Adults: 48-Week Data. | The open AIDS journal 20100101 |
| Effect of Maternal HIV-1 Status and Antiretroviral Drugs on Haematological Profiles of South African Infants in Early Life. | The open AIDS journal 20100101 |
| Incidence of Severe Hepatotoxicity Related to Antiretroviral Therapy in HIV/HCV Coinfected Patients. | AIDS research and treatment 20100101 |
| Lipid Metabolism and Cardiovascular Risk in HIV-1 Infection and HAART: Present and Future Problems. | Cholesterol 20100101 |
| Tuberculosis of spine. | Journal of craniovertebral junction & spine 20100101 |
| Pharmacogenetics - challenges and opportunities ahead. | Frontiers in pharmacology 20100101 |
| Raltegravir in combination with other antiretroviral agents for the treatment of HIV infection. | Infection and drug resistance 20100101 |
| The use of anti-tuberculosis therapy for latent TB infection. | Infection and drug resistance 20100101 |
| Extended use of raltegravir in the treatment of HIV-1 infection: optimizing therapy. | Infection and drug resistance 20100101 |
| Clinical safety and tolerability issues in use of triazole derivatives in management of fungal infections. | Drug, healthcare and patient safety 20100101 |
| Immune reconstitution inflammatory syndrome in a unique clinical scenario. | Indian journal of sexually transmitted diseases and AIDS 20100101 |
| Unusual cause of weight loss in a patient with HIV-hepatitis C virus coinfection. | Indian journal of sexually transmitted diseases and AIDS 20100101 |
| Tenofovir-associated renal dysfunction in clinical practice: An observational cohort from western India. | Indian journal of sexually transmitted diseases and AIDS 20100101 |
| Disseminated histoplasmosis with conjunctival involvement in an immunocompromised patient. | Indian journal of sexually transmitted diseases and AIDS 20100101 |
| Optimizing management of treatment-naïve and treatment-experienced HIV+ patients: the role of maraviroc. | HIV/AIDS (Auckland, N.Z.) 20100101 |
| Novel strategies in the use of lopinavir/ritonavir for the treatment of HIV infection in children. | HIV/AIDS (Auckland, N.Z.) 20100101 |
| An update on the use of Atripla in the treatment of HIV in the United States. | HIV/AIDS (Auckland, N.Z.) 20100101 |
| Role of etravirine in the management of treatment-experienced patients with human immunodeficiency virus type 1. | HIV/AIDS (Auckland, N.Z.) 20100101 |
| Profile of maraviroc: a CCR5 antagonist in the management of treatment-experienced HIV patients. | HIV/AIDS (Auckland, N.Z.) 20100101 |
| Long-term treatment of patients with HIV-1: the role of atazanavir. | HIV/AIDS (Auckland, N.Z.) 20100101 |
| New and emerging agents in the management of lipodystrophy in HIV-infected patients. | HIV/AIDS (Auckland, N.Z.) 20100101 |
| Histological effects of chronic administration of efavirenz on lateral geniculate body of adult Wistar rats. | North American journal of medical sciences 20100101 |
| Viremia, resuppression, and time to resistance in human immunodeficiency virus (HIV) subtype C during first-line antiretroviral therapy in South Africa. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20091215 |
| Synthesis and biological evaluation of C-5 methyl substituted 4-arylthio and 4-aryloxy-3-Iodopyridin-2(1H)-one type anti-HIV agents. | Journal of medicinal chemistry 20091210 |
| Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy. | The New England journal of medicine 20091203 |
| Good neurocognitive performance measured by the international HIV dementia scale in early HIV-1 infection. | Journal of acquired immune deficiency syndromes (1999) 20091201 |
| Activity and molecular modeling of a new small molecule active against NNRTI-resistant HIV-1 mutants. | European journal of medicinal chemistry 20091201 |
| Low-frequency K103N strengthens the impact of transmitted drug resistance on virologic responses to first-line efavirenz or nevirapine-based highly active antiretroviral therapy. | Journal of acquired immune deficiency syndromes (1999) 20091201 |
| Synthesis, pharmacological and antiviral activity of 1,3-thiazepine derivatives. | European journal of medicinal chemistry 20091201 |
| New small-molecule inhibitor class targeting human immunodeficiency virus type 1 virion maturation. | Antimicrobial agents and chemotherapy 20091201 |
| Application of an allele-specific PCR to clinical HIV genotyping samples detects additional K103N mutations in both therapy naïve and experienced patients. | Journal of medical virology 20091201 |
| Validation of an electrospray ionization LC-MS/MS method for quantitative analysis of raltegravir, etravirine, and 9 other antiretroviral agents in human plasma samples. | Therapeutic drug monitoring 20091201 |
| Reversal of growth failure in HIV-infected Thai children treated with non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy. | AIDS patient care and STDs 20091201 |
| Satisfactory cross-cultural validity of the ACTG symptom distress module in HIV-1-infected antiretroviral-naive patients. | Clinical trials (London, England) 20091201 |
| Drug-drug interaction between itraconazole and the protease inhibitor lopinavir/ritonavir. | The Annals of pharmacotherapy 20091201 |
| Antiretroviral genotypic resistance mutations in HIV-1 infected Korean patients with virologic failure. | Journal of Korean medical science 20091201 |
| Early and late direct costs in a Southern African antiretroviral treatment programme: a retrospective cohort analysis. | PLoS medicine 20091201 |
| NanoART synthesis, characterization, uptake, release and toxicology for human monocyte-macrophage drug delivery. | Nanomedicine (London, England) 20091201 |
| Effect of efavirenz on high-density lipoprotein antioxidant properties in HIV-infected patients. | British journal of clinical pharmacology 20091201 |
| FDA notifications. Generic efavirenz capsules tentatively approved by FDA. | AIDS alert 20091201 |
| Antiretroviral therapy: new drugs, formulations, ideas, and strategies. | Topics in HIV medicine : a publication of the International AIDS Society, USA 20091201 |
| [Chronic abdominal pain and fever in an Ivoirian woman: Mycobacterium avium-intracellulare duodenitis in an AIDS patient in Abidjan, Cote d'Ivoire]. | Medecine tropicale : revue du Corps de sante colonial 20091201 |
| [Compulsory licensing of efavirenz in Brazil in 2007: contextualization]. | Revista panamericana de salud publica = Pan American journal of public health 20091201 |
| [Chemical characteristics, mechanism of action and antiviral activity of etravirine]. | Enfermedades infecciosas y microbiologia clinica 20091201 |
| [Etravirine: genetic barrier and resistance development]. | Enfermedades infecciosas y microbiologia clinica 20091201 |
| [Role of etravirine in combination antiretroviral therapy]. | Enfermedades infecciosas y microbiologia clinica 20091201 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20091201 |
| (S)-6-Chloro-4-cyclo-propyl-ethynyl-4-trifluoro-methyl-1H-3,1-benzoxazin-2(4H)-one. | Acta crystallographica. Section E, Structure reports online 20091201 |
| Mutation rates and intrinsic fidelity of retroviral reverse transcriptases. | Viruses 20091201 |
| Synthesis and biological evaluation of novel 2-(substituted phenylaminocarbonylmethylthio)-6-(2,6-dichlorobenzyl)-pyrimidin-4(3H)-ones as potent HIV-1 NNRTIs. | Bioorganic & medicinal chemistry 20091115 |
| Substituting nevirapine for efavirenz: risk factors for toxicity in nonnaive patients in a resource-constrained setting. | AIDS (London, England) 20091113 |
| Synthesis and anti-HIV activity evaluation of 2-(4-(naphthalen-2-yl)-1,2,3-thiadiazol-5-ylthio)-N-acetamides as novel non-nucleoside HIV-1 reverse transcriptase inhibitors. | European journal of medicinal chemistry 20091101 |
| Sustained antiretroviral effect of raltegravir after 96 weeks of combination therapy in treatment-naive patients with HIV-1 infection. | Journal of acquired immune deficiency syndromes (1999) 20091101 |
| [Regimen simplification: lopinavir/ritonavir with or without efavirenz]. | Enfermedades infecciosas y microbiologia clinica 20091101 |
| Intracellular accumulation of efavirenz and nevirapine is independent of P-glycoprotein activity in cultured CD4 T cells and primary human lymphocytes. | The Journal of antimicrobial chemotherapy 20091101 |
| Efavirenz: a decade of clinical experience in the treatment of HIV. | The Journal of antimicrobial chemotherapy 20091101 |
| Synthesis of novel uracil non-nucleoside derivatives as potential reverse transcriptase inhibitors of HIV-1. | Archiv der Pharmazie 20091101 |
| Antiretroviral drug-resistant mutations at baseline and at time of failure of antiretroviral therapy in HIV type 1-coinfected TB patients. | AIDS research and human retroviruses 20091101 |
| A novel polymorphism in ABCB1 gene, CYP2B6*6 and sex predict single-dose efavirenz population pharmacokinetics in Ugandans. | British journal of clinical pharmacology 20091101 |
| FDA notifications. FDA approves generic combination of efavirenz, lamivudine & tenofovir. | AIDS alert 20091101 |
| Drugs in traditional drug classes (nucleoside reverse transcriptase inhibitor/nonnucleoside reverse transcriptase inhibitor/protease inhibitors) with activity against drug-resistant virus (tipranavir, darunavir, etravirine). | Current opinion in HIV and AIDS 20091101 |
| Human immunodeficiency virus type 1 subtypes prevalence in central China. | Yonsei medical journal 20091031 |
| Efavirenz plasma concentrations did not predict cessation of therapy due to neuropsychiatric symptoms in a large randomized trial. | AIDS (London, England) 20091023 |
| CYP2B6, CYP2A6 and UGT2B7 genetic polymorphisms are predictors of efavirenz mid-dose concentration in HIV-infected patients. | AIDS (London, England) 20091023 |
| Pyrazole NNRTIs 4: selection of UK-453,061 (lersivirine) as a development candidate. | Bioorganic & medicinal chemistry letters 20091015 |
| [Acute renal failure and hypercalcemia in an AIDS patient on tenofovir and low-dose vitamin D therapy with immune reconstitution inflammatory syndrome]. | Medizinische Klinik (Munich, Germany : 1983) 20091015 |
| Antiretroviral compounds and cholesterol efflux from macrophages. | Atherosclerosis 20091001 |
| Discordance in HIV-1 viral loads and antiretroviral drug concentrations comparing semen and blood plasma. | HIV medicine 20091001 |
| Allele and genotype frequencies of cytochrome P450 2B6 gene in a Mongolian population. | Drug metabolism and disposition: the biological fate of chemicals 20091001 |
| Efavirenz dose reduction is safe in patients with high plasma concentrations and may prevent efavirenz discontinuations. | Journal of acquired immune deficiency syndromes (1999) 20091001 |
| Pharmacokinetics and safety of etravirine administered once or twice daily after 2 weeks treatment with efavirenz in healthy volunteers. | Journal of acquired immune deficiency syndromes (1999) 20091001 |
| Dissection of regenerating T-Cell responses against tuberculosis in HIV-infected adults sensitized by Mycobacterium tuberculosis. | American journal of respiratory and critical care medicine 20091001 |
| Clinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in Nigeria. | Journal of acquired immune deficiency syndromes (1999) 20091001 |
| Development of HIV-1 drug resistance through 144 weeks in antiretroviral-naïve subjects on emtricitabine, tenofovir disoproxil fumarate, and efavirenz compared with lamivudine/zidovudine and efavirenz in study GS-01-934. | Journal of acquired immune deficiency syndromes (1999) 20091001 |
| A comparison of HIV-1 drug susceptibility as provided by conventional phenotyping and by a phenotype prediction tool based on viral genotype. | Journal of medical virology 20091001 |
| A liquid chromatography-tandem mass spectrometry assay for quantification of nevirapine, indinavir, atazanavir, amprenavir, saquinavir, ritonavir, lopinavir, efavirenz, tipranavir, darunavir and maraviroc in the plasma of patients infected with HIV. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20091001 |
| Pyrazole NNRTIs 1: design and initial optimisation of a novel template. | Bioorganic & medicinal chemistry letters 20091001 |
| Pyrazole NNRTIs 3: optimisation of physicochemical properties. | Bioorganic & medicinal chemistry letters 20091001 |
| Task shifting for scale-up of HIV care: evaluation of nurse-centered antiretroviral treatment at rural health centers in Rwanda. | PLoS medicine 20091001 |
| FDA notifications. Generic efavirenz/emtricitabine/fenofovir has tentative approval. | AIDS alert 20091001 |
| A prospective, observational cohort study to elicit adverse effects of antiretroviral agents in a remote resource-restricted tribal population of Chhattisgarh. | Indian journal of pharmacology 20091001 |
| Effectiveness of highly active antiretroviral therapy (HAART) used concomitantly with rifampicin in patients with tuberculosis and AIDS. | The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases 20091001 |
| Reply to 'kidney transplantation in a patient with HIV disease'. | Indian journal of nephrology 20091001 |
| Opsoclonus-myoclonus syndrome and HIV-infection. | Journal of the neurological sciences 20090915 |
| CYP2B6 variants and plasma efavirenz concentrations during antiretroviral therapy in Port-au-Prince, Haiti. | The Journal of infectious diseases 20090915 |
| Raltegravir: a new choice in HIV and new chances for research. | Lancet (London, England) 20090905 |
| Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial. | Lancet (London, England) 20090905 |
| Extreme variability in the formation of chlorpyrifos oxon (CPO) in patients poisoned by chlorpyrifos (CPF). | Biochemical pharmacology 20090901 |
| CYP2B6 G516T genotyping in a UK cohort of HIV-positive patients: polymorphism frequency and influence on efavirenz discontinuation. | HIV medicine 20090901 |
| Glucuronidation of the antiretroviral drug efavirenz by UGT2B7 and an in vitro investigation of drug-drug interaction with zidovudine. | Drug metabolism and disposition: the biological fate of chemicals 20090901 |
| The in vivo response of novel buprenorphine metabolites, M1 and M3, to antiretroviral inducers and inhibitors of buprenorphine metabolism. | Basic & clinical pharmacology & toxicology 20090901 |
| Design, synthesis, and SAR of naphthyl-substituted Diarylpyrimidines as non-nucleoside inhibitors of HIV-1 reverse transcriptase. | ChemMedChem 20090901 |
| Synthesis and anti-HIV-1 activity of 1-substiuted 6-(3-cyanobenzoyl) and [(3-cyanophenyl)fluoromethyl]-5-ethyl-uracils. | Archiv der Pharmazie 20090901 |
| 1,2,3-Selenadiazole thioacetanilides: synthesis and anti-HIV activity evaluation. | Bioorganic & medicinal chemistry 20090901 |
| Predictors of virologic failure and genotypic resistance mutation patterns in thai children receiving non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy. | The Pediatric infectious disease journal 20090901 |
| Substrate specificity, regulation, and polymorphism of human cytochrome P450 2B6. | Current drug metabolism 20090901 |
| The history of antiretrovirals: key discoveries over the past 25 years. | Reviews in medical virology 20090901 |
| Changes in cognition during antiretroviral therapy: comparison of 2 different ranking systems to measure antiretroviral drug efficacy on HIV-associated neurocognitive disorders. | Journal of acquired immune deficiency syndromes (1999) 20090901 |
| [Efficacy and safety of TAM-sparing antiretroviral regimens in naïve HIV-positive patients]. | Le infezioni in medicina : rivista periodica di eziologia, epidemiologia, diagnostica, clinica e terapia delle patologie infettive 20090901 |
| Long-term effectiveness and safety outcomes in HIV-1-infected patients after a median time of 6 years on nevirapine. | Current HIV research 20090901 |
| Loss of bone mineral density after antiretroviral therapy initiation, independent of antiretroviral regimen. | Journal of acquired immune deficiency syndromes (1999) 20090815 |
| A randomized comparative trial of continued zidovudine/lamivudine or replacement with tenofovir disoproxil fumarate/emtricitabine in efavirenz-treated HIV-1-infected individuals. | Journal of acquired immune deficiency syndromes (1999) 20090815 |
| Design, synthesis, and structure-activity relationships of 1,3-dihydrobenzimidazol-2-one analogues as anti-HIV agents. | Bioorganic & medicinal chemistry 20090815 |
| Novel 1,2,3-thiadiazole derivatives as HIV-1 NNRTIs with improved potency: Synthesis and preliminary SAR studies. | Bioorganic & medicinal chemistry 20090815 |
| Synthesis and biological evaluation of imidazole thioacetanilides as novel non-nucleoside HIV-1 reverse transcriptase inhibitors. | Bioorganic & medicinal chemistry 20090815 |
| Stepped-dose versus full-dose efavirenz for HIV infection and neuropsychiatric adverse events: a randomized trial. | Annals of internal medicine 20090804 |
| Comparison of side effects with 2 doses of the HIV drug efavirenz. | Annals of internal medicine 20090804 |
| The relationships of ABCB1 3435C>T and CYP2B6 516G>T with high-density lipoprotein cholesterol in HIV-infected patients receiving Efavirenz. | Clinical pharmacology and therapeutics 20090801 |
| Human immunodeficiency virus: 25 years of diagnostic and therapeutic strategies and their impact on hepatitis B and C virus. | Medical microbiology and immunology 20090801 |
| Pharmacokinetics of plasma efavirenz and CYP2B6 polymorphism in southern Chinese. | Therapeutic drug monitoring 20090801 |
| Synthesis, antiviral activity and molecular modeling of oxoquinoline derivatives. | Bioorganic & medicinal chemistry 20090801 |
| Effects of oral posaconazole on the pharmacokinetics of atazanavir alone and with ritonavir or with efavirenz in healthy adult volunteers. | Journal of acquired immune deficiency syndromes (1999) 20090801 |
| 96-Week MERIT ES analysis shows efficacy of Celsentri=Selzentry. | AIDS patient care and STDs 20090801 |
| Raltegravir as effective as efavirenz in 144-week data. | AIDS patient care and STDs 20090801 |
| Nucleoside reverse transcriptase inhibitor-sparing regimen (nonnucleoside reverse transcriptase inhibitor + protease inhibitor) was more likely associated with resistance comparing to nonnucleoside reverse transcriptase inhibitor or protease inhibitor + nucleoside reverse transcriptase inhibitor in the randomized ANRS 121 trial. | AIDS (London, England) 20090731 |
| Rapid method for the quantitative determination of efavirenz in human plasma. | Journal of pharmaceutical and biomedical analysis 20090712 |
| A combination drug of abacavir-lamivudine-zidovudine (Trizivir) for treating HIV infection and AIDS. | The Cochrane database of systematic reviews 20090708 |
| Cytotoxicological analysis of a gp120 binding aptamer with cross-clade human immunodeficiency virus type 1 entry inhibition properties: comparison to conventional antiretrovirals. | Antimicrobial agents and chemotherapy 20090701 |
| A randomized trial of two-drug versus three-drug tenofovir-containing maintenance regimens in virologically controlled HIV-1 patients. | The Journal of antimicrobial chemotherapy 20090701 |
| The effect of individual antiretroviral drugs on body composition in HIV-infected persons initiating highly active antiretroviral therapy. | Journal of acquired immune deficiency syndromes (1999) 20090701 |
| Influence of the cytochrome P450 2B6 genotype on population pharmacokinetics of efavirenz in human immunodeficiency virus patients. | Antimicrobial agents and chemotherapy 20090701 |
| Validation and clinical application of a high performance liquid chromatography tandem mass spectrometry (LC-MS/MS) method for the quantitative determination of 10 anti-retrovirals in human peripheral blood mononuclear cells. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20090701 |
| Rilpivirine: a novel non-nucleoside reverse transcriptase inhibitor. | Expert opinion on investigational drugs 20090701 |
| Artemisinin--a possible CYP2B6 probe substrate? | Biopharmaceutics & drug disposition 20090701 |
| Polyclonal B cell differentiation and loss of gastrointestinal tract germinal centers in the earliest stages of HIV-1 infection. | PLoS medicine 20090701 |
| New pyridinone derivatives as potent HIV-1 nonnucleoside reverse transcriptase inhibitors. | Journal of medicinal chemistry 20090625 |
| Efavirenz treatment and false-positive results in benzodiazepine screening tests. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20090615 |
| Efavirenz and nevirapine interactions with rifampicin: resolving the dilemmas? | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20090615 |
| A randomized trial comparing plasma drug concentrations and efficacies between 2 nonnucleoside reverse-transcriptase inhibitor-based regimens in HIV-infected patients receiving rifampicin: the N2R Study. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20090615 |
| Effects of nevirapine and efavirenz on HDL cholesterol levels and reverse cholesterol transport in mice. | Atherosclerosis 20090601 |
| Adherence to first-line antiretroviral therapy affects non-virologic outcomes among patients on treatment for more than 12 months in Lusaka, Zambia. | International journal of epidemiology 20090601 |
| Model-based approach to characterize efavirenz autoinduction and concurrent enzyme induction with carbamazepine. | Antimicrobial agents and chemotherapy 20090601 |
| Regulation of human vitamin D(3) 25-hydroxylases in dermal fibroblasts and prostate cancer LNCaP cells. | Molecular pharmacology 20090601 |
| Antiviral activity of MK-4965, a novel nonnucleoside reverse transcriptase inhibitor. | Antimicrobial agents and chemotherapy 20090601 |
| Population pharmacokinetics of ritonavir-boosted atazanavir in HIV-infected patients and healthy volunteers. | The Journal of antimicrobial chemotherapy 20090601 |
| The nucleoside backbone affects durability of efavirenz- or nevirapine-based highly active antiretroviral therapy in antiretroviral-naive individuals. | Journal of acquired immune deficiency syndromes (1999) 20090601 |
| Simplification of antiretroviral therapy to a single-tablet regimen consisting of efavirenz, emtricitabine, and tenofovir disoproxil fumarate versus unmodified antiretroviral therapy in virologically suppressed HIV-1-infected patients. | Journal of acquired immune deficiency syndromes (1999) 20090601 |
| Maraviroc: perspectives for use in antiretroviral-naive HIV-1-infected patients. | The Journal of antimicrobial chemotherapy 20090601 |
| HIV infection and the central nervous system: a primer. | Neuropsychology review 20090601 |
| Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment. | AIDS (London, England) 20090601 |
| Drug resistance in the Chinese National Pediatric Highly Active Antiretroviral Therapy Cohort: implications for paediatric treatment in the developing world. | International journal of STD & AIDS 20090601 |
| Efavirenz and bone health. | AIDS (London, England) 20090601 |
| Interaction of Ginkgo biloba with efavirenz. | AIDS (London, England) 20090601 |
| Tapping into combination pills for HIV. | Nature reviews. Drug discovery 20090601 |
| How much fat loss is needed for lipoatrophy to become clinically evident? | AIDS research and human retroviruses 20090601 |
| Pattern and predictors of immunologic recovery in human immunodeficiency virus-infected children receiving non-nucleoside reverse transcriptase inhibitor-based highly active antiretroviral therapy. | The Pediatric infectious disease journal 20090601 |
| Efavirenz + emtricitabine + tenofovir: new combination. HIV infection: do not modify ongoing therapy just to use one less tablet. Better adherence than with separate dosing has not been demonstrated, while reduced efficacy is plausible. | Prescrire international 20090601 |
| Evaluation of HIV/AIDS patients' knowledge on antiretroviral drugs. | The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases 20090601 |
| The transport of anti-HIV drugs across blood-CNS interfaces: summary of current knowledge and recommendations for further research. | Antiviral research 20090501 |
| Improvement in lipid profiles over 6 years of follow-up in adults with AIDS and immune reconstitution. | HIV medicine 20090501 |
| Pharmacogenetics-based population pharmacokinetic analysis of efavirenz in HIV-1-infected individuals. | Clinical pharmacology and therapeutics 20090501 |
| Response to zidovudine/didanosine-containing combination antiretroviral therapy among HIV-1 subtype C-infected adults in Botswana: two-year outcomes from a randomized clinical trial. | Journal of acquired immune deficiency syndromes (1999) 20090501 |
| Long-term efficacy and safety of TDM-assisted combination of voriconazole plus efavirenz in an AIDS patient with cryptococcosis and liver cirrhosis. | The Annals of pharmacotherapy 20090501 |
| Synthesis and studies of new 2-(coumarin-4-yloxy)-4,6-(substituted)-S-triazine derivatives as potential anti-HIV agents. | Archiv der Pharmazie 20090501 |
| Leishmania infantum amastigotes enhance HIV-1 production in cocultures of human dendritic cells and CD4 T cells by inducing secretion of IL-6 and TNF-alpha. | PLoS neglected tropical diseases 20090501 |
| [Tolerance study of a triple first-line antiretroviral combination zidovudine, lamivudine and efavirenz in Dakar, Senegal]. | Bulletin de la Societe de pathologie exotique (1990) 20090501 |
| High rates of regimen change due to drug toxicity among a cohort of South Indian adults with HIV infection initiated on generic, first-line antiretroviral treatment. | The Journal of the Association of Physicians of India 20090501 |
| Heart Disease in Patients with HIV/AIDS-An Emerging Clinical Problem. | Current cardiology reviews 20090501 |
| [Medication change due to side effects or possible long-term complications. Side effect management with vision]. | MMW Fortschritte der Medizin 20090430 |
| [One year with Atripla. Changeover to complete HIV therapy in a single tablet has proven successful]. | MMW Fortschritte der Medizin 20090430 |
| Antiretroviral drug susceptibility among drug-naive adults with recent HIV infection in Rakai, Uganda. | AIDS (London, England) 20090427 |
| Screening and monitoring antiretrovirals and antivirals in the serum of acquired immunodeficiency syndrome patients by micellar liquid chromatography. | Journal of chromatography. A 20090417 |
| Voltammetric studies on the HIV-1 inhibitory drug Efavirenz: the interaction between dsDNA and drug using electrochemical DNA biosensor and adsorptive stripping voltammetric determination on disposable pencil graphite electrode. | Biosensors & bioelectronics 20090415 |
| Effect of rifampicin on efavirenz pharmacokinetics in HIV-infected children with tuberculosis. | Journal of acquired immune deficiency syndromes (1999) 20090415 |
| The combined effect of modern highly active antiretroviral therapy regimens and adherence on mortality over time. | Journal of acquired immune deficiency syndromes (1999) 20090415 |
| Proinflammatory cytokine changes in clinically stable, virologically suppressed, HIV-infected patients switching from protease inhibitors to abacavir. | Journal of acquired immune deficiency syndromes (1999) 20090415 |
| Maraviroc: a coreceptor CCR5 antagonist for management of HIV infection. | American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20090415 |
| Nonnucleoside reverse transcriptase inhibitor pharmacokinetics in a large unselected cohort of HIV-infected women. | Journal of acquired immune deficiency syndromes (1999) 20090415 |
| Indolylarylsulfones bearing natural and unnatural amino acids. Discovery of potent inhibitors of HIV-1 non-nucleoside wild type and resistant mutant strains reverse transcriptase and coxsackie B4 virus. | Journal of medicinal chemistry 20090409 |
| Effectiveness and safety of simplification from tenofovir-lamivudine (TDF-3TC) to tenofovir-emtricitabine (TDF-FTC) co-formulation (Truvada) in virologically suppressed HIV-infected patients on HAART. | European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology 20090401 |
| Simultaneous quantification of a non-nucleoside reverse transcriptase inhibitor efavirenz, a nucleoside reverse transcriptase inhibitor emtricitabine and a nucleotide reverse transcriptase inhibitor tenofovir in plasma by liquid chromatography positive ion electrospray tandem mass spectrometry. | Biomedical chromatography : BMC 20090401 |
| Novel modifications in the series of O-(2-phthalimidoethyl)-N-substituted thiocarbamates and their ring-opened congeners as non-nucleoside HIV-1 reverse transcriptase inhibitors. | European journal of medicinal chemistry 20090401 |
| Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV. | International journal of antimicrobial agents 20090401 |
| Viral dynamics of hepatitis B virus DNA in human immunodeficiency virus-1-hepatitis B virus coinfected individuals: similar effectiveness of lamivudine, tenofovir, or combination therapy. | Hepatology (Baltimore, Md.) 20090401 |
| Association of high T allele frequency of CYP2B6 G516T polymorphism among ethnic south Indian HIV-infected patients with elevated plasma efavirenz and nevirapine. | The Journal of antimicrobial chemotherapy 20090401 |
| Raltegravir: the first HIV type 1 integrase inhibitor. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20090401 |
| In vivo analysis of efavirenz metabolism in individuals with impaired CYP2A6 function. | Pharmacogenetics and genomics 20090401 |
| Synthesis and biological evaluation of N4-(hetero)arylsulfonylquinoxalinones as HIV-1 reverse transcriptase inhibitors. | Bioorganic & medicinal chemistry 20090401 |
| Elite suppressor-derived HIV-1 envelope glycoproteins exhibit reduced entry efficiency and kinetics. | PLoS pathogens 20090401 |
| Therapeutic effects of Nigella sativa on chronic HAART-induced hyperinsulinemia in rats. | Canadian journal of physiology and pharmacology 20090401 |
| CYP2B6 (c.516G-->T) and CYP2A6 (*9B and/or *17) polymorphisms are independent predictors of efavirenz plasma concentrations in HIV-infected patients. | British journal of clinical pharmacology 20090401 |
| The RNA polymerase dictates ORF1 requirement and timing of LINE and SINE retrotransposition. | PLoS genetics 20090401 |
| [Establishment of pharmacological evaluation system for non-nucleoside reverse-transcriptase inhibitors resistant HIV-1]. | Yao xue xue bao = Acta pharmaceutica Sinica 20090401 |
| Metabolic effects associated to the highly active antiretroviral therapy (HAART) in AIDS patients. | The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases 20090401 |
| Characterization of vaginal transmission of a simian human immunodeficiency virus (SHIV) encoding the reverse transcriptase gene from HIV-1 in Chinese rhesus macaques. | Virology 20090330 |
| Efavirenz dose reduction to 200 mg once daily in a patient treated with rifampicin. | AIDS (London, England) 20090327 |
| New synthetic technologies for the construction of heterocycles and tryptamines. | Journal of the American Chemical Society 20090318 |
| Associations between CYP2B6 polymorphisms and pharmacokinetics after a single dose of nevirapine or efavirenz in African americans. | The Journal of infectious diseases 20090315 |
| Decreased susceptibility of the cytochrome P450 2B6 variant K262R to inhibition by several clinically important drugs. | Drug metabolism and disposition: the biological fate of chemicals 20090301 |
| Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase. | Antimicrobial agents and chemotherapy 20090301 |
| CYP2B6 G516T polymorphism but not rifampin coadministration influences steady-state pharmacokinetics of efavirenz in human immunodeficiency virus-infected patients in South India. | Antimicrobial agents and chemotherapy 20090301 |
| Physicochemical characterization of efavirenz-cyclodextrin inclusion complexes. | AAPS PharmSciTech 20090301 |
| Ultrasensitive assessment of residual HIV viraemia in HAART-treated patients with persistently undetectable plasma HIV-RNA: a cross-sectional evaluation. | Journal of medical virology 20090301 |
| A paediatric case of acute liver failure associated with efavirenz-based highly active antiretroviral therapy and effective use of raltegravir in combination antiretroviral treatment after liver transplantation. | The Journal of antimicrobial chemotherapy 20090301 |
| Influence of liver fibrosis stage on plasma levels of efavirenz in HIV-infected patients with chronic hepatitis B or C. | The Journal of antimicrobial chemotherapy 20090301 |
| Etravirine and rilpivirine: nonnucleoside reverse transcriptase inhibitors with activity against human immunodeficiency virus type 1 strains resistant to previous nonnucleoside agents. | Pharmacotherapy 20090301 |
| Predicting factors for unsuccessful switching from nevirapine to efavirenz in HIV-infected patients who developed nevirapine-associated skin rash. | International journal of STD & AIDS 20090301 |
| Safety and efficacy of nevirapine- and efavirenz-based antiretroviral treatment in adults treated for TB-HIV co-infection in Botswana. | The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease 20090301 |
| Timing the emergence of resistance to anti-HIV drugs with large genetic barriers. | PLoS computational biology 20090301 |
| FDA notifications. Efavirenz 100 mg scored tablets approved for pediatric treatment. | AIDS alert 20090301 |
| Isentress equal to Sustiva in first line therapy. | Project Inform perspective 20090301 |
| Hyperhidrosis in association with efavirenz. | AIDS patient care and STDs 20090301 |
| Specific targeting of highly conserved residues in the HIV-1 reverse transcriptase primer grip region. 2. Stereoselective interaction to overcome the effects of drug resistant mutations. | Journal of medicinal chemistry 20090226 |
| Novel indazole non-nucleoside reverse transcriptase inhibitors using molecular hybridization based on crystallographic overlays. | Journal of medicinal chemistry 20090226 |
| Antiretroviral therapy and congenital abnormalities in infants born to HIV-infected women in the UK and Ireland, 1990-2007. | AIDS (London, England) 20090220 |
| Discovery of chiral cyclopropyl dihydro-alkylthio-benzyl-oxopyrimidine (S-DABO) derivatives as potent HIV-1 reverse transcriptase inhibitors with high activity against clinically relevant mutants. | Journal of medicinal chemistry 20090212 |
| Efavirenz Mannich bases: synthesis, anti-HIV and antitubercular activities. | Journal of enzyme inhibition and medicinal chemistry 20090201 |
| Low prevalence of insulin resistance among HIV-infected children receiving nonnucleoside reverse transcriptase inhibitor-based highly active antiretroviral therapy in Thailand. | HIV medicine 20090201 |
| Inhibition of human immunodeficiency virus type 1 infection by the candidate microbicide dapivirine, a nonnucleoside reverse transcriptase inhibitor. | Antimicrobial agents and chemotherapy 20090201 |
| Structural modifications of DAPY analogues with potent anti-HIV-1 activity. | ChemMedChem 20090201 |
| Steady-state pharmacokinetics of lopinavir/ritonavir in combination with efavirenz in human immunodeficiency virus-infected pediatric patients. | The Pediatric infectious disease journal 20090201 |
| A prospective study evaluating clinical outcomes and costs of three NNRTI-based HAART regimens in Kerala, India. | Journal of clinical pharmacy and therapeutics 20090201 |
| Head-to-head comparison of two first-line regimens and an NRTI-sparing regimen for initial therapy of HIV-1 infection: what should we start? | Current HIV/AIDS reports 20090201 |
| Pharmacologic aspects of new antiretroviral drugs. | Current HIV/AIDS reports 20090201 |
| Warfarin-antiretroviral interactions. | The Annals of pharmacotherapy 20090201 |
| Pregnancy among HIV-infected refugees in Rhode Island. | AIDS care 20090201 |
| Induction of multiple drug transporters by efavirenz. | Journal of pharmacological sciences 20090201 |
| [Atazanavir-induced nephrolithiasis]. | Enfermedades infecciosas y microbiologia clinica 20090201 |
| Pharmacokinetic interaction between efavirenz and ketoconazole in rats. | Xenobiotica; the fate of foreign compounds in biological systems 20090201 |
| Role of NEDD8 in HIV-associated lipodystrophy. | Differentiation; research in biological diversity 20090201 |
| Successful genotype-tailored treatment with small-dose efavirenz. | AIDS (London, England) 20090128 |
| Mutations at human immunodeficiency virus type 1 reverse transcriptase tryptophan repeat motif attenuate the inhibitory effect of efavirenz on virus production. | Virology 20090120 |
| Minority quasispecies of drug-resistant HIV-1 that lead to early therapy failure in treatment-naive and -adherent patients. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20090115 |
| Efavirenz-induced osteomalacia. | AIDS (London, England) 20090114 |
| Non-nucleoside HIV-1 reverse transcriptase inhibitors di-halo-indolyl aryl sulfones achieve tight binding to drug-resistant mutants by targeting the enzyme-substrate complex. | Antiviral research 20090101 |
| Effectiveness and safety of didanosine, lamivudine and efavirenz versus zidovudine, lamivudine and efavirenz for the initial treatment of HIV-infected patients from the Spanish VACH cohort. | The Journal of antimicrobial chemotherapy 20090101 |
| Quantification of 8 HIV-protease inhibitors and 2 nonnucleoside reverse transcriptase inhibitors by ultra-performance liquid chromatography with diode array detection. | Clinical chemistry 20090101 |
| The effects of Thiazolidinediones on metabolic complications and Lipodystrophy in HIV-infected patients. | PPAR research 20090101 |
| Antiretroviral-related adipocyte dysfunction and lipodystrophy in HIV-infected patients: Alteration of the PPARγ-dependent pathways. | PPAR research 20090101 |
| Human cyclin T1 expression ameliorates a T-cell-specific transcriptional limitation for HIV in transgenic rats, but is not sufficient for a spreading infection of prototypic R5 HIV-1 strains ex vivo. | Retrovirology 20090101 |
| Survey of physician knowledge regarding antiretroviral medications in hospitalized HIV-infected patients. | Journal of the International AIDS Society 20090101 |
| Facilitated monocyte-macrophage uptake and tissue distribution of superparmagnetic iron-oxide nanoparticles. | PloS one 20090101 |
| Prescribing and using self-injectable antiretrovirals: how concordant are physician and patient perspectives? | AIDS research and therapy 20090101 |
| Clinical deterioration during antitubercular treatment at a district hospital in South Africa: the importance of drug resistance and AIDS defining illnesses. | PloS one 20090101 |
| Development and evaluation of a clinical algorithm to monitor patients on antiretrovirals in resource-limited settings using adherence, clinical and CD4 cell count criteria. | Journal of the International AIDS Society 20090101 |
| Raltegravir, elvitegravir, and metoogravir: the birth of 'me-too' HIV-1 integrase inhibitors. | Retrovirology 20090101 |
| Emergence of primary NNRTI resistance mutations without antiretroviral selective pressure in a HAART-treated child. | PloS one 20090101 |
| Absence of a relation between efavirenz plasma concentrations and toxicity-driven efavirenz discontinuations in the EuroSIDA study. | Antiviral therapy 20090101 |
| Is PPARγ a prospective player in HIV-1-associated bone disease? | PPAR research 20090101 |
| A randomized, controlled trial of initial anti-retroviral therapy with abacavir/lamivudine/zidovudine twice-daily compared to atazanavir once-daily with lamivudine/zidovudine twice-daily in HIV-infected patients over 48 weeks (ESS100327, the ACTION Study). | AIDS research and therapy 20090101 |
| Effects of first-line use of nucleoside analogues, efavirenz, and ritonavir-boosted protease inhibitors on lipid levels. | HIV clinical trials 20090101 |
| HIV care and treatment factors associated with improved survival during TB treatment in Thailand: an observational study. | BMC infectious diseases 20090101 |
| Physical and emotional health outcomes after 12 months of public-sector antiretroviral treatment in the Free State Province of South Africa: a longitudinal study using structural equation modelling. | BMC public health 20090101 |
| Efficacy and safety of darunavir and etravirine in an antiretroviral multi-experienced youth with vertically HIV-1 infection. | European journal of medical research 20090101 |
| Rifampin pharmacokinetics in children, with and without human immunodeficiency virus infection, hospitalized for the management of severe forms of tuberculosis. | BMC medicine 20090101 |
| Quality of life and the impact of drug toxicities in a South African community-based antiretroviral programme. | Journal of the International AIDS Society 20090101 |
| Neurologic complications of HIV disease and their treatment. | Topics in HIV medicine : a publication of the International AIDS Society, USA 20090101 |
| TLR2 and TLR4 triggering exerts contrasting effects with regard to HIV-1 infection of human dendritic cells and subsequent virus transfer to CD4+ T cells. | Retrovirology 20090101 |
| Reducing stillbirths: prevention and management of medical disorders and infections during pregnancy. | BMC pregnancy and childbirth 20090101 |
| Mutations in the thumb-connection and RNase H domain of HIV type-1 reverse transcriptase of antiretroviral treatment-experienced patients. | Antiviral therapy 20090101 |
| Constraints on the dominant mechanism for HIV viral dynamics in patients on raltegravir. | Antiviral therapy 20090101 |
| Evolution of drug resistance after virological failure of a first-line highly active antiretroviral therapy regimen in Uganda. | Antiviral therapy 20090101 |
| Role of atazanavir in the treatment of HIV infection. | Therapeutics and clinical risk management 20090101 |
| The triple combination of tenofovir, emtricitabine and efavirenz shows synergistic anti-HIV-1 activity in vitro: a mechanism of action study. | Retrovirology 20090101 |
| Emtricitabine/tenofovir disoproxil fumarate: in combination with a protease inhibitor in HIV-1 infection. | Drugs 20090101 |
| Plasma efavirenz concentrations and the association with CYP2B6-516G >T polymorphism in HIV-infected Thai children. | Antiviral therapy 20090101 |
| Resistance profiles after different periods of exposure to a first-line antiretroviral regimen in a Cameroonian cohort of HIV type-1-infected patients. | Antiviral therapy 20090101 |
| Zidovudine/lamivudine for HIV-1 infection contributes to limb fat loss. | PloS one 20090101 |
| Risk factors for virological failure and subtherapeutic antiretroviral drug concentrations in HIV-positive adults treated in rural northwestern Uganda. | BMC infectious diseases 20090101 |
| Adrenal suppression due to an interaction between ritonavir and injected triamcinolone: a case report. | AIDS research and therapy 20090101 |
| Comparison of brachial and carotid artery ultrasound for assessing extent of subclinical atherosclerosis in HIV: a prospective cohort study. | AIDS research and therapy 20090101 |
| Neuropsychiatric symptoms associated with efavirenz: prevalence, correlates, and management. A neurobehavioral review. | AIDS reviews 20090101 |
| Emerging role of integrase inhibitors in the management of treatment-experienced patients with HIV infection. | Therapeutics and clinical risk management 20090101 |
| Switch from a ZDV/3TC-based regimen to a completely once daily (QD) regimen of emtricitabine/tenofovir DF fixed dose combination plus a third QD agent (SONETT). | European journal of medical research 20090101 |
| Pregnancy outcomes among HIV-infected women undergoing antiretroviral therapy. | The open AIDS journal 20090101 |
| Serum lipid profiles among patients initiating ritonavir-boosted atazanavir versus efavirenz-based regimens. | AIDS research and therapy 20090101 |
| Low-abundance HIV drug-resistant viral variants in treatment-experienced persons correlate with historical antiretroviral use. | PloS one 20090101 |
| Synergistic activation of HIV-1 expression by deacetylase inhibitors and prostratin: implications for treatment of latent infection. | PloS one 20090101 |
| Reduction of the HIV-1 reservoir in resting CD4+ T-lymphocytes by high dosage intravenous immunoglobulin treatment: a proof-of-concept study. | AIDS research and therapy 20090101 |
| Effect of Immunomodulating Adjuvant Dzherelo (Immunoxel) in HIV Infected Patients Receiving Standard Antiretroviral Therapy. | The open virology journal 20090101 |
| The y271 and i274 amino acids in reverse transcriptase of human immunodeficiency virus-1 are critical to protein stability. | PloS one 20090101 |
| Virological efficacy and emergence of drug resistance in adults on antiretroviral treatment in rural Tanzania. | BMC infectious diseases 20090101 |
| Tetraspanins regulate cell-to-cell transmission of HIV-1. | Retrovirology 20090101 |
| Characterization of the patterns of drug-resistance mutations in newly diagnosed HIV-1 infected patients naïve to the antiretroviral drugs. | BMC infectious diseases 20090101 |
| Early initiation of antiretroviral therapy results in decreased morbidity and mortality among patients with TB and HIV. | Journal of the International AIDS Society 20090101 |
| High prevalence of undiagnosed chronic kidney disease among at-risk population in Kinshasa, the Democratic Republic of Congo. | BMC nephrology 20090101 |
| Clinical factors associated with plasma F2-isoprostane levels in HIV-infected adults. | HIV clinical trials 20090101 |
| A model and risk score for predicting nevirapine-associated rash among HIV-infected patients: in settings of low CD4 cell counts and resource limitation. | The open AIDS journal 20090101 |
| HIV-1 resistance to first- and second-generation non-nucleoside reverse transcriptase inhibitors. | AIDS reviews 20090101 |
| Mortality and loss-to-follow-up during the pre-treatment period in an antiretroviral therapy programme under normal health service conditions in Uganda. | BMC public health 20090101 |
| Isolation and characterization of a replication-competent molecular clone of an HIV-1 circulating recombinant form (CRF33_01B). | PloS one 20090101 |
| Bosentan in the treatment of pulmonary arterial hypertension with the focus on the mildly symptomatic patient. | Vascular health and risk management 20090101 |
| Excellent outcomes among HIV+ children on ART, but unacceptably high pre-ART mortality and losses to follow-up: a cohort study from Cambodia. | BMC pediatrics 20090101 |
| Effect of rifampicin-based antitubercular therapy and the cytochrome P450 2B6 516G>T polymorphism on efavirenz concentrations in adults in South Africa. | Antiviral therapy 20090101 |
| Short-term randomized proof-of-principle trial of TMC278 in patients with HIV type-1 who have previously failed antiretroviral therapy. | Antiviral therapy 20090101 |
| Pharmacotherapy of pediatric and adolescent HIV infection. | Therapeutics and clinical risk management 20090101 |
| Managing treatment-experienced pediatric and adolescent HIV patients: role of darunavir. | Therapeutics and clinical risk management 20090101 |
| Five-year follow-up of children with perinatal HIV-1 infection receiving early highly active antiretroviral therapy. | BMC infectious diseases 20090101 |
| Monitoring virologic responses to antiretroviral therapy in HIV-infected adults in Kenya: evaluation of a low-cost viral load assay. | PloS one 20090101 |
| Renal impairment in a rural African antiretroviral programme. | BMC infectious diseases 20090101 |
| Observational study to evaluate clinical outcomes after first-line efavirenz-or lopinavir-ritonavir-based HAART in treatment-naive patients. | Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002) 20090101 |
| Adverse drug reactions to nonnucleoside reverse transcriptase inhibitor-based antiretroviral regimen: a 24-week prospective study. | Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002) 20090101 |
| Antiretroviral therapy initiation before, during, or after pregnancy in HIV-1-infected women: maternal virologic, immunologic, and clinical response. | PloS one 20090101 |
| Tenofovir-emtricitabine-efavirenz in HIV-I-infected adults in Senegal: a 96-week pilot trial in treatment-naive patients. | Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002) 20090101 |
| Comparison of 3-drug versus 4-drug and PI versus non-PI combinations as initial HAART: experience from 1998 to 2007. | Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002) 20090101 |
| Evidence for limited genetic compartmentalization of HIV-1 between lung and blood. | PloS one 20090101 |
| Brazilian Network for HIV Drug Resistance Surveillance: a survey of individuals recently diagnosed with HIV. | Journal of the International AIDS Society 20090101 |
| Perinatal acquisition of drug-resistant HIV-1 infection: mechanisms and long-term outcome. | Retrovirology 20090101 |
| [Budget impact of a set-dose combination of efavirenz-emtricitabine-tenofovir in the treatment of patients infected with HIV-1]. | Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria 20090101 |
| Early outcomes of MDR-TB treatment in a high HIV-prevalence setting in Southern Africa. | PloS one 20090101 |
| The risk of virologic failure decreases with duration of HIV suppression, at greater than 50% adherence to antiretroviral therapy. | PloS one 20090101 |
| Drugs associated with more suicidal ideations are also associated with more suicide attempts. | PloS one 20090101 |
| XVII International AIDS Conference: From Evidence to Action - Clinical and biomedical prevention science. | Journal of the International AIDS Society 20090101 |
| XVII International AIDS Conference: From Evidence to Action - AIDS 2008 and the global response to AIDS. | Journal of the International AIDS Society 20090101 |
| Virological and immunological responses to efavirenz or boosted lopinavir as first-line therapy for patients with HIV. | Antiviral therapy 20090101 |
| The impact of combination antiretroviral therapy and its interruption on anxiety, stress, depression and quality of life in Thai patients. | The open AIDS journal 20090101 |
| Influence of non-nucleoside reverse transcriptase inhibitors (efavirenz and nevirapine) on the pharmacodynamic activity of gliclazide in animal models. | Diabetology & metabolic syndrome 20090101 |
| Whole body bone scintigraphy in tenofovir-related osteomalacia: a case report. | Journal of medical case reports 20090101 |
| High molecular weight form of adiponectin in antiretroviral drug-induced dyslipidemia in HIV-infected Japanese individuals based on in vivo and in vitro analyses. | Internal medicine (Tokyo, Japan) 20090101 |
| Barriers to the care of HIV-infected children in rural Zambia: a cross-sectional analysis. | BMC infectious diseases 20090101 |
| Immune control of HIV-1 infection after therapy interruption: immediate versus deferred antiretroviral therapy. | BMC infectious diseases 20090101 |
| HLA-Cw*04 allele associated with nevirapine-induced rash in HIV-infected Thai patients. | AIDS research and therapy 20090101 |
| Five-year follow up of genotypic resistance patterns in HIV-1 subtype C infected patients in Botswana after failure of thymidine analogue-based regimens. | Journal of the International AIDS Society 20090101 |
| Oxidative imbalance in HIV-1 infected patients treated with antiretroviral therapy. | Journal of biomedicine & biotechnology 20090101 |
| RT-SHIV subpopulation dynamics in infected macaques during anti-HIV therapy. | Retrovirology 20090101 |
| RT-SHIV, an infectious CCR5-tropic chimeric virus suitable for evaluating HIV reverse transcriptase inhibitors in macaque models. | AIDS research and therapy 20090101 |
| The cost effectiveness of home-based provision of antiretroviral therapy in rural Uganda. | Applied health economics and health policy 20090101 |
| Viral load decay in antiretroviral-naïve patients receiving once-daily tenofovir and emtricitabine plus twice-daily nevirapine. | HIV clinical trials 20090101 |
| The prognosis of late presenters in the era of highly active antiretroviral therapy in serbia. | The open virology journal 20090101 |
| Progress in basic and clinical research on HIV resistance: report on the XVIII International HIV Drug Resistance Workshop. | Antiviral therapy 20090101 |
| Treatment of HIV infection: Swedish recommendations 2009. | Scandinavian journal of infectious diseases 20090101 |
| Factors influencing global antiretroviral procurement prices. | BMC public health 20090101 |
| Safety and tolerability of artemether-lumefantrine versus dihydroartemisinin-piperaquine for malaria in young HIV-infected and uninfected children. | Malaria journal 20090101 |
| German-Austrian recommendations for HIV1-therapy in pregnancy and in HIV1-exposed newborn, update 2008. | European journal of medical research 20090101 |
| Raltegravir in treatment naive patients. | European journal of medical research 20090101 |
| The association between alcohol use, alcohol use disorders and tuberculosis (TB). A systematic review. | BMC public health 20090101 |
| Combination antiretroviral drugs in PLGA nanoparticle for HIV-1. | BMC infectious diseases 20090101 |
| Early severe morbidity and resource utilization in South African adults on antiretroviral therapy. | BMC infectious diseases 20090101 |
| HIV reverse transcriptase: structural interpretation of drug resistant genetic variants from India. | Bioinformation 20090101 |
| Impact of previous virological treatment failures and adherence on the outcome of antiretroviral therapy in 2007. | PloS one 20090101 |
| Long term outcomes of antiretroviral therapy in a large HIV/AIDS care clinic in urban South Africa: a prospective cohort study. | Journal of the International AIDS Society 20090101 |
| Treatment outcomes and plasma level of ritonavir-boosted lopinavir monotherapy among HIV-infected patients who had NRTI and NNRTI failure. | AIDS research and therapy 20090101 |
| Effectiveness and safety of antiretrovirals with rifampicin: crucial issues for high-burden countries. | Antiviral therapy 20090101 |
| Adipocyte differentiation, mitochondrial gene expression and fat distribution: differences between zidovudine and tenofovir after 6 months. | Antiviral therapy 20090101 |
| Correlations between atazanavir C(trough )and hyperbilirubinemia: a case report. | Journal of medical case reports 20090101 |
| Long-term impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals (ACTG 5097s). | HIV clinical trials 20090101 |
| Virologic suppression, treatment adherence, and improved quality of life on a once-daily efavirenz-based regimen in treatment-Naïve HIV-1-infected patients over 96 weeks. | HIV clinical trials 20090101 |
| Resistance and virological response analyses in a three initial treatment strategy trial: a substudy of the INITIO trial. | HIV clinical trials 20090101 |
| Long-term efficacy and safety of once-daily nevirapine in combination with tenofovir and emtricitabine in the treatment of HIV-infected patients: a 72-week prospective multicenter study (TENOR-trial). | European journal of medical research 20090101 |
| Genital tuberculosis as the cause of tuboovarian abscess in an immunosuppressed patient. | Infectious diseases in obstetrics and gynecology 20090101 |
| Raltegravir: The evidence of its therapeutic value in HIV-1 infection. | Core evidence 20090101 |
| Etravirine (TMC-125): The evidence for its place in the treatment of HIV-1 infection. | Core evidence 20090101 |
| Immune reconstitution inflammatory syndrome in AIDS-related non-hodgkin's lymphoma. | Indian journal of medical and paediatric oncology : official journal of Indian Society of Medical & Paediatric Oncology 20090101 |
| Rapid and persistent selection of the K103N mutation as a majority quasispecies in a HIV1-patient exposed to efavirenz for three weeks: a case report and review of the literature. | Journal of medical case reports 20090101 |
| Severe myositis on commencement of efavirenz, abacavir and lamivudine, in the absence of lactic acidosis or classical abacavir hypersensitivity. | BMJ case reports 20090101 |
| CCR5 inhibitors: Emerging promising HIV therapeutic strategy. | Indian journal of sexually transmitted diseases and AIDS 20090101 |
| Clinico-epidemiological profile of HIV/TB coinfected patients in Vadodara, Gujarat. | Indian journal of sexually transmitted diseases and AIDS 20090101 |
| Role of darunavir in the management of HIV infection. | HIV/AIDS (Auckland, N.Z.) 20090101 |
| Pharmacologic and nonpharmacologic options for the management of HIV infection during pregnancy. | HIV/AIDS (Auckland, N.Z.) 20090101 |
| Neuropsychiatric sequelae in an efavirenz treated patient with hepatitis B. | BMJ case reports 20090101 |
| Limited-sampling strategies for anti-infective agents: systematic review. | The Canadian journal of hospital pharmacy 20090101 |
| Efavirenz induces CYP2B6-mediated hydroxylation of bupropion in healthy subjects. | Journal of acquired immune deficiency syndromes (1999) 20081215 |
| Design of annulated pyrazoles as inhibitors of HIV-1 reverse transcriptase. | Journal of medicinal chemistry 20081211 |
| Detection of low-frequency K103N mutants after unstructured discontinuation of efavirenz in the presence of the CYP2B6 516 TT polymorphism. | The Journal of antimicrobial chemotherapy 20081201 |
| Effects of the HIV treatment drugs nevirapine and efavirenz on brain creatine kinase activity. | Metabolic brain disease 20081201 |
| An HPLC-PDA method for the simultaneous quantification of the HIV integrase inhibitor raltegravir, the new nonnucleoside reverse transcriptase inhibitor etravirine, and 11 other antiretroviral agents in the plasma of HIV-infected patients. | Therapeutic drug monitoring 20081201 |
| Atazanavir: its role in HIV treatment. | Expert review of anti-infective therapy 20081201 |
| Gilead AIDS pill effective in study with weekends off. | The AIDS reader 20081201 |
| Renal impairment and hypersensitivity reaction due to efavirenz. | Nephrology (Carlton, Vic.) 20081201 |
| Switch to Viramune safe for some who can't tolerate Sustiva. | Project Inform perspective 20081201 |
| Study shows people can safely switch to Atripla. | Project Inform perspective 20081201 |
| Report from the 2008 joint ICAAC/IDSA meeting. Raltegravir vs. efavirenz in treatment-naive patients. | AIDS clinical care 20081201 |
| Report from the 2008 joint ICAAC/IDSA meeting. Maraviroc vs. efavirenz: a reanalysis of MERIT. | AIDS clinical care 20081201 |
| Increase of R-/S-methadone enantiomer concentration ratio in serum of patients treated with either nevirapine or efavirenz. | Drug metabolism letters 20081201 |
| Effect of African potato (Hypoxis hemerocallidea) on the pharmacokinetics of efavirenz. | South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde 20081201 |
| [The 'induction-maintenance' strategy]. | Enfermedades infecciosas y microbiologia clinica 20081201 |
| [Clinical utility of atazanavir]. | Enfermedades infecciosas y microbiologia clinica 20081201 |
| Efavirenz-rifampicin interaction: therapeutic drug monitoring to efavirenz dosage optimization in HIV/TBC patients. | AIDS (London, England) 20081130 |
| Regression of HIV-related diffuse large B-cell lymphoma in response to antiviral therapy alone. | Blood 20081115 |
| Human immunodeficiency virus-induced uveitis: intraocular and plasma human immunodeficiency virus-1 RNA loads. | Ophthalmology 20081101 |
| Efficacy and tolerability of nevirapine- versus efavirenz-containing regimens in HIV-infected Thai children. | International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases 20081101 |
| Impact of lipoatrophy on quality of life in HIV patients receiving anti-retroviral therapy. | AIDS care 20081101 |
| Changes in antioxidant profile among HIV-infected individuals on generic highly active antiretroviral therapy in southern India. | International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases 20081101 |
| Prevalence of etravirine-associated mutations in clinical samples with resistance to nevirapine and efavirenz. | The Journal of antimicrobial chemotherapy 20081101 |
| Switch from zidovudine- to non-zidovudine-containing regimens is associated with modest haematological improvement and no obvious clinical benefit: a substudy of the ANRS 099 ALIZE trial. | The Journal of antimicrobial chemotherapy 20081101 |
| Modeling, prediction, and in vitro in vivo correlation of CYP3A4 induction. | Drug metabolism and disposition: the biological fate of chemicals 20081101 |
| Sensitive analysis of anti-HIV drugs, efavirenz, lopinavir and ritonavir, in human hair by liquid chromatography coupled with tandem mass spectrometry. | Rapid communications in mass spectrometry : RCM 20081101 |
| Towards novel S-DABOC inhibitors: synthesis, biological investigation, and molecular modeling studies. | Bioorganic & medicinal chemistry letters 20081101 |
| Slow efavirenz metabolism genotype is common in Botswana. | Journal of acquired immune deficiency syndromes (1999) 20081101 |
| HIV pharmacogenetics in clinical practice: recent achievements and future challenges. | Current HIV research 20081101 |
| Does short-term virologic failure translate to clinical events in antiretroviral-naïve patients initiating antiretroviral therapy in clinical practice? | AIDS (London, England) 20081101 |
| Short communication: Different mutation patterns in subtype CRF06_cpx after mother-to-child transmission. | AIDS research and human retroviruses 20081101 |
| Raltegravir phase III study data released. | AIDS patient care and STDs 20081101 |
| [Potential of integrase inhibitors to deplete HIV reservoirs or prevent their replenishment]. | Enfermedades infecciosas y microbiologia clinica 20081101 |
| [Pharmacokinetics and interactions of raltegravir]. | Enfermedades infecciosas y microbiologia clinica 20081101 |
| [Secondary effects associated with raltegravir]. | Enfermedades infecciosas y microbiologia clinica 20081101 |
| [Role of the new molecules in antiretroviral therapy. Position of raltegravir]. | Enfermedades infecciosas y microbiologia clinica 20081101 |
| Low trough levels of tipranavir in a combination antiretroviral therapy of tipranavir/ritonavir and tenofovir require therapeutic drug monitoring. | European journal of medical research 20081027 |
| Discovery of 3-{5-[(6-amino-1H-pyrazolo[3,4-b]pyridine-3-yl)methoxy]-2-chlorophenoxy}-5-chlorobenzonitrile (MK-4965): a potent, orally bioavailable HIV-1 non-nucleoside reverse transcriptase inhibitor with improved potency against key mutant viruses. | Journal of medicinal chemistry 20081023 |
| Bayesian network analyses of resistance pathways against efavirenz and nevirapine. | AIDS (London, England) 20081018 |
| Efavirenz versus nevirapine-based initial treatment of HIV infection: clinical and virological outcomes in Southern African adults. | AIDS (London, England) 20081018 |
| The 3-year renal safety of a tenofovir disoproxil fumarate vs. a thymidine analogue-containing regimen in antiretroviral-naive patients. | AIDS (London, England) 20081018 |
| Didanosine, lamivudine, and efavirenz versus zidovudine, lamivudine, and efavirenz for the initial treatment of HIV type 1 infection: final analysis (48 weeks) of a prospective, randomized, noninferiority clinical trial, GESIDA 3903. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20081015 |
| Phase II study of vicriviroc versus efavirenz (both with zidovudine/lamivudine) in treatment-naive subjects with HIV-1 infection. | The Journal of infectious diseases 20081015 |
| 1,2,3-Thiadiazole thioacetanilides as a novel class of potent HIV-1 non-nucleoside reverse transcriptase inhibitors. | Bioorganic & medicinal chemistry letters 20081015 |
| Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1. | Journal of medicinal chemistry 20081009 |
| Pharmacokinetic interactions between depot medroxyprogesterone acetate and combination antiretroviral therapy. | Fertility and sterility 20081001 |
| Trends in the prescription of antiretroviral drugs and impact on plasma HIV-RNA measurements. | The Journal of antimicrobial chemotherapy 20081001 |
| Investigation of the mechanisms underlying the differential effects of the K262R mutation of P450 2B6 on catalytic activity. | Molecular pharmacology 20081001 |
| MAPPIT (MAmmalian Protein-Protein Interaction Trap) as a tool to study HIV reverse transcriptase dimerization in intact human cells. | Journal of virological methods 20081001 |
| Efavirenz concentrations in HIV-infected patients with and without viral hepatitis. | British journal of clinical pharmacology 20081001 |
| A randomized trial of combination hepatitis B therapy in HIV/HBV coinfected antiretroviral naïve individuals in Thailand. | Hepatology (Baltimore, Md.) 20081001 |
| Liver enzymes improve over twenty-four months of first-line non-nucleoside reverse transcriptase inhibitor-based therapy in rural Uganda. | AIDS patient care and STDs 20081001 |
| The pharmacokinetics and pharmacogenomics of efavirenz and lopinavir/ritonavir in HIV-infected persons requiring hemodialysis. | AIDS (London, England) 20081001 |
| The cost-effectiveness of HLA-B*5701 genetic screening to guide initial antiretroviral therapy for HIV. | AIDS (London, England) 20081001 |
| Cystoprostatectomy with ileal neobladder for treatment of severe cystitis glandularis in an AIDS patient. | Clinics (Sao Paulo, Brazil) 20081001 |
| [Two novel fixed formulations of nucleoside analogues (tenofovir-emtricitabine, and abacavir-lamivudine). Prospective, open study on clinical practice and therapeutic perspectives, in patients naïve and in subjects pre-treated with antiretrovirals]. | Recenti progressi in medicina 20081001 |
| [Maraviroc efficacy in clinical studies on the development of the molecule]. | Enfermedades infecciosas y microbiologia clinica 20081001 |
| Lopinavir/ritonavir in the treatment of HIV-1 infection: a review. | Therapeutics and clinical risk management 20081001 |
| Miscellaneous. | Indian journal of pharmacology 20081001 |
| Therapeutic monitoring is necessary for the association itraconazole and efavirenz in a patient with AIDS and disseminated histoplasmosis. | AIDS (London, England) 20080912 |
| Clinical impact of patient population differences and genomic variation in efavirenz therapy. | AIDS (London, England) 20080912 |
| Validation of the Accutrend lactate meter for hyperlactatemia screening during antiretroviral therapy in a resource-poor setting. | International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases 20080901 |
| A survey of the syntheses of active pharmaceutical ingredients for antiretroviral drug combinations critical to access in emerging nations. | Antiviral research 20080901 |
| Effect of treatment with efavirenz on neuropsychiatric adverse events of interferon in HIV/HCV-coinfected patients. | Journal of acquired immune deficiency syndromes (1999) 20080901 |
| Pharmacokinetics of efavirenz when co-administered with rifampin in TB/HIV co-infected patients: pharmacogenetic effect of CYP2B6 variation. | Journal of clinical pharmacology 20080901 |
| CYP2B6: new insights into a historically overlooked cytochrome P450 isozyme. | Current drug metabolism 20080901 |
| Correlation between HIV-1 RNA load in blood and seminal plasma depending on antiretroviral treatment status, regimen and penetration of semen by antiretroviral drugs. | Current HIV research 20080901 |
| HIV infection in the elderly. | Clinical interventions in aging 20080901 |
| Structural basis for the improved drug resistance profile of new generation benzophenone non-nucleoside HIV-1 reverse transcriptase inhibitors. | Journal of medicinal chemistry 20080828 |
| Initial treatment of HIV-1 infection. | The New England journal of medicine 20080828 |
| Initial treatment of HIV-1 infection. | The New England journal of medicine 20080828 |
| Influence of antiretroviral drugs on the pharmacokinetics of prednisolone in HIV-infected individuals. | Journal of acquired immune deficiency syndromes (1999) 20080815 |
| 5-Alkyl-6-benzyl-2-(2-oxo-2-phenylethylsulfanyl)pyrimidin-4(3H)-ones, a series of anti-HIV-1 agents of the dihydro-alkoxy-benzyl-oxopyrimidine family with peculiar structure-activity relationship profile. | Journal of medicinal chemistry 20080814 |
| Endothelial function in human immunodeficiency virus-infected antiretroviral-naive subjects before and after starting potent antiretroviral therapy: The ACTG (AIDS Clinical Trials Group) Study 5152s. | Journal of the American College of Cardiology 20080812 |
| Outcomes of nevirapine- and efavirenz-based antiretroviral therapy when coadministered with rifampicin-based antitubercular therapy. | JAMA 20080806 |
| Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. | JAMA 20080806 |
| CYP3A induction and inhibition by different antiretroviral regimens reflected by changes in plasma 4beta-hydroxycholesterol levels. | European journal of clinical pharmacology 20080801 |
| The role of efavirenz compared with protease inhibitors in the body fat changes associated with highly active antiretroviral therapy. | The Journal of antimicrobial chemotherapy 20080801 |
| Pharmacokinetic interaction between efavirenz and carbamazepine after multiple-dose administration in healthy subjects. | Journal of clinical pharmacology 20080801 |
| Preclinical evaluation of 1H-benzylindole derivatives as novel human immunodeficiency virus integrase strand transfer inhibitors. | Antimicrobial agents and chemotherapy 20080801 |
| Efavirenz replacement by immediate full-dose nevirapine is safe in HIV-1-infected patients in Cambodia. | HIV medicine 20080801 |
| Novel N1-substituted 1,3-dihydro-2H-benzimidazol-2-ones as potent non-nucleoside reverse transcriptase inhibitors. | Bioorganic & medicinal chemistry 20080801 |
| Urogenital tuberculosis in a patient with AIDS: an unusual presentation. | Nature clinical practice. Urology 20080801 |
| Prevalence of possible drug-drug interactions between antiretroviral agents in different age groups in a section of the private health care sector setting in South Africa. | Journal of clinical pharmacy and therapeutics 20080801 |
| Efavirenz in human breast milk, mothers', and newborns' plasma. | Journal of acquired immune deficiency syndromes (1999) 20080801 |
| Lymphocyte mitochondrial depolarization and apoptosis in HIV-1-infected HAART patients. | Journal of acquired immune deficiency syndromes (1999) 20080801 |
| Anti-platelet-activating factor effects of highly active antiretroviral therapy (HAART): a new insight in the drug therapy of HIV infection? | AIDS research and human retroviruses 20080801 |
| Discovery and optimization of pyridazinone non-nucleoside inhibitors of HIV-1 reverse transcriptase. | Bioorganic & medicinal chemistry letters 20080801 |
| Determination of unbound antiretroviral drug concentrations by a modified ultrafiltration method reveals high variability in the free fraction. | Therapeutic drug monitoring 20080801 |
| Two cases of multidrug-resistant human immunodeficiency virus infection treated with atazanavir and lopinavir/ritonavir combination therapy. | Journal of Korean medical science 20080801 |
| The Relationship Between HIV Infection and Cardiovascular Disease. | Current cardiology reviews 20080801 |
| Hepatotoxicity in patients prescribed efavirenz or nevirapine. | European journal of medical research 20080728 |
| A 96-week comparison of lopinavir-ritonavir combination therapy followed by lopinavir-ritonavir monotherapy versus efavirenz combination therapy. | The Journal of infectious diseases 20080715 |
| Selective targeting of the HIV-1 reverse transcriptase catalytic complex through interaction with the 'primer grip' region by pyrrolobenzoxazepinone non-nucleoside inhibitors correlates with increased activity towards drug-resistant mutants. | Biochemical pharmacology 20080715 |
| Targeting of efavirenz loaded tuftsin conjugated poly(propyleneimine) dendrimers to HIV infected macrophages in vitro. | European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 20080703 |
| Pharmacokinetics and tolerability of artesunate and amodiaquine alone and in combination in healthy volunteers. | European journal of clinical pharmacology 20080701 |
| Pharmacy-refill measure of adherence to efavirenz can predict maintenance of HIV viral suppression. | AIDS care 20080701 |
| Safety and efficacy of simvastatin for the treatment of dyslipidemia in human immunodeficiency virus-infected patients receiving efavirenz-based highly active antiretroviral therapy. | Pharmacotherapy 20080701 |
| A multimodal, evidence-based approach to achieve lipid targets in the treatment of antiretroviral-associated dyslipidemia: case report and review of the literature. | Pharmacotherapy 20080701 |
| Improving non-nucleoside reverse transcriptase inhibitors for first-line treatment of HIV infection: the development pipeline and recent clinical data. | Current opinion in drug discovery & development 20080701 |
| Public-health and individual approaches to antiretroviral therapy: township South Africa and Switzerland compared. | PLoS medicine 20080701 |
| Efavirenz--still first-line king? | Expert opinion on drug metabolism & toxicology 20080701 |
| Outlook on Thailand's genomics and computational biology research and development. | PLoS computational biology 20080701 |
| Status epilepticus resulting from severe efavirenz toxicity in an HIV-infected patient. | The AIDS reader 20080701 |
| Minority HIV-1 drug resistance mutations are present in antiretroviral treatment-naïve populations and associate with reduced treatment efficacy. | PLoS medicine 20080701 |
| Transmitted minority drug-resistant HIV variants: a new epidemic? | PLoS medicine 20080701 |
| Concomitant use of nonnucleoside analogue reverse transcriptase inhibitors and rifampicin in TB/HIV type 1-coinfected patients. | AIDS research and human retroviruses 20080701 |
| Maraviroc: a CCR5-receptor antagonist for the treatment of HIV-1 infection. | Clinical therapeutics 20080701 |
| Antiretroviral rounds. Is that 'one pill' treatment enough? | AIDS clinical care 20080701 |
| Severe psoriasis due to cessation of antiretroviral therapy in a patient with human immunodeficiency virus. | The Israel Medical Association journal : IMAJ 20080701 |
| Clinical manifestations and antiretroviral management of HIV/AIDS patients with tuberculosis co-infection in Kramat 128 Hospital. | Acta medica Indonesiana 20080701 |
| Reverse transcriptase inhibitors induce cell differentiation and enhance the immunogenic phenotype in human renal clear-cell carcinoma. | International journal of cancer 20080615 |
| Parallel one-pot synthesis and structure-activity relationship study of symmetric formimidoester disulfides as a novel class of potent non-nucleoside HIV-1 reverse transcriptase inhibitors. | Bioorganic & medicinal chemistry 20080615 |
| Effect of semen sampling frequency on seminal antiretroviral drug concentration. | Clinical pharmacology and therapeutics 20080601 |
| Structural basis for drug resistance mechanisms for non-nucleoside inhibitors of HIV reverse transcriptase. | Virus research 20080601 |
| Comparison of immortalized Fa2N-4 cells and human hepatocytes as in vitro models for cytochrome P450 induction. | Drug metabolism and disposition: the biological fate of chemicals 20080601 |
| Identification and characterization of potent CYP2B6 inhibitors in Woohwangcheongsimwon suspension, an herbal preparation used in the treatment and prevention of apoplexy in Korea and China. | Drug metabolism and disposition: the biological fate of chemicals 20080601 |
| Antiviral efficacy, tolerability and pharmacokinetics of efavirenz in an unselected cohort of HIV-infected children. | The Journal of antimicrobial chemotherapy 20080601 |
| First-line antiretroviral therapy with efavirenz or lopinavir/ritonavir plus two nucleoside analogues: the SUSKA study, a non-randomized comparison from the VACH cohort. | The Journal of antimicrobial chemotherapy 20080601 |
| Mechanisms of inhibition of HIV replication by non-nucleoside reverse transcriptase inhibitors. | Virus research 20080601 |
| Effects of HIV antiretrovirals on the pharmacokinetics of hormonal contraceptives. | The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception 20080601 |
| Successful use of reduced-dose efavirenz in a patient with human immunodeficiency virus infection: case report and review of the literature. | Pharmacotherapy 20080601 |
| Long-term efficacy and tolerance of efavirenz- and nevirapine-containing regimens in adult HIV type 1 Senegalese patients. | AIDS research and human retroviruses 20080601 |
| Short communication: oral lesions in HIV/AIDS patients undergoing HAART including efavirenz. | AIDS research and human retroviruses 20080601 |
| Pharmacogenomics of antiretrovirals. | Recent patents on anti-infective drug discovery 20080601 |
| Atriplatrade mark - HIV therapy in one pill. | Therapeutics and clinical risk management 20080601 |
| The cost-effectiveness analysis of initiating HIV/AIDS treatment with efavirenz-based regimens compared with nevirapine-based regimens in Thailand. | Journal of the Medical Association of Thailand = Chotmaihet thangphaet 20080601 |
| [Current role of tenofovir in clinical medicine]. | Enfermedades infecciosas y microbiologia clinica 20080601 |
| Stability of antiretroviral regimens in patients with viral suppression. | AIDS (London, England) 20080531 |
| Plasma drug concentrations and virologic evaluations after stopping treatment with nonnucleoside reverse-transcriptase inhibitors in HIV type 1-infected children. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20080515 |
| Quantification of protease inhibitors and non-nucleoside reverse transcriptase inhibitors in dried blood spots by liquid chromatography-triple quadrupole mass spectrometry. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20080515 |
| Class-sparing regimens for initial treatment of HIV-1 infection. | The New England journal of medicine 20080515 |
| Initial treatment for HIV infection--an embarrassment of riches. | The New England journal of medicine 20080515 |
| Does tenofovir increase efavirenz hepatotoxicity? | AIDS (London, England) 20080511 |
| Haematological changes after switching from stavudine to zidovudine in HIV-infected children receiving highly active antiretroviral therapy. | HIV medicine 20080501 |
| A study of the binding energies of efavirenz to wild-type and K103N/Y181C HIV-1 reverse transcriptase based on the ONIOM method. | ChemMedChem 20080501 |
| [Efavirenz versus indinavir among HIV-1 naive patients in Abidjan (Ivory Coast)]. | Medecine et maladies infectieuses 20080501 |
| Standard-dose efavirenz vs. standard-dose nevirapine in antiretroviral regimens among HIV-1 and tuberculosis co-infected patients who received rifampicin. | HIV medicine 20080501 |
| Complexity of interactions between voriconazole and antiretroviral agents. | The Annals of pharmacotherapy 20080501 |
| Viral population estimation using pyrosequencing. | PLoS computational biology 20080501 |
| Undetectable HIV-1 viral load in the fluid of bullous skin lesion in a patient receiving highly active antiretroviral therapy. | International journal of STD & AIDS 20080501 |
| Pharmacy refill adherence compared with CD4 count changes for monitoring HIV-infected adults on antiretroviral therapy. | PLoS medicine 20080501 |
| Antiretroviral therapy in developing countries: pharmacologic considerations. | Current opinion in HIV and AIDS 20080501 |
| Switch to efavirenz (EFV) after protease-inhibitor (PI)-failure: explorative analysis of outcome by baseline viral VS tolerability failure. | European journal of medical research 20080430 |
| [Complete HAART in a single pill. New milestone for improving compliance]. | MMW Fortschritte der Medizin 20080428 |
| [HIV therapy and adherence]. | MMW Fortschritte der Medizin 20080428 |
| [One pill--all HAART. Complete divergent HAART in a single tablet per day]. | MMW Fortschritte der Medizin 20080428 |
| Factors associated with the emergence of K65R in patients with HIV-1 infection treated with combination antiretroviral therapy containing tenofovir. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20080415 |
| High prevalence of the CYP2B6 516G-->T(*6) variant and effect on the population pharmacokinetics of efavirenz in HIV/AIDS outpatients in Zimbabwe. | European journal of clinical pharmacology 20080401 |
| Aberrant splicing caused by single nucleotide polymorphism c.516G>T [Q172H], a marker of CYP2B6*6, is responsible for decreased expression and activity of CYP2B6 in liver. | The Journal of pharmacology and experimental therapeutics 20080401 |
| Anti-HIV activity and resistance profile of the CXC chemokine receptor 4 antagonist POL3026. | Molecular pharmacology 20080401 |
| Optimizing efavirenz treatment: CYP2B6 genotyping or therapeutic drug monitoring? | European journal of clinical pharmacology 20080401 |
| Thiocarbamates as non-nucleoside HIV-1 reverse transcriptase inhibitors. Part 1: Parallel synthesis, molecular modelling and structure-activity relationship studies on O-[2-(hetero)arylethyl]-N-phenylthiocarbamates. | Bioorganic & medicinal chemistry 20080401 |
| Thiocarbamates as non-nucleoside HIV-1 reverse transcriptase inhibitors. Part 2: Parallel synthesis, molecular modelling and structure-activity relationship studies on analogues of O-(2-phenylethyl)-N-phenylthiocarbamate. | Bioorganic & medicinal chemistry 20080401 |
| Synthesis and biological evaluation of novel 6-substituted 5-alkyl-2-(arylcarbonylmethylthio)pyrimidin-4(3H)-ones as potent non-nucleoside HIV-1 reverse transcriptase inhibitors. | Bioorganic & medicinal chemistry 20080401 |
| Impact of CYP2B6 983T>C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients. | The Journal of antimicrobial chemotherapy 20080401 |
| Recent availability of two novel, fixed formulations of antiretroviral nucleoside analogues: a 12-month prospective, open-label survey of their practical use and therapeutic perspectives in antiretroviral-naive and -experienced patients. | AIDS patient care and STDs 20080401 |
| Pharmacokinetic interactions of efavirenz and voriconazole in healthy volunteers. | British journal of clinical pharmacology 20080401 |
| Are literature references sufficient for dose recommendations? An FDA case study of efavirenz and rifampin. | Journal of clinical pharmacology 20080401 |
| Effects of CYP3A4 inducers with and without CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers. | British journal of clinical pharmacology 20080401 |
| A novel probe drug interaction study to investigate the effect of selected antiretroviral combinations on the pharmacokinetics of a single oral dose of maraviroc in HIV-positive subjects. | British journal of clinical pharmacology 20080401 |
| Efavirenz-based regimens in treatment-naive patients with a range of pretreatment HIV-1 RNA levels and CD4 cell counts. | The Journal of infectious diseases 20080401 |
| Spectrum of adverse events after generic HAART in southern Indian HIV-infected patients. | AIDS patient care and STDs 20080401 |
| [Evaluation of antiretroviral therapy in HIV-infected adults in the Department of Haematology, University Hospital of Brazzavllle, Congo]. | Bulletin de la Societe de pathologie exotique (1990) 20080401 |
| The debate about marijuana usage in transplant candidates: recent medical evidence on marijuana health effects. | Current opinion in organ transplantation 20080401 |
| New approaches in the treatment of HIV/AIDS - focus on maraviroc and other CCR5 antagonists. | Therapeutics and clinical risk management 20080401 |
| Raltegravir: first in class HIV integrase inhibitor. | Therapeutics and clinical risk management 20080401 |
| 'One pill, once daily': what clinicians need to know about Atriplatrade mark. | Therapeutics and clinical risk management 20080401 |
| FDA notifications. Generic stavudine and efavirenz are tentatively approved by FDA. | AIDS alert 20080401 |
| Association of antiretroviral therapy with fibrinogen levels in HIV-infection. | AIDS (London, England) 20080330 |
| Preexisting resistance to nonnucleoside reverse-transcriptase inhibitors predicts virologic failure of an efavirenz-based regimen in treatment-naive HIV-1-infected subjects. | The Journal of infectious diseases 20080315 |
| Hemochromatosis gene polymorphisms, mitochondrial haplogroups, and peripheral lipoatrophy during antiretroviral therapy. | The Journal of infectious diseases 20080315 |
| Monitoring the development of non-nucleoside reverse transcriptase inhibitor-associated resistant HIV-1 using an electrochemiluminescence-based reverse transcriptase polymerase assay. | Analytical biochemistry 20080301 |
| Pharmacokinetic interaction between efavirenz and dual protease inhibitors in healthy volunteers. | Biopharmaceutics & drug disposition 20080301 |
| A human immunodeficiency virus protease inhibitor is a novel functional inhibitor of human pregnane X receptor. | Drug metabolism and disposition: the biological fate of chemicals 20080301 |
| Lipodystrophy and weight changes: data from the Swiss HIV Cohort Study, 2000-2006. | HIV medicine 20080301 |
| Antiretroviral drug concentrations and HIV RNA in the genital tract of HIV-infected women receiving long-term highly active antiretroviral therapy. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20080301 |
| Efavirenz-induced hypersensitivity reaction manifesting in rash and hepatitis in a Latino male. | The Annals of pharmacotherapy 20080301 |
| Determination of abacavir, amprenavir, didanosine, efavirenz, nevirapine, and stavudine concentration in human plasma by MALDI-TOF/TOF. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20080301 |
| Prevalence and epidemiology of HIV type 1 drug resistance among newly diagnosed therapy-naive patients in Belgium from 2003 to 2006. | AIDS research and human retroviruses 20080301 |
| Impact of residues in the nonnucleoside reverse transcriptase inhibitor binding pocket on HIV-1 reverse transcriptase heterodimer stability. | Current HIV research 20080301 |
| Changes in lipid profile over 24 months among adults on first-line highly active antiretroviral therapy in the home-based AIDS care program in rural Uganda. | Journal of acquired immune deficiency syndromes (1999) 20080301 |
| A case of human bite by an 11-year old HIV positive girl in a paediatrics ward. | African journal of medicine and medical sciences 20080301 |
| Ischemic maculopathy in zidovudine-induced anemia in an HIV-positive man. | Clinical ophthalmology (Auckland, N.Z.) 20080301 |
| HLA-DRB1*01 associated with cutaneous hypersensitivity induced by nevirapine and efavirenz. | AIDS (London, England) 20080219 |
| Maternal 12-month response to antiretroviral therapy following prevention of mother-to-child transmission of HIV type 1, Ivory Coast, 2003-2006. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20080215 |
| Pharmacokinetics and pharmacodynamics of efavirenz and nelfinavir in HIV-infected children participating in an area-under-the-curve controlled trial. | Clinical pharmacology and therapeutics 20080201 |
| Efavirenz accelerates HIV-1 reverse transcriptase ribonuclease H cleavage, leading to diminished zidovudine excision. | Molecular pharmacology 20080201 |
| Triazole derivatives as non-nucleoside inhibitors of HIV-1 reverse transcriptase--structure-activity relationships and crystallographic analysis. | Bioorganic & medicinal chemistry letters 20080201 |
| 3D-QSAR models on clinically relevant K103N mutant HIV-1 reverse transcriptase obtained from two strategic considerations. | Bioorganic & medicinal chemistry letters 20080201 |
| Energetic effects for observed and unobserved HIV-1 reverse transcriptase mutations of residues L100, V106, and Y181 in the presence of nevirapine and efavirenz. | Bioorganic & medicinal chemistry letters 20080201 |
| Intra-individual variability in efavirenz plasma concentrations supports therapeutic drug monitoring based on quarterly sampling in the first year of therapy. | Therapeutic drug monitoring 20080201 |
| Safety and tolerability of depot medroxyprogesterone acetate among HIV-infected women on antiretroviral therapy: ACTG A5093. | Contraception 20080201 |
| Impact of nevirapine or efavirenz co-administration on ritonavir-boosted amprenavir pharmacokinetics in HIV-infected patients. | Fundamental & clinical pharmacology 20080201 |
| A ten-year analysis of the incidence and risk factors for acute pancreatitis requiring hospitalization in an urban HIV clinical cohort. | AIDS patient care and STDs 20080201 |
| Cost-effectiveness analysis of emtricitabine/tenofovir versus lamivudine/zidovudine, in combination with efavirenz, in antiretroviral-naive, HIV-1-infected patients. | Clinical therapeutics 20080201 |
| Hemorrhagic cardiomyopathy in male mice treated with an NNRTI: the role of vitamin K. | Toxicologic pathology 20080201 |
| Validated enantiospecific LC method for determination of (R)-enantiomer impurity in (S)-efavirenz. | Die Pharmazie 20080201 |
| [Polyneuropathies in patients treated with HAART in Bobo-Dioulasso hospital, Burkina Faso]. | Bulletin de la Societe de pathologie exotique (1990) 20080201 |
| FDA notifications. FDA grants tentative approval of generic efavirenz tablets. | AIDS alert 20080201 |
| Comparison of genotypic resistance profiles and virological response between patients starting nevirapine and efavirenz in EuroSIDA. | AIDS (London, England) 20080130 |
| Induction therapy with trizivir plus efavirenz or lopinavir/ritonavir followed by trizivir alone in naive HIV-1-infected adults. | AIDS (London, England) 20080130 |
| Efficacy and tolerability of long-term efavirenz plus nucleoside reverse transcriptase inhibitors for HIV-1 infection. | AIDS (London, England) 20080111 |
| Mechanism of inhibition of HIV-1 reverse transcriptase by the novel broad-range DNA polymerase inhibitor N-{2-[4-(aminosulfonyl)phenyl]ethyl}-2-(2-thienyl)acetamide. | Biochemistry 20080108 |
| Antiretroviral therapy using zidovudine, lamivudine, and efavirenz in South Africa: tolerability and clinical events. | AIDS (London, England) 20080102 |
| Clinical interaction between efavirenz and phenytoin. | AIDS (London, England) 20080102 |
| Synthesis and antiviral activity of new dimeric inhibitors against HIV-1. | Bioorganic & medicinal chemistry 20080101 |
| Comparative evaluation of the inhibitory activities of a series of pyrimidinedione congeners that inhibit human immunodeficiency virus types 1 and 2. | Antimicrobial agents and chemotherapy 20080101 |
| Tenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with zidovudine/lamivudine and efavirenz in treatment-naive patients: 144-week analysis. | Journal of acquired immune deficiency syndromes (1999) 20080101 |
| Pharmacokinetic interaction between voriconazole and efavirenz at steady state in healthy male subjects. | Journal of clinical pharmacology 20080101 |
| Synthesis and antiviral evaluation of 6-(trifluoromethylbenzyl) and 6-(fluorobenzyl) analogues of HIV drugs emivirine and GCA-186. | Archiv der Pharmazie 20080101 |
| Association between exposure to nevirapine and reduced liver fibrosis progression in patients with HIV and hepatitis C virus coinfection. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20080101 |
| Drug interactions between warfarin and efavirenz or lopinavir-ritonavir in clinical treatment. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20080101 |
| Low-level HIV-1 replication and the dynamics of the resting CD4+ T cell reservoir for HIV-1 in the setting of HAART. | BMC infectious diseases 20080101 |
| Oral adverse effects due to the use of Nevirapine. | The journal of contemporary dental practice 20080101 |
| Antiretroviral pre-exposure prophylaxis prevents vaginal transmission of HIV-1 in humanized BLT mice. | PLoS medicine 20080101 |
| Patterns and predictors of the use of different antiretroviral drug regimens at treatment initiation in the UK. | HIV medicine 20080101 |
| Association of efavirenz hypersusceptibility with virologic response in ACTG 368, a randomized trial of abacavir (ABC) in combination with efavirenz (EFV) and indinavir (IDV) in HIV-infected subjects with prior nucleoside analog experience. | HIV clinical trials 20080101 |
| Going beyond efficacy: strategies for cancer pain management. | Current oncology (Toronto, Ont.) 20080101 |
| Summary of presentations at the NIH/NIAID New Humanized Rodent Models 2007 Workshop. | AIDS research and therapy 20080101 |
| The incidence of multidrug and full class resistance in HIV-1 infected patients is decreasing over time (2001-2006) in Portugal. | Retrovirology 20080101 |
| Implementation and effectiveness of antiretroviral therapy in Greenland. | Emerging infectious diseases 20080101 |
| Long-term assessment of didanosine, lamivudine, and efavirenz in antiretroviral-naive patients: 3-year follow-up. | AIDS research and human retroviruses 20080101 |
| The cost of antiretroviral therapy in Haiti. | Cost effectiveness and resource allocation : C/E 20080101 |
| Plasma HIV load and proviral DNA decreases after two standard antiretroviral regimens in HIV-positive patients naïve to antiretrovirals. | Current HIV research 20080101 |
| Twenty-four-week safety and tolerability of nevirapine vs. abacavir in combination with zidovudine/lamivudine as first-line antiretroviral therapy: a randomized double-blind trial (NORA). | Tropical medicine & international health : TM & IH 20080101 |
| Adaptation of antiretroviral therapy in human immunodeficiency virus infection with central nervous system involvement. | Journal of neurovirology 20080101 |
| Overestimates of survival after HAART: implications for global scale-up efforts. | PloS one 20080101 |
| Anti-tuberculosis therapy-induced hepatotoxicity among Ethiopian HIV-positive and negative patients. | PloS one 20080101 |
| Aqueous extracts from peppermint, sage and lemon balm leaves display potent anti-HIV-1 activity by increasing the virion density. | Retrovirology 20080101 |
| Efficacy and safety of once-daily regimens in the treatment of HIV infection. | Drugs 20080101 |
| Extracellular ATP reduces HIV-1 transfer from immature dendritic cells to CD4+ T lymphocytes. | Retrovirology 20080101 |
| Fosamprenavir or atazanavir once daily boosted with ritonavir 100 mg, plus tenofovir/emtricitabine, for the initial treatment of HIV infection: 48-week results of ALERT. | AIDS research and therapy 20080101 |
| Acute renal failure in an AIDS patient on tenofovir: a case report. | Journal of medical case reports 20080101 |
| Characterization of drug resistance in antiretroviral-treated patients infected with HIV-1 CRF02_AG and AGK subtypes in Mali and Burkina Faso. | Antiviral therapy 20080101 |
| Predictors of mortality in HIV-infected patients starting antiretroviral therapy in a rural hospital in Tanzania. | BMC infectious diseases 20080101 |
| Metabolic and immune activation effects of treatment interruption in chronic HIV-1 infection: implications for cardiovascular risk. | PloS one 20080101 |
| Streamlining tasks and roles to expand treatment and care for HIV: randomised controlled trial protocol. | Trials 20080101 |
| Imbalanced effector and regulatory cytokine responses may underlie mycobacterial immune restoration disease. | AIDS research and therapy 20080101 |
| European Commission approves Atripla. | AIDS patient care and STDs 20080101 |
| Impact of switching virologically suppressed, HIV-1-infected patients from twice-daily fixed-dose zidovudine/lamivudine to once-daily fixed-dose tenofovir disoproxil fumarate/emtricitabine. | HIV clinical trials 20080101 |
| Antiviral activity and safety of aplaviroc with lamivudine/zidovudine in HIV-infected, therapy-naive patients: the ASCENT (CCR102881) study. | Antiviral therapy 20080101 |
| Highly diversified multiply drug-resistant HIV-1 quasispecies in PBMCs: a case report. | Retrovirology 20080101 |
| Prevalence of dyslipidemia and dysglycaemia in HIV infected patients. | East African medical journal 20080101 |
| Randomization to once-daily stavudine extended release/lamivudine/efavirenz versus a more frequent regimen improves adherence while maintaining viral suppression. | HIV clinical trials 20080101 |
| How long is the window of opportunity between adherence failure and virologic failure on efavirenz-based HAART? | HIV clinical trials 20080101 |
| Adverse effects of antiretroviral treatment. | Indian journal of dermatology, venereology and leprology 20080101 |
| Mouse T-cells restrict replication of human immunodeficiency virus at the level of integration. | Retrovirology 20080101 |
| Viral complementation allows HIV-1 replication without integration. | Retrovirology 20080101 |
| Risk factors for poor virological outcome at 12 months in a workplace-based antiretroviral therapy programme in South Africa: a cohort study. | BMC infectious diseases 20080101 |
| Viral hepatitis and HIV-associated tuberculosis: risk factors and TB treatment outcomes in Thailand. | BMC public health 20080101 |
| Prevalence of drug resistance and associated mutations in HIV-positive Puerto Ricans: sex variations. | Ethnicity & disease 20080101 |
| CCR5Delta32 genotypes in a German HIV-1 seroconverter cohort and report of HIV-1 infection in a CCR5Delta32 homozygous individual. | PloS one 20080101 |
| Not all missed doses are the same: sustained NNRTI treatment interruptions predict HIV rebound at low-to-moderate adherence levels. | PloS one 20080101 |
| Prevalence and risk factors for etravirine resistance among patients failing on non-nucleoside reverse transcriptase inhibitors. | Antiviral therapy 20080101 |
| Hepatic steatosis in patients with HIV-Hepatitis C Virus coinfection: is it associated with antiretroviral therapy and more advanced hepatic fibrosis? | BMC research notes 20080101 |
| Correlation between CD4 counts of HIV patients and enteric protozoan in different seasons - an experience of a tertiary care hospital in Varanasi (India). | BMC gastroenterology 20080101 |
| Factors influencing efavirenz and nevirapine plasma concentration: effect of ethnicity, weight and co-medication. | Antiviral therapy 20080101 |
| Adherence to antiretroviral therapy in young children in Cape Town, South Africa, measured by medication return and caregiver self-report: a prospective cohort study. | BMC pediatrics 20080101 |
| In vitro evidence for a new therapeutic approach in renal cell carcinoma. | International braz j urol : official journal of the Brazilian Society of Urology 20080101 |
| General framework for the prediction of oral drug interactions caused by CYP3A4 induction from in vivo information. | Clinical pharmacokinetics 20080101 |
| Resting regulatory CD4 T cells: a site of HIV persistence in patients on long-term effective antiretroviral therapy. | PloS one 20080101 |
| Success with antiretroviral treatment for children in Kigali, Rwanda: experience with health center/nurse-based care. | BMC pediatrics 20080101 |
| A pharmacokinetic and pharmacogenetic study of efavirenz in children: dosing guidelines can result in subtherapeutic concentrations. | Antiviral therapy 20080101 |
| Durability of stavudine, lamivudine and nevirapine among advanced HIV-1 infected patients with/without prior co-administration of rifampicin: a 144-week prospective study. | BMC infectious diseases 20080101 |
| Impending flop for brand antiretrovirals in the emerging markets? | The open AIDS journal 20080101 |
| Dyslipidemia and cardiovascular disease risk factor management in HIV-1-infected subjects treated with HAART in the Spanish VACH cohort. | The open AIDS journal 20080101 |
| Effectiveness and safety of generic fixed-dose combination of tenofovir/emtricitabine/efavirenz in HIV-1-infected patients in Western India. | Medscape journal of medicine 20080101 |
| Single-measurement therapeutic drug monitoring of the HIV/AIDS drugs abacavir, zidovudine, lamivudine, efavirenz, nevirapine, lopinavir and nelfinavir. | Pharmacology 20080101 |
| Outcome of protease inhibitor substitution with nevirapine in HIV-1 infected children. | BMC infectious diseases 20080101 |
| A feasibility study of immediate versus deferred antiretroviral therapy in children with HIV infection. | AIDS research and therapy 20080101 |
| Successful treatment with azithromycin and rifampicin of penicillin and cephalosporin insensitive pneumococcal osteomyelitis in a child with HIV infection: a case report. | Cases journal 20080101 |
| Magnitude and complexity of rectal mucosa HIV-1-specific CD8+ T-cell responses during chronic infection reflect clinical status. | PloS one 20080101 |
| Virologic, immunologic, clinical, safety, and resistance outcomes from a long-term comparison of efavirenz-based versus nevirapine-based antiretroviral regimens as initial therapy in HIV-1-infected persons. | HIV clinical trials 20080101 |
| Prevention of the sexual transmission of HIV-1: preparing for success. | Journal of the International AIDS Society 20080101 |
| Biphasic decay kinetics suggest progressive slowing in turnover of latently HIV-1 infected cells during antiretroviral therapy. | Retrovirology 20080101 |
| Variability in the plasma concentration of efavirenz and nevirapine is associated with genotypic resistance after treatment interruption. | Antiviral therapy 20080101 |
| Human immunodeficiency virus seroconversion presenting with acute inflammatory demyelinating polyneuropathy: a case report. | Journal of medical case reports 20080101 |
| Adherence to highly active antiretroviral therapy and its correlates among HIV infected pediatric patients in Ethiopia. | BMC pediatrics 20080101 |
| Three generic nevirapine-based antiretroviral treatments in Chinese HIV/AIDS patients: multicentric observation cohort. | PloS one 20080101 |
| Small individual loans and mental health: a randomized controlled trial among South African adults. | BMC public health 20080101 |
| Topical application of entry inhibitors as 'virustats' to prevent sexual transmission of HIV infection. | Retrovirology 20080101 |
| Hepatitis A, B and C viral co-infections among HIV-infected adults presenting for care and treatment at Muhimbili National Hospital in Dar es Salaam, Tanzania. | BMC public health 20080101 |
| Depressive symptoms and exposure to efavirenz in West African HIV-infected adults. | HIV clinical trials 20080101 |
| High treatment success rates when switching to once daily nevirapine containing antiretroviral therapy. | The open AIDS journal 20080101 |
| Determinants of Treatment Access in a Population-based Cohort of HIV-positive Men and Women Living in Argentina. | Journal of the International AIDS Society 20080101 |
| Effectiveness and Safety of Generic Fixed-Dose Combination of Tenofovir/Emtricitabine/Efavirenz in HIV-1-Infected Patients in Western India. | Journal of the International AIDS Society 20080101 |
| Maraviroc in the treatment of HIV infection. | Drug design, development and therapy 20080101 |
| Raltegravir in the management of HIV-infected patients. | Drug design, development and therapy 20080101 |
| Determinants of retention in care in an antiretroviral therapy (ART) program in urban Cameroon, 2003-2005. | The Pan African medical journal 20080101 |
| Dihydro-alkylthio-benzyl-oxopyrimidines as inhibitors of reverse transcriptase: synthesis and rationalization of the biological data on both wild-type enzyme and relevant clinical mutants. | Journal of medicinal chemistry 20071227 |
| Racial differences in virologic failure associated with adherence and quality of life on efavirenz-containing regimens for initial HIV therapy: results of ACTG A5095. | Journal of acquired immune deficiency syndromes (1999) 20071215 |
| [HIV-1 genotypic resistance profiles in children failing highly active antiretroviral therapy]. | Zhonghua yi xue za zhi 20071211 |
| Pharmacogenetics of efavirenz: adherence and virologic outcomes. | Annals of internal medicine 20071204 |
| A randomized controlled trial of therapeutic drug monitoring in treatment-naive and -experienced HIV-1-infected patients. | Journal of acquired immune deficiency syndromes (1999) 20071201 |
| Adherence to HAART therapy measured by electronic monitoring in newly diagnosed HIV patients in Botswana. | European journal of clinical pharmacology 20071201 |
| Immunosuppressant pharmacokinetics and dosing modifications in HIV-1 infected liver and kidney transplant recipients. | American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 20071201 |
| Improved interpretation of genotypic changes in the HIV-1 reverse transcriptase coding region that determine the virological response to didanosine. | The Journal of infectious diseases 20071201 |
| N348I in the connection domain of HIV-1 reverse transcriptase confers zidovudine and nevirapine resistance. | PLoS medicine 20071201 |
| Initiating highly active antiretroviral therapy with newer protease inhibitors is associated with better survival compared to first-generation protease inhibitors or nevirapine. | AIDS patient care and STDs 20071201 |
| Nitroimidazoles. V. Synthesis and anti-HIV evaluation of new 5-substituted piperazinyl-4-nitroimidazole derivatives. | Acta pharmaceutica (Zagreb, Croatia) 20071201 |
| Characterization of HIV-1 subtypes and viral antiretroviral drug resistance in men who have sex with men in Beijing, China. | AIDS (London, England) 20071201 |
| Review of tenofovir-emtricitabine. | Therapeutics and clinical risk management 20071201 |
| Metabolic syndrome, cardiovascular disease and type 2 diabetes mellitus after initiation of antiretroviral therapy in HIV infection. | AIDS (London, England) 20071130 |
| Vanadium induces VL30 retrotransposition at an unusually high level: a possible carcinogenesis mechanism. | Journal of molecular biology 20071116 |
| HPLC-MS method for the simultaneous quantification of the new HIV protease inhibitor darunavir, and 11 other antiretroviral agents in plasma of HIV-infected patients. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20071115 |
| Psychosis in a 12-year-old HIV-positive girl with an increased serum concentration of efavirenz. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20071115 |
| Positive outcomes of HAART at 24 months in HIV-infected patients in Cambodia. | AIDS (London, England) 20071112 |
| Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phase. | AIDS (London, England) 20071112 |
| Investigation of human pharmacoscintigraphic behavior of two tablets and a capsule formulation of a high dose, poorly water soluble/highly permeable drug (efavirenz). | Journal of pharmaceutical sciences 20071101 |
| HIV/AIDS-specific quality of life and adherence to antiretroviral therapy over time. | Journal of acquired immune deficiency syndromes (1999) 20071101 |
| Synthesis and biological properties of novel 2-aminopyrimidin-4(3H)-ones highly potent against HIV-1 mutant strains. | Journal of medicinal chemistry 20071101 |
| Successful efavirenz dose reduction in HIV type 1-infected individuals with cytochrome P450 2B6 *6 and *26. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20071101 |
| From docking false-positive to active anti-HIV agent. | Journal of medicinal chemistry 20071101 |
| Is it safe to switch between efavirenz and nevirapine in the event of toxicity? | The Lancet. Infectious diseases 20071101 |
| Evolution of antiretroviral drug costs in Brazil in the context of free and universal access to AIDS treatment. | PLoS medicine 20071101 |
| Liver enzymes elevation and immune reconstitution among treatment-naïve HIV-infected patients instituting antiretroviral therapy. | The American journal of the medical sciences 20071101 |
| Design, synthesis and pharmacological evaluation of HIV-1 reverse transcriptase inhibition of new indolin-2-ones. | Medicinal chemistry (Shariqah (United Arab Emirates)) 20071101 |
| Quantifying antiretroviral risk in pregnancy. | South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde 20071101 |
| European CHMP issues positive opinion for Atripla. | AIDS patient care and STDs 20071101 |
| Outcomes in HIV-infected patients on antiretroviral therapy with tuberculosis. | The Southeast Asian journal of tropical medicine and public health 20071101 |
| Clinical outcomes and CD4 cell response in children receiving antiretroviral therapy at primary health care facilities in Zambia. | JAMA 20071024 |
| CYP2B6 genetic variants are associated with nevirapine pharmacokinetics and clinical response in HIV-1-infected children. | AIDS (London, England) 20071018 |
| CCR5 antagonists: comparison of efficacy, side effects, pharmacokinetics and interactions--review of the literature. | European journal of medical research 20071015 |
| CCR5 antagonists in the treatment of treatment-naive patients infected with CCR5 tropic HIV-1. | European journal of medical research 20071015 |
| Treatment with CCR5 antagonists: which patient may have a benefit? | European journal of medical research 20071015 |
| Indolyl aryl sulfones as HIV-1 non-nucleoside reverse transcriptase inhibitors: role of two halogen atoms at the indole ring in developing new analogues with improved antiviral activity. | Journal of medicinal chemistry 20071004 |
| N2-benzyloxycarbonylguan-9-yl acetic acid derivatives as HIV-1 reverse transcriptase non-nucleoside inhibitors with decreased loss of potency against common drug-resistance mutations. | ChemMedChem 20071001 |
| Identification and characterization of UK-201844, a novel inhibitor that interferes with human immunodeficiency virus type 1 gp160 processing. | Antimicrobial agents and chemotherapy 20071001 |
| Bioequivalence of efavirenz/emtricitabine/tenofovir disoproxil fumarate single-tablet regimen. | Journal of acquired immune deficiency syndromes (1999) 20071001 |
| Polymorphism and drug selected mutations of reverse transcriptase gene in 102 HIV-1 infected patients living in China. | Journal of medical virology 20071001 |
| Prednisolone mediated suppression of HIV-1 viral load strongly correlates with C-C chemokine CCL2: In vivo and in vitro findings. | Clinical immunology (Orlando, Fla.) 20071001 |
| Rapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study. | Journal of acquired immune deficiency syndromes (1999) 20071001 |
| Treatment of an atazanivir associated grade 4 hyperbilirubinaemia with efavirenz. | Gut 20071001 |
| Partial deletion of CYP2B6 owing to unequal crossover with CYP2B7. | Pharmacogenetics and genomics 20071001 |
| Genotypic resistance in HIV-infected naive patients receiving abacavir plus lamivudine and efavirenz. | Journal of acquired immune deficiency syndromes (1999) 20071001 |
| Effect of anticoagulants on plasma nevirapine and efavirenz concentrations. | Therapeutic drug monitoring 20071001 |
| The validation of plasma darunavir concentrations determined by the HPLC method for protease inhibitors. | Biological & pharmaceutical bulletin 20071001 |
| Early contraceptive failure of Implanon in an HIV-seropositive patient on triple antiretroviral therapy with zidovudine, lamivudine and efavirenz. | The journal of family planning and reproductive health care 20071001 |
| Health-related quality of life outcomes in HIV-infected patients starting different combination regimens in a randomized multinational trial: the INITIO-QoL substudy. | AIDS research and human retroviruses 20071001 |
| Efficacy and safety of a once daily regimen with efavirenz, lamivudine, and didanosine, with and without food, as initial therapy for HIV Infection: the ELADI study. | AIDS research and human retroviruses 20071001 |
| Use of fMRI to predict psychiatric adverse effects of interferon treatment for Hepatitis C - preliminary report. | Neuropsychiatric disease and treatment 20071001 |
| Potent inhibition of HIV-1 replication by novel non-peptidyl small molecule inhibitors of protease dimerization. | The Journal of biological chemistry 20070928 |
| Drug-drug interaction between itraconazole and efavirenz in a patient with AIDS and disseminated histoplasmosis. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20070915 |
| Antiretroviral drug exposure in the female genital tract: implications for oral pre- and post-exposure prophylaxis. | AIDS (London, England) 20070912 |
| Efavirenz urolithiasis. | AIDS (London, England) 20070912 |
| A comparison of three initial antiretroviral AIDS regimens. | The New England journal of medicine 20070906 |
| CYP2B6 983T>C polymorphism is prevalent in West Africa but absent in Papua New Guinea: implications for HIV/AIDS treatment. | British journal of clinical pharmacology 20070901 |
| Response to efavirenz-containing regimens in previously antiretroviral-naive HIV-positive patients: the role of gender. | Journal of acquired immune deficiency syndromes (1999) 20070901 |
| Hepatotoxicity of antiretroviral drugs is reduced after successful treatment of chronic hepatitis C in HIV-infected patients. | The Journal of infectious diseases 20070901 |
| Optimal timing and best antiretroviral regimen in treatment-naive HIV-infected individuals with advanced disease. | Journal of acquired immune deficiency syndromes (1999) 20070901 |
| Patient preferences among third agent HIV medications: a US and German perspective. | AIDS care 20070901 |
| Maraviroc reduces viral load in naive patients at 48 weeks. | AIDS patient care and STDs 20070901 |
| FDA notifications. FDA grants tentative approval of efavirenz. | AIDS alert 20070901 |
| Children with HIV are not small adults: what is different in pharmacology? | Current opinion in HIV and AIDS 20070901 |
| Efavirenz-therapy in HIV-patients with underlying liver disease: importance of continuous TDM of EFV. | European journal of medical research 20070816 |
| Long-term body fat outcomes in antiretroviral-naive participants randomized to nelfinavir or efavirenz or both plus dual nucleosides. Dual X-ray absorptiometry results from A5005s, a substudy of Adult Clinical Trials Group 384. | Journal of acquired immune deficiency syndromes (1999) 20070815 |
| Safety of switching to nevirapine-based highly active antiretroviral therapy at elevated CD4 cell counts in a resource-constrained setting. | Journal of acquired immune deficiency syndromes (1999) 20070815 |
| Amodiaquine metabolism is impaired by common polymorphisms in CYP2C8: implications for malaria treatment in Africa. | Clinical pharmacology and therapeutics 20070801 |
| Long-term safety and efficacy of a once-daily regimen of emtricitabine, didanosine, and efavirenz in HIV-infected, therapy-naive children and adolescents: Pediatric AIDS Clinical Trials Group Protocol P1021. | Pediatrics 20070801 |
| Hair loss induced by lopinavir-ritonavir. | Pharmacotherapy 20070801 |
| Probing nonnucleoside inhibitor-induced active-site distortion in HIV-1 reverse transcriptase by transient kinetic analyses. | Protein science : a publication of the Protein Society 20070801 |
| Efavirenz-induced neurological symptoms in rare homozygote CYP2B6 *2/*2 (C64T). | International journal of STD & AIDS 20070801 |
| Data shows long-term nevirapine efficacy and increases in good cholesterol. | AIDS patient care and STDs 20070801 |
| Antiretroviral treatment and prevention of peripartum and postnatal HIV transmission in West Africa: evaluation of a two-tiered approach. | PLoS medicine 20070801 |
| No observable correlation between central nervous system side effects and EFV plasma concentrations in Japanese HIV type 1-infected patients treated with EFV containing HAART. | AIDS research and human retroviruses 20070801 |
| Baseline genotype as a predictor of virological failure to emtricitabine or stavudine in combination with didanosine and efavirenz. | AIDS research and human retroviruses 20070801 |
| Genotypic analysis of the protease and reverse transcriptase of HIV type 1 isolates from recently infected injecting drug users in western China. | AIDS research and human retroviruses 20070801 |
| Teratogenicity risk of antiretroviral therapy in pregnancy. | Current HIV/AIDS reports 20070801 |
| 144-week data released on Gilead's study 934. | AIDS patient care and STDs 20070801 |
| The renaissance of fixed dose combinations: Combivir. | Therapeutics and clinical risk management 20070801 |
| Review of tipranavir in the treatment of drug-resistant HIV. | Therapeutics and clinical risk management 20070801 |
| Adherence, virological and immunological outcomes for HIV-infected veterans starting combination antiretroviral therapies. | AIDS (London, England) 20070731 |
| Efavirenz to nevirapine switch in HIV-1-infected patients with dyslipidemia: a randomized, controlled study. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20070715 |
| [Insulin resistance in HIV-infected patients receiving long-term therapy with efavirenz, lopinavir/ritonavir and atazanavir]. | Medicina clinica 20070714 |
| Abbott's AIDS fight-back. | Nature 20070705 |
| The acyclic nucleoside phosphonates from inception to clinical use: historical perspective. | Antiviral research 20070701 |
| A new methodology for the simulation of flexible protein-ligand interactions. | Journal of molecular graphics & modelling 20070701 |
| Efavirenz pharmacokinetics in HIV-1-infected children are associated with CYP2B6-G516T polymorphism. | Journal of acquired immune deficiency syndromes (1999) 20070701 |
| Early response to highly active antiretroviral therapy in HIV-1-infected Kenyan children. | Journal of acquired immune deficiency syndromes (1999) 20070701 |
| Pregnancy rates and birth outcomes among women on efavirenz-containing highly active antiretroviral therapy in Botswana. | Journal of acquired immune deficiency syndromes (1999) 20070701 |
| Methadone dosing strategies in HIV-infected injection drug users enrolled in a directly observed therapy program. | Journal of acquired immune deficiency syndromes (1999) 20070701 |
| Dynamics of 103K/N and 184M/V HIV-1 drug resistant populations: relative comparison in plasma virus RNA versus CD45RO+T cell proviral DNA. | Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology 20070701 |
| Effects of potent antiretroviral therapy on free testosterone levels and fat-free mass in men in a prospective, randomized trial: A5005s, a substudy of AIDS Clinical Trials Group Study 384. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20070701 |
| Polymorphic CYP2B6: molecular mechanisms and emerging clinical significance. | Pharmacogenomics 20070701 |
| Comparison of the effectiveness of initial combined antiretroviral therapy with nelfinavir or efavirenz at a university-based outpatient service in Brazil. | Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas 20070701 |
| The first once-daily single-tablet regimen for the treatment of HIV-infected patients. | Drugs of today (Barcelona, Spain : 1998) 20070701 |
| Alopecia induced by lopinavir plus ritonavir therapy in an HIV patient. | Journal of drugs in dermatology : JDD 20070701 |
| Antiretroviral therapy during tuberculosis treatment and marked reduction in death rate of HIV-infected patients, Thailand. | Emerging infectious diseases 20070701 |
| Disseminated histoplasmosis and tuberculosis in a patient with HIV infection. | Yonsei medical journal 20070630 |
| Distinct roles for LINE-1 and HERV-K retroelements in cell proliferation, differentiation and tumor progression. | Oncogene 20070621 |
| Hepatotoxicity in an African antiretroviral therapy cohort: the effect of tuberculosis and hepatitis B. | AIDS (London, England) 20070619 |
| Misleading results of screening for illicit drugs during efavirenz treatment. | AIDS (London, England) 20070619 |
| Efavirenz: innocent bystander or direct nephrotoxin? | AIDS (London, England) 20070619 |
| Development of written information for antiretroviral therapy: comprehension in a Tanzanian population. | Pharmacy world & science : PWS 20070601 |
| Role of antiretroviral treatment in prolonging QTc interval in HIV-positive patients. | The Journal of infection 20070601 |
| Constant mitochondrial DNA levels in blood leukocytes of patients enrolled in a NRTI-free therapeutic trial (BIKS-2 study). | The Journal of infection 20070601 |
| Variability in non-nucleoside reverse transcriptase and protease inhibitors concentrations among HIV-infected adults in routine clinical practice. | British journal of clinical pharmacology 20070601 |
| High prevalence of subtherapeutic plasma concentrations of efavirenz in children. | Journal of acquired immune deficiency syndromes (1999) 20070601 |
| Efavirenz. | Expert opinion on pharmacotherapy 20070601 |
| Switching to a protease inhibitor-containing, nucleoside-sparing regimen (lopinavir/ritonavir plus efavirenz) increases limb fat but raises serum lipid levels: results of a prospective randomized trial (AIDS clinical trial group 5125s). | Journal of acquired immune deficiency syndromes (1999) 20070601 |
| Impact of CYP2B6 polymorphism on hepatic efavirenz metabolism in vitro. | Pharmacogenomics 20070601 |
| Antiretroviral pharmacokinetic profile: a review of sex differences. | Gender medicine 20070601 |
| Antiretroviral Drug Levels and Interactions Affect Lipid, Lipoprotein, and Glucose Metabolism in HIV-1 Seronegative Subjects: A Pharmacokinetic-Pharmacodynamic Analysis. | Metabolic syndrome and related disorders 20070601 |
| Alterations in circulating osteoimmune factors may be responsible for high bone resorption rate in HIV-infected children and adolescents. | AIDS (London, England) 20070531 |
| Characterization of novel non-nucleoside reverse transcriptase (RT) inhibitor resistance mutations at residues 132 and 135 in the 51 kDa subunit of HIV-1 RT. | The Biochemical journal 20070515 |
| Buprenorphine assay and plasma concentration monitoring in HIV-infected substance users. | Journal of pharmaceutical and biomedical analysis 20070509 |
| Novel CCR5 monoclonal antibodies with potent and broad-spectrum anti-HIV activities. | Antiviral research 20070501 |
| Determination of 19 antiretroviral agents in pharmaceuticals or suspected products with two methods using high-performance liquid chromatography. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20070501 |
| Synthesis of novel diarylpyrimidine analogues of TMC278 and their antiviral activity against HIV-1 wild-type and mutant strains. | European journal of medicinal chemistry 20070501 |
| Effect of efavirenz on the pharmacokinetics of ketoconazole in HIV-infected patients. | European journal of clinical pharmacology 20070501 |
| No response to first-line tenofovir+lamivudine+efavirenz despite optimization according to baseline resistance testing: impact of resistant minority variants on efficacy of low genetic barrier drugs. | Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology 20070501 |
| Association of serum lipid levels with HIV serostatus, specific antiretroviral agents, and treatment regimens. | Journal of acquired immune deficiency syndromes (1999) 20070501 |
| Synthesis and pharmacological activity of urea and thiourea derivatives of 4-azatricyclo[5.2.2.0(2,6)]undec-8-ene-3,5-dione. | Chemical & pharmaceutical bulletin 20070501 |
| Multiple-dose pharmacokinetics of efavirenz with and without the use of rifampicin in HIV-positive patients. | Current HIV research 20070501 |
| Discontinuation of non-nucleoside reverse transcriptase inhibitor-based highly active antiretroviral therapy due to nucleoside analogue reverse transcriptase inhibitor-related metabolic toxicity. | International journal of STD & AIDS 20070501 |
| Tenofovir disoproxil fumarate for prevention of HIV infection in women: a phase 2, double-blind, randomized, placebo-controlled trial. | PLoS clinical trials 20070501 |
| Emergence of NNRTI drug resistance mutations after single-dose nevirapine exposure in HIV type 1 subtype C-infected infants in India. | AIDS research and human retroviruses 20070501 |
| [Number and nature of drug interactions concerning antineoplastic drugs]. | Bulletin du cancer 20070501 |
| FDA notifications. FDA tentatively approves generic efavirenz. | AIDS alert 20070501 |
| Thailand: government issues compulsory licences for HIV/AIDS drugs. | HIV/AIDS policy & law review 20070501 |
| Intensification of a triple-nucleoside regimen with tenofovir or efavirenz in HIV-1-infected patients with virological suppression. | AIDS (London, England) 20070423 |
| Development of a competitive immunoassay for efavirenz: hapten design and validation studies. | Analytica chimica acta 20070418 |
| Metabolic effects of protease inhibitor-sparing antiretroviral regimens given as initial treatment of HIV-1 Infection (AIDS Clinical Trials Group Study A5095). | Journal of acquired immune deficiency syndromes (1999) 20070415 |
| Plasma HIV-1 RNA dynamics in antiretroviral-naive subjects receiving either triple-nucleoside or efavirenz-containing regimens: ACTG A5166s. | The Journal of infectious diseases 20070415 |
| Genetic variability of CYP2B6 polymorphisms in four southern Chinese populations. | World journal of gastroenterology 20070414 |
| Acyclic nucleoside phosphonates: past, present and future. Bridging chemistry to HIV, HBV, HCV, HPV, adeno-, herpes-, and poxvirus infections: the phosphonate bridge. | Biochemical pharmacology 20070401 |
| An isocratic liquid chromatography method for determining HIV non-nucleoside reverse transcriptase inhibitor and protease inhibitor concentrations in human plasma. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20070401 |
| Predictive value of known and novel alleles of CYP2B6 for efavirenz plasma concentrations in HIV-infected individuals. | Clinical pharmacology and therapeutics 20070401 |
| Discovery of novel benzimidazolones as potent non-nucleoside reverse transcriptase inhibitors active against wild-type and mutant HIV-1 strains. | Bioorganic & medicinal chemistry letters 20070401 |
| Clinical toxicity of highly active antiretroviral therapy in a home-based AIDS care program in rural Uganda. | Journal of acquired immune deficiency syndromes (1999) 20070401 |
| Slow-, tight-binding HIV-1 reverse transcriptase non-nucleoside inhibitors highly active against drug-resistant mutants. | ChemMedChem 20070401 |
| Influence of liver fibrosis stage on plasma levels of antiretroviral drugs in HIV-infected patients with chronic hepatitis C. | The Journal of infectious diseases 20070401 |
| ART suppresses plasma HIV-1 RNA to a stable set point predicted by pretherapy viremia. | PLoS pathogens 20070401 |
| Efavirenz: a review. | Expert opinion on pharmacotherapy 20070401 |
| Medicines Control Council and registration backlog of antiretrovirals. | South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde 20070401 |
| NNRTI data in naive patients. | AIDS patient care and STDs 20070401 |
| FDA notifications. Sustiva packaging instructions updated. | AIDS alert 20070401 |
| Reinduction of cell differentiation and 131I uptake in a poorly differentiated thyroid tumor in response to the reverse transcriptase (RT) inhibitor nevirapine. | Cancer biotherapy & radiopharmaceuticals 20070401 |
| HIV-1 reverse transcriptase plus-strand initiation exhibits preferential sensitivity to non-nucleoside reverse transcriptase inhibitors in vitro. | The Journal of biological chemistry 20070316 |
| Hepatotoxicity due to a drug interaction between amodiaquine plus artesunate and efavirenz. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20070315 |
| High-performance liquid chromatography assay for the determination of the HIV-protease inhibitor tipranavir in human plasma in combination with nine other antiretroviral medications. | Journal of pharmaceutical and biomedical analysis 20070312 |
| Pharmacogenetics of antiretroviral drugs for the treatment of HIV-infected patients: an update. | Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases 20070301 |
| Inhibition of MRP1/ABCC1, MRP2/ABCC2, and MRP3/ABCC3 by nucleoside, nucleotide, and non-nucleoside reverse transcriptase inhibitors. | Drug metabolism and disposition: the biological fate of chemicals 20070301 |
| Liver toxicity induced by non-nucleoside reverse transcriptase inhibitors. | The Journal of antimicrobial chemotherapy 20070301 |
| Once-daily highly active antiretroviral therapy for HIV-infected children: safety and efficacy of an efavirenz-containing regimen. | Pediatrics 20070301 |
| Dyslipidemia in an Asian population after treatment for two years with protease inhibitor-containing regimens. | Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002) 20070301 |
| Quality of life and depression among HIV-infected patients receiving efavirenz- or protease inhibitor-based therapy in Senegal. | HIV medicine 20070301 |
| Neuropsychiatric side effects of efavirenz therapy. | Expert opinion on drug safety 20070301 |
| Factors in AIDS dementia complex trial design: results and lessons from the abacavir trial. | PLoS clinical trials 20070301 |
| New package inserts for efavirenz and T-20. | AIDS clinical care 20070301 |
| FDA notifications. FDA grants tentative approval of generic efavirenz. | AIDS alert 20070301 |
| Update on the CNS adverse effects of Sustiva (efavirenz). | AIDS alert 20070301 |
| Neurokinin-1 receptor antagonist (aprepitant) inhibits drug-resistant HIV-1 infection of macrophages in vitro. | Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology 20070301 |
| Comparison of echinocandin antifungals. | Therapeutics and clinical risk management 20070301 |
| [Antiretrovirals]. | Nihon rinsho. Japanese journal of clinical medicine 20070227 |
| Thailand and the compulsory licensing of efavirenz. | The New England journal of medicine 20070208 |
| Less lipoatrophy and better lipid profile with abacavir as compared to stavudine: 96-week results of a randomized study. | Journal of acquired immune deficiency syndromes (1999) 20070201 |
| A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors. | Antimicrobial agents and chemotherapy 20070201 |
| Structure-activity relationship in the 3-iodo-4-phenoxypyridinone (IOPY) series: The nature of the C-3 substituent on anti-HIV activity. | Bioorganic & medicinal chemistry letters 20070201 |
| Depo-medroxyprogesterone in women on antiretroviral therapy: effective contraception and lack of clinically significant interactions. | Clinical pharmacology and therapeutics 20070201 |
| Effects on growth after switching protease inhibitors to efavirenz in HIV-1-infected children. | International journal of antimicrobial agents 20070201 |
| Modulation of human BCRP (ABCG2) activity by anti-HIV drugs. | The Journal of antimicrobial chemotherapy 20070201 |
| Visual loss secondary to acquired immunodeficiency virus-related progressive multifocal leukoencephalopathy demonstrating clinical improvement with highly active antiretroviral therapy. | Optometry (St. Louis, Mo.) 20070201 |
| Efavirenz/emtricitabine/tenofovir disoproxil fumarate fixed-dose combination: first-line therapy for all? | Expert opinion on pharmacotherapy 20070201 |
| Transitory severe CNS adverse effects after accidental efavirenz overdose during post-exposure HIV prophylaxis. | Journal of chemotherapy (Florence, Italy) 20070201 |
| Update in HIV care. | Journal of general internal medicine 20070201 |
| Anti-HIV agents. New drugs, new hope, old lessons. | TreatmentUpdate 20070201 |
| Anti-HIV agents. American study finds efavirenz linked to fat wasting. | TreatmentUpdate 20070201 |
| Anti-HIV agents. A second study confirms fat loss issues with efavirenz. | TreatmentUpdate 20070201 |
| Anti-HIV agents. Efavirenz and fat wasting--what might be happening? | TreatmentUpdate 20070201 |
| Clinical and laboratory characteristics of hospitalised patients with neurological manifestations of HIV/AIDS at the Nairobi hospital. | East African medical journal 20070201 |
| Randomized open-label trial of two simplified, class-sparing regimens following a first suppressive three or four-drug regimen. | AIDS (London, England) 20070130 |
| Three-year follow-up of protease inhibitor-based regimen simplification in HIV-infected patients. | AIDS (London, England) 20070130 |
| Substrate-dependent inhibition or stimulation of HIV RNase H activity by non-nucleoside reverse transcriptase inhibitors (NNRTIs). | Biochemical and biophysical research communications 20070112 |
| Efavirenz-associated podocyte damage. | AIDS (London, England) 20070111 |
| [Treatment of HIV infection in 2006: highlights]. | Revue medicale suisse 20070110 |
| Efavirenz related compounds preparation by hydrolysis procedure: setting reference standards for chromatographic purity analysis. | Journal of pharmaceutical and biomedical analysis 20070104 |
| A mutagenetic tree hidden Markov model for longitudinal clonal HIV sequence data. | Biostatistics (Oxford, England) 20070101 |
| 4-Aminopyrimidines as novel HIV-1 inhibitors. | Bioorganic & medicinal chemistry letters 20070101 |
| Relative activation of human pregnane X receptor versus constitutive androstane receptor defines distinct classes of CYP2B6 and CYP3A4 inducers. | The Journal of pharmacology and experimental therapeutics 20070101 |
| MALDI-TOF mass spectrometry for multiplex genotyping of CYP2B6 single-nucleotide polymorphisms. | Clinical chemistry 20070101 |
| Comparative biological and clinical outcomes after a switch from a virologically unsuccessful first protease inhibitor-containing antiretroviral combination to a 3-drug regimen containing efavirenz, nevirapine, or abacavir. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20070101 |
| HIV DNA and dementia in treatment-naïve HIV-1-infected individuals in Bangkok, Thailand. | International journal of medical sciences 20070101 |
| The emergence of HIV transmitted resistance in Botswana: 'when will the WHO detection threshold be exceeded?'. | PloS one 20070101 |
| A novel substrate-based HIV-1 protease inhibitor drug resistance mechanism. | PLoS medicine 20070101 |
| Non-nucleoside reverse transcriptase inhibitors: a review. | International journal of clinical practice 20070101 |
| Cost-effectiveness of genotypic antiretroviral resistance testing in HIV-infected patients with treatment failure. | PloS one 20070101 |
| Efavirenz and nevirapine in HIV-1 infection : is there a role for clinical pharmacokinetic monitoring? | Clinical pharmacokinetics 20070101 |
| Lack of indinavir-associated nephrological complications in HIV-infected adults (predominantly women) with high indinavir plasma concentration in Abidjan, Côte d'Ivoire. | AIDS research and human retroviruses 20070101 |
| Abacavir hypersensitivity reaction after switching from the twice-daily to the once-daily formulation. | AIDS patient care and STDs 20070101 |
| New pandemics: HIV and AIDS, HCV and chronic hepatitis, influenza virus and flu. | Retrovirology 20070101 |
| Schizophrenia, AIDS and the decision to prescribe HAART: results of a national survey of HIV clinicians. | Journal of prevention & intervention in the community 20070101 |
| Public health the leading force of the Indonesian response to the HIV/AIDS crisis among people who inject drugs. | Harm reduction journal 20070101 |
| Retroviral rebound syndrome after treatment discontinuation in a 15 year old girl with HIV attracted through mother-to-child transmission: case report. | AIDS research and therapy 20070101 |
| Methodological standards in non-inferiority AIDS trials: moving from adherence to compliance: response. | BMC medical research methodology 20070101 |
| Plasma nevirapine levels, adverse events and efficacy of antiretroviral therapy among HIV-infected patients concurrently receiving nevirapine-based antiretroviral therapy and fluconazole. | BMC infectious diseases 20070101 |
| Safety and efficacy of a generic fixed-dose combination of stavudine, lamivudine and nevirapine antiretroviral therapy between HIV-infected patients with baseline CD4 <50 versus CD4 > or = 50 cells/mm3. | AIDS research and therapy 20070101 |
| Poly (propyleneimine) dendrimer based nanocontainers for targeting of efavirenz to human monocytes/macrophages in vitro. | Journal of drug targeting 20070101 |
| Preliminary outcomes of a paediatric highly active antiretroviral therapy cohort from KwaZulu-Natal, South Africa. | BMC pediatrics 20070101 |
| HIV/AIDS drugs for Sub-Saharan Africa: how do brand and generic supply compare? | PloS one 20070101 |
| Pilot study of a novel short-cycle antiretroviral treatment interruption strategy: 48-week results of the five-days-on, two-days-off (FOTO) study. | HIV clinical trials 20070101 |
| How labour intensive is a doctor-based delivery model for antiretroviral treatment (ART)? Evidence from an observational study in Siem Reap, Cambodia. | Human resources for health 20070101 |
| The NEFA study: results at three years. | AIDS reviews 20070101 |
| Interpreting cerebrospinal fluid pleocytosis in HIV in the era of potent antiretroviral therapy. | BMC infectious diseases 20070101 |
| Dideoxynucleoside HIV reverse transcriptase inhibitors and drug-related hepatotoxicity: a case report. | Journal of medical case reports 20070101 |
| Predictors of disease progression in HIV infection: a review. | AIDS research and therapy 20070101 |
| A computer-based system to aid in the interpretation of plasma concentrations of antiretrovirals for therapeutic drug monitoring. | Antiviral therapy 20070101 |
| Does tenofovir influence efavirenz pharmacokinetics? | Antiviral therapy 20070101 |
| Plasma levels of soluble urokinase-type plasminogen activator receptor (suPAR) and early mortality risk among patients enrolling for antiretroviral treatment in South Africa. | BMC infectious diseases 20070101 |
| TRIPS, the Doha declaration and paragraph 6 decision: what are the remaining steps for protecting access to medicines? | Globalization and health 20070101 |
| AIDS in the Third World: how to stop the HIV infection? | Verhandelingen - Koninklijke Academie voor Geneeskunde van Belgie 20070101 |
| Anti-HIV drugs. | Verhandelingen - Koninklijke Academie voor Geneeskunde van Belgie 20070101 |
| Healthcare utilization of patients accessing an African national treatment program. | BMC health services research 20070101 |
| BK virus associated meningoencephalitis in an AIDS patient treated with HAART. | AIDS research and therapy 20070101 |
| Normalization of fat accrual in lipoatrophic, HIV-infected children switched from stavudine to tenofovir and from protease inhibitor to efavirenz. | Antiviral therapy 20070101 |
| First-line highly active antiretroviral regimens in 2001-2002 in the French Hospital Database on HIV: combination prescribed and biological outcomes. | Antiviral therapy 20070101 |
| Five-year follow up of once-daily therapy with emtricitabine, didanosine and efavirenz (Montana ANRS 091 trial). | Antiviral therapy 20070101 |
| Didanosine enteric-coated capsule: current role in patients with HIV-1 infection. | Drugs 20070101 |
| Fast and simultaneous determination of darunavir and eleven other antiretroviral drugs for therapeutic drug monitoring: method development and validation for the determination of all currently approved HIV protease inhibitors and non-nucleoside reverse transcriptase inhibitors in human plasma by liquid chromatography coupled with electrospray ionization tandem mass spectrometry. | Rapid communications in mass spectrometry : RCM 20070101 |
| Protease inhibitor associated mutations compromise the efficacy of therapy in human immunodeficiency virus-1 (HIV-1) infected pediatric patients: a cross-sectional study. | AIDS research and therapy 20070101 |
| The safety and efficacy of tenofovir DF in combination with lamivudine and efavirenz through 6 years in antiretroviral-naïve HIV-1-infected patients. | HIV clinical trials 20070101 |
| Electrospray tandem mass spectroscopic characterisation of 18 antiretroviral drugs and simultaneous quantification of 12 antiretrovirals in plasma. | Rapid communications in mass spectrometry : RCM 20070101 |
| Primary T-cells from human CD4/CCR5-transgenic rats support all early steps of HIV-1 replication including integration, but display impaired viral gene expression. | Retrovirology 20070101 |
| Validation of the SCID-hu Thy/Liv mouse model with four classes of licensed antiretrovirals. | PloS one 20070101 |
| Pharmacokinetic interaction between TMC114/r and efavirenz in healthy volunteers. | Antiviral therapy 20070101 |
| Differential drug resistance acquisition in HIV-1 of subtypes B and C. | PloS one 20070101 |
| Quadruple nucleoside therapy with zidovudine, lamivudine, abacavir and tenofovir in the treatment of HIV. | Antiviral therapy 20070101 |
| Substitutions due to antiretroviral toxicity or contraindication in the first 3 years of antiretroviral therapy in a large South African cohort. | Antiviral therapy 20070101 |
| Comparative efficacy of nucleoside/nucleotide reverse transcriptase inhibitors in combination with efavirenz: results of a systematic overview. | HIV clinical trials 20070101 |
| Access, use and perceptions regarding Internet, cell phones and PDAs as a means for health promotion for people living with HIV in Peru. | BMC medical informatics and decision making 20070101 |
| Policy maker and health care provider perspectives on reproductive decision-making amongst HIV-infected individuals in South Africa. | BMC public health 20070101 |
| Effect of highly active antiretroviral therapy on tacrolimus pharmacokinetics in hepatitis C virus and HIV co-infected liver transplant recipients in the ANRS HC-08 study. | Clinical pharmacokinetics 20070101 |
| Amprenavir and lopinavir pharmacokinetics following coadministration of amprenavir or fosamprenavir with lopinavir/ritonavir, with or without efavirenz. | Antiviral therapy 20070101 |
| Mycobacterium avium complex immune reconstitution inflammatory syndrome: long term outcomes. | Journal of translational medicine 20070101 |
| Utilization and spending trends for antiretroviral medications in the U.S. Medicaid program from 1991 to 2005. | AIDS research and therapy 20070101 |
| Effectiveness and safety of simplification therapy with once-daily tenofovir, lamivudine, and efavirenz in HIV-1-infected patients with undetectable plasma viral load on HAART. | HIV clinical trials 20070101 |
| The association of bone mineral density with HIV infection and antiretroviral treatment in women. | Antiviral therapy 20070101 |
| Cost-effectiveness of tipranavir versus comparator protease inhibitor regimens in HIV infected patients previously exposed to antiretroviral therapy in the Netherlands. | Cost effectiveness and resource allocation : C/E 20070101 |
| Anti-HIV agents. Using maraviroc in first-line therapy. | TreatmentUpdate 20070101 |
| The safety and efficacy of switching stavudine to tenofovir df in combination with lamivudine and efavirenz in hiv-1-infected patients: three-year follow-up after switching therapy. | HIV clinical trials 20070101 |
| [Intestinal microbiota of individuals who suffered occupational accidents with biological materials and underwent antiretroviral prophylaxis]. | Revista da Sociedade Brasileira de Medicina Tropical 20070101 |
| Lipodystrophy and metabolic changes in HIV-infected children on non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy. | Antiviral therapy 20070101 |
| Relationships between drug exposure, changes in metabolic parameters and body fat in HIV-infected patients switched to a nucleoside sparing regimen. | Antiviral therapy 20070101 |
| Poor efficacy and tolerability of stavudine, didanosine, and efavirenz-based regimen in treatment-naive patients in Senegal. | MedGenMed : Medscape general medicine 20070101 |
| [Pilot study of antiretroviral therapy in Djibouti]. | Eastern Mediterranean health journal = La revue de sante de la Mediterranee orientale = al-Majallah al-sihhiyah li-sharq al-mutawassit 20070101 |
| Active methamphetamine use is associated with transmitted drug resistance to non-nucleoside reverse transcriptase inhibitors in individuals with HIV infection of unknown duration. | The open AIDS journal 20070101 |
| A cluster-randomised trial to compare home-based with health facility-based antiretroviral treatment in Uganda: study design and baseline findings. | The open AIDS journal 20070101 |
| Clinical implications of mutations at reverse transcriptase codon 135 on response to NNRTI-based therapy. | The open virology journal 20070101 |
| Poor Efficacy and Tolerability of Stavudine, Didanosine, and Efavirenz-based Regimen in Treatment-Naive Patients in Senegal. | Journal of the International AIDS Society 20070101 |
| Anidulafungin: an evidence-based review of its use in invasive fungal infections. | Core evidence 20070101 |
| Maraviroc: the evidence for its potential in the management of HIV. | Core evidence 20070101 |
| Targeting human immunodeficiency virus type 1 assembly, maturation and budding. | Drug target insights 20070101 |
| Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral-naive patients: virologic, immunologic, and morphologic changes--a 96-week analysis. | Journal of acquired immune deficiency syndromes (1999) 20061215 |
| Interactions between buprenorphine and antiretrovirals. I. The nonnucleoside reverse-transcriptase inhibitors efavirenz and delavirdine. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20061215 |
| Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals. | Journal of acquired immune deficiency syndromes (1999) 20061215 |
| Administration of efavirenz (600 mg/day) with rifampicin results in highly variable levels but excellent clinical outcomes in patients treated for tuberculosis and HIV. | The Journal of antimicrobial chemotherapy 20061201 |
| Highly active antiretroviral treatment containing efavirenz or nevirapine and related toxicity in the TREAT Asia HIV Observational Database. | Journal of acquired immune deficiency syndromes (1999) 20061201 |
| Evaluation of 227 drugs for in vitro inhibition of cytochrome P450 2B6. | Journal of clinical pharmacology 20061201 |
| Lack of mucosal immune reconstitution during prolonged treatment of acute and early HIV-1 infection. | PLoS medicine 20061201 |
| Didanosine, lamivudine-emtricitabine and efavirenz as initial therapy in naive patients. | Expert review of anti-infective therapy 20061201 |
| Atripla approval in Europe. | AIDS patient care and STDs 20061201 |
| Meeting report. Report from ICAAC. | AIDS clinical care 20061201 |
| Nevirapine versus efavirenz based antiretroviral treatment in naive Indian patients: comparison of effectiveness in clinical cohort. | The Journal of the Association of Physicians of India 20061201 |
| Long-term survival and immuno-virological response of African HIV-1-infected children to highly active antiretroviral therapy regimens. | AIDS (London, England) 20061128 |
| Nevirapine versus efavirenz in 742 patients: no link of liver toxicity with female sex, and a baseline CD4 cell count greater than 250 cells/microl. | AIDS (London, England) 20061114 |
| Intracellular and plasma efavirenz concentrations in HIV-infected patients switching from successful protease inhibitor-based highly active antiretroviral therapy (HAART) to efavirenz-based HAART (SUSTIPHAR Study). | The Journal of antimicrobial chemotherapy 20061101 |
| Optimization of pyrimidinyl- and triazinyl-amines as non-nucleoside inhibitors of HIV-1 reverse transcriptase. | Bioorganic & medicinal chemistry letters 20061101 |
| Efavirenz trough levels are not associated with virological failure throughout therapy with 800 mg daily and a rifampicin-containing antituberculosis regimen. | The Journal of antimicrobial chemotherapy 20061101 |
| Long-term results of initial therapy with abacavir and Lamivudine combined with Efavirenz, Amprenavir/Ritonavir, or Stavudine. | Journal of acquired immune deficiency syndromes (1999) 20061101 |
| Viral decay dynamics in HIV-infected patients receiving ritonavir-boosted saquinavir and efavirenz with or without enfuvirtide: a randomized, controlled trial (HIV-NAT 012). | The Journal of infectious diseases 20061101 |
| Multilocus genetic interactions and response to efavirenz-containing regimens: an adult AIDS clinical trials group study. | Pharmacogenetics and genomics 20061101 |
| Variability in non-nucleoside reverse transcriptase and protease inhibitor concentrations among HIV-infected adults in routine clinical practice. | British journal of clinical pharmacology 20061101 |
| Criteria for drugs used in pre-exposure prophylaxis trials against HIV infection. | PLoS medicine 20061101 |
| Potent nonnucleoside reverse transcriptase inhibitors target HIV-1 Gag-Pol. | PLoS pathogens 20061101 |
| Efavirenz and chronic neuropsychiatric symptoms: a cross-sectional case control study. | HIV medicine 20061101 |
| Report from the XVI International AIDS Conference. Efavirenz for high viral load and low CD4--a secondary analysis of ACTG 5095. | AIDS clinical care 20061101 |
| Switch from a first virologically effective protease inhibitor-containing regimen to a regimen containing efavirenz, nevirapine or abacavir. | AIDS (London, England) 20061024 |
| Use of immortalized human hepatocytes to predict the magnitude of clinical drug-drug interactions caused by CYP3A4 induction. | Drug metabolism and disposition: the biological fate of chemicals 20061001 |
| Resistance development over 144 weeks in treatment-naive patients receiving tenofovir disoproxil fumarate or stavudine with lamivudine and efavirenz in Study 903. | HIV medicine 20061001 |
| Clinical and economic outcomes of nonadherence to highly active antiretroviral therapy in patients with human immunodeficiency virus. | Medical care 20061001 |
| Pharmacogenetics of HIV therapy. | Pharmacogenetics and genomics 20061001 |
| Orosomucoid (alpha1-acid glycoprotein) plasma concentration and genetic variants: effects on human immunodeficiency virus protease inhibitor clearance and cellular accumulation. | Clinical pharmacology and therapeutics 20061001 |
| HIV-1 viral load assays for resource-limited settings. | PLoS medicine 20061001 |
| Pyrosequencing-based screening for genetic polymorphisms in cytochrome P450 2B6 of potential clinical relevance. | Pharmacogenomics 20061001 |
| No increase in CNS defects. | AIDS patient care and STDs 20061001 |
| [Effects of traditional Chinese medicine on CD4 + T cell counts and HIV viral loads during structured treatment interruption in highly active antiretroviral therapy]. | Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae 20061001 |
| Need for therapeutic drug monitoring in HIV-1 infected children receiving efavirenz doses according to international guidelines. | European journal of medical research 20060929 |
| A once-daily combination tablet (Atripla) for HIV. | The Medical letter on drugs and therapeutics 20060925 |
| Relative replication fitness of efavirenz-resistant mutants of HIV-1: correlation with frequency during clinical therapy and evidence of compensation for the reduced fitness of K103N + L100I by the nucleoside resistance mutation L74V. | Virology 20060915 |
| Drug transporter and metabolizing enzyme gene variants and nonnucleoside reverse-transcriptase inhibitor hepatotoxicity. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20060915 |
| Severe vitamin D deficiency diagnosed after introduction of antiretroviral therapy including efavirenz in a patient living at latitude 59 degrees N. | AIDS (London, England) 20060911 |
| Potency and vulnerability: troubled 'selves' in the context of antiretroviral therapy. | Social science & medicine (1982) 20060901 |
| Ritonavir, saquinavir, and efavirenz, but not nevirapine, inhibit bile acid transport in human and rat hepatocytes. | The Journal of pharmacology and experimental therapeutics 20060901 |
| QSAR for non-nucleoside inhibitors of HIV-1 reverse transcriptase. | Bioorganic & medicinal chemistry 20060901 |
| CXCR4 tropic human immunodeficiency virus type 1 induces an apoptotic cascade in immature infected thymocytes that resembles thymocyte negative selection. | Virology 20060901 |
| Differential susceptibility of HIV-1 reverse transcriptase to inhibition by RNA aptamers in enzymatic reactions monitoring specific steps during genome replication. | The Journal of biological chemistry 20060901 |
| Tri-substituted triazoles as potent non-nucleoside inhibitors of the HIV-1 reverse transcriptase. | Bioorganic & medicinal chemistry letters 20060901 |
| Human immunodeficiency virus-1 and preconception care. | Maternal and child health journal 20060901 |
| Monitoring the toxicity of antiretroviral therapy in resource limited settings: a prospective clinical trial cohort in Thailand. | The Journal of antimicrobial chemotherapy 20060901 |
| Rates of disease progression according to initial highly active antiretroviral therapy regimen: a collaborative analysis of 12 prospective cohort studies. | The Journal of infectious diseases 20060901 |
| Changes in body composition and mitochondrial nucleic acid content in patients switched from failed nucleoside analogue therapy to ritonavir-boosted indinavir and efavirenz. | The Journal of infectious diseases 20060901 |
| Plasma lipid concentrations after 1.5 years of exposure to nevirapine or efavirenz together with stavudine and lamivudine. | HIV medicine 20060901 |
| Incidence and risk factors of rash associated with efavirenz in HIV-infected patients with preceding nevirapine-associated rash. | HIV medicine 20060901 |
| Genetic, ethnic, and gender differences in the pharmacokinetics of antiretroviral agents. | Current HIV/AIDS reports 20060901 |
| Efavirenz in plasma from HIV-infected patients does not directly block reverse transcriptase activity in cell-free assays but inhibits HIV replication in cellular assays. | AIDS research and human retroviruses 20060901 |
| One pill, once daily: now an option for HIV patients. | AIDS clinical care 20060901 |
| Once-daily dosing and the treatment of HIV disease. | The AIDS reader 20060901 |
| [Observance of antiretroviral treatments: African specificities]. | Medecine et maladies infectieuses 20060901 |
| Virological and immunological responses of efavirenz-based HAART regimen initiated in HIV-infected patients at CD4 < 100 versus CD4 > or = 100 cells/mm3. | Journal of the Medical Association of Thailand = Chotmaihet thangphaet 20060901 |
| Membrane transporter proteins: a challenge for CNS drug development. | Dialogues in clinical neuroscience 20060901 |
| Nucleotide HIV reverse transcriptase inhibitors: tenofovir and beyond. | Current opinion in HIV and AIDS 20060901 |
| Management of antiretroviral drug toxicity. | Current opinion in HIV and AIDS 20060901 |
| Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial. | JAMA 20060816 |
| Synthesis and biological evaluations of sulfanyltriazoles as novel HIV-1 non-nucleoside reverse transcriptase inhibitors. | Bioorganic & medicinal chemistry letters 20060815 |
| Design, synthesis, and biological evaluations of novel quinolones as HIV-1 non-nucleoside reverse transcriptase inhibitors. | Bioorganic & medicinal chemistry letters 20060815 |
| The implications of a high allelic frequency of CYP2B6 G516T in ethnic Chinese persons. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20060815 |
| [The use of the non-nucleoside reverse transcriptase inhibitors nevirapine and efavirenz in the treatment of patients with a chronic HIV-I infection]. | Nederlands tijdschrift voor geneeskunde 20060805 |
| Discovery of TSAO derivatives with an unusual HIV-1 activity/resistance profile. | Antiviral research 20060801 |
| Efavirenz-induced urolithiasis. | Urological research 20060801 |
| Depressive symptoms predict increased incidence of neuropsychiatric side effects in patients treated with efavirenz. | Journal of acquired immune deficiency syndromes (1999) 20060801 |
| Oxidant stress and peripheral neuropathy during antiretroviral therapy: an AIDS clinical trials group study. | Journal of acquired immune deficiency syndromes (1999) 20060801 |
| Effect of baseline- and treatment-related factors on immunologic recovery after initiation of antiretroviral therapy in HIV-1-positive subjects: results from ACTG 384. | Journal of acquired immune deficiency syndromes (1999) 20060801 |
| Novel nonnucleoside inhibitors that select nucleoside inhibitor resistance mutations in human immunodeficiency virus type 1 reverse transcriptase. | Antimicrobial agents and chemotherapy 20060801 |
| Reduced valproate plasma levels possible after introduction of efavirenz in a bipolar patient. | Bipolar disorders 20060801 |
| How do intellectual property law and international trade agreements affect access to antiretroviral therapy? | PLoS medicine 20060801 |
| Full validation of an analytical method for the HIV-protease inhibitor atazanavir in combination with 8 other antiretroviral agents and its applicability to therapeutic drug monitoring. | Therapeutic drug monitoring 20060801 |
| Switch from efavirenz to nevirapine associated with resolution of efavirenz-related neuropsychiatric adverse events and improvement in lipid profiles. | AIDS patient care and STDs 20060801 |
| Urinary NO3 excretion and renal failure in indinavir-treated patients. | Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas 20060801 |
| Structural insights into mechanisms of non-nucleoside drug resistance for HIV-1 reverse transcriptases mutated at codons 101 or 138. | The FEBS journal 20060801 |
| Computer-aided molecular design of highly potent HIV-1 RT inhibitors: 3D QSAR and molecular docking studies of efavirenz derivatives. | SAR and QSAR in environmental research 20060801 |
| Virological and immunological outcomes at 3 years after starting antiretroviral therapy with regimens containing non-nucleoside reverse transcriptase inhibitor, protease inhibitor, or both in INITIO: open-label randomised trial. | Lancet (London, England) 20060722 |
| Hemochromatosis (HFE) gene mutations and peripheral neuropathy during antiretroviral therapy. | AIDS (London, England) 20060713 |
| Human genetic variability and HIV treatment response. | Current HIV/AIDS reports 20060701 |
| Metabolism of efavirenz and 8-hydroxyefavirenz by P450 2B6 leads to inactivation by two distinct mechanisms. | The Journal of pharmacology and experimental therapeutics 20060701 |
| Synthesis and biological investigation of S-aryl-S-DABO derivatives as HIV-1 inhibitors. | Bioorganic & medicinal chemistry letters 20060701 |
| Synthesis and evaluation of N-aryl pyrrolidinones as novel anti-HIV-1 agents. Part 1. | Bioorganic & medicinal chemistry letters 20060701 |
| A comparison between abacavir and efavirenz as the third drug used in combination with a background therapy regimen of 2 nucleoside reverse-transcriptase inhibitors in patients with initially suppressed viral loads. | The Journal of infectious diseases 20060701 |
| Concurrent use of efavirenz and oxcarbazepine may not affect efavirenz plasma concentrations. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20060701 |
| Influence of tenofovir, nevirapine and efavirenz on ritonavir-boosted atazanavir pharmacokinetics in HIV-infected patients. | European journal of clinical pharmacology 20060701 |
| Efavirenz does not interact with the ABCB1 transporter at the blood-brain barrier. | Pharmaceutical research 20060701 |
| Dihydroxythiophenes are novel potent inhibitors of human immunodeficiency virus integrase with a diketo acid-like pharmacophore. | Journal of virology 20060701 |
| Scrutinized: the TRIPS agreement and public health. | McGill journal of medicine : MJM : an international forum for the advancement of medical sciences by students 20060701 |
| Use of efavirenz is not associated with a higher risk of depressive disorders: a substudy of the randomized clinical trial ALIZE-ANRS 099. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20060615 |
| Modulation of human immunodeficiency virus type 1 synergistic inhibition by reverse transcriptase mutations. | Biochemistry 20060613 |
| A case of voluntary intoxication with efavirenz and lamivudine. | AIDS (London, England) 20060612 |
| New HIV-1 reverse transcriptase inhibitors based on a tricyclic benzothiophene scaffold: synthesis, resolution, and inhibitory activity. | Bioorganic & medicinal chemistry letters 20060601 |
| Antiretroviral drug resistance and routine therapy, Cameroon. | Emerging infectious diseases 20060601 |
| Oral absorption of poorly water-soluble drugs: computer simulation of fraction absorbed in humans from a miniscale dissolution test. | Pharmaceutical research 20060601 |
| Design, molecular modeling, synthesis, and anti-HIV-1 activity of new indolyl aryl sulfones. Novel derivatives of the indole-2-carboxamide. | Journal of medicinal chemistry 20060601 |
| Nevirapine toxicity. | International journal of STD & AIDS 20060601 |
| Are plasma levels valid surrogates for cellular concentrations of antiretroviral drugs in HIV-infected patients? | Therapeutic drug monitoring 20060601 |
| Changes in the immune system in depression and dementia: causal or coincidental effects? | Dialogues in clinical neuroscience 20060601 |
| HIV infection. | Clinical evidence 20060601 |
| Haemolytic anaemia associated with efavirenz. | AIDS (London, England) 20060512 |
| The HIV-1 reverse transcriptase mutants G190S and G190A, which confer resistance to non-nucleoside reverse transcriptase inhibitors, demonstrate reductions in RNase H activity and DNA synthesis from tRNA(Lys, 3) that correlate with reductions in replication efficiency. | Virology 20060510 |
| HIV protease inhibitor therapy reverses neutrophil apoptosis in AIDS patients by direct calpain inhibition. | Apoptosis : an international journal on programmed cell death 20060501 |
| Clinical and genotypic correlates of mutation K65R in HIV-infected patients failing regimens not including tenofovir. | Journal of medical virology 20060501 |
| Natural polymorphism in protease and reverse transcriptase genes and in vitro antiretroviral drug susceptibilities of non-B HIV-1 strains from treatment-naive patients. | Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology 20060501 |
| Simple and rapid liquid chromatography method for determination of efavirenz in plasma. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20060501 |
| Frequency and treatment-related predictors of thymidine-analogue mutation patterns in HIV-1 isolates after unsuccessful antiretroviral therapy. | The Journal of infectious diseases 20060501 |
| Changes in sleep quality and brain wave patterns following initiation of an efavirenz-containing triple antiretroviral regimen. | HIV medicine 20060501 |
| Characterization of interference with 6 commercial delta9-tetrahydrocannabinol immunoassays by efavirenz (glucuronide) in urine. | Clinical chemistry 20060501 |
| Efficacy and safety of an anti-retroviral combination regimen including either efavirenz or lopinavir-ritonavir with a backbone of two nucleoside reverse transcriptase inhibitors. | Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 20060501 |
| Long-term and concentration-dependent beneficial effect of efavirenz on HDL-cholesterol in HIV-infected patients. | British journal of clinical pharmacology 20060501 |
| [Clinical and subclinical neuropathy in patients with human immunodeficiency virus receiving antiretroviral therapy]. | Revista de neurologia 20060501 |
| Response to: Are all non-thymidine analogue backbones appropriate for treating antiretroviral-naïve patients? | International journal of clinical practice 20060501 |
| Atypical presentation of HIV in a pregnant patient. | The Ulster medical journal 20060501 |
| Tolerance and acceptability of an efavirenz-based regimen in 740 adults (predominantly women) in West Africa. | Journal of acquired immune deficiency syndromes (1999) 20060501 |
| [Evolution of mortality and current status of an HIV-infected population cared for at a comprehensive HIV/AIDS center in Chile]. | Revista medica de Chile 20060501 |
| Towards discovering dual functional inhibitors against both wild type and K103N mutant HIV-1 reverse transcriptases: molecular docking and QSAR studies on 4,1-benzoxazepinone analogues. | Journal of computer-aided molecular design 20060501 |
| Reverse transcriptase mutations 118I, 208Y, and 215Y cause HIV-1 hypersusceptibility to non-nucleoside reverse transcriptase inhibitors. | AIDS (London, England) 20060424 |
| Antiretroviral medications associated with elevated blood pressure among patients receiving highly active antiretroviral therapy. | AIDS (London, England) 20060424 |
| Maintenance of successful ritonavir-boosted indinavir and efavirenz therapy in an HIV-infected patient with tuberculosis. | AIDS (London, England) 20060424 |
| Biosensor-based kinetic characterization of the interaction between HIV-1 reverse transcriptase and non-nucleoside inhibitors. | Journal of medicinal chemistry 20060420 |
| Stavudine, lamivudine and nevirapine combination therapy for treatment of HIV infection and AIDS in adults. | The Cochrane database of systematic reviews 20060419 |
| Design, synthesis, and biological evaluations of novel oxindoles as HIV-1 non-nucleoside reverse transcriptase inhibitors. Part 2. | Bioorganic & medicinal chemistry letters 20060415 |
| Design, synthesis and biological evaluations of novel oxindoles as HIV-1 non-nucleoside reverse transcriptase inhibitors. Part I. | Bioorganic & medicinal chemistry letters 20060415 |
| Marked intraindividual variability in antiretroviral concentrations may limit the utility of therapeutic drug monitoring. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20060415 |
| Effect of co-trimoxazole prophylaxis, antiretroviral therapy, and insecticide-treated bednets on the frequency of malaria in HIV-1-infected adults in Uganda: a prospective cohort study. | Lancet (London, England) 20060415 |
| Mixed patterns of changes in central and peripheral fat following initiation of antiretroviral therapy in a randomized trial. | Journal of acquired immune deficiency syndromes (1999) 20060415 |
| Genital HIV-1 viral load is correlated with blood plasma HIV-1 viral load in Brazilian women and is reduced by antiretroviral therapy. | The Journal of infection 20060401 |
| Synthesis and anti-HIV activity of new alkenyldiarylmethane (ADAM) non-nucleoside reverse transcriptase inhibitors (NNRTIs) incorporating benzoxazolone and benzisoxazole rings. | Bioorganic & medicinal chemistry 20060401 |
| Use of tenofovir disoproxil fumarate and emtricitabine combination in HIV-infected patients. | Expert opinion on pharmacotherapy 20060401 |
| The effects of the Roche AMPLICOR HIV-1 MONITOR UltraSensitive Test versions 1.0 and 1.5 viral load assays and plasma collection tube type on determination of response to antiretroviral therapy and the inappropriateness of cross-study comparisons. | Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology 20060401 |
| Nonnucleoside reverse transcriptase inhibitor fold change or plasma concentration as a predictor of virological response over 48 weeks in highly treatment experienced HIV-positive individuals. | AIDS research and human retroviruses 20060401 |
| Comparative bioavailability of a generic capsule formulation of the reverse transcriptase inhibitor efavirenz and the innovator product. | International journal of clinical pharmacology and therapeutics 20060401 |
| False-positive results in urine drug screening in healthy volunteers participating in phase 1 studies with efavirenz and rifampin. | Therapeutic drug monitoring 20060401 |
| Pharmacologic optimization of protease inhibitors and nonnucleoside reverse transcriptase inhibitors (POPIN)--a randomized controlled trial of therapeutic drug monitoring and adherence support. | Journal of acquired immune deficiency syndromes (1999) 20060401 |
| HIV transmission in correctional facility. | Emerging infectious diseases 20060401 |
| Immune restoration disease in HIV patient. | Emerging infectious diseases 20060401 |
| Report from the 13th retrovirus conference. Vicriviroc less effective than efavirenz in treatment-naive patients. | AIDS clinical care 20060401 |
| [Severe psychosis in an African woman due to the antiretroviral agent efavirenz]. | Nederlands tijdschrift voor geneeskunde 20060318 |
| [Severe psychosis in an African woman due to the antiretroviral agent efavirenz]. | Nederlands tijdschrift voor geneeskunde 20060318 |
| Effects of efavirenz binding on the subunit equilibria of HIV-1 reverse transcriptase. | Biochemistry 20060307 |
| Initiation of antiretroviral therapy in advanced AIDS with active tuberculosis: clinical experiences from Thailand. | The Journal of infection 20060301 |
| Influence of HCV or HBV coinfection on adverse drug reactions to antiretroviral drugs in HIV patients. | European journal of clinical pharmacology 20060301 |
| Associations among race/ethnicity, ApoC-III genotypes, and lipids in HIV-1-infected individuals on antiretroviral therapy. | PLoS medicine 20060301 |
| Antiretroviral therapy and dyslipidaemia: unlocking the code. | PLoS medicine 20060301 |
| HIV-related neutropaenia exacerbated by efavirenz. | HIV medicine 20060301 |
| Identification of a novel specific CYP2B6 allele in Africans causing impaired metabolism of the HIV drug efavirenz. | Pharmacogenetics and genomics 20060301 |
| Effect of buprenorphine and antiretroviral agents on the QT interval in opioid-dependent patients. | The Annals of pharmacotherapy 20060301 |
| Pharmacokinetic parameters of nevirapine and efavirenz in relation to antiretroviral efficacy. | AIDS research and human retroviruses 20060301 |
| Phenotypic drug resistance patterns in subtype A HIV-1 clones with nonnucleoside reverse transcriptase resistance mutations. | AIDS research and human retroviruses 20060301 |
| API TB Consensus Guidelines 2006: Management of pulmonary tuberculosis, extra-pulmonary tuberculosis and tuberculosis in special situations. | The Journal of the Association of Physicians of India 20060301 |
| Determination of the novel non-peptidic HIV-protease inhibitor tipranavir by HPLC-UV after solid-phase extraction. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20060217 |
| Major role of hepatitis B genotypes in liver fibrosis during coinfection with HIV. | AIDS (London, England) 20060214 |
| Simultaneous determination of 16 anti-HIV drugs in human plasma by high-performance liquid chromatography. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20060202 |
| Severe efavirenz-induced hypersensitivity syndrome (not-DRESS) with acute renal failure. | The Journal of infection 20060201 |
| Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: an Adult AIDS Clinical Trials Group Study. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20060201 |
| Efavirenz and CYP2B6 polymorphism: implications for drug toxicity and resistance. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20060201 |
| HIV-1 reverse transcriptase gene 103K/N and 184M/V combinations in tandem: detection and quantification of HIV-1 populations in the CD45RO+ T-cell compartment by a double-ARMS real-time PCR assay. | Journal of acquired immune deficiency syndromes (1999) 20060201 |
| Interpatient variability in the pharmacokinetics of the HIV non-nucleoside reverse transcriptase inhibitor efavirenz: the effect of gender, race, and CYP2B6 polymorphism. | British journal of clinical pharmacology 20060201 |
| Study of efavirenz over 96 weeks shows durability, efficacious regimen. Results from 48-96 weeks essentially same. | AIDS alert 20060201 |
| Structure-activity relationship studies of novel benzophenones leading to the discovery of a potent, next generation HIV nonnucleoside reverse transcriptase inhibitor. | Journal of medicinal chemistry 20060126 |
| Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. | The New England journal of medicine 20060119 |
| Body fat and other metabolic effects of atazanavir and efavirenz, each administered in combination with zidovudine plus lamivudine, in antiretroviral-naive HIV-infected patients. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20060115 |
| Economic impact of antiretroviral therapy prescription decisions in the context of rapid scaling-up of access to treatment: lessons from Mexico. | AIDS (London, England) 20060102 |
| Efavirenz 600 mg/day versus efavirenz 800 mg/day in HIV-infected patients with tuberculosis receiving rifampicin: 48 weeks results. | AIDS (London, England) 20060102 |
| Simultaneous determination of six HIV protease inhibitors (amprenavir, indinavir, lopinavir, nelfinavir, ritonavir and saquinavir), the active metabolite of nelfinavir (M8) and non-nucleoside reverse transcriptase inhibitor (efavirenz) in human plasma by high-performance liquid chromatography. | Biomedical chromatography : BMC 20060101 |
| Assessment of drug-drug interactions between tenofovir disoproxil fumarate and the nonnucleoside reverse transcriptase inhibitors nevirapine and efavirenz in HIV-infected patients. | Journal of acquired immune deficiency syndromes (1999) 20060101 |
| Reasons for modification of generic highly active antiretroviral therapeutic regimens among patients in southern India. | Journal of acquired immune deficiency syndromes (1999) 20060101 |
| Population pharmacokinetics of efavirenz in an unselected cohort of HIV-1-infected individuals. | Clinical pharmacokinetics 20060101 |
| Better quality of life with neuropsychological improvement on HAART. | Health and quality of life outcomes 20060101 |
| Understanding and avoiding antiretroviral adverse events. | Current pharmaceutical design 20060101 |
| Increased antiretroviral potency by the addition of enfuvirtide to a four-drug regimen in antiretroviral-naive, HIV-infected patients. | Antiviral therapy 20060101 |
| An open-label, randomized comparative pilot study of a single-class quadruple therapy regimen versus a 2-class triple therapy regimen for individuals initiating antiretroviral therapy. | Antiviral therapy 20060101 |
| Direct and fast determination of antiretroviral drugs by automated online solid-phase extraction-liquid chromatography-tandem mass spectrometry in human plasma. | Clinical chemistry and laboratory medicine 20060101 |
| DR_SEQAN: a PC/Windows-based software to evaluate drug resistance using human immunodeficiency virus type 1 genotypes. | BMC infectious diseases 20060101 |
| [Neuro-psychiatric adverse effects associated with efavirenz]. | Enfermedades infecciosas y microbiologia clinica 20060101 |
| CD4 cell count recovery among HIV-infected patients with very advanced immunodeficiency commencing antiretroviral treatment in sub-Saharan Africa. | BMC infectious diseases 20060101 |
| Antiretroviral treatment of HIV infection: Swedish recommendations 2005. | Scandinavian journal of infectious diseases 20060101 |
| Cerebrospinal fluid HIV-1 RNA, intrathecal immunoactivation, and drug concentrations after treatment with a combination of saquinavir, nelfinavir, and two nucleoside analogues: the M61022 study. | BMC infectious diseases 20060101 |
| Antiretroviral therapy at a district hospital in Ethiopia prevents death and tuberculosis in a cohort of HIV patients. | AIDS research and therapy 20060101 |
| Efavirenz use during pregnancy and for women of child-bearing potential. | AIDS research and therapy 20060101 |
| Neuropsychiatric adverse events after switching from an antiretroviral regimen containing efavirenz without tenofovir to an efavirenz regimen containing tenofovir: a report of nine cases. | Antiviral therapy 20060101 |
| API consensus guidelines for use of antiretroviral therapy in adults (API-ART guidelines). Endorsed by the AIDS Society of India. | The Journal of the Association of Physicians of India 20060101 |
| Pulmonary thromboembolism in AIDS patient with chronic venous insufficiency, pulmonary tuberculosis and breast cancer: a case report and pathophysiology review. | Revista do Instituto de Medicina Tropical de Sao Paulo 20060101 |
| Affective disorders in patients with HIV infection: impact of antiretroviral therapy. | CNS drugs 20060101 |
| Treating HIV during pregnancy: an update on safety issues. | Drug safety 20060101 |
| Concentration of circulating oxidized LDL in HIV-infected patients treated with antiretroviral agents: relation to HIV-related lipodystrophy. | HIV clinical trials 20060101 |
| Tipranavir: a novel nonpeptidic protease inhibitor of HIV. | Clinical pharmacokinetics 20060101 |
| [Efavirenz (Sustiva) in pregnancy: a study about 12 HIV patients]. | Gynecologie, obstetrique & fertilite 20060101 |
| Burning mouth syndrome due to efavirenz therapy. | The Annals of pharmacotherapy 20060101 |
| Lopinavir/ritonavir: a review of its use in the management of HIV infection. | Drugs 20060101 |
| Effects of highly active antiretroviral therapy with nelfinavir in vertically HIV-1 infected children: 3 years of follow-up. Long-term response to nelfinavir in children. | BMC infectious diseases 20060101 |
| Genotyping of CYP2B6 and therapeutic drug monitoring in an HIV-infected patient with high efavirenz plasma concentrations and severe CNS side-effects. | Scandinavian journal of infectious diseases 20060101 |
| The effect of different combination therapies on oxidative stress markers in HIV infected patients in Cameroon. | AIDS research and therapy 20060101 |
| Efavirenz/emtricitabine/tenofovir disoproxil fumarate: triple combination tablet. | Drugs 20060101 |
| Local tumor control and toxicity in HIV-associated anal carcinoma treated with radiotherapy in the era of antiretroviral therapy. | Radiation oncology (London, England) 20060101 |
| Efficacy, safety and pharmacokinetics of once-daily saquinavir soft-gelatin capsule/ritonavir in antiretroviral-naive, HIV-infected patients. | MedGenMed : Medscape general medicine 20060101 |
| Long-term safety and tolerability of the lamivudine/abacavir combination as components of highly active antiretroviral therapy. | Drug safety 20060101 |
| Predictors of early death in a cohort of Ethiopian patients treated with HAART. | BMC infectious diseases 20060101 |
| Lopinavir/ritonavir or efavirenz plus two nucleoside analogues as first-line antiretroviral therapy: a non-randomized comparison. | Antiviral therapy 20060101 |
| Neuropsychiatric complications of antiretroviral therapy. | Drug safety 20060101 |
| Cytotoxic T cell recognition of an HIV-1 reverse transcriptase variant peptide incorporating the K103N drug resistance mutation. | AIDS research and therapy 20060101 |
| Indolyl aryl sulphones as HIV-1 non-nucleoside reverse transcriptase inhibitors: synthesis, biological evaluation and binding mode studies of new derivatives at indole-2-carboxamide. | Antiviral chemistry & chemotherapy 20060101 |
| Antiretroviral therapy in AIDS patients with tuberculosis. | AIDS reviews 20060101 |
| [Methadone: from pharmacokinetic profile to clinical pharmacology]. | L'Encephale 20060101 |
| Nucleoside analogue reverse transcriptase inhibitor options: a re-examination of the class. | Topics in HIV medicine : a publication of the International AIDS Society, USA 20060101 |
| The cost-effectiveness of antiretroviral treatment in Khayelitsha, South Africa--a primary data analysis. | Cost effectiveness and resource allocation : C/E 20060101 |
| Can efavirenz be taken in the morning? | Scandinavian journal of infectious diseases 20060101 |
| An immunological comparison of third companion in advanced drug-naive HIV-infected patients. | HIV clinical trials 20060101 |
| Pilot study of once-daily simplification therapy with abacavir/lamivudine/zidovudine and efavirenz for treatment of HIV-1 infection. | HIV clinical trials 20060101 |
| Tuberculosis and HIV co-infection: a practical therapeutic approach. | Drugs 20060101 |
| Strong HIV-1-specific T cell responses in HIV-1-exposed uninfected infants and neonates revealed after regulatory T cell removal. | PloS one 20060101 |
| A comparative study on the cost of new antibiotics and drugs of other therapeutic categories. | PloS one 20060101 |
| Clinical outcome of HIV-infected patients with sustained virologic response to antiretroviral therapy: long-term follow-up of a multicenter cohort. | PloS one 20060101 |
| Use of taste-masking product, FLAVORx, to assist Thai children to ingest generic antiretrovirals. | AIDS research and therapy 20060101 |
| No virological failure in semen during properly suppressive antiretroviral therapy despite subtherapeutic local drug concentrations. | HIV clinical trials 20060101 |
| Cost to achieve an undetectable viral load using recommended antiretroviral regimens. | HIV clinical trials 20060101 |
| Synthesis of amino derivatives of 10-(diphenylmethylene)-4-azatricyclo[5.2.1.0(2,6)]dec-8-ene-3,5-dione as potential psychotropic and/or anti HIV agents. | Acta poloniae pharmaceutica 20060101 |
| Anti-HIV agents. Some drug interactions with Merck's integrase inhibitor. | TreatmentUpdate 20060101 |
| Drug interactions. Super pills-the treatments of the future? | TreatmentUpdate 20060101 |
| Switching strategies to improve lipid profile and morphologic changes. | AIDS reviews 20060101 |
| Antiretroviral therapy at conception in pregnant women with HIV in Italy: wide range of variability and frequent exposure to contraindicated drugs. | Antiviral therapy 20060101 |
| Rare selection of the K65R mutation in antiretroviral-naive patients failing a first-line abacavir/ lamivudine-containing HAART regimen. | Antiviral therapy 20060101 |
| First of a kind in HIV treatment. | FDA consumer 20060101 |
| Sustiva: revised drug-interaction information. | AIDS treatment news 20060101 |
| Disease Management - Constructing Optimal NRTI-Based Combinations: Past, Present, and Future. | Journal of the International AIDS Society 20060101 |
| Neurocognitive deficits in HIV-positive patients-two case reports: Revising current AANTF guidelines in view of recent revelation of new neurocognitive symptoms. | Indian journal of psychiatry 20060101 |
| The Chilean AIDS cohort: a model for evaluating the impact of an expanded access program to antiretroviral therapy in a middle-income country--organization and preliminary results. | Journal of acquired immune deficiency syndromes (1999) 20051215 |
| Efficacy of cerebrospinal fluid (CSF)-penetrating antiretroviral drugs against HIV in the neurological compartment: different patterns of phenotypic resistance in CSF and plasma. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20051215 |
| Spontaneous hepatic decompensation in patients coinfected with HIV and hepatitis C virus during interferon-ribavirin combination treatment. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20051215 |
| Parallel solution-phase and microwave-assisted synthesis of new S-DABO derivatives endowed with subnanomolar anti-HIV-1 activity. | Journal of medicinal chemistry 20051215 |
| Effect of first line therapy including efavirenz and two nucleoside reverse transcriptase inhibitors in HIV-infected children. | European journal of medical research 20051207 |
| Prediction of neuropsychiatric adverse events associated with long-term efavirenz therapy, using plasma drug level monitoring. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20051201 |
| Early virologic nonresponse to tenofovir, abacavir, and lamivudine in HIV-infected antiretroviral-naive subjects. | The Journal of infectious diseases 20051201 |
| Pharmacogenetics of long-term responses to antiretroviral regimens containing Efavirenz and/or Nelfinavir: an Adult Aids Clinical Trials Group Study. | The Journal of infectious diseases 20051201 |
| Genetic variability of CYP2B6 in populations of African and Asian origin: allele frequencies, novel functional variants, and possible implications for anti-HIV therapy with efavirenz. | Pharmacogenetics and genomics 20051201 |
| Assessment of adherence to highly active antiretroviral therapy in a cohort of African HIV-infected children in Abidjan, Côte d'Ivoire. | Journal of acquired immune deficiency syndromes (1999) 20051201 |
| Allosteric modulation of anti-HIV drug and ferric heme binding to human serum albumin. | The FEBS journal 20051201 |
| Genotypic human immunodeficiency virus type 1 drug resistance in highly active antiretroviral therapy-treated children in Abidjan, Côte d'Ivoire. | The Pediatric infectious disease journal 20051201 |
| Stevens - Johnson syndrome due to nevirapine. | African health sciences 20051201 |
| HIV infection. | Clinical evidence 20051201 |
| [Severe psychosis in an African woman due to the antiretroviral agent efavirenz]. | Nederlands tijdschrift voor geneeskunde 20051126 |
| Specific targeting highly conserved residues in the HIV-1 reverse transcriptase primer grip region. Design, synthesis, and biological evaluation of novel, potent, and broad spectrum NNRTIs with antiviral activity. | Journal of medicinal chemistry 20051117 |
| Mitochondrial DNA and RNA increase in peripheral blood mononuclear cells from HIV-1-infected patients randomized to receive stavudine-containing or stavudine-sparing combination therapy. | The Journal of infectious diseases 20051115 |
| Summaries for patients. Neuropsychological side effects of efavirenz. | Annals of internal medicine 20051115 |
| Impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals. | Annals of internal medicine 20051115 |
| Glucose metabolism, lipid, and body fat changes in antiretroviral-naive subjects randomized to nelfinavir or efavirenz plus dual nucleosides. | AIDS (London, England) 20051104 |
| Evaluation of the drug interaction between rifabutin and efavirenz in patients with HIV infection and tuberculosis. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20051101 |
| Initial response to highly active antiretroviral therapy in HIV-1C-infected adults in a public sector treatment program in Botswana. | Journal of acquired immune deficiency syndromes (1999) 20051101 |
| Anti-human immunodeficiency virus type 1 activity of the nonnucleoside reverse transcriptase inhibitor GW678248 in combination with other antiretrovirals against clinical isolate viruses and in vitro selection for resistance. | Antimicrobial agents and chemotherapy 20051101 |
| High potency of indolyl aryl sulfone nonnucleoside inhibitors towards drug-resistant human immunodeficiency virus type 1 reverse transcriptase mutants is due to selective targeting of different mechanistic forms of the enzyme. | Antimicrobial agents and chemotherapy 20051101 |
| Prenatal exposure to fluconazole: an identifiable dysmorphic phenotype. | Birth defects research. Part A, Clinical and molecular teratology 20051101 |
| Triple nucleoside reverse transcriptase inhibitor- vs. nonnucleoside reverse transcriptase inhibitor-containing regimens as first-line therapy: efficacy and durability in a prospective cohort of French HIV-infected patients. | HIV medicine 20051101 |
| Impact of antiretroviral choice on hypercholesterolaemia events: the role of the nucleoside reverse transcriptase inhibitor backbone. | HIV medicine 20051101 |
| Drug-resistance mutations in antiretroviral-naïve patients with established HIV-1 infection in Mexico. | HIV medicine 20051101 |
| Indinavir/ritonavir 800/100 mg bid and efavirenz 600 mg qd in patients failing treatment with combination nucleoside reverse transcriptase inhibitors: 96-week outcomes of HIV-NAT 009. | HIV medicine 20051101 |
| Neuropsychiatric effects of efavirenz: delayed onset. | International journal of STD & AIDS 20051101 |
| Antiretroviral treatment in the Northern Cape. | South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde 20051101 |
| Synthesis and evaluation of anti-HIV activity of isatin beta-thiosemicarbazone derivatives. | Bioorganic & medicinal chemistry letters 20051015 |
| Gilbert syndrome and the development of antiretroviral therapy-associated hyperbilirubinemia. | The Journal of infectious diseases 20051015 |
| The rate of viral rebound after attainment of an HIV load <50 copies/mL according to specific antiretroviral drugs in use: results from a multicenter cohort study. | The Journal of infectious diseases 20051015 |
| Efavirenz detectable in plasma 8 weeks after stopping therapy and subsequent development of non-nucleoside reverse transcriptase inhibitor-associated resistance. | AIDS (London, England) 20051014 |
| Determination of antiretroviral agents in human serum by capillary electrophoresis. | Journal of chromatography. A 20051014 |
| Reverse transcriptase inhibitors down-regulate cell proliferation in vitro and in vivo and restore thyrotropin signaling and iodine uptake in human thyroid anaplastic carcinoma. | The Journal of clinical endocrinology and metabolism 20051001 |
| Recreational substance use and tolerance of efavirenz in HIV-1 infected patients. | AIDS care 20051001 |
| Intracellular and plasma pharmacokinetics of efavirenz in HIV-infected individuals. | The Journal of antimicrobial chemotherapy 20051001 |
| Oxadiazols: a new class of rationally designed anti-human immunodeficiency virus compounds targeting the nuclear localization signal of the viral matrix protein. | Journal of virology 20051001 |
| Antiviral activity of GW678248, a novel benzophenone nonnucleoside reverse transcriptase inhibitor. | Antimicrobial agents and chemotherapy 20051001 |
| Meeting notes from the 3rd IAS Conference. Old drugs, new data. | AIDS clinical care 20051001 |
| Hopes dashed for formulation. | AIDS patient care and STDs 20051001 |
| Sequencing antiretroviral drugs for long-lasting suppression of HIV replication. | The new microbiologica 20051001 |
| Pharmacokinetic drug interactions with non-nucleoside reverse transcriptase inhibitors. | Expert opinion on drug metabolism & toxicology 20051001 |
| Efavirenz levels and 24-week efficacy in HIV-infected patients with tuberculosis receiving highly active antiretroviral therapy and rifampicin. | AIDS (London, England) 20050923 |
| Pharmacokinetic interactions between efavirenz and rifampicin in the treatment of HIV and tuberculosis: one size does not fit all. | AIDS (London, England) 20050923 |
| Mitochondrial haplogroups and peripheral neuropathy during antiretroviral therapy: an adult AIDS clinical trials group study. | AIDS (London, England) 20050902 |
| Genotypic and phenotypic resistance patterns at virological failure in a simplification trial with nevirapine, efavirenz or abacavir. | AIDS (London, England) 20050902 |
| [Rashes in HIV-infected patients undergoing therapy with nevirapine or efavirenz]. | Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete 20050901 |
| The role of Thr139 in the human immunodeficiency virus type 1 reverse transcriptase sensitivity to (+)-calanolide A. | Molecular pharmacology 20050901 |
| Risk factors for and outcome of hyperlactatemia in HIV-infected persons: is there a need for routine lactate monitoring? | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20050901 |
| Population pharmacokinetics of indinavir alone and in combination with ritonavir in HIV-1-infected patients. | British journal of clinical pharmacology 20050901 |
| Study of MMLV RT- binding with DNA using surface plasmon resonance biosensor. | Acta biochimica et biophysica Sinica 20050901 |
| Therapeutic drug monitoring of efavirenz: trough levels cannot be estimated on the basis of earlier plasma determinations. | Journal of acquired immune deficiency syndromes (1999) 20050815 |
| A K103N resistance mutation is not an absolute contraindication to adding efavirenz to a salvage regimen: a case report. | AIDS (London, England) 20050812 |
| Effect of efavirenz on intestinal p-glycoprotein and hepatic p450 function in rats. | Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques 20050804 |
| Impact of rosiglitazone treatment on the bioavailability of antiretroviral compounds in HIV-positive patients. | The Journal of antimicrobial chemotherapy 20050801 |
| Determination of nevirapine and efavirenz in plasma using GC/MS in selected ion monitoring mode. | Therapeutic drug monitoring 20050801 |
| Myelomeningocele in an infant with intrauterine exposure to efavirenz. | Journal of perinatology : official journal of the California Perinatal Association 20050801 |
| Antiretroviral therapy in HIV-1 infected children. | Indian pediatrics 20050801 |
| Early virologic failure in HIV-1 infected subjects on didanosine/tenofovir/efavirenz: 12-week results from a randomized trial. | AIDS (London, England) 20050722 |
| A potentially significant interaction between efavirenz and phenytoin: a case report and review of the literature. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20050715 |
| Antiviral activity of lamivudine in salvage therapy for multidrug-resistant HIV-1 infection. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20050715 |
| The amino acid Asn136 in HIV-1 reverse transcriptase (RT) maintains efficient association of both RT subunits and enables the rational design of novel RT inhibitors. | Molecular pharmacology 20050701 |
| Exploratory analysis for the evaluation of lopinavir/ritonavir-versus efavirenz-based HAART regimens in antiretroviral-naive HIV-positive patients: results from the Italian MASTER Cohort. | The Journal of antimicrobial chemotherapy 20050701 |
| Efficacy of highly active antiretroviral therapy in HIV-infected children participating in Thailand's National Access to Antiretroviral Program. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20050701 |
| Substitution of nevirapine or efavirenz for protease inhibitor versus lipid-lowering therapy for the management of dyslipidaemia. | AIDS (London, England) 20050701 |
| HIV-1 intermittent viraemia in patients treated by non-nucleoside reverse transcriptase inhibitor-based regimen. | AIDS (London, England) 20050701 |
| Pharmacokinetic evidence for the induction of lopinavir metabolism by efavirenz. | British journal of clinical pharmacology 20050701 |
| Induction with abacavir/lamivudine/zidovudine plus efavirenz for 48 weeks followed by 48-week maintenance with abacavir/lamivudine/zidovudine alone in antiretroviral-naive HIV-1-infected patients. | Journal of acquired immune deficiency syndromes (1999) 20050701 |
| Efficacy and tolerability of a nucleoside reverse transcriptase inhibitor-sparing combination of lopinavir/ritonavir and efavirenz in HIV-1-infected patients. | Journal of acquired immune deficiency syndromes (1999) 20050701 |
| Effect of efavirenz on the pharmacokinetics of simvastatin, atorvastatin, and pravastatin: results of AIDS Clinical Trials Group 5108 Study. | Journal of acquired immune deficiency syndromes (1999) 20050701 |
| Conventional HPLC method used for simultaneous determination of the seven HIV protease inhibitors and nonnucleoside reverse transcription inhibitor efavirenz in human plasma. | Biological & pharmaceutical bulletin 20050701 |
| Effects on immunological and virological outcome of patients using one protease inhibitor or one non-nucleoside reverse transcriptase inhibitor in a triple antiretroviral therapy: normal clinical practice versus clinical trial findings. | Current HIV research 20050701 |
| Use of amitriptyline to offset sleep disturbances caused by efavirenz. | AIDS patient care and STDs 20050701 |
| Treatment of opioid dependence and coinfection with HIV and hepatitis C virus in opioid-dependent patients: the importance of drug interactions between opioids and antiretroviral agents. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20050701 |
| Novel 1-[2-(diarylmethoxy)ethyl]-2-methyl-5-nitroimidazoles as HIV-1 non-nucleoside reverse transcriptase inhibitors. A structure-activity relationship investigation. | Journal of medicinal chemistry 20050630 |
| Identification of amino acid residues in the human immunodeficiency virus type-1 reverse transcriptase tryptophan-repeat motif that are required for subunit interaction using infectious virions. | Journal of molecular biology 20050617 |
| Metabolic benefits 24 months after replacing a protease inhibitor with abacavir, efavirenz or nevirapine. | AIDS (London, England) 20050610 |
| Inhibition of endogenous reverse transcriptase antagonizes human tumor growth. | Oncogene 20050602 |
| Structure-based design, parallel synthesis, structure-activity relationship, and molecular modeling studies of thiocarbamates, new potent non-nucleoside HIV-1 reverse transcriptase inhibitor isosteres of phenethylthiazolylthiourea derivatives. | Journal of medicinal chemistry 20050602 |
| The naturally occurring cytochrome P450 (P450) 2B6 K262R mutant of P450 2B6 exhibits alterations in substrate metabolism and inactivation. | Drug metabolism and disposition: the biological fate of chemicals 20050601 |
| Simultaneous quantitative assay of atazanavir and 6 other HIV protease inhibitors by isocratic reversed-phase liquid chromatography in human plasma. | Therapeutic drug monitoring 20050601 |
| A long-term survival case of small cell lung cancer in an HIV-infected patient. | Japanese journal of clinical oncology 20050601 |
| Prediction of genotoxicity of chemical compounds by statistical learning methods. | Chemical research in toxicology 20050601 |
| Comparison of efavirenz and nevirapine in HIV-infected patients (NEEF Cohort). | International journal of STD & AIDS 20050601 |
| Pregnancy category change for efavirenz. | AIDS patient care and STDs 20050601 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20050601 |
| Intracellular measurements of anti-HIV drugs indinavir, amprenavir, saquinavir, ritonavir, nelfinavir, lopinavir, atazanavir, efavirenz and nevirapine in peripheral blood mononuclear cells by liquid chromatography coupled to tandem mass spectrometry. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20050525 |
| The molecular basis of resilience to the effect of the Lys103Asn mutation in non-nucleoside HIV-1 reverse transcriptase inhibitors studied by targeted molecular dynamics simulations. | Journal of the American Chemical Society 20050525 |
| Quantum study of mutational effect in binding of efavirenz to HIV-1 RT. | Proteins 20050515 |
| Influence of 516G>T polymorphisms at the gene encoding the CYP450-2B6 isoenzyme on efavirenz plasma concentrations in HIV-infected subjects. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20050501 |
| Spectrum of antiviral activity of o-(acetoxyphenyl)hept-2-ynyl sulphide (APHS). | International journal of antimicrobial agents 20050501 |
| Increased dose of lopinavir/ritonavir compensates for efavirenz-induced drug-drug interaction in HIV-1-infected children. | Journal of acquired immune deficiency syndromes (1999) 20050501 |
| Nonnucleoside reverse transcriptase inhibitor phenotypic hypersusceptibility can be demonstrated in different assays. | Journal of acquired immune deficiency syndromes (1999) 20050501 |
| Combination of candidate microbicides cellulose acetate 1,2-benzenedicarboxylate and UC781 has synergistic and complementary effects against human immunodeficiency virus type 1 infection. | Antimicrobial agents and chemotherapy 20050501 |
| The Protease Inhibitor Transfer Study (PROTRA 1): abacavir and efavirenz in combination as a substitute for a protease inhibitor in heavily pretreated HIV-1-infected patients with undetectable plasma viral load. | HIV medicine 20050501 |
| Better maintained adherence on switching from twice-daily to once-daily therapy for HIV: a 24-week randomized trial of treatment simplification using stavudine prolonged-release capsules. | HIV medicine 20050501 |
| The development of vaginal microbicides for the prevention of HIV transmission. | PLoS medicine 20050501 |
| Emerging anti-HIV drugs. | Expert opinion on emerging drugs 20050501 |
| [Efavirenz]. | Revue de l'infirmiere 20050501 |
| The N137 and P140 amino acids in the p51 and the P95 amino acid in the p66 subunit of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase are instrumental to maintain catalytic activity and to design new classes of anti-HIV-1 drugs. | FEBS letters 20050425 |
| [Efavirenz--comprehensive status of studies]. | MMW Fortschritte der Medizin 20050425 |
| [Didanosine--stability as backbone drug]. | MMW Fortschritte der Medizin 20050425 |
| Long-term neuropsychiatric disorders on efavirenz-based approaches: quality of life, psychologic issues, and adherence. | Journal of acquired immune deficiency syndromes (1999) 20050415 |
| Long-term renal safety of tenofovir disoproxil fumarate in antiretroviral-naive HIV-1-infected patients. Data from a double-blind randomized active-controlled multicentre study. | Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20050401 |
| Predictors of residual viremia in HIV-infected patients successfully treated with efavirenz and lamivudine plus either tenofovir or stavudine. | The Journal of infectious diseases 20050401 |
| Abacavir once or twice daily combined with once-daily lamivudine and efavirenz for the treatment of antiretroviral-naive HIV-infected adults: results of the Ziagen Once Daily in Antiretroviral Combination Study. | Journal of acquired immune deficiency syndromes (1999) 20050401 |
| Simple and simultaneous determination of the hiv-protease inhibitors amprenavir, atazanavir, indinavir, lopinavir, nelfinavir, ritonavir and saquinavir plus M8 nelfinavir metabolite and the nonnucleoside reverse transcriptase inhibitors efavirenz and nevirapine in human plasma by reversed-phase liquid chromatography. | Therapeutic drug monitoring 20050401 |
| Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: results of a global collaboration. | PLoS medicine 20050401 |
| Evaluation of a low cost reverse transcriptase assay for plasma HIV-1 viral load monitoring. | Current HIV research 20050401 |
| Molecular mechanics PBSA ligand binding energy and interaction of Efavirenz derivatives with HIV-1 reverse transcriptase. | Journal of enzyme inhibition and medicinal chemistry 20050401 |
| The effect of baseline CD4 cell count and HIV-1 viral load on the efficacy and safety of nevirapine or efavirenz-based first-line HAART. | AIDS (London, England) 20050325 |
| From 4,5,6,7-tetrahydro-5-methylimidazo[4,5,1-jk](1,4)benzodiazepin-2(1H)-one (TIBO) to etravirine (TMC125): fifteen years of research on non-nucleoside inhibitors of HIV-1 reverse transcriptase. | Journal of medicinal chemistry 20050324 |
| In search of a novel anti-HIV drug: multidisciplinary coordination in the discovery of 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2- pyrimidinyl]amino]benzonitrile (R278474, rilpivirine). | Journal of medicinal chemistry 20050324 |
| Design, synthesis, and SAR of a novel pyrazinone series with non-nucleoside HIV-1 reverse transcriptase inhibitory activity. | Journal of medicinal chemistry 20050324 |
| 4-Benzyl and 4-benzoyl-3-dimethylaminopyridin-2(1H)-ones: in vitro evaluation of new C-3-amino-substituted and C-5,6-alkyl-substituted analogues against clinically important HIV mutant strains. | Journal of medicinal chemistry 20050324 |
| Synthesis of novel diarylpyrimidine analogues and their antiviral activity against human immunodeficiency virus type 1. | Journal of medicinal chemistry 20050324 |
| Rapid viral load suppression following generic highly active antiretroviral therapy in Southern Indian HIV-infected patients. | AIDS (London, England) 20050324 |
| [Efficacy of anti-HIV treatment and drug-resistance mutations in some parts of China]. | Zhonghua yi xue za zhi 20050323 |
| Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects. | The Journal of infectious diseases 20050315 |
| Simplification therapy with once-daily emtricitabine, didanosine, and efavirenz in HIV-1-infected adults with viral suppression receiving a protease inhibitor-based regimen: a randomized trial. | The Journal of infectious diseases 20050315 |
| 5-Alkyl-2-alkylamino-6-(2,6-difluorophenylalkyl)-3,4-dihydropyrimidin-4(3H)-ones, a new series of potent, broad-spectrum non-nucleoside reverse transcriptase inhibitors belonging to the DABO family. | Bioorganic & medicinal chemistry 20050315 |
| Inhibition of phosphorolysis catalyzed by HIV-1 reverse transcriptase is responsible for the synergy found in combinations of 3'-azido-3'-deoxythymidine with nonnucleoside inhibitors. | Biochemistry 20050308 |
| An MDR1-3435 variant is associated with higher plasma nelfinavir levels and more rapid virologic response in HIV-1 infected children. | AIDS (London, England) 20050304 |
| Plasma HIV-1 RNA decline within the first two weeks of treatment is comparable for nevirapine, efavirenz, or both drugs combined and is not predictive of long-term virologic efficacy: A 2NN substudy. | Journal of acquired immune deficiency syndromes (1999) 20050301 |
| Can we get more HIV-positive tuberculosis patients on antiretroviral treatment in a rural district of Malawi? | The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease 20050301 |
| Adverse effects of antiretroviral therapy for HIV infection: a review of selected topics. | Expert opinion on drug safety 20050301 |
| The safety of antiretroviral drugs in pregnancy. | Expert opinion on drug safety 20050301 |
| Risk of AIDS and death at given HIV-RNA and CD4 cell count, in relation to specific antiretroviral drugs in the regimen. | AIDS (London, England) 20050218 |
| The efavirenz-induced increase in HDL-cholesterol is influenced by the multidrug resistance gene 1 C3435T polymorphism. | AIDS (London, England) 20050218 |
| Studies of non-nucleoside HIV-1 reverse transcriptase inhibitors. Part 2: synthesis and structure-activity relationships of 2-cyano and 2-hydroxy thiazolidenebenzenesulfonamide derivatives. | Bioorganic & medicinal chemistry 20050215 |
| Influence of liver fibrosis on highly active antiretroviral therapy-associated hepatotoxicity in patients with HIV and hepatitis C virus coinfection. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20050215 |
| A randomized study comparing a three- and four-drug HAART regimen in first-line therapy (QUAD study). | The Journal of antimicrobial chemotherapy 20050201 |
| Variations of CYP3A activity induced by antiretroviral treatment in HIV-1 infected patients. | European journal of clinical pharmacology 20050201 |
| Efavirenz intoxication due to slow hepatic metabolism. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20050201 |
| An extremely different dysmetabolic profile between the two available nonnucleoside reverse transcriptase inhibitors: efavirenz and nevirapine. | Journal of acquired immune deficiency syndromes (1999) 20050201 |
| 6-[1-(4-Fluorophenyl)methyl-1H-pyrrol-2-yl)]-2,4-dioxo-5-hexenoic acid ethyl ester a novel diketo acid derivative which selectively inhibits the HIV-1 viral replication in cell culture and the ribonuclease H activity in vitro. | Antiviral research 20050201 |
| Collaboration begins on combined drug. | AIDS patient care and STDs 20050201 |
| Efavirenz reclassified as FDA pregnancy category D. | AIDS clinical care 20050201 |
| [HIV-1 polymorphism and development of resistance mutations against non-nucleoside reverse transcriptase inhibitor, efavirenz]. | The Japanese journal of antibiotics 20050201 |
| Incidence and risk factors for rash in Thai patients randomized to regimens with nevirapine, efavirenz or both drugs. | AIDS (London, England) 20050128 |
| Early virological failure in treatment-naive HIV-infected adults receiving didanosine and tenofovir plus efavirenz or nevirapine. | AIDS (London, England) 20050128 |
| Efavirenz enhances the proteolytic processing of an HIV-1 pol polyprotein precursor and reverse transcriptase homodimer formation. | FEBS letters 20050117 |
| Docking and 3-D QSAR studies on indolyl aryl sulfones. Binding mode exploration at the HIV-1 reverse transcriptase non-nucleoside binding site and design of highly active N-(2-hydroxyethyl)carboxamide and N-(2-hydroxyethyl)carbohydrazide derivatives. | Journal of medicinal chemistry 20050113 |
| Detection of minority populations of HIV-1 expressing the K103N resistance mutation in patients failing nevirapine. | Journal of acquired immune deficiency syndromes (1999) 20050101 |
| Antiretroviral drug pharmacokinetics in hepatitis with hepatic dysfunction. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20050101 |
| Drug resistance mutations in the nucleotide binding pocket of human immunodeficiency virus type 1 reverse transcriptase differentially affect the phosphorolysis-dependent primer unblocking activity in the presence of stavudine and zidovudine and its inhibition by efavirenz. | Antimicrobial agents and chemotherapy 20050101 |
| Substituting abacavir for hyperlipidemia-associated protease inhibitors in HAART regimens improves fasting lipid profiles, maintains virologic suppression, and simplifies treatment. | BMC infectious diseases 20050101 |
| No influence of the P-glycoprotein polymorphisms MDR1 G2677T/A and C3435T on the virological and immunological response in treatment naïve HIV-positive patients. | Annals of clinical microbiology and antimicrobials 20050101 |
| NNRTI hypersusceptibility. | The AIDS reader 20050101 |
| Changes in lipids over twelve months after initiating protease inhibitor therapy among persons treated for HIV/AIDS. | Lipids in health and disease 20050101 |
| Molecular strategies to inhibit HIV-1 replication. | Retrovirology 20050101 |
| Top stories of 2004. ACTG 5095: efavirenz beats AZT + 3TC + abacavir. | AIDS clinical care 20050101 |
| Top stories of 2004. Nevirapine and efavirenz: similar efficacy, different toxicities, and better separately than combined. | AIDS clinical care 20050101 |
| New York City HIV superbug: fear or fear not? | Retrovirology 20050101 |
| Nevirapine and efavirenz pharmacokinetics and covariate analysis in the 2NN study. | Antiviral therapy 20050101 |
| Early virological failure with a combination of tenofovir, didanosine and efavirenz. | Antiviral therapy 20050101 |
| [Cost-effectiveness analysis of tenofovir versus zidovudine in combination therapy with efavirenz and lamivudine for the treatment of HIV in naive patients]. | Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria 20050101 |
| Should non-nucleoside reverse transcriptase inhibitors be combined? | Drugs in R&D 20050101 |
| Insomnia in HIV infection: a systematic review of prevalence, correlates, and management. | Psychosomatic medicine 20050101 |
| Abacavir, efavirenz, didanosine, with or without hydroxyurea, in HIV-infected adults failing initial nucleoside/protease inhibitor-containing regimens. | BMC infectious diseases 20050101 |
| The non-nukes. Sustiva. Viramune. The two major players. | Positively aware : the monthly journal of the Test Positive Aware Network 20050101 |
| Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients. | Pharmacogenetics and genomics 20050101 |
| Rare one and two amino acid inserts adjacent to codon 103 of the HIV-1 reverse transcriptase (RT) affect susceptibility to non-nucleoside RT inhibitors. | Antiviral therapy 20050101 |
| Pharmacokinetics and pharmacodynamics of low dose mycophenolate mofetil in HIV-infected patients treated with abacavir, efavirenz and nelfinavir. | Clinical pharmacokinetics 20050101 |
| The two-year impact of first generation protease inhibitor based antiretroviral therapy (PI-ART) on health-related quality of life. | Health and quality of life outcomes 20050101 |
| Recurrence of post-traumatic stress disorder and antiretrovirals. | Scandinavian journal of infectious diseases 20050101 |
| Breakthrough Candida infections in patients receiving voriconazole. | The Annals of pharmacotherapy 20050101 |
| Enantiopure drug synthesis: from methyldopa to imipenem to efavirenz. | Chirality 20050101 |
| [Efavirenz and nevirapine plasma levels in HIV-infected patients with hemophilia]. | Enfermedades infecciosas y microbiologia clinica 20050101 |
| Virologic and immunologic response to a boosted double-protease inhibitor-based therapy in highly pretreated HIV-1-infected patients. | HIV clinical trials 20050101 |
| Severe CNS side-effect and persistent high efavirenz plasma levels in a patient with HIV/HCV coinfection and liver cirrhosis. | Scandinavian journal of infectious diseases 20050101 |
| Incidence and risk factors for liver enzyme elevation during highly active antiretroviral therapy in HIV-HCV co-infected patients: results from the Italian EPOKA-MASTER Cohort. | BMC infectious diseases 20050101 |
| Population pharmacokinetics of efavirenz in an unselected cohort of HIV-1-infected individuals. | Clinical pharmacokinetics 20050101 |
| Are adverse events of nevirapine and efavirenz related to plasma concentrations? | Antiviral therapy 20050101 |
| Early virological failure after tenofovir + didanosine + efavirenz combination in HIV-positive patients upon starting antiretroviral therapy. | Antiviral therapy 20050101 |
| Reverse transcriptase inhibitors alter uncoupling protein-1 and mitochondrial biogenesis in brown adipocytes. | Antiviral therapy 20050101 |
| Drug-drug interactions and the pharmacotherapy of HIV infection. | Topics in HIV medicine : a publication of the International AIDS Society, USA 20050101 |
| Safety and tolerability of nevirapine-based antiretroviral therapy in HIV-infected patients receiving fluconazole for cryptococcal prophylaxis: a retrospective cohort study. | BMC infectious diseases 20050101 |
| Lipid profiles for antiretroviral-naive patients starting PI- and NNRTI-based therapy in the Swiss HIV cohort study. | Antiviral therapy 20050101 |
| Low density lipoprotein apolipoprotein B metabolism in treatment-naive HIV patients and patients on antiretroviral therapy. | Antiviral therapy 20050101 |
| Efavirenz induces depressive-like behaviour, increased stress response and changes in the immune response in rats. | Neuroimmunomodulation 20050101 |
| Will pharmacogenomic discoveries improve HIV therapeutics? | Topics in HIV medicine : a publication of the International AIDS Society, USA 20050101 |
| Clinical pharmacokinetics and summary of efficacy and tolerability of atazanavir. | Clinical pharmacokinetics 20050101 |
| Mycobacterial immune reconstitution inflammatory syndrome in HIV-1 infection after antiretroviral therapy is associated with deregulated specific T-cell responses: beneficial effect of IL-2 and GM-CSF immunotherapy. | Journal of immune based therapies and vaccines 20050101 |
| The nonnucleoside reverse transcriptase inhibitors efavirenz and nevirapine in the treatment of HIV. | HIV clinical trials 20050101 |
| Quantification of antiretroviral drugs in dried blood spot samples by means of liquid chromatography/tandem mass spectrometry. | Rapid communications in mass spectrometry : RCM 20050101 |
| Comparison of neuropsychiatric side effects in an observational cohort of efavirenz- and protease inhibitor-treated patients. | HIV clinical trials 20050101 |
| Viral load responses to HAART is an independent predictor of a new AIDS event in late stage HIV infected patients: prospective cohort study. | Journal of translational medicine 20050101 |
| Cerebrospinal fluid HIV infection and pleocytosis: relation to systemic infection and antiretroviral treatment. | BMC infectious diseases 20050101 |
| First-line antiretroviral therapy in Africa--how evidence-base are our recommendations? | AIDS reviews 20050101 |
| Are specific antiretrovirals associated with an increased risk of discontinuation due to toxicities or patient/physician choice in patients with hepatitis C virus coinfection? | Antiviral therapy 20050101 |
| Simplification therapy with once-daily didanosine, tenofovir and efavirenz in HIV-1-infected adults with viral suppression receiving a more complex antiretroviral regimen: final results of the EFADITE trial. | Antiviral therapy 20050101 |
| Do non-nucleoside reverse transcriptase inhibitors contribute to lipodystrophy? | Drug safety 20050101 |
| Scutellaria baicalensis decreases ritonavir-induced nausea. | AIDS research and therapy 20050101 |
| TMC125: new results, large phase III trial begins. | AIDS treatment news 20050101 |
| [Non-nucleoside inhibitors of reverse transcriptase in therapy of HIV-infection]. | Antibiotiki i khimioterapiia = Antibiotics and chemoterapy [sic] 20050101 |
| Role of the inhibitory quotient in HIV therapy. | Antiviral therapy 20050101 |
| Improvement in dyslipidaemia after switching stavudine to tenofovir and replacing protease inhibitors with efavirenz in HIV-infected children. | Antiviral therapy 20050101 |
| Prospective, open-label comparative study of liver toxicity in an unselected population of HIV-infected patients treated for the first time with efavirenz or nevirapine. | HIV clinical trials 20050101 |
| Higher virological effectiveness of NNRTI-based antiretroviral regimens containing nevirapine or efavirenz compared to a triple NRTI regimen as initial therapy in HIV-1-infected adults. | HIV clinical trials 20050101 |
| Simplicity and efficacy of a once-daily antiretroviral regimen with didanosine, lamivudine, and efavirenz in naïve patients: the VESD study. | HIV clinical trials 20050101 |
| Antiretroviral Therapy in the Real World : Population-Based Pharmacoeconomic Analysis of Administration of Anti-HIV Regimens to 990 Patients. | Clinical drug investigation 20050101 |
| [Efficacy and tolerance of non nucleosidic reverse transcriptase inhibitors containing tritherapy in HIV-1 infection]. | Dakar medical 20050101 |
| Substitutions in the Reverse Transcriptase and Protease Genes of HIV-1 Subtype B in Untreated Individuals and Patients Treated With Antiretroviral Drugs. | Journal of the International AIDS Society 20050101 |
| The HIV-1 Non-subtype B Workgroup: An International Collaboration for the Collection and Analysis of HIV-1 Non-subtype B Data. | Journal of the International AIDS Society 20050101 |
| Triple-nucleoside analog antiretroviral therapy: is there still a role in clinical practice? A review. | Journal of the International AIDS Society 20050101 |
| Genetic barriers to resistance and impact on clinical response. | Journal of the International AIDS Society 20050101 |
| Simultaneous determination of the antiretroviral agents: amprenavir, lopinavir, ritonavir, saquinavir and efavirenz in human peripheral blood mononuclear cells by high-performance liquid chromatography-mass spectrometry. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20041225 |
| Determination of atazanavir and other antiretroviral drugs (indinavir, amprenavir, nelfinavir and its active metabolite M8, saquinavir, ritonavir, lopinavir, nevirapine and efavirenz) plasma levels by high performance liquid chromatography with UV detection. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20041225 |
| Phenotypic susceptibility to nonnucleoside inhibitors of virion-associated reverse transcriptase from different HIV types and groups. | Journal of acquired immune deficiency syndromes (1999) 20041215 |
| Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study. | AIDS (London, England) 20041203 |
| Flexible docking of pyridinone derivatives into the non-nucleoside inhibitor binding site of HIV-1 reverse transcriptase. | Bioorganic & medicinal chemistry 20041201 |
| Studies of nonnucleoside HIV-1 reverse transcriptase inhibitors. Part 1: Design and synthesis of thiazolidenebenzenesulfonamides. | Bioorganic & medicinal chemistry 20041201 |
| Mutations associated with hypersusceptibility...and with good adherence. | The Journal of infectious diseases 20041201 |
| TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1. | Antimicrobial agents and chemotherapy 20041201 |
| Effect of efavirenz treatment on the pharmacokinetics of nelfinavir boosted by ritonavir in healthy volunteers. | British journal of clinical pharmacology 20041201 |
| New once-daily HIV combination better tolerated. | Expert review of anti-infective therapy 20041201 |
| Atazanavir for the treatment of human immunodeficiency virus infection. | Pharmacotherapy 20041201 |
| Randomized, controlled trial of therapy interruption in chronic HIV-1 infection. | PLoS medicine 20041201 |
| Antiretroviral resistance and genetic diversity of human immunodeficiency virus type 1 isolates from the Federal District, Central Brazil. | Memorias do Instituto Oswaldo Cruz 20041201 |
| First-line efavirenz versus lopinavir-ritonavir-based highly active antiretroviral therapy for naive patients. | AIDS (London, England) 20041119 |
| Design of non-nucleoside inhibitors of HIV-1 reverse transcriptase with improved drug resistance properties. 2. | Journal of medicinal chemistry 20041118 |
| Gynecomastia among HIV-infected patients is associated with hypogonadism: a case-control study. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20041115 |
| CADA, a novel CD4-targeted HIV inhibitor, is synergistic with various anti-HIV drugs in vitro. | AIDS (London, England) 20041105 |
| Effects of the G190A substitution of HIV reverse transcriptase on phenotypic susceptibility of patient isolates to delavirdine. | Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology 20041101 |
| Pharmacologic perspectives for once-daily antiretroviral therapy. | The Annals of pharmacotherapy 20041101 |
| Induction of CYP3A4 by efavirenz in primary human hepatocytes: comparison with rifampin and phenobarbital. | Journal of clinical pharmacology 20041101 |
| Human immunodeficiency virus type 1 infection in Oman: antiretroviral therapy and frequencies of drug resistance mutations. | AIDS research and human retroviruses 20041101 |
| Persistent HIV type 1 infection in semen and blood compartments in patients after long-term potent antiretroviral therapy. | AIDS research and human retroviruses 20041101 |
| Atazanavir: A novel once-daily protease inhibitor. | Drugs of today (Barcelona, Spain : 1998) 20041101 |
| Pharmacokinetics of Telzir (fosamprenavir). | Journal of HIV therapy 20041101 |
| Warning on two specific 3-drug regimens: Viread + Didanosine + either Sustiva or Viramune. | AIDS treatment news 20041029 |
| 4-benzyl- and 4-benzoyl-3-dimethylaminopyridin-2(1H)-ones, a new family of potent anti-HIV agents: optimization and in vitro evaluation against clinically important HIV mutant strains. | Journal of medicinal chemistry 20041021 |
| Higher efavirenz concentrations determine the response to viruses carrying non-nucleoside reverse transcriptase resistance mutations. | AIDS (London, England) 20041021 |
| Determination of the new HIV-protease inhibitor atazanavir by liquid chromatography after solid-phase extraction. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20041015 |
| Acute onset of pancreatitis with concomitant use of tenofovir and didanosine. | The Annals of pharmacotherapy 20041001 |
| Atazanavir. | The Annals of pharmacotherapy 20041001 |
| Automated, fast, and sensitive quantification of drugs in human plasma by LC/LC-MS: quantification of 6 protease inhibitors and 3 nonnucleoside transcriptase inhibitors. | Therapeutic drug monitoring 20041001 |
| Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral-naive HIV-infected adults. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20041001 |
| Efavirenz for HIV-1 infection in adults: an overview. | Expert review of anti-infective therapy 20041001 |
| Tenofovir: new indication. For first-line antiretroviral therapy: wait and see. | Prescrire international 20041001 |
| Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1. | PLoS medicine 20041001 |
| [Simplified treatments for HIV infection]. | Therapeutische Umschau. Revue therapeutique 20041001 |
| Quality of life in patients treated with first-line antiretroviral therapy containing nevirapine and/or efavirenz. | Antiviral therapy 20041001 |
| Efavirenz-associated Stevens-Johnson syndrome. | Infection 20041001 |
| [Neurospychiatric symptoms in HIV infected patients and the role of efavirenz]. | Medecine et maladies infectieuses 20041001 |
| Binding of anti-HIV drugs to human serum albumin. | IUBMB life 20041001 |
| Penetration of enfuvirtide, tenofovir, efavirenz, and protease inhibitors in the genital tract of HIV-1-infected men. | AIDS (London, England) 20040924 |
| Genetic correlates of efavirenz hypersusceptibility. | AIDS (London, England) 20040903 |
| Rate of viral rebound according to specific drugs in the regimen in 2120 patients with HIV suppression. | AIDS (London, England) 20040903 |
| Safety and antiretroviral effectiveness of concomitant use of rifampicin and efavirenz for antiretroviral-naive patients in India who are coinfected with tuberculosis and HIV-1. | Journal of acquired immune deficiency syndromes (1999) 20040901 |
| Lopinavir/ritonavir treatment in HIV antiretroviral-experienced patients: evaluation of risk factors for liver enzyme elevation. | HIV medicine 20040901 |
| Failure of treatment of tuberculous adenitis due to an unexpected drug interaction with rifabutin and efavirenz. | AIDS (London, England) 20040820 |
| Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV. | Journal of acquired immune deficiency syndromes (1999) 20040815 |
| HIV-1 drug resistance in subjects with advanced HIV-1 infection in whom antiretroviral combination therapy is failing: a substudy of AIDS Clinical Trials Group Protocol 388. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20040815 |
| Triple-nucleoside regimens versus efavirenz. | The New England journal of medicine 20040812 |
| Triple-nucleoside regimens versus efavirenz. | The New England journal of medicine 20040812 |
| A naphthyridine carboxamide provides evidence for discordant resistance between mechanistically identical inhibitors of HIV-1 integrase. | Proceedings of the National Academy of Sciences of the United States of America 20040803 |
| A comparison of the CD4 response to antiretroviral regimens in patients commencing therapy with low CD4 counts. | The Journal of antimicrobial chemotherapy 20040801 |
| A pilot study of once-daily antiretroviral therapy integrated with tuberculosis directly observed therapy in a resource-limited setting. | Journal of acquired immune deficiency syndromes (1999) 20040801 |
| Protease inhibitor-sparing simplified maintenance therapy: a need for perspective. | The Journal of antimicrobial chemotherapy 20040801 |
| Once-daily versus twice-daily lamivudine, in combination with zidovudine and efavirenz, for the treatment of antiretroviral-naive adults with HIV infection: a randomized equivalence trial. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20040801 |
| Gynaecomastia in HIV-infected men on highly active antiretroviral therapy: association with efavirenz and didanosine treatment. | Antiviral therapy 20040801 |
| [Progress in HIV non-nucleoside reverse transcriptase inhibitors (NNRTIs)]. | Yao xue xue bao = Acta pharmaceutica Sinica 20040801 |
| Simple, short peptide derivatives of a sulfonylindolecarboxamide (L-737,126) active in vitro against HIV-1 wild type and variants carrying non-nucleoside reverse transcriptase inhibitor resistance mutations. | Journal of medicinal chemistry 20040715 |
| Efficacy and safety of emtricitabine vs stavudine in combination therapy in antiretroviral-naive patients: a randomized trial. | JAMA 20040714 |
| Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. | JAMA 20040714 |
| Homozygous CYP2B6 *6 (Q172H and K262R) correlates with high plasma efavirenz concentrations in HIV-1 patients treated with standard efavirenz-containing regimens. | Biochemical and biophysical research communications 20040709 |
| Factors associated with efavirenz discontinuation in a large community-based sample of patients. | AIDS care 20040701 |
| First-line and second-line antiretroviral therapy. | Lancet (London, England) 20040701 |
| Atazanavir: a new protease inhibitor to treat HIV infection. | American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20040701 |
| Photosensitive drug eruption induced by efavirenz in a patient with HIV infection. | Internal medicine (Tokyo, Japan) 20040701 |
| The first case of efavirenz-induced photosensitivity in a Japanese patient with HIV infection. | Internal medicine (Tokyo, Japan) 20040701 |
| Mutations and polymorphisms associated with antiretroviral drugs in HIV-1C-infected African patients. | Antiviral chemistry & chemotherapy 20040701 |
| 5-Alkyl-2-[(aryl and alkyloxylcarbonylmethyl)thio]-6-(1-naphthylmethyl) pyrimidin-4(3H)-ones as an unique HIV reverse transcriptase inhibitors of S-DABO series. | Bioorganic & medicinal chemistry letters 20040621 |
| High-performance liquid chromatography assay for the quantification of HIV protease inhibitors and non-nucleoside reverse transcriptase inhibitors in human plasma. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20040615 |
| Antiviral drugs in current clinical use. | Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology 20040601 |
| Styrylquinolines, integrase inhibitors acting prior to integration: a new mechanism of action for anti-integrase agents. | Journal of virology 20040601 |
| A proof-of-concept study of short-cycle intermittent antiretroviral therapy with a once-daily regimen of didanosine, lamivudine, and efavirenz for the treatment of chronic HIV infection. | The Journal of infectious diseases 20040601 |
| Efavirenz plasma concentrations in HIV-infected patients: inter- and intraindividual variability and clinical effects. | Therapeutic drug monitoring 20040601 |
| HIV/AIDS news: comparable anti-HIV antiviral efficacy of Viramune and Efavirenz--the Lancet publishes first large-scale comparison study. | Infection 20040601 |
| Evaluation of the virological and metabolic effects of switching protease inhibitor combination antiretroviral therapy to nevirapine-based therapy for the treatment of HIV infection. | AIDS research and human retroviruses 20040601 |
| Efficacy and safety of Efavirenz in HIV patients on Rifampin for tuberculosis. | The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases 20040601 |
| Effect of stereo and regiochemistry towards wild and multidrug resistant HIV-1 virus: viral potency of chiral PETT derivatives. | Biochemical pharmacology 20040515 |
| Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variants. | Journal of medicinal chemistry 20040506 |
| Mutations in HIV-1 reverse transcriptase potentially associated with hypersusceptibility to nonnucleoside reverse-transcriptase inhibitors: effect on response to efavirenz-based therapy in an urban observational cohort. | The Journal of infectious diseases 20040501 |
| Predictors of virologic failure and resistance in HIV-infected patients treated with nevirapine- or efavirenz-based antiretroviral therapy. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20040501 |
| Genes, ethnicity, and efavirenz response: clinical pharmacology update from the 11th CROI. | The Hopkins HIV report : a bimonthly newsletter for healthcare providers 20040501 |
| Clinical utility of current NNRTIs and perspectives of new agents in this class under development. | Antiviral chemistry & chemotherapy 20040501 |
| TMC125: important one-year trial now recruiting in U.S. | AIDS treatment news 20040430 |
| Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. | The New England journal of medicine 20040429 |
| [Protease inhibitor sparing standard. Once daily efavirenz continues to be effective]. | MMW Fortschritte der Medizin 20040426 |
| [3 years' data of tenofovir. Confirmed as a valuable building block]. | MMW Fortschritte der Medizin 20040426 |
| [Valuable combination partner. Great benefit for therapy naive patients]. | MMW Fortschritte der Medizin 20040426 |
| [CROI--presentation of new study results. In a comparison of NNRTI nevirapine is equally effective]. | MMW Fortschritte der Medizin 20040426 |
| [5 years' data are convincing. Lopinavir as primary therapy is effective and safe in the long term]. | MMW Fortschritte der Medizin 20040426 |
| Structural and energetic analyses of the effects of the K103N mutation of HIV-1 reverse transcriptase on efavirenz analogues. | Journal of medicinal chemistry 20040422 |
| Antiretroviral therapy for previously untreated HIV-1-infected adults: 2NN, or just one? | Lancet (London, England) 20040417 |
| Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study. | Lancet (London, England) 20040417 |
| Efavirenz versus nevirapine in current clinical practice: a prospective, open-label observational study. | Journal of acquired immune deficiency syndromes (1999) 20040415 |
| In vitro suppression of the lipogenic pathway by the nonnucleoside reverse transcriptase inhibitor efavirenz in 3T3 and human preadipocytes or adipocytes. | The Journal of biological chemistry 20040409 |
| Pharmacokinetics and safety of GW433908 and ritonavir, with and without efavirenz, in healthy volunteers. | AIDS (London, England) 20040409 |
| Genetic variation at NNRTI resistance-associated positions in patients infected with HIV-1 subtype C. | AIDS (London, England) 20040409 |
| Tenofovir-related nephrotoxicity in HIV-infected patients. | AIDS (London, England) 20040409 |
| Therapeutic drug monitoring of lopinavir/ritonavir given alone or with a non-nucleoside reverse transcriptase inhibitor. | British journal of clinical pharmacology 20040401 |
| Clinical, virologic, and immunologic response to efavirenz-or protease inhibitor-based highly active antiretroviral therapy in a cohort of antiretroviral-naive patients with advanced HIV infection (EfaVIP 2 study). | Journal of acquired immune deficiency syndromes (1999) 20040401 |
| Safety and efficacy of a NRTI-sparing HAART regimen of efavirenz and lopinavir/ritonavir in HIV-1-infected children. | Antiviral therapy 20040401 |
| In vivo dynamics of the 103N mutation following the withdrawal of non-nucleoside reverse transcriptase inhibitors in HIV-infected patients: preliminary results. | The new microbiologica 20040401 |
| Efavirenz induces a striking and generalized increase of HDL-cholesterol in HIV-infected patients. | AIDS (London, England) 20040326 |
| Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: are different antiretroviral drugs associated with different lipid profiles? | The Journal of infectious diseases 20040315 |
| Merck broke AIDS drug price promise, says MSF. | Lancet (London, England) 20040313 |
| Synthesis of 6-arylvinyl analogues of the HIV drugs SJ-3366 and Emivirine. | Bioorganic & medicinal chemistry 20040301 |
| Pharmacokinetics of emtricitabine, didanosine and efavirenz administered once-daily for the treatment of HIV-infected adults (pharmacokinetic substudy of the ANRS 091 trial). | HIV medicine 20040301 |
| Nevirapine- versus efavirenz-based highly active antiretroviral therapy regimens in antiretroviral-naïve patients with advanced HIV infection. | HIV medicine 20040301 |
| Treatment of HIV-infected patients with a combination of efavirenz, nevirapine and nucleoside reverse transcriptase inhibitors. | HIV medicine 20040301 |
| Virological and immunological outcomes in HIV-1-infected Chinese patients treated with a combination of Efavirenz and Indinavir for 48 weeks. | Chinese medical journal 20040301 |
| Chemokine mRNA levels in mononucleated cells of HIV-infected patients before and after initiation of PI- versus NNRTI-containing HAART. | Antiviral research 20040301 |
| Novel benzophenones as non-nucleoside reverse transcriptase inhibitors of HIV-1. | Journal of medicinal chemistry 20040226 |
| Defining a molecular mechanism of synergy between nucleoside and nonnucleoside AIDS drugs. | The Journal of biological chemistry 20040220 |
| Pharmacokinetics of indinavir/ritonavir (800/100 mg twice a day) combined with efavirenz in HIV-infected patients. | AIDS (London, England) 20040220 |
| Dose escalation or immediate full dose when switching from efavirenz to nevirapine-based highly active antiretroviral therapy in HIV-1-infected individuals? | AIDS (London, England) 20040220 |
| Computer-aided design, synthesis, and anti-HIV-1 activity in vitro of 2-alkylamino-6-[1-(2,6-difluorophenyl)alkyl]-3,4-dihydro-5-alkylpyrimidin-4(3H)-ones as novel potent non-nucleoside reverse transcriptase inhibitors, also active against the Y181C variant. | Journal of medicinal chemistry 20040212 |
| Genotypic resistance profile in treatment-experienced HIV-infected individuals after abacavir and efavirenz salvage regimen. | Antiviral research 20040201 |
| Analyzing sleep abnormalities in HIV-infected patients treated with Efavirenz. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20040201 |
| Newer treatments for HIV in children. | Current opinion in pediatrics 20040201 |
| Experience with efavirenz in end-stage renal disease. | International journal of STD & AIDS 20040201 |
| Susceptibility of HIV-2, SIV and SHIV to various anti-HIV-1 compounds: implications for treatment and postexposure prophylaxis. | Antiviral therapy 20040201 |
| Monitoring of didanosine and stavudine intracellular trisphosphorylated anabolite concentrations in HIV-infected patients. | AIDS (London, England) 20040123 |
| Stereoselective metabolism of methadone N-demethylation by cytochrome P4502B6 and 2C19. | Chirality 20040101 |
| Emtricitabine: a new nucleoside analogue for once-daily antiretroviral therapy. | Expert opinion on investigational drugs 20040101 |
| Intensification of antiretroviral therapy accelerates the decay of the HIV-1 latent reservoir and decreases, but does not eliminate, ongoing virus replication. | Journal of acquired immune deficiency syndromes (1999) 20040101 |
| Susceptibility of feline immunodeficiency virus/human immunodeficiency virus type 1 reverse transcriptase chimeras to non-nucleoside RT inhibitors. | Molecular pharmacology 20040101 |
| Treatment of primary HIV-1 infection with nonnucleoside reverse transcriptase inhibitor-based therapy is effective and well tolerated. | HIV medicine 20040101 |
| A case-control study of gynecomastia in HIV-1-infected patients receiving HAART. | The AIDS reader 20040101 |
| Editorial comment: unraveling the cause of HIV-related gynecomastia. | The AIDS reader 20040101 |
| Safe substitution for efavirenz. | AIDS patient care and STDs 20040101 |
| Higher Sustiva levels seen in some African-Americans. | GMHC treatment issues : the Gay Men's Health Crisis newsletter of experimental AIDS therapies 20040101 |
| Efavirenz-associated gynecomastia: report of five cases and review of the literature. | The breast journal 20040101 |
| Anti-HIV drug distribution to the central nervous system. | Current pharmaceutical design 20040101 |
| Current status of the non-nucleoside reverse transcriptase inhibitors of human immunodeficiency virus type 1. | Current topics in medicinal chemistry 20040101 |
| Emtricitabine/tenofovir disoproxil fumarate. | Drugs in R&D 20040101 |
| Anti-retrovirals and immunosuppressive drug interactions in a HIV-positive patient after liver transplantation. | Hepato-gastroenterology 20040101 |
| Recent advances in the development of next generation non-nucleoside reverse transcriptase inhibitors. | Current topics in medicinal chemistry 20040101 |
| Life after Sustiva. | Survival news (Atlanta, Ga.) 20040101 |
| Efficacy of quality criteria to identify potentially harmful information: a cross-sectional survey of complementary and alternative medicine web sites. | Journal of medical Internet research 20040101 |
| Cortisol serum levels and their relationship to certain antiretroviral drugs. | Scandinavian journal of infectious diseases 20040101 |
| Emtricitabine/tenofovir disoproxil fumarate. | Drugs 20040101 |
| HAART drugs induce oxidative stress in human endothelial cells and increase endothelial recruitment of mononuclear cells: exacerbation by inflammatory cytokines and amelioration by antioxidants. | Cardiovascular toxicology 20040101 |
| Practical guidelines to interpret plasma concentrations of antiretroviral drugs. | Clinical pharmacokinetics 20040101 |
| Proteomics computational analyses suggest that the carboxyl terminal glycoproteins of Bunyaviruses are class II viral fusion protein (beta-penetrenes). | Theoretical biology & medical modelling 20040101 |
| Antiretrovirals, Part II: focus on non-protease inhibitor antiretrovirals (NRTIs, NNRTIs, and fusion inhibitors). | Psychosomatics 20040101 |
| Spectrum of clinical disease in a series of 135 hospitalised HIV-infected patients from north India. | BMC infectious diseases 20040101 |
| Pharmacokinetics of antiretrovirals administered to HIV-infected children via gastrostomy tube. | HIV clinical trials 20040101 |
| Pharmacokinetics of antiretrovirals in pregnant women. | Clinical pharmacokinetics 20040101 |
| The unmasking of Pneumocystis jiroveci pneumonia during reversal of immunosuppression: case reports and literature review. | BMC infectious diseases 20040101 |
| FDA issues labeling changes for efavirenz. | AIDS reviews 20040101 |
| Behind 'AIDS breakthrough' headlines, December 2004: important research, not so new. | AIDS treatment news 20040101 |
| Non-nucleoside reverse transcriptase inhibitors (NNRTIs): past, present, and future. | Chemistry & biodiversity 20040101 |
| Substitution for protease inhibitors in HIV therapy. | The New England journal of medicine 20031218 |
| 3-iodo-4-phenoxypyridinones (IOPY's), a new family of highly potent non-nucleoside inhibitors of HIV-1 reverse transcriptase. | Bioorganic & medicinal chemistry letters 20031215 |
| Oxidant stress is increased during treatment of human immunodeficiency virus infection. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20031215 |
| Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection. | The New England journal of medicine 20031211 |
| Comparison of four-drug regimens and pairs of sequential three-drug regimens as initial therapy for HIV-1 infection. | The New England journal of medicine 20031211 |
| No influence of the P-glycoprotein genotype (MDR1 C3435T) on plasma levels of lopinavir and efavirenz during antiretroviral treatment. | European journal of medical research 20031209 |
| Provider bias in the selection of non-nucleoside reverse transcriptase inhibitor and protease inhibitor-based highly active antiretroviral therapy and HIV treatment outcomes in observational studies. | AIDS (London, England) 20031205 |
| An open-label assessment of TMC 125--a new, next-generation NNRTI, for 7 days in HIV-1 infected individuals with NNRTI resistance. | AIDS (London, England) 20031205 |
| Therapeutic drug monitoring of the HIV/AIDS drugs abacavir, zidovudine, efavirenz, nevirapine, indinavir, lopinavir, and nelfinavir. | Pharmacology 20031201 |
| Nevirapine plus efavirenz plus didanosine: a simple, safe, and effective once-daily regimen for patients with HIV infection. | Journal of the National Medical Association 20031201 |
| A randomized trial of nelfinavir and abacavir in combination with efavirenz and adefovir dipivoxil in HIV-1-infected persons with virological failure receiving indinavir. | Antiviral therapy 20031201 |
| The continuing evolution of HIV therapy. | The AIDS reader 20031201 |
| Meta-analysis of randomized controlled trials of simplified versus continued protease inhibitor-based antiretroviral therapy in HIV-1-infected patients. | AIDS (London, England) 20031121 |
| Efavirenz-containing highly active antiretroviral therapy in an HIV-infected patient with myasthenia gravis. | AIDS (London, England) 20031121 |
| Evaluation of cutpoints for phenotypic hypersusceptibility to efavirenz. | AIDS (London, England) 20031107 |
| Treating advanced HIV infection. | Journal of acquired immune deficiency syndromes (1999) 20031101 |
| Does prior short-course nevirapine reduce the effectiveness of subsequent combination treatment with efavirenz? | Journal of acquired immune deficiency syndromes (1999) 20031101 |
| Triple combinations regimens for HIV. | The Lancet. Infectious diseases 20031101 |
| Risk and determinants of developing severe liver toxicity during therapy with nevirapine-and efavirenz-containing regimens in HIV-infected patients. | International journal of STD & AIDS 20031101 |
| [Tuberculosis in compromised hosts]. | Kekkaku : [Tuberculosis] 20031101 |
| Atazanavir sulphate. | Nature reviews. Drug discovery 20031101 |
| Risk of severe hepatotoxicity associated with antiretroviral therapy in the HIV-NAT Cohort, Thailand, 1996-2001. | AIDS (London, England) 20031017 |
| Failures of 1 week on, 1 week off antiretroviral therapies in a randomized trial. | AIDS (London, England) 20031017 |
| Activity predictions for efavirenz analogues with the K103N mutant of HIV reverse transcriptase. | Bioorganic & medicinal chemistry letters 20031006 |
| In silico structure-based design of a potent, mutation resilient, small peptide inhibitor of HIV-1 reverse transcriptase. | Journal of biomolecular structure & dynamics 20031001 |
| Pharmacokinetics of indinavir/ritonavir (800/100 mg) in combination with efavirenz (600 mg) in HIV-1-infected subjects. | Journal of acquired immune deficiency syndromes (1999) 20031001 |
| Issues in antiretroviral toxicity. | The AIDS reader 20031001 |
| Once-daily therapy: less is more. | International journal of STD & AIDS 20031001 |
| Efavirenz: enhancing the gold standard. | International journal of STD & AIDS 20031001 |
| Releasing the true power of protease inhibitors. | International journal of STD & AIDS 20031001 |
| Predictors of the virological response to a change in the antiretroviral treatment regimen in HIV-1-infected patients enrolled in a randomized trial comparing genotyping, phenotyping and standard of care (Narval trial, ANRS 088). | Antiviral therapy 20031001 |
| Atazanavir: improving the HIV protease inhibitor class. | Expert review of anti-infective therapy 20031001 |
| Evaluation of a didanosin-containing regimen including genotypic resistance testing: an open-label, multicenter study. | European journal of medical research 20030929 |
| Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection. | The New England journal of medicine 20030911 |
| [Antiretroviral-induced toxiderma in HIV-infected patients]. | Presse medicale (Paris, France : 1983) 20030906 |
| A randomized trial of 2 different 4-drug antiretroviral regimens versus a 3-drug regimen, in advanced human immunodeficiency virus disease. | The Journal of infectious diseases 20030901 |
| Inhibition of human immunodeficiency virus by a new class of pyridine oxide derivatives. | Antimicrobial agents and chemotherapy 20030901 |
| Factors associated with maintenance of long-term plasma human immunodeficiency virus RNA suppression. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20030901 |
| [Use of antiretroviral drugs in HIV infected children in a tropical area: a real benefit]. | Archives de pediatrie : organe officiel de la Societe francaise de pediatrie 20030901 |
| Perspectives on HAART: switch maintenance therapy. | International journal of STD & AIDS 20030901 |
| A comprehensive hepatic safety analysis of nevirapine in different populations of HIV infected patients. | Journal of acquired immune deficiency syndromes (1999) 20030901 |
| Efficacy and durability of nevirapine in antiretroviral drug näive patients. | Journal of acquired immune deficiency syndromes (1999) 20030901 |
| Tipranavir: a protease inhibitor from a new class with distinct antiviral activity. | Journal of acquired immune deficiency syndromes (1999) 20030901 |
| Drug resistance profiles of recombinant reverse transcriptases from human immunodeficiency virus type 1 subtypes A/E, B, and C. | AIDS research and human retroviruses 20030901 |
| Protein binding in antiretroviral therapies. | AIDS research and human retroviruses 20030901 |
| Meeting notes from the 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment. Trizivir vs. efavirenz: results from ACTG 5095. | AIDS clinical care 20030901 |
| The effects of protease inhibitors and nonnucleoside reverse transcriptase inhibitors on p-glycoprotein expression in peripheral blood mononuclear cells in vitro. | Journal of acquired immune deficiency syndromes (1999) 20030815 |
| Evaluation of a ristocetin bonded stationary phase for subcritical fluid chromatography of enantiomers. | Chirality 20030801 |
| Hyperlipidaemia in patients with HIV-1 infection receiving highly active antiretroviral therapy: epidemiology, pathogenesis, clinical course and management. | International journal of antimicrobial agents 20030801 |
| The effect of NNRTIs on HIV reverse transcriptase dimerization. | Current opinion in investigational drugs (London, England : 2000) 20030801 |
| A controlled Phase II trial assessing three doses of enfuvirtide (T-20) in combination with abacavir, amprenavir, ritonavir and efavirenz in non-nucleoside reverse transcriptase inhibitor-naive HIV-infected adults. | Antiviral therapy 20030801 |
| Low frequency of the V106M mutation among HIV-1 subtype C-infected pregnant women exposed to nevirapine. | AIDS (London, England) 20030725 |
| A manic episode associated with efavirenz therapy for HIV infection. | AIDS (London, England) 20030725 |
| Simple and rapid method for the simultaneous determination of the non-nucleoside reverse transcriptase inhibitors efavirenz and nevirapine in human plasma using liquid chromatography. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20030725 |
| Alternation of antiretroviral drug regimens for HIV infection. A randomized, controlled trial. | Annals of internal medicine 20030715 |
| Use of HIV-1 reverse transcriptase recovered from human plasma for phenotypic drug susceptibility testing. | AIDS (London, England) 20030704 |
| The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity. | The Journal of pharmacology and experimental therapeutics 20030701 |
| Outcome of 2 simplification strategies for the treatment of human immunodeficiency virus type 1 infection. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20030701 |
| Photodermatitis in a patient with HIV infection. | Journal of the American Academy of Dermatology 20030701 |
| Recurrence of post-traumatic stress disorder symptoms after initiation of antiretrovirals including efavirenz: a report of two cases. | HIV medicine 20030701 |
| Experience with efavirenz in end-stage renal disease. | International journal of STD & AIDS 20030701 |
| NNRTI choice: has 2NN changed our practice? | The AIDS reader 20030701 |
| Synthesis of novel MKC-442 analogues with potent activities against HIV-1. | Archiv der Pharmazie 20030701 |
| Variable prediction of antiretroviral treatment outcome by different systems for interpreting genotypic human immunodeficiency virus type 1 drug resistance. | The Journal of infectious diseases 20030615 |
| Hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in HIV-1. | AIDS (London, England) 20030613 |
| Novel indolyl aryl sulfones active against HIV-1 carrying NNRTI resistance mutations: synthesis and SAR studies. | Journal of medicinal chemistry 20030605 |
| Reverse phase high-performance liquid chromatography method for the analysis of amprenavir, efavirenz, indinavir, lopinavir, nelfinavir and its active metabolite (M8), ritonavir, and saquinavir in heparinized human plasma. | Therapeutic drug monitoring 20030601 |
| A simple HPLC method for simultaneous determination of lopinavir, ritonavir and efavirenz. | Chemical & pharmaceutical bulletin 20030601 |
| Use of SAM2 biotin capture membrane in microarrayed compound screening (muARCS) format for nucleic acid polymerization assays. | Journal of biomolecular screening 20030601 |
| Nucleoside-free regimen tested. | AIDS patient care and STDs 20030601 |
| Comparison of nine resistance interpretation systems for HIV-1 genotyping. | Antiviral therapy 20030601 |
| Protease inhibitor-sparing regimens: new evidence strengthens position. | Journal of acquired immune deficiency syndromes (1999) 20030601 |
| NIAID comments on AACTG Study A5095. | IAPAC monthly 20030601 |
| Sensitive and specific determination of eight antiretroviral agents in plasma by high-performance liquid chromatography-mass spectrometry. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20030525 |
| Validation of a model for the complex of HIV-1 reverse transcriptase with nonnucleoside inhibitor TMC125. | Journal of the American Chemical Society 20030521 |
| [Assessment of adherence to antiretroviral: role of determination of plasma levels of non nucleosides anologues]. | Medicina clinica 20030517 |
| [HIV-infection, HAART (highly-active antiretroviral therapy) and hyperlipidemia]. | Deutsche medizinische Wochenschrift (1946) 20030509 |
| [Decrease of HIV-1 virus load by nevirapin/efavirenz]. | Deutsche medizinische Wochenschrift (1946) 20030509 |
| [ACTG-study 5095: superiority of efavirenz containing drug scheme]. | Deutsche medizinische Wochenschrift (1946) 20030509 |
| Once-a-day highly active antiretroviral therapy in treatment-naive HIV-1-infected adults in Senegal. | AIDS (London, England) 20030502 |
| Adherence to highly active antiretroviral therapy is better in patients receiving non-nucleoside reverse transcriptase inhibitor-containing regimens than in those receiving protease inhibitor-containing regimens. | AIDS (London, England) 20030502 |
| APHS can act synergically with clinically available HIV-1 reverse transcriptase and protease inhibitors and is active against several drug-resistant HIV-1 strains in vitro. | The Journal of antimicrobial chemotherapy 20030501 |
| Once-a-day highly active antiretroviral therapy: a systematic review. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20030501 |
| Efavirenz-based regimen as treatment of advanced AIDS with cryptococcal meningitis. | Journal of acquired immune deficiency syndromes (1999) 20030501 |
| Toxicity of non-nucleoside analogue reverse transcriptase inhibitors. | Seminars in liver disease 20030501 |
| [A 'once daily' drug that with proven effectiveness. Efavirenz has successful outcome also in direct comparisons]. | MMW Fortschritte der Medizin 20030428 |
| [Highly effective drug without modifying the lipid profile. Atazanavir, the protease inhibitor for 'once daily' administration]. | MMW Fortschritte der Medizin 20030428 |
| [Ensuring high adherence. Clever combination assures therapeutic success]. | MMW Fortschritte der Medizin 20030428 |
| [Psychiatric diseases and HIV infection. These patients are dually stigmatized]. | MMW Fortschritte der Medizin 20030428 |
| [Nevirapine has gained acceptance. Good antiretroviral effect--favorable lipid profile]. | MMW Fortschritte der Medizin 20030428 |
| [Lipid profile and body fat--significant 'side effect' of antiretroviral therapy. Tenofovir: favorable profile of adverse effects]. | MMW Fortschritte der Medizin 20030428 |
| [CROI highlights of D:A:D Study (Data Collection on Adverse Events of Anti-HIV Drugs Study) and 2NN Study. Stepping into the grease pot]. | MMW Fortschritte der Medizin 20030428 |
| ['Once daily' drugs simplify therapy. Rp. HAART once daily]. | MMW Fortschritte der Medizin 20030428 |
| Phenotypic susceptibility and virological outcome in nucleoside-experienced patients receiving three or four antiretroviral drugs. | AIDS (London, England) 20030411 |
| Treatment with indinavir, efavirenz, and adefovir after failure of nelfinavir therapy. | The Journal of infectious diseases 20030401 |
| Report from the Tenth Retrovirus Conference. Comparing efavirenz and nevirapine: the 2NN study. | AIDS clinical care 20030401 |
| AIDS drug in halted trial less effective as monotherapy. | The AIDS reader 20030401 |
| HIV-1 reverse transcriptase and protease resistance mutations selected during 16-72 weeks of therapy in isolates from antiretroviral therapy-experienced patients receiving abacavir/efavirenz/amprenavir in the CNA2007 study. | Antiviral therapy 20030401 |
| [Measuring the HIV viral load with LCx (Abbott): importance for the therapeutic follow-up of 3 patients infected by type O HIV]. | Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine 20030401 |
| [Complete immune and clinical recovery after highly active antiretroviral therapy in advanced vertically HIV-1 infected children]. | Medicina clinica 20030329 |
| Determining the relative efficacy of highly active antiretroviral therapy. | The Journal of infectious diseases 20030315 |
| Retroviruses Conference clinical news; interview with Cal Cohen, M.D. Interview by John S. James. | AIDS treatment news 20030314 |
| Concurrent use of bupropion with CYP2B6 inhibitors, nelfinavir, ritonavir and efavirenz: a case series. | AIDS (London, England) 20030307 |
| Impact of protease inhibitor substitution with efavirenz in HIV-infected children: results of the First Pediatric Switch Study. | Pediatrics 20030301 |
| Evaluation of antiretroviral drug measurements by an interlaboratory quality control program. | Journal of acquired immune deficiency syndromes (1999) 20030301 |
| Response to efavirenz plus two nucleoside reverse-transcriptase inhibitors in patients with advanced stage human immunodeficiency virus-1 infection in Taiwan. | Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi 20030301 |
| Efavirenz-induced psychosis leading to involuntary detention. | AIDS (London, England) 20030214 |
| Simultaneous determination of nine antiretroviral compounds in human plasma using liquid chromatography. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20030205 |
| Once-daily saquinavir-sgc plus low-dose ritonavir (1200/100 mg) in combination with efavirenz: pharmacokinetics and efficacy in HIV-infected patients with prior antiretroviral therapy. | Journal of acquired immune deficiency syndromes (1999) 20030201 |
| Effect of therapeutic drug monitoring on outcome in antiretroviral experienced HIV-infected individuals. | Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology 20030201 |
| Performance analysis of a rapid HPLC determination with the solvent demixing extraction of HIV antiproteases and efavirenz in plasma. | Journal of chromatographic science 20030201 |
| Non-nucleoside reverse transcriptase inhibitors--an overview. | International journal of STD & AIDS 20030201 |
| Simplification of protease inhibitor-containing regimens with efavirenz, nevirapine or abacavir: safety and efficacy outcomes. | Antiviral therapy 20030201 |
| [Antiretrovirals]. | Nihon rinsho. Japanese journal of clinical medicine 20030201 |
| [Highly effective and tolerable protease inhibitor. New trump card against HIV]. | MMW Fortschritte der Medizin 20030116 |
| A V106M mutation in HIV-1 clade C viruses exposed to efavirenz confers cross-resistance to non-nucleoside reverse transcriptase inhibitors. | AIDS (London, England) 20030103 |
| Amino acid substitutions at position 190 of human immunodeficiency virus type 1 reverse transcriptase increase susceptibility to delavirdine and impair virus replication. | Journal of virology 20030101 |
| Tenofovir: a nucleotide analog for the management of human immunodeficiency virus infection. | Pharmacotherapy 20030101 |
| Long-term assessment of neuropsychiatric adverse reactions associated with efavirenz. | HIV medicine 20030101 |
| Efavirenz effects worse than reported, study says. | AIDS alert 20030101 |
| Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection. | Clinical pharmacology and therapeutics 20030101 |
| Sequencing to NRTI plus NNRTI-only combinations after virological failure of protease inhibitor-based combination HIV-1 therapy. | HIV clinical trials 20030101 |
| Lipid changes in patients initiating efavirenz- and indinavir-based antiretroviral regimens. | HIV clinical trials 20030101 |
| Hypersensitivity to efavirenz treated with corticosteroids in a 6-year-old child. | AIDS patient care and STDs 20030101 |
| In vitro activity of potential anti-poxvirus agents. | Antiviral research 20030101 |
| Therapeutic drug monitoring: an aid to optimising response to antiretroviral drugs? | Drugs 20030101 |
| Lopinavir/ritonavir: a review of its use in the management of HIV infection. | Drugs 20030101 |
| Medium chain triglycerides as vehicle for palatable oral liquids. | Pharmaceutical development and technology 20030101 |
| Incidence of liver injury after beginning antiretroviral therapy with efavirenz or nevirapine. | HIV clinical trials 20030101 |
| Nevirapine found to be as effective as efavirenz. | TreatmentUpdate 20030101 |
| Kidney damage reported in some tenofovir users. | TreatmentUpdate 20030101 |
| Functional asymmetry in the lysyl-tRNA synthetase explored by molecular dynamics, free energy calculations and experiment. | BMC structural biology 20030101 |
| Twice-daily amprenavir 1200 mg versus amprenavir 600 mg/ritonavir 100 mg, in combination with at least 2 other antiretroviral drugs, in HIV-1-infected patients. | BMC infectious diseases 20030101 |
| Tolerance of efavirenz-induced central nervous system side effects in HIV-infected individuals with a history of substance abuse. | HIV clinical trials 20030101 |
| Does Viramune = Sustiva? | Positively aware : the monthly journal of the Test Positive Aware Network 20030101 |
| Anatomy of a study: Trizivir vs. Sustiva. | Positively aware : the monthly journal of the Test Positive Aware Network 20030101 |
| [Acute liver toxicity of antiretroviral therapy (HAART) after liver transplantation in a patient with HIV-HCV coinfection and associated hepatocarcinoma (HCC)]. | Tumori 20030101 |
| Compact quadruple therapy with the lamivudine/zidovudine combination tablet plus abacavir and efavirenz, followed by the lamivudine/zidovudine/abacavir triple nucleoside tablet plus efavirenz in treatment-naïve HIV-infected adults. | HIV clinical trials 20030101 |
| Replacement of protease inhibitors by nevirapine or efavirenz in simplification and rescue interventions: which works better? | HIV clinical trials 20030101 |
| Dealing with Sustiva side effects. | Positively aware : the monthly journal of the Test Positive Aware Network 20030101 |
| Prevalence of drug-resistant human immunodeficiency virus type 1 in therapy-naive patients and usefulness of genotype testing. | Microbiology and immunology 20030101 |
| An unusual presentation of Castleman's disease:a case report. | BMC infectious diseases 20030101 |
| Impact of various antiretroviral drugs and their plasma concentrations on plasma lipids in heavily pretreated HIV-infected patients. | HIV clinical trials 20030101 |
| Comparison of efficacy of efavirenz and nevirapine: lessons learned for cohort analysis in light of the 2NN Study. | HIV clinical trials 20030101 |
| Long-term safety and efficacy of NNRTI within the central nervous system. | HIV clinical trials 20030101 |
| Genotypic resistance tests for the management of patients at simplification of highly active antiretroviral therapy. | Scandinavian journal of infectious diseases. Supplementum 20030101 |
| Antenatal and neonatal antiretroviral therapy in HIV-infected women and their infants: a review of safety issues. | Medycyna wieku rozwojowego 20030101 |
| Report from the 4th International Workshop on Clinical Pharmacology of HIV Therapy. Efavirenz levels in the blood found higher in women. | TreatmentUpdate 20030101 |
| Nelfinavir and non-nucleoside reverse transcriptase inhibitor-based salvage regimens in heavily HIV pretreated patients. | The Canadian journal of infectious diseases = Journal canadien des maladies infectieuses 20030101 |
| Synthesis of novel N-1 (allyloxymethyl) analogues of 6-benzyl-1-(ethoxymethyl)-5-isopropyluracil (MKC-442, emivirine) with improved activity against HIV-1 and its mutants. | Journal of medicinal chemistry 20021219 |
| HIV and antiretroviral drug distribution in plasma and fat tissue of HIV-infected patients with lipodystrophy. | AIDS (London, England) 20021206 |
| [Simple, safe and effective. New protease inhibitor means progress]. | MMW Fortschritte der Medizin 20021205 |
| Genotypic and phenotypic resistance patterns in early-stage HIV-1-infected patients failing initial therapy with stavudine, didanosine and nevirapine. | Antiviral therapy 20021201 |
| Chronic cough induced by abacavir apart from a context of hypersensitivity. | Allergie et immunologie 20021201 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20021201 |
| Virologic outcomes of complex drug regimens for human immunodeficiency virus. | JAMA 20021120 |
| Increased long-term mitochondrial toxicity in combinations of nucleoside analogue reverse-transcriptase inhibitors. | AIDS (London, England) 20021108 |
| Polymorphisms of cytotoxic T-lymphocyte (CTL) and T-helper epitopes within reverse transcriptase (RT) of HIV-1 subtype C from Ethiopia and Botswana following selection of antiretroviral drug resistance. | Antiviral research 20021101 |
| New anti-HIV agents and targets. | Medicinal research reviews 20021101 |
| Drug-drug interactions in inmates treated for human immunodeficiency virus and Mycobacterium tuberculosis infection or disease: an institutional tuberculosis outbreak. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20021101 |
| Pharmacokinetic and pharmacodynamic investigation of efavirenz in the semen and blood of human immunodeficiency virus type 1-infected men. | The Journal of infectious diseases 20021101 |
| Fulminant hepatic failure after the start of an efavirenz-based HAART regimen in a treatment-naive female AIDS patient without hepatitis virus co-infection. | The Journal of antimicrobial chemotherapy 20021101 |
| Therapeutic responses to AZT + 3TC + EFV in advanced antiretroviral naive HIV type 1-infected Ugandan patients. | AIDS research and human retroviruses 20021101 |
| Can HIV infection be treated successfully with a once-daily regimen? | The AIDS reader 20021101 |
| Population pharmacokinetic meta-analysis with efavirenz. | International journal of clinical pharmacology and therapeutics 20021101 |
| NNRTI hepatotoxicity: efavirenz versus nevirapine. | Journal of HIV therapy 20021101 |
| Structure of HIV-2 reverse transcriptase at 2.35-A resolution and the mechanism of resistance to non-nucleoside inhibitors. | Proceedings of the National Academy of Sciences of the United States of America 20021029 |
| Intravenous drug users risk group should also benefit from simpler highly active antiretroviral therapy. | AIDS (London, England) 20021018 |
| The clinical relevance of non-nucleoside reverse transcriptase inhibitor hypersusceptibility: a prospective cohort analysis. | AIDS (London, England) 20021018 |
| Hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in HIV-1: clinical, phenotypic and genotypic correlates. | AIDS (London, England) 20021018 |
| Activity of reverse transcriptase inhibitors in monocyte-derived dendritic cells: a possible in vitro model for postexposure prophylaxis of sexual HIV transmission. | AIDS research and human retroviruses 20021010 |
| Inhibitor binding alters the directions of domain motions in HIV-1 reverse transcriptase. | Proteins 20021001 |
| Once-daily quadruple-drug therapy with adefovir dipivoxil, Lamivudine, Didanosine, and efavirenz in treatment-naive human immunodeficiency virus type 1-infected patients. | The Journal of infectious diseases 20021001 |
| Interactions between recreational drugs and antiretroviral agents. | The Annals of pharmacotherapy 20021001 |
| Simultaneous determination of rifampicin and efavirenz in plasma. | Therapeutic drug monitoring 20021001 |
| Symptomatic orthostasis with extended-release nifedipine and protease inhibitors. | Pharmacotherapy 20021001 |
| Efficacy and safety of a quadruple combination Combivir + abacavir + efavirenz regimen in antiretroviral treatment-naive HIV-1-infected adults: La Francilienne. | Journal of acquired immune deficiency syndromes (1999) 20021001 |
| Low increase in serum lipids in patients receiving a combination of ritonavir, saquinavir and efavirenz. | HIV medicine 20021001 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20021001 |
| Efavirenz-associated severe hyperlipidemia. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20020915 |
| High-density lipoprotein cholesterol is low in HIV-infected patients with lipodystrophic fat expansions: implications for pathogenesis of fat redistribution. | AIDS (London, England) 20020906 |
| Efavirenz-induced catatonia. | AIDS (London, England) 20020906 |
| Modulation of human immunodeficiency virus (HIV)-specific immune response by using efavirenz, nelfinavir, and stavudine in a rescue therapy regimen for HIV-infected, drug-experienced patients. | Clinical and diagnostic laboratory immunology 20020901 |
| Determination of lamivudine/stavudine/efavirenz in human serum using liquid chromatography/electrospray tandem mass spectrometry with ionization polarity switch. | Biomedical chromatography : BMC 20020901 |
| Development of drug resistance in HIV-1 patients receiving a combination of stavudine, lamivudine and efavirenz. | International journal of antimicrobial agents 20020901 |
| Antiretroviral therapy regimens for neuro-AIDS. | Current drug targets. Infectious disorders 20020901 |
| Analysis of the virological response with respect to baseline viral phenotype and genotype in protease inhibitor-experienced HIV-1-infected patients receiving lopinavir/ritonavir therapy. | Antiviral therapy 20020901 |
| [Efficacy of efavirenz in a mixed population of patients. Identification of drop-out causes]. | Le infezioni in medicina : rivista periodica di eziologia, epidemiologia, diagnostica, clinica e terapia delle patologie infettive 20020901 |
| ['Normal' compliance is not enough. HIV therapy loses effectiveness]. | MMW Fortschritte der Medizin 20020822 |
| Cross-resistance among nonnucleoside reverse transcriptase inhibitors limits recycling efavirenz after nevirapine failure. | AIDS research and human retroviruses 20020810 |
| Simultaneous quantitative assay of six HIV protease inhibitors, one metabolite, and two non-nucleoside reverse transcriptase inhibitors in human plasma by isocratic reversed-phase liquid chromatography. | Therapeutic drug monitoring 20020801 |
| Effect of coadministration of nelfinavir, indinavir, and saquinavir on the pharmacokinetics of amprenavir. | Clinical pharmacology and therapeutics 20020801 |
| HIV and refractory anemia with excess blasts (RAEB). | American journal of hematology 20020801 |
| Anti-HIV agents. Efavirenz makes its mark in AIDS. | TreatmentUpdate 20020801 |
| High effectiveness of efavirenz-based highly active antiretroviral therapy in HIV-1-infected patients with fewer than 100 CD4 cells/microl and opportunistic diseases: the EfaVIP Study (Efavirenz in Very Immunosuppressed Patients). | AIDS (London, England) 20020726 |
| Female sex but not ethnicity is a strong predictor of non-nucleoside reverse transcriptase inhibitor-induced rash. | AIDS (London, England) 20020726 |
| Efavirenz plasma levels for the prediction of treatment failure in heavily pretreated HIV-1 infected patients. | European journal of medical research 20020724 |
| Extent and importance of cross-resistance to efavirenz after nevirapine failure. | AIDS research and human retroviruses 20020720 |
| New developments in anti-HIV chemotherapy. | Biochimica et biophysica acta 20020718 |
| Determination of lopinavir and nevirapine by high-performance liquid chromatography after solid-phase extraction: application for the assessment of their transplacental passage at delivery. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20020715 |
| Dual vs single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial. | JAMA 20020710 |
| Simple and rapid quantification of the non-nucleoside reverse transcriptase inhibitors nevirapine, delavirdine, and efavirenz in human blood plasma using high-performance liquid chromatography with ultraviolet absorbance detection. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20020705 |
| Prediction of activity for nonnucleoside inhibitors with HIV-1 reverse transcriptase based on Monte Carlo simulations. | Journal of medicinal chemistry 20020704 |
| Long-term metabolic consequences of switching from protease inhibitors to efavirenz in therapy for human immunodeficiency virus-infected patients with lipoatrophy. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20020701 |
| Genetic divergence of human immunodeficiency virus type 1 Ethiopian clade C reverse transcriptase (RT) and rapid development of resistance against nonnucleoside inhibitors of RT. | Antimicrobial agents and chemotherapy 20020701 |
| Central nervous system adverse effects with efavirenz: case report and review. | Pharmacotherapy 20020701 |
| Hepatic but not intestinal CYP3A4 displays dose-dependent induction by efavirenz in humans. | Clinical pharmacology and therapeutics 20020701 |
| Differential modulation of P-glycoprotein expression and activity by non-nucleoside HIV-1 reverse transcriptase inhibitors in cell culture. | Pharmaceutical research 20020701 |
| Efavirenz liquid formulation in human immunodeficiency virus-infected children. | The Pediatric infectious disease journal 20020701 |
| Potency of nonnucleoside reverse transcriptase inhibitors (NNRTIs) used in combination with other human immunodeficiency virus NNRTIs, NRTIs, or protease inhibitors. | Antimicrobial agents and chemotherapy 20020601 |
| High-performance liquid chromatographic method for the simultaneous determination of the six HIV-protease inhibitors and two non-nucleoside reverse transcriptase inhibitors in human plasma. | Therapeutic drug monitoring 20020601 |
| Efavirenz-associated QT prolongation and Torsade de Pointes arrhythmia. | The Annals of pharmacotherapy 20020601 |
| Determination of efavirenz, a selective non-nucleoside reverse transcriptase inhibitor, in human plasma using HPLC with post-column photochemical derivatization and fluorescence detection. | Journal of pharmaceutical and biomedical analysis 20020601 |
| NNRTIs compared in switch group. | AIDS patient care and STDs 20020601 |
| Gateways to Clinical Trials. June 2002. | Methods and findings in experimental and clinical pharmacology 20020601 |
| Normalization of liver enzymes in an HIV-hepatitis C virus-co-infected patient after potent antiretroviral therapy. | AIDS (London, England) 20020524 |
| Persistence of human immunodeficiency virus (HIV) type 1 DNA in peripheral blood despite prolonged suppression of plasma HIV-1 RNA in children. | The Journal of infectious diseases 20020515 |
| Efficacy and safety of abacavir plus efavirenz as a salvage regimen in HIV-infected individuals after 48 weeks. | AIDS (London, England) 20020503 |
| A prospective comparison of the two main indications of efavirenz in 2001 highly active antiretroviral therapy (HAART) regimens: first-line versus salvage use. | The Journal of antimicrobial chemotherapy 20020501 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20020501 |
| Virologic and immunologic response to regimens containing nevirapine or efavirenz in combination with 2 nucleoside analogues in the Italian Cohort Naive Antiretrovirals (I.Co.N.A.) study. | The Journal of infectious diseases 20020415 |
| Investigation of critical factors for the resolution of SR695, a key impurity, from efavirenz in the reversed-phase assay of efavirenz dosage forms. | Journal of pharmaceutical and biomedical analysis 20020401 |
| Simultaneous determination of the six HIV protease inhibitors (amprenavir, indinavir, lopinavir, nelfinavir, ritonavir, and saquinavir) plus M8 nelfinavir metabolite and the nonnucleoside reverse transcription inhibitor efavirenz in human plasma by solid-phase extraction and column liquid chromatography. | Therapeutic drug monitoring 20020401 |
| Lack of hepatotoxicity associated with nonnucleoside reverse transcriptase inhibitors. | Journal of acquired immune deficiency syndromes (1999) 20020401 |
| Therapeutic effects of nonnucleoside reverse transcriptase inhibitors on the central nervous system in HIV-1-infected patients. | Journal of acquired immune deficiency syndromes (1999) 20020401 |
| FDA notifications. Changes approved for Sustiva. | AIDS alert 20020401 |
| Kinetics and mechanism of hydrolysis of efavirenz. | Pharmaceutical research 20020401 |
| Undefined duration of opiate withdrawal induced by efavirenz in drug users with HIV infection and undergoing chronic methadone treatment. | AIDS research and human retroviruses 20020320 |
| FDA approves once-daily efavirenz formulation, revised labeling. | AIDS treatment news 20020308 |
| Quality of life, emotional status, and adherence of HIV-1-infected patients treated with efavirenz versus protease inhibitor-containing regimens. | Journal of acquired immune deficiency syndromes (1999) 20020301 |
| Management of a patient with HIV infection-induced anemia and thrombocytopenia who presented with thrombotic thrombocytopenic purpura. | American journal of hematology 20020301 |
| Efavirenz-induced skin eruption and successful desensitization. | The Annals of pharmacotherapy 20020301 |
| Structural basis for the inhibitory efficacy of efavirenz (DMP-266), MSC194 and PNU142721 towards the HIV-1 RT K103N mutant. | European journal of biochemistry 20020301 |
| Simple rapid method for quantification of antiretrovirals by liquid chromatography-tandem mass-spectrometry. | Clinical biochemistry 20020301 |
| Target molecules - design, optimization and production. The Knud Lind Larsen Symposium. 25-26 January 2002, Copenhagen, Denmark. | IDrugs : the investigational drugs journal 20020301 |
| Virological, immunological, and clinical impact of switching from protease inhibitors to nevirapine or to efavirenz in patients with human immunodeficiency virus infection and long-lasting viral suppression. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20020215 |
| Switching from protease inhibitors to efavirenz: differences in efficacy and tolerance among risk groups: a case-control study from the Swiss HIV Cohort. | AIDS (London, England) 20020215 |
| HIV-1 genotype and phenotype correlate with virological response to abacavir, amprenavir and efavirenz in treatment-experienced patients. | AIDS (London, England) 20020215 |
| Probable interaction between efavirenz and cyclosporine. | AIDS (London, England) 20020215 |
| Gynaecomastia without lipodystrophy in HIV-1-seropositive patients on efavirenz: an alternative hypothesis. | AIDS (London, England) 20020215 |
| Periconceptional exposure to efavirenz and neural tube defects. | Archives of internal medicine 20020211 |
| Efavirenz-induced leukocytoclastic vasculitis. | Archives of internal medicine 20020211 |
| Antimicrobial and anti-lipase activity of quercetin and its C2-C16 3-O-acyl-esters. | Bioorganic & medicinal chemistry 20020201 |
| Role of sequencing in therapy selection. | Journal of acquired immune deficiency syndromes (1999) 20020201 |
| Pharmacokinetics of methadone in HIV-positive patients receiving the non-nucleoside reverse transcriptase efavirenz. | British journal of clinical pharmacology 20020201 |
| Nevirapine + efavirenz based salvage therapy in heavily pretreated HIV infected patients. | Sexually transmitted infections 20020201 |
| Immune reconstitution eosinophilia due to schistosomiasis. | Sexually transmitted infections 20020201 |
| Efficacy of highly active antiretroviral therapy in HIV-1 infected children. | The Lancet. Infectious diseases 20020201 |
| Swiss study switching to efavirenz. | TreatmentUpdate 20020201 |
| Efavirenz helps get rid of Kaposi's sarcoma (KS). | TreatmentUpdate 20020201 |
| Birth defect in baby born to efavirenz-user. | TreatmentUpdate 20020201 |
| Comparing liver toxicity between efavirenz and nevirapine. | TreatmentUpdate 20020201 |
| Effect of antiretroviral combination therapies including efavirenz in heavily pretreated HIV-infected children. | European journal of medical research 20020129 |
| Myelomeningocele in a child with intrauterine exposure to efavirenz. | AIDS (London, England) 20020125 |
| Complete remission of AIDS/Kaposi's sarcoma after treatment with a combination of two nucleoside reverse transcriptase inhibitors and one non-nucleoside reverse transcriptase inhibitor. | AIDS (London, England) 20020125 |
| Evidence of immune reconstitution in antiretroviral drug-experienced patients with advanced HIV disease. | AIDS research and human retroviruses 20020120 |
| Association between efavirenz and selected psychiatric and neurological conditions. | The Journal of infectious diseases 20020115 |
| Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. | Lancet (London, England) 20020105 |
| Virological suppression at 6 months is related to choice of initial regimen in antiretroviral-naive patients: a cohort study. | AIDS (London, England) 20020104 |
| Primary infection with a lamivudine-resistant hepatitis B virus. | AIDS (London, England) 20020104 |
| Pilot study of the effects of intermittent interleukin-2 on human immunodeficiency virus (HIV)-specific immune responses in patients treated during recently acquired HIV infection. | The Journal of infectious diseases 20020101 |
| Dioxolane guanosine, the active form of the prodrug diaminopurine dioxolane, is a potent inhibitor of drug-resistant HIV-1 isolates from patients for whom standard nucleoside therapy fails. | Journal of acquired immune deficiency syndromes (1999) 20020101 |
| Brief report: two-year outcome of a multidrug regimen in patients who did not respond to a protease inhibitor regimen. | Journal of acquired immune deficiency syndromes (1999) 20020101 |
| Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections. | Hepatology (Baltimore, Md.) 20020101 |
| Antiretroviral rounds. A very discordant response. | AIDS clinical care 20020101 |
| The influence of efavirenz on the pharmacokinetics of a twice-daily combination of indinavir and low-dose ritonavir in healthy volunteers. | Clinical pharmacology and therapeutics 20020101 |
| Efavirenz and retinal toxicity. | Eye (London, England) 20020101 |
| Two protease inhibitor switch studies show longer virologic response in patients switching to a regimen containing Sustiva. | The Journal of the Association of Nurses in AIDS Care : JANAC 20020101 |
| Non-nucleoside HIV-1 reverse transcriptase (RT) inhibitors: past, present, and future perspectives. | Current pharmaceutical design 20020101 |
| Genotype resistance profiles in patients failing an NNRTI-containing regimen, and modifications after stopping NNRTI therapy. | Journal of clinical laboratory analysis 20020101 |
| SENC (Spanish efavirenz vs. nevirapine comparison) trial: a randomized, open-label study in HIV-infected naive individuals. | HIV clinical trials 20020101 |
| Pharmacokinetic interactions between efavirenz and rifampicin in HIV-infected patients with tuberculosis. | Clinical pharmacokinetics 20020101 |
| Clinical implications of CNS penetration of antiretroviral drugs. | CNS drugs 20020101 |
| [Plasmatic dosage of antiretroviral drugs by high performance liquid chromathography ]. | Therapie 20020101 |
| The HYDILE trial: efficacy and tolerance of a quadruple combination of reverse transcriptase inhibitors versus the same regimen plus hydroxyurea or hydroxyurea and interleukin-2 in HIV-infected patients failing protease inhibitor-based combinations. | HIV clinical trials 20020101 |
| Safety and tolerance of efavirenz in different antiretroviral regimens: results from a national multicenter prospective study in 1,033 HIV-infected patients. | HIV clinical trials 20020101 |
| Comparison of nevirapine- and efavirenz-containing antiretroviral regimens in antiretroviral-naïve patients: a cohort study. | HIV clinical trials 20020101 |
| Antiretroviral pharmacokinetics in the paediatric population: a review. | Clinical pharmacokinetics 20020101 |
| Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence. | Clinical pharmacokinetics 20020101 |
| Interactions between antiretroviral drugs and drugs used for the therapy of the metabolic complications encountered during HIV infection. | Clinical pharmacokinetics 20020101 |
| NNRTI plus PI combinations in the perspective of nucleoside-sparing or nucleoside-failing antiretroviral regimens. | AIDS reviews 20020101 |
| Hepatic adverse events during highly active antiretroviral therapy containing nevirapine: a case report. | Annals of clinical microbiology and antimicrobials 20020101 |
| Stavudine once daily. | Drugs 20020101 |
| A comparative study reveals that a regimen containing sustiva provides an effective alternative to protease inhibitor-based therapy. | The Journal of the Association of Nurses in AIDS Care : JANAC 20020101 |
| Discovery of second generation quinazolinone non-nucleoside reverse transcriptase inhibitors of HIV-1. | Progress in medicinal chemistry 20020101 |
| Simplification of antiretroviral treatment--how to sustain success, reduce toxicity and ensure adherence avoiding PI use. | AIDS reviews 20020101 |
| [Efficiency and side effects of antiretroviral treatment of HIV infected pregnant women]. | Zentralblatt fur Gynakologie 20020101 |
| Management of protease inhibitor-associated hyperlipidemia. | American journal of cardiovascular drugs : drugs, devices, and other interventions 20020101 |
| Viral load outcome of non-nucleoside reverse transcriptase inhibitor regimens for 2203 mainly antiretroviral-experienced patients. | AIDS (London, England) 20011207 |
| Baseline CD4(+) cell count, not viral load, correlates with virologic suppression induced by potent antiretroviral therapy. | Journal of acquired immune deficiency syndromes (1999) 20011201 |
| Higher efavirenz plasma levels correlate with development of insomnia. | Journal of acquired immune deficiency syndromes (1999) 20011201 |
| Changes in metabolic parameters and body shape after replacement of protease inhibitor With efavirenz in virologically controlled HIV-1-positive persons: single-arm observational cohort. | Journal of acquired immune deficiency syndromes (1999) 20011201 |
| Skin eruption 8 days after a single dose of efavirenz-containing combination therapy. | Japanese journal of infectious diseases 20011201 |
| Virological and immunological responses to a once-a-day antiretroviral regimen with didanosine, lamivudine and efavirenz. | Antiviral therapy 20011201 |
| Electronic and resonance effects on the ionization of structural analogues of efavirenz. | AAPS pharmSci 20011201 |
| The stereoselective targeting of a specific enzyme-substrate complex is the molecular mechanism for the synergic inhibition of HIV-1 reverse transcriptase by (R)-(-)-PPO464: a novel generation of nonnucleoside inhibitors. | The Journal of biological chemistry 20011130 |
| [Antiviral therapy of HIV infection in adults]. | Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke 20011130 |
| Drugs for HIV infection. | The Medical letter on drugs and therapeutics 20011126 |
| Determination of efavirenz in human plasma by high-performance liquid chromatography with ultraviolet detection. | Journal of chromatography. B, Biomedical sciences and applications 20011105 |
| New developments in anti-HIV chemotherapy. | Current medicinal chemistry 20011101 |
| The role of NNRTIs in antiretroviral combination therapy: an introduction. | International journal of STD & AIDS 20011101 |
| Comparison of NNRTIs in antiretroviral-naïve patients. | International journal of STD & AIDS 20011101 |
| Comparison of NNRTIs in antiretroviral-experienced patients. | International journal of STD & AIDS 20011101 |
| Factors affecting adherence and convenience in antiretroviral therapy. | International journal of STD & AIDS 20011101 |
| Other issues: penetration into sanctuary sites, immune reconstitution and NNRTI sequencing. | International journal of STD & AIDS 20011101 |
| Resistance profile and cross-resistance of HIV-1 among patients failing a non-nucleoside reverse transcriptase inhibitor-containing regimen. | Journal of medical virology 20011101 |
| Hepatotoxicity with antiretroviral treatment of pregnant women. | Obstetrics and gynecology 20011101 |
| Phylogenetic analysis of reverse transcriptase in antiretroviral drug-naive Korean HIV type 1 patients. | AIDS research and human retroviruses 20011101 |
| Synthesis and anti-HIV-1 activity of new delavirdine analogues carrying arylpyrrole moieties. | Chemical & pharmaceutical bulletin 20011101 |
| Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV Cohort Study. | Lancet (London, England) 20011020 |
| Penetration of efavirenz into the male genital tract: drug concentrations and antiviral activity in semen and blood of HIV-1-infected men. | AIDS (London, England) 20011019 |
| Structural mechanisms of drug resistance for mutations at codons 181 and 188 in HIV-1 reverse transcriptase and the improved resilience of second generation non-nucleoside inhibitors. | Journal of molecular biology 20010928 |
| Response to first protease inhibitor- and efavirenz-containing antiretroviral combination therapy. The Swiss HIV Cohort Study. | AIDS (London, England) 20010928 |
| Efavirenz-induced psychosis. | AIDS (London, England) 20010928 |
| Comparison of initial combination antiretroviral therapy with a single protease inhibitor, ritonavir and saquinavir, or efavirenz. | AIDS (London, England) 20010907 |
| Evolution of anti-HIV drug candidates. Part 3: Diarylpyrimidine (DAPY) analogues. | Bioorganic & medicinal chemistry letters 20010903 |
| Mismatched double-stranded RNA (polyI-polyC(12)U) is synergistic with multiple anti-HIV drugs and is active against drug-sensitive and drug-resistant HIV-1 in vitro. | Antiviral research 20010901 |
| Thiosugars. VIII. Preparation of new 4'-thio-L-lyxo pyrimidine nucleoside analogues. | Nucleosides, nucleotides & nucleic acids 20010901 |
| Efavirenz may have treatment advantage. | AIDS patient care and STDs 20010901 |
| Three-year durability for efavirenz. | AIDS patient care and STDs 20010901 |
| Efavirenz switches may be beneficial. | AIDS patient care and STDs 20010901 |
| DPC-083. DuPont Pharmaceuticals. | Current opinion in investigational drugs (London, England : 2000) 20010901 |
| Does efavirenz cause breast enlargement? | TreatmentUpdate 20010901 |
| Solution structures and reactivities of the mixed aggregates derived from n-butyllithium and vicinal amino alkoxides. | Journal of the American Chemical Society 20010822 |
| Non-nucleoside reverse transcriptase inhibitor failure impairs HIV-RNA responses to efavirenz-containing salvage antiretroviral therapy. | AIDS (London, England) 20010817 |
| Efavirenz as a substitute for protease inhibitors in HIV-1-infected patients with undetectable plasma viral load on HAART: a median follow-up of 64 weeks. | Journal of acquired immune deficiency syndromes (1999) 20010815 |
| Nelfinavir, efavirenz, or both after the failure of nucleoside treatment of HIV infection. | The New England journal of medicine 20010809 |
| Antiretroviral therapy for previously treated patients. | The New England journal of medicine 20010809 |
| Structure-based design, synthesis, and biological evaluation of conformationally restricted novel 2-alkylthio-6-[1-(2,6-difluorophenyl)alkyl]-3,4-dihydro-5-alkylpyrimidin-4(3H)-ones as non-nucleoside inhibitors of HIV-1 reverse transcriptase. | Journal of medicinal chemistry 20010802 |
| Antiviral drugs: current state of the art. | Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology 20010801 |
| Preliminary data of a prospective study on neuropsychiatric side effects after initiation of efavirenz. | Journal of acquired immune deficiency syndromes (1999) 20010801 |
| Antiretrovirals: simultaneous determination of five protease inhibitors and three nonnucleoside transcriptase inhibitors in human plasma by a rapid high-performance liquid chromatography--mass spectrometry assay. | Therapeutic drug monitoring 20010801 |
| Antiretroviral rounds. When success is a pain. | AIDS clinical care 20010801 |
| Gynecomastia without lipodystrophy syndrome in HIV-infected men treated with efavirenz. | AIDS (London, England) 20010727 |
| Synthesis and evaluation of novel quinolinones as HIV-1 reverse transcriptase inhibitors. | Bioorganic & medicinal chemistry letters 20010723 |
| Manic syndrome associated with efavirenz overdose. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20010715 |
| Management of sudden psychiatric disorders related to efavirenz. | AIDS (London, England) 20010706 |
| The steady-state pharmacokinetics of efavirenz and nevirapine when used in combination in human immunodeficiency virus type 1-infected persons. | The Journal of infectious diseases 20010701 |
| Predictors of protease inhibitor-associated adverse events. | Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 20010701 |
| Phenotypic hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in treatment-experienced HIV-infected patients: impact on virological response to efavirenz-based therapy. | AIDS (London, England) 20010615 |
| Efavirenz plasma concentrations and efficiency. | AIDS (London, England) 20010615 |
| Identification of a putative binding site for [2',5'-bis-O-(tert-butyldimethylsilyl)-beta-D-ribofuranosyl]-3'-spiro-5''-(4''-amino-1'',2''-oxathiole-2'',2''-dioxide)thymine (TSAO) derivatives at the p51-p66 interface of HIV-1 reverse transcriptase. | Journal of medicinal chemistry 20010607 |
| 2-Amino-6-arylsulfonylbenzonitriles as non-nucleoside reverse transcriptase inhibitors of HIV-1. | Journal of medicinal chemistry 20010607 |
| Use of MM-PBSA in reproducing the binding free energies to HIV-1 RT of TIBO derivatives and predicting the binding mode to HIV-1 RT of efavirenz by docking and MM-PBSA. | Journal of the American Chemical Society 20010606 |
| 4,1-Benzoxazepinone analogues of efavirenz (Sustiva) as HIV-1 reverse transcriptase inhibitors. | Bioorganic & medicinal chemistry letters 20010604 |
| [Vertical trasmission of human immunodeficiency virus (HIV) and other sexually transmitted infections (STI)]. | Minerva ginecologica 20010601 |
| Limits of deep salvage antiretroviral therapy with nelfinavir plus either efavirenz or nevirapine, in highly pre-treated patients with HIV disease. | International journal of antimicrobial agents 20010601 |
| In vitro anti-HIV-1 synergy between non-nucleoside reverse transcriptase inhibitors nevirapine and efavirenz. | Antiviral therapy 20010601 |
| Efavirenz-induced photoallergic dermatitis in HIV. | AIDS (London, England) 20010525 |
| Pulmonary hypersensitivity reaction induced by efavirenz. | Lancet (London, England) 20010512 |
| Synthesis and evaluation of efavirenz (Sustiva) analogues as HIV-1 reverse transcriptase inhibitors: replacement of the cyclopropylacetylene side chain. | Bioorganic & medicinal chemistry letters 20010507 |
| High-performance liquid chromatographic method for the determination of HIV-1 non-nucleoside reverse transcriptase inhibitor efavirenz in plasma of patients during highly active antiretroviral therapy. | Journal of chromatography. B, Biomedical sciences and applications 20010505 |
| Development and validation of a reverse-phase HPLC method for analysis of efavirenz and its related substances in the drug substance and in a capsule formulation. | Journal of pharmaceutical and biomedical analysis 20010501 |
| Efavirenz-induced acute eosinophilic hepatitis. | Journal of hepatology 20010501 |
| A pilot study of the use of mycophenolate mofetil as a component of therapy for multidrug-resistant HIV-1 infection. | Journal of acquired immune deficiency syndromes (1999) 20010415 |
| High prevalence of genotypic and phenotypic HIV-1 drug-resistant strains among patients receiving antiretroviral therapy in Abidjan, Côte d'Ivoire. | Journal of acquired immune deficiency syndromes (1999) 20010415 |
| Determination of serum levels of thirteen human immunodeficiency virus-suppressing drugs by high-performance liquid chromatography. | Journal of chromatography. A 20010413 |
| [Progress in HIV therapy. Effective and simple therapy with efavirenz]. | MMW Fortschritte der Medizin 20010402 |
| [Positive change from protease inhibitor to non-nucleoside reverse transcriptase inhibitor efavirenz. Improved virus control thanks to protease inhibitor switch]. | MMW Fortschritte der Medizin 20010402 |
| [Results of the AIDS-In-Europe Study. Non-nucleoside reverse transcriptase inhibitor does not equal non-nucleoside reverse transcriptase inhibitor]. | MMW Fortschritte der Medizin 20010402 |
| Amino acid deletion at codon 67 and Thr-to-Gly change at codon 69 of human immunodeficiency virus type 1 reverse transcriptase confer novel drug resistance profiles. | Journal of virology 20010401 |
| An open-label randomized trial to evaluate different therapeutic strategies of combination therapy in HIV-1 infection: design, rationale, and methods of the initio trial. | Controlled clinical trials 20010401 |
| Persistent dyslipidemia in HIV-infected individuals switched from a protease inhibitor-containing to an efavirenz-containing regimen. | Journal of acquired immune deficiency syndromes (1999) 20010401 |
| Performance of a quadruple combination including nelfinavir plus efavirenz in naive subjects with high baseline viral load and in patients failing protease inhibitor-containing regimens. | Journal of acquired immune deficiency syndromes (1999) 20010401 |
| Smaller amounts of antiretroviral drugs are needed when combined with an active ribozyme against HIV-1. | Molecular therapy : the journal of the American Society of Gene Therapy 20010401 |
| Retinal toxicity due to Efavirenz. | Eye (London, England) 20010401 |
| Sequencing antiretroviral drugs. | AIDS (London, England) 20010330 |
| Competition prompts drug companies to cut antiretroviral drug prices. | Lancet (London, England) 20010317 |
| Anti-AIDS drugs available 'at cost'. | Nature 20010315 |
| Synthesis and biological activities of potential metabolites of the non-nucleoside reverse transcriptase inhibitor efavirenz. | Bioorganic & medicinal chemistry letters 20010312 |
| International perspectives on antiretroviral resistance. Nonnucleoside reverse transcriptase inhibitor resistance. | Journal of acquired immune deficiency syndromes (1999) 20010301 |
| The pharmacokinetics of methadone in HIV-positive patients receiving the non-nucleoside reverse transcriptase inhibitor efavirenz. | British journal of clinical pharmacology 20010301 |
| Dynamics of seminal plasma HIV-1 decline after antiretroviral treatment. | AIDS (London, England) 20010216 |
| Trifluoromethyl-containing 3-alkoxymethyl- and 3-aryloxymethyl-2-pyridinones are potent inhibitors of HIV-1 non-nucleoside reverse transcriptase. | Bioorganic & medicinal chemistry letters 20010212 |
| Therapy with efavirenz plus indinavir in patients with extensive prior nucleoside reverse-transcriptase inhibitor experience: a randomized, double-blind, placebo-controlled trial. | The Journal of infectious diseases 20010201 |
| Ritonavir, efavirenz, and nelfinavir inhibit CYP2B6 activity in vitro: potential drug interactions with bupropion. | Drug metabolism and disposition: the biological fate of chemicals 20010201 |
| Quinoxalinylethylpyridylthioureas (QXPTs) as potent non-nucleoside HIV-1 reverse transcriptase (RT) inhibitors. Further SAR studies and identification of a novel orally bioavailable hydrazine-based antiviral agent. | Journal of medicinal chemistry 20010201 |
| Tolerance of efavirenz in children. | AIDS (London, England) 20010126 |
| 3,3a-Dihydropyrano[4,3,2-de]quinazolin-2(1H)-ones are potent non-nucleoside reverse transcriptase inhibitors. | Bioorganic & medicinal chemistry letters 20010122 |
| Efavirenz-associated breast hypertrophy in HIV-infection patients. | AIDS (London, England) 20010105 |
| Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. | AIDS (London, England) 20010105 |
| The emerging roles of non-nucleoside reverse transcriptase inhibitors in antiretroviral therapy. | Drugs 20010101 |
| Inhibition of human cytochrome P450 isoforms by nonnucleoside reverse transcriptase inhibitors. | Journal of clinical pharmacology 20010101 |
| Economic analysis of initial HIV treatment. Efavirenz- versus indinavir-containing triple therapy. | PharmacoEconomics 20010101 |
| New developments in anti-HIV chemotherapy. | Farmaco (Societa chimica italiana : 1989) 20010101 |
| Efavirenz: a pharmacoeconomic review of its use in HIV infection. | PharmacoEconomics 20010101 |
| Evidence of hypertriglyceridemia in managing HIV patients on efavirenz. | The Journal of the Association of Nurses in AIDS Care : JANAC 20010101 |
| A single amino acid change at Leu-188 in the reverse transcriptase of HIV-2 and SIV renders them sensitive to non-nucleoside reverse transcriptase inhibitors. | Archives of virology 20010101 |
| [Drug interactions with antiretroviral agents]. | Therapie 20010101 |
| Metformin in an HIV-infected patient with protease inhibitor-induced diabetic ketoacidosis. | The Annals of pharmacotherapy 20010101 |
| Eruptive cheilitis: a new adverse effect in reactive HIV-positive patients subjected to high activity antiretroviral therapy (HAART). Presentation of six clinical cases. | Medicina oral : organo oficial de la Sociedad Espanola de Medicina Oral y de la Academia Iberoamericana de Patologia y Medicina Bucal 20010101 |
| [Apropos of atypical melancholia with Sustiva (efavirenz)]. | L'Encephale 20010101 |
| Antiretroviral therapy in pregnancy: a focus on safety. | Drug safety 20010101 |
| Switching from protease inhibitors to the non-nuke efavirenz. | TreatmentUpdate 20010101 |
| Protease-sparing regimen in a real-life practice with naïve patients: an equal opportunity approach? | HIV clinical trials 20010101 |
| Nevirapine or efavirenz combined with two nucleoside reverse transcriptase inhibitors compared to HAART: a meta-analysis of randomized clinical trials. | HIV clinical trials 20010101 |
| Switch to efavirenz in a protease inhibitor-containing regimen. | HIV clinical trials 20010101 |
| DABOs as candidates to prevent mucosal HIV transmission. | Antiviral chemistry & chemotherapy 20010101 |
| The use of efavirenz as a part of late rescue antiretroviral treatment. | HIV clinical trials 20010101 |
| Evaluation of an efavirenz-containing regimen: an open-label, multicenter study. | HIV clinical trials 20010101 |
| Disseminated manifestation of Kaposi's Sarcoma in newly diagnosed AIDS in an african female. | Medical science monitor : international medical journal of experimental and clinical research 20010101 |
| Clinical pharmacokinetics of non-nucleoside reverse transcriptase inhibitors. | Clinical pharmacokinetics 20010101 |
| Analysis of HIV-1 drug resistant mutations by line probe assay and direct sequencing in a cohort of therapy naive HIV-1 infected Italian patients. | BMC microbiology 20010101 |
| Sustiva 'dirty drops' put prisoners in solitary. | Positively aware : the monthly journal of the Test Positive Aware Network 20010101 |
| The tolerability of efavirenz after nevirapine-related adverse events. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20000901 |
| In vitro inhibition of HIV-1 by Met-SDF-1beta alone or in combination with antiretroviral drugs. | Antiviral therapy 20000901 |
| Prevalence and characteristics of multinucleoside-resistant human immunodeficiency virus type 1 among European patients receiving combinations of nucleoside analogues. | Antimicrobial agents and chemotherapy 20000801 |
| Inhibition of clinically relevant mutant variants of HIV-1 by quinazolinone non-nucleoside reverse transcriptase inhibitors. | Journal of medicinal chemistry 20000518 |
| Selective interaction of the human immunodeficiency virus type 1 reverse transcriptase nonnucleoside inhibitor efavirenz and its thio-substituted analog with different enzyme-substrate complexes. | Antimicrobial agents and chemotherapy 20000501 |
| Mutational analysis of trp-229 of human immunodeficiency virus type 1 reverse transcriptase (RT) identifies this amino acid residue as a prime target for the rational design of new non-nucleoside RT inhibitors. | Molecular pharmacology 20000501 |
| Long-term exposure of HIV type 1-infected cell cultures to combinations of the novel quinoxaline GW420867X with lamivudine, abacavir, and a variety of nonnucleoside reverse transcriptase inhibitors. | AIDS research and human retroviruses 20000410 |
| Non-nucleoside HIV-1 reverse transcriptase inhibitors: synthesis and biological evaluation of novel quinoxalinylethylpyridylthioureas as potent antiviral agents. | Antiviral chemistry & chemotherapy 20000301 |
| Novel 2,2-dioxide-4,4-disubstituted-1,3-H-2,1,3-benzothiadiazines as non-nucleoside reverse transcriptase inhibitors. | Bioorganic & medicinal chemistry letters 20000117 |
| Expanded-spectrum nonnucleoside reverse transcriptase inhibitors inhibit clinically relevant mutant variants of human immunodeficiency virus type 1. | Antimicrobial agents and chemotherapy 19991201 |
| Synthesis and evaluation of benzoxazinones as HIV-1 reverse transcriptase inhibitors. Analogs of Efavirenz (SUSTIVA). | Bioorganic & medicinal chemistry letters 19991115 |
| Urea-PETT compounds as a new class of HIV-1 reverse transcriptase inhibitors. 3. Synthesis and further structure-activity relationship studies of PETT analogues. | Journal of medicinal chemistry 19991007 |
| Synthesis and evaluation of analogs of Efavirenz (SUSTIVA) as HIV-1 reverse transcriptase inhibitors. | Bioorganic & medicinal chemistry letters 19991004 |
| A novel genotype encoding a single amino acid insertion and five other substitutions between residues 64 and 74 of the HIV-1 reverse transcriptase confers high-level cross-resistance to nucleoside reverse transcriptase inhibitors. Abacavir CNA2007 International Study Group. | Journal of acquired immune deficiency syndromes (1999) 19991001 |
| Patterns of resistance and cross-resistance to human immunodeficiency virus type 1 reverse transcriptase inhibitors in patients treated with the nonnucleoside reverse transcriptase inhibitor loviride. | Antimicrobial agents and chemotherapy 19981201 |
| Four new antiretroviral medications will soon offer more options to HIV patients. | Faculty notes (New Orleans, La.) 19980101 |
| L-743, 726 (DMP-266): a novel, highly potent nonnucleoside inhibitor of the human immunodeficiency virus type 1 reverse transcriptase. | Antimicrobial agents and chemotherapy 19951201 |